//Chapter  5 Section 13
import React from 'react';
const foreword = {
  short_title: "Foreword",
  long_title: "Foreword on the 15th Edition",
  content:
    <span>
      <h1>Foreword on the 15th Edition</h1>
      <p>It is the national objective that the health care needs of Zimbabweans are met through the provision and proper use of essential medicines. Sometimes we do not need to give medicines, that is, there is not always a - "pill for every ill".  Thus, there is need to use medicines appropriately, efficiently, and effectively.</p>
      <p>The guidelines in EDLIZ have always reflected the consensus of local experts, and takes into consideration factors such as the Zimbabwean setting, prevailing economic climate, practical experience as well as evidence-based therapeutics.</p>
      <p>This new EDLIZ has taken into account the dynamic changes in the Burden of Disease as reflected by the inclusion of antiretroviral medicines and treatment of other opportunistic infections other than Tuberculosis (TB). Many of the therapeutic regimens of the previous EDLIZ still hold true and remain the same, and should reinforce the confidence of the prescriber in making reliable therapeutic choices.</p>
      <p>I urge all health workers to familiarise themselves with the revised guidelines, to prescribe within the bounds of this publication, and to recognise the critical importance of providing a quality service to all health care recipients through the rational use of medicines.</p>
      <p>EDLIZ <strong>REMAINS</strong> good medicine! Use it.</p>
      <hr />
      <p>Hon. Dr. P.D, Parirenyatwa<br /><small> Minister of Health &amp; Child Care </small></p>
    </span>
}
const major_highlights = {
  short_title: "Highlights",
  long_title: "Major Highlights in the Latest EDLIZ",
  content:
    <span>
      <h1>Major Highlights in the Latest EDLIZ</h1>
      <h2>Preamble</h2>
      <p>The major changes in this latest edition of EDLIZ will be highlighted here so that you are aware of recommendations that you need to consider in your medicine management or supply issues. Ideally each hospital should create its own local medicine formulary which shows which medicines are considered very useful in that setting so that you do not have to order medicines that your doctors will not prescribe or use. For instance you should not keep specialist medicines if there is no specialist to prescribe them. Hospital Medicine and Therapeutics Committees should select medicines for use in their hospital using the EDLIZ.</p>
      <h2>New chapter</h2>
      <p>There is one new chapter – Overview of Surgical Conditions.</p>
      <h2>Antibiotics</h2>
      <p>A new cephalosporin, Cefixime, has been added to the treatment of sexually transmitted illnesses. Azithromycin has also been added to the treatment of gonococcus.</p>
      <h2>Immunisation</h2>
      <p>Rotavirus immunisation has now become routinely available. Human Papilloma Virus (HPV) vaccination is currently being used in a limited setting but it is hoped that it will be rolled out nationally in 2016.</p>
      <h2>Asthma Treatment</h2>
      <p>Given that salbutamol Inhalers are more accessible, <strong>oral</strong> salbutamol has been phased out completely. You will need to ensure that your patients are aware of this change. Use of steroids as an inhaler should be used in place of regular oral Salbutamol. Health care workers will need to check that their clients can use the inhalers appropriately.</p>
      <h2>ART Guidelines (use latest ART guidelines)</h2>
      <p>Stavudine containing regimens are being phased out and will not be available except for a limited number of patients who will still need them. For first line therapy, tenofovir/lamivudine and efavirenz will be used in most instances for adults, adolescents and children as well as pregnant women.</p>
      <p>Third line antiretroviral medicines will be available in selected hospitals. These third line medicines will include raltegravirraltegravir and darunavir. Please familiarise yourself with the dosing of these new medicines and the algorithm for their use.</p>
    </span>
}
const seventh_edition = {
  short_title: "7th Edition",
  long_title: "EDLIZ 7th Edition 2015",
  content:
    <span>
      <h1>Published By:</h1>
      <p>The National Medicine and Therapeutics Policy Advisory Committee (NMTPAC) <br /> Ministry of Health & Child Care Republic of Zimbabwe</p>
      <p>Further copies may be obtained through the relevant Provincial Medical Directorate, City Health Directorate, the NMTPAC, Ministry of Health & Child Care (MOHCC), PO Box CY 1122, Causeway, Harare, Zimbabwe, or the <a href="http://www.mohcc.gov.zw" target="_blank" rel="noopener noreferrer">MOHCC website</a>. Copies of the text may be obtained on soft copy if required for teaching purposes from email address: <a href="mailto:dps@mohcc.gov.zw">dps@mohcc.gov.zw</a> or <a href="mailto:nmtpac@gmail.com">nmtpac@gmail.com</a> EDLIZ was prepared using Microsoft® Word.  The information presented in these guidelines conforms to current medical, nursing and pharmaceutical practice. It is provided in good faith. Whilst every effort was made to ensure that medicine doses are correct, no responsibility can be taken for errors and omissions.</p>
      <p><strong>- EDLIZ Review Co-ordinator </strong></p>
      <p>No part of this publication may be reproduced by any process without the written permission of the copyright holder, exception being made for the purpose of private study, research, criticism or review, or for teaching, but not for sale or other commercial use.</p>
      <p>Original Cover Design: Regina Gapa and Charon Lessing.</p>
      <p>Cover redesign & Layout: Kim Hoppenworth.</p>
      <p>Cover redesign and layout 2015: Newman B Madzikwa</p>
      <p>&copy; Copyright June 2015, Ministry of Health &amp; Child Care</p>
      <h1>EDLIZ Review Committee</h1>
      <ul>
        <li>Apollo Tsitsi</li>
        <li>Samukange Emma</li>
        <li>Borok Margaret</li>
        <li>Mujuru Hilda</li>
        <li>Chakanyuka Christine C.</li>
        <li>Mushavi Angela</li>
        <li>Hove Ropafadzai</li>
        <li>Madzikwa Newman B.</li>
        <li>Mungwadzi Godfrey</li>
        <li>Ndhlovu Chiratidzo E.</li>
        <li>Bakasa Clemenciana</li>
        <li>Sifeku Florah N.</li>
        <li>Mudzimu Forward</li>
        <li>Wellington Maureen</li>
        <li>Torongo Mabel</li>
        <li>Vuragu Davison N.</li>
        <li>Nyamayaro Raphael</li>
        <li>Maunganidze Aspect</li>
        <li>Khoza Star</li>
        <li> Basopo Victor</li>
      </ul>
    </span>
}
const acknowledgements = {
  short_title: "Acknowledgements",
  long_title: "Acknowledgements",
  content:
    <span>
      <h1>Acknowledgements</h1>
      <p>We would like to thank all the individuals who made contributions through colleagues or discussion forums or by communicating through electronic mail. We are grateful to all who made this edition a national guide that serves as the standard for Zimbabwe. Thank you to all the healthcare workers for your support</p>
      <p>The following attended our review workshops as well as being instrumental in current chapter reviews:</p>
      <ul>
        <li>Akinjide-Obonyo Akindele P, Dr</li>
        <li>Maunga Simbarashe, Dr</li>
        <li>Apollo Tsitsi, Dr</li>
        <li>Maunganidze Aspect, Dr</li>
        <li>Bakasa Clemenciana, Ms</li>
        <li>Mbuzi Tonnie, Mr</li>
        <li>Bare Blessing, </li>
        <li>Mhazo Tichatyei, Mr</li>
        <li>Basopo Victor, Mr</li>
        <li>Mhembere Josephine, Dr</li>
        <li>Bepe Tafadzwa, Dr</li>
        <li>Midzi Stanley, Dr</li>
        <li>Borok Margaret, Dr</li>
        <li>Misihairambwi Silence, Ms</li>
        <li>Burutsa Patricia, Ms</li>
        <li>Mlilo Lindiwe, Dr</li>
        <li>Bwakura Tapiwanashe, Dr</li>
        <li>Moyo Dothan, Mr</li>
        <li>Cakana Andrew, Prof</li>
        <li>Moyo Mluleki, Mr</li>
        <li>Chakanyuka Artmore, Dr</li>
        <li>Moyo Sifiso, Mr</li>
        <li>Chakanyuka Christine C., Dr</li>
        <li>Mudombi Wisdom, Dr</li>
        <li>Chari Godfrey,</li>
        <li>Mudzimu Forward, Mr</li>
        <li>Charimari Lincoln, Dr</li>
        <li>Mujuru Hilda A., Dr</li>
        <li>Chemhuru Milton, Dr</li>
        <li>Mungwadzi Godfrey, Dr</li>
        <li>Chikanya Sonia Irene, Ms</li>
        <li>Munjanja Stephen P., Prof</li>
        <li>Chimhini Gwendoline, Dr</li>
        <li>Mushavi Angela, Dr</li>
        <li>Chirenje Mike Z., Prof.</li>
        <li>Musiya N., Dr</li>
        <li>Chiro Erick, Mr</li>
        <li>Musungwa Alexio, Mr</li>
        <li>Cowan Frances M, Prof.</li>
        <li>Musvipa Mary, Ms</li>
        <li>Deda Petunia, Ms</li>
        <li>Mutsvairo Sitembile, Ms</li>
        <li>Dliwayo Thokozile, Ms</li>
        <li>Mwaramba Charles, Mr</li>
        <li>Dube Siphathisiwe Noreen, Mrs</li>
        <li>Mwonzora Muchaneta, Mrs</li>
        <li>Dube Tirivashoma, Mr</li>
        <li>Nathoo Kusum J., Prof.</li>
        <li>Fana Golden, Dr</li>
        <li>Ncube Phumuzile, Ms</li>
        <li>Gambanga Pauline, Dr</li>
        <li>Ndamukwa Pikirai, Mr</li>
        <li>Glavintcheva Iskra L., Dr</li>
        <li>Ndhlovu Chiratidzo E., Prof</li>
        <li>Gunguwo Hillary, Dr</li>
        <li>Ndlovu Misheck, Mr</li>
        <li>Gwanzura Lovemore, Prof.</li>
        <li>Ndowa Francis, Dr</li>
        <li>Gwata Beatrice, Mrs</li>
        <li>Nembiri Tinashe,</li>
        <li>Ms Hove Ropafadzai Mrs</li>
        <li>Ngwende Gift W., Dr.</li>
        <li>Kambarani Rose, Prof</li>
        <li>Nkala Lee, Mr</li>
        <li>Kandawasvika Petronella, Dr</li>
        <li>Nyadzayo Tasiana K., Mr</li>
        <li>Khoza Star, Dr</li>
        <li>Nyakabau Anna M., Dr</li>
        <li>Khumalo Brian, Mr</li>
        <li>Nyamayaro Raphael, Dr</li>
        <li>Khumalo Mhlawempi, </li>
        <li>Nyaruwanga Albert, Mr</li>
        <li>Kufa Tarisai, Dr</li>
        <li>Pasi Christopher, Dr</li>
        <li>Kusemwa Muyambi Preetyosa, Ms</li>
        <li>Phiri Isaac, Dr</li>
        <li>Latif AS, Prof</li>
        <li>Reid Andrew, Dr</li>
        <li>Machisa Vimbainashe, Ms</li>
        <li>Rimai Ruth, Ms</li>
        <li>Madhombiro Munyaradzi, Dr</li>
        <li>Samukange Emma, Mrs</li>
        <li>Madzikwa Newman B. Mr</li>
        <li>Sandy Charles, Dr</li>
        <li>Magombeyi Rudo, Ms</li>
        <li>Sanyanga Arthur, Mr</li>
        <li>Magunda Farai, </li>
        <li>Shumba Godfrey, Mr</li>
        <li>Mandimika, Florence</li>
        <li>Sibanda Elopy N., Prof</li>
        <li>Mandire Joice, Ms</li>
        <li>Sifeku Florah N., Mrs</li>
        <li>Mangezi Walter, Dr</li>
        <li>Sithole Dorcas, Ms</li>
        <li>Mangoma Tariro, Ms</li>
        <li>Tagwirei Dexter, Prof</li>
        <li>Mangwiro John C., Dr</li>
        <li>Takaruza Kelvin, Mr</li>
        <li>Masanganise Rangarirai, Prof</li>
        <li>Tambudze Gaundencia, Ms</li>
        <li>Masendu Maureen, Dr</li>
        <li>Tekasala Lumbu Jerry, Mr</li>
        <li>Mashinge Farayi, Mr</li>
        <li>Ticklay Ismail, Dr</li>
        <li>Mashoko Tsungai, Ms</li>
        <li>Vuragu Davison N., Mr</li>
        <li>Mashumba Azza, Dr</li>
        <li>Wellington Maureen, Dr</li>
        <li>Maswaure Laucas,</li>
        <li>Zaranyika Trust, Dr</li>
        <li>Matonhodze Alex, Mr</li>
      </ul>
      <p><strong>Thank You!</strong></p>
      <p>Mrs R.F. Hove <br /><small>Director of Pharmacy Services </small></p>
      <p>Prof. C. E. Ndhlovu<br /><small>NMTPAC Chairperson</small></p>
    </span>
}
const preface = {
  short_title: "Preface",
  long_title: "The Essential Medicines List for Zimbabwe",
  content:
    <span>
      <h1>The Essential Medicines List for Zimbabwe - EDLIZ 7<sup>th</sup> Edition</h1>
      <p>This 7th essential medicines list and standard treatment guidelines for the most common health conditions in Zimbabwe has been endorsed by the National Medicine & Therapeutics Policy Advisory Committee [NMTPAC]. It is the product of many years of combined efforts by hundreds of health workers at all levels of the health care system in Zimbabwe – from the front line health care providers to the providers of specialist care. It has been refined over the years as a result of its widespread use by our healthcare workers. We continue to revise the standard treatment guidelines and take into account medicine developments and new healthcare problems. Thus this latest edition has included more essential medicines.</p>
      <p>The essential medicine list is based on the Essential Medicines Concept. Medicines in EDLIZ are chosen to meet the health care needs of the majority of the population, and should therefore always be available and accessible at a price that both the patient and the nation can afford.</p>
      <h2>Selection of medicines for inclusion </h2>
      <p>Selection of medicines for inclusion in EDLIZ has been based on the following criteria, with special emphasis on proven evidence for their use in the Zimbabwean setting:</p>
      <ul>
        <li>relevance to prevalent diseases</li>
        <li>proven efficacy and safety </li>
        <li>adequate scientific data in a variety of settings </li>
        <li>adequate quality</li>
        <li>favourable cost-benefit ratio</li>
        <li>desirable pharmacokinetics</li>
        <li>possibilities for local manufacture </li>
        <li>available as single ingredient items </li>
      </ul>
      <ul className="boxedlist">
        <li>Safe</li>
        <li>Efficacious</li>
        <li>Quality</li>
        <li>Available</li>
        <li>Affordable</li>
        <li>Accessible</li>
        <li>Rationally used</li>
      </ul>
      <h3>Generic Medicines</h3>
      <p>Every medicine has a chemical name and a generic name. For example, paracetamol, its chemical name is N-(4-Hydroxyphenol) acetamide and the international non-proprietary name (INN) or generic name is paracetamol. The INN is the medicine's official name regardless of who manufactures or markets it. An additional brand name is chosen by the manufacturer to facilitate recognition and association of the product with a particular manufacturer for marketing purposes.</p>
      <p>For most common medicines there are several branded products that all contain the same active ingredient and therefore share the same INN. For example, the <em>African Monthly Index of Medical Specialties</em> (MIMS) lists over fifteen different brand names of paracetamol. There are 12 different preparations containing aspirin, 13 different brands of amoxicillin and 12 different brands of ampicillin.</p>
      <p>The use of generic names for medicine procurement as well as prescribing carries considerations of clarity, quality, and price. Proponents of generic medicines procurement and prescribing point out that:</p>
      <ul>
        <li>generic names are more informative than brand names and facilitate purchasing of products from multiple suppliers, whether as brandname or as generic products; </li>
        <li>generic medicines are generally cheaper than products sold by brand name; this is demonstrateddemonstrated very clearly when it comes to antiretroviral medicines </li>
        <li>generic prescribing also facilitates product substitution, whenever appropriate. </li>
      </ul>
      <p>Opponents argue that the quality of generic medicines is inferior to that of brand (innovator) products. However quality assurance and naming of medicines are completely separate issues. Generic medicines from reliable suppliers are as safe, effective, and high in quality as medicines with brand names. At the same time, branded medicines from a manufacturer with inadequate procedures for quality control can be of poor quality, despite the brand name. Also, although any medicine can be counterfeited, there are more incentives for counterfeiting brandname medicines than generic medicines. Some pharmaceutical companies also sell their branded products under the generic name, for a much lower price.</p>
      <p>Bio-equivalence is often misused as an argument against the use of generic equivalents. For many medicines, the variation in bioavailability among individual patients is much larger than the variation among products of different manufacturers. In fact, bioavailability is clinically relevant for only a relatively small number of medicines such as furosemide, digoxin, levodopa, isoniazid, theophylline and phenytoin.</p>
      <p>Zimbabwe has a well understood generic policy which requires that all prescribing is in the generic name and the dispenser can make generic substitutions (unless bioavailability is an issue in which case the prescriber should indicate accordingly).</p>
      <h3>Advantages of EDLIZ</h3>
      <p>The benefits of the selection and use of a limited number of essential medicines are:</p>
      <ul>
        <li>Improved medicines supply</li>
        <li>More rational prescribing</li>
        <li>Lower costs</li>
        <li>Improved patient use</li>
      </ul>
      <h4>Improved Medicines Supply</h4>
      <ul className="boxedlist">
        <li>easier procurement, storage & distribution</li>
        <li>lower holding stocks</li>
        <li>lower losses</li>
        <li>better quality assurance</li>
      </ul>
      <p>The regular supply of medicines is difficult in many countries, and the consequent health implications are many. Improved medicines availability should lead to improved clinical outcomes. With fewer essential medicines being purchased, the mechanisms and logistics for procurement, storage & distribution will clearly be easier. It is not practical for each clinic in Zimbabwe to attempt to procure, transport and warehouse all the hundreds of items in EDLIZ. Conversely, limiting the number of medicines available at the primary health care level makes a regular supply of medicines more practical and possible.</p>
      <p>With an improved supply the possibilities of holding lower quantities exist. This has financial implications as well as reducing the likelihood of medicines expiring or being damaged during storage.</p>
      <p>Quality assurance can be better managed when the number of medicines is limited, and quality checks can be performed more frequently.</p>
      <h3>More Rational Prescribing</h3>
      <ul className="boxedlist">
        <li>focused, more effective training </li>
        <li>more experience with fewer medicines</li>
        <li>no irrational treatment alternatives available</li>
        <li>focused medicine information </li>
        <li> better recognition of adverse medicine reactions</li>
      </ul>
      <p>In the absence of limited lists, the large variety of products available on the market contributes to inconsistent prescribing and consequently, variation in clinical practice even within the same health care facility. Irrational prescribing may lead to therapeutic hazards and increased costs.</p>
      <p>When the number of medicines is limited, training can be more focused and the quality of care enhanced. This is especially true when the list represents a consensus of opinion on first choice of treatment such as in EDLIZ</p>
      <p>Using EDLIZ enables the prescriber to become more familiar with the medicines they use, and better able to recognise adverse effects.</p>
      <p>The use of EDLIZ also eliminates irrational products from being available for prescribing, and allows for more focused medicine information to be provided on suitable essential medicines</p>
      <h3>Lower Costs</h3>
      <ul className="boxedlist">
        <li>more competition</li>
        <li>lower prices</li>
      </ul>
      <p>Improved effectiveness and efficiency in patient treatment leads to lower health care costs. The essential medicines concept is increasingly being accepted as a universal tool to promote both quality of care and cost control.</p>
      <p>Essential medicines are usually available from multiple suppliers. With increased competition, more favourable prices can be negotiated.</p>
      <p>By limiting the number of different medicines that can be used to treat a particular clinical problem, larger quantities of the selected medicine will be needed, with potential opportunities to achieve economies of scale.</p>
      <h3>Improved Patients Use</h3>
      <p>Focusing on fewer medicines can enhance patient education and efforts to promote the proper use of medicines in both patients and prescribers</p>
      <ul className="boxedlist">
        <li>focused education efforts</li>
        <li>reduced confusion & increased adherence to treatment </li>
      </ul>
      <p>Additionally, with improved medicine availability changes to chronic medication regimens are less likely and as a consequence patients have a better understanding of their disease, their medication and the need for compliance.</p>
      <h2>Implementation of EDLIZ and Setting up of Hospital Medicine and Therapeutics Committees (HMTCS)</h2>
      <p>The advantages presented here however do not just happen. EDLIZ itself will not ensure rational prescribing or facilitate good procurement or quality assurance. Educational, regulatory, financial or managerial strategies on their own are less effective in promoting the rational use of medicines than combined strategies. The production of EDLIZ is one such regulatory strategy, but further steps such as training and retraining, patient education and the establishment and effective functioning of hospital medicine and therapeutic committees (HMTCs) have to be taken to ensure cost-effective prescribing and patient care. It is therefore necessary for every hospital to have a forum where medicine issues can be discussed. Ideally, a separate hospital medicine and therapeutics committee (HMTC) should be formed. Given the current manpower constraints, we encourage hospitals to exploit every opportunity such as the regular divisionaldivisional meetings heldheld in Central Hospitals to discuss and address medicine related problems.   The NMTPAC is available to assist those hospitals that are ready to set up an HMTC. A technical guideline to set up a HMTC developed by the NMTPAC is available.</p>
      <h2>Explanations and Changes from the Previous Version </h2>
      <p>This edition is essentially the same in format and layout, categorisation as the last edition.  You will need to read it carefully to note changes in recommendations that apply to your areas of interest. Extra bulletins will be sent out where drastic changes in medicine recommendations have occurred.</p>
      <p>All medicines in EDLIZ are categorised firstly by level of availability (ABCS) in the health care system, and secondly, according to priority (VEN). Hence in the example below, amoxicillin is available at primary health care facility (C) level and is ranked vital (V).</p>
      <table>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>amoxicillin po</td><td>C V</td><td>500mg</td><td>3 times a day</td><td>7 Days</td></tr>
        </tbody>
      </table>
      <h3>Level of Availability</h3>
      <p><strong>C medicines</strong> are those required at primary health care level and should be available at all levels of care</p>
      <p><strong>B medicines</strong> are found at district hospital level or secondary and higher levels of care. Some B medicines may be held at primary health care</p>
      <p><strong>A medicines</strong> are prescribed at provincial or central hospital levels</p>
      <p><strong>S medicines</strong> (specialist only) have been brought back into this edition. These are medicines that require special expertise and /or diagnostic tests before being prescribed.</p>
      <h2>VEN Classification</h2>
      <p>All medicines are also classified according to their priority. This is mostly a tool to assist in giving priority to medicines based on economic considerations. Thus <strong>V</strong> medicines are <strong>vital</strong>, they are considered lifesaving or their unavailability would cause serious harm and efforts should always be aimed at making them 100% available.</p>
      <p><strong>E</strong> medicines are <strong>essential</strong>, and are given second priority. Without E medicines there would be major discomfort or irreversible harm. And <strong>N</strong> medicines are still <strong>necessary</strong> but are lower in priority than V and E medicines.</p>
      <p>The NMTPAC is a standing committee that reviews the therapeutic guidelines in EDLIZ on a continual basis, and always looks forward to feedback from the providers of health care in Zimbabwe.  Contact the NMTPAC through Directorate of Pharmacy Services on <a href="mailto:dps@mohcc.gov.zw">dps@mohcc.gov.zw</a> or <a href="mailto:nmtpacnmtpac@gmail.com">nmtpacnmtpac@gmail.com</a>  with your comments.</p>
      <p><small>
        Brigadier General (Dr) G. Gwinji <br />Permanent Secretary <br />Ministry of Health & Child Care <br />Republic of Zimbabwe </small></p>
    </span>
}
const chapter_one = {
  short_title: "Chapter 1",
  long_title: "Guidelines on Antimicrobial Treatment and Prophylaxis ",
  content:
    <span>
      <h1>Guidelines on Antimicrobial Treatment and Prophylaxis</h1>
      <h2>General Guidelines</h2>
      <p>Antimicrobials are the most over-used class of medicines worldwide and in Zimbabwe. Apart from the unnecessary cost and risk to the patient, overuse encourages development of resistant organisms, a problem that has proven serious and expensive in many countries. Antimicrobials should be used only in patients with likely bacterial illness requiring systemic therapy. In many cases anti-microbial medicines will initially be given "blind" or "empirically", the choice being based on clinical suspicion without microbiological confirmation. Positive identification of the pathogen and anti-microbial susceptibility testing should be sought wherever possible as this will result in better and more cost-effective treatment.</p>
      <h3>Principles of antimicrobial use </h3>
      <ol>
        <li><strong>Choice of agent</strong> should be based on factors such as spectrum of activity, anticipated efficacy, safety, previous clinical experience, cost, and potential for resistance. These will be influenced by the severity of illness and whether the medicine is to be used for prophylaxis, empirical therapy or therapy directed by identification of one or more pathogens </li>
        <li><strong>Prophylactic therapy</strong> should be restricted to the use of a limited range of agents of proven efficacy in invasive procedures with a high risk of infection or where the consequences of infection are disastrous. Most surgical prophylaxis should be parenteral and commence just before the procedure, continuing for no more than one or two doses after the end of the operation. The aim is to achieve high plasma and tissue levels at the time that contamination is most likely i.e. during the operation.</li>
        <li><strong>Empirical therapy</strong> should be based on local epidemiological data on potential pathogens and their patterns of antibiotic susceptibility. Appropriate specimens for Gram stain, culture and sensitivity testing should be obtained before commencing antimicrobial therapy. Maintain a database of susceptibility profile in order to guide intelligent choice of empirical antibiotic therapy at regional and national patterns.</li>
        <li><strong>Directed antimicrobial therapy</strong> for proven pathogens should include the most effective, least toxic, narrowest spectrum agent available. This practice reduces the problems associated with broad-spectrum therapy, that is, selection of resistant microorganisms and superinfection.</li>
        <li><strong>Choice of route</strong> should be determined by the site and severity of infection. It is important that topical antimicrobial therapy be restricted to a few proven indications, for example, eye infections because of the capacity of most agents to select resistant microorganisms and to cause sensitisation; topical antiseptics are preferred in most situations.</li>
        <li><strong>Antimicrobial combinations</strong> have few indications. These include:
                <ul>
            <li>to extend the spectrum of cover, for example, in empirical therapy or in mixed infections,</li>
            <li> to achieve a more rapid and complete bactericidal effect, for example, in enterococcal endocarditis,</li>
            <li> to prevent the emergence of resistant micro-organisms, for example in the therapy of tuberculosis.</li>
          </ul>
        </li>
      </ol>
      <small><em>Note: Doses given are for a 70kg adult with normal hepatic and renal function. Paediatric doses are given in the chapter on Paediatric Conditions. In the elderly, as a general rule, doses given could be lower than the recommended adult dose (see Chapter on Medicines and the Elderly). </em></small>
      <h2>Notes on Specific Microbials</h2>
      <p>Note that some antibiotics are becoming ineffective because microorganisms are generally resistant to them. Antimicrobial susceptibility testing should therefore be sought where possible. Patients should be counselled to complete courses even when they feel better.</p>
      <p>Oral <strong>amoxicillin</strong> should be used in preference to oral ampicillin because of its better absorption, efficacy and lower cost. However, the same is <u>not</u> true of the injectable preparations that have similar efficacy.</p>
      <p><strong>Chloramphenicol</strong> must be limited to serious infection such as typhoid, <em>Klebsiella</em> pneumonia, <em>Haemophilus influenzae</em> infections, difficult to treat pelvic inflammatory disease and brain abscesses and <u>not</u> used indiscriminately in the treatment of fever. An exception to this is when a broad-spectrum antibiotic is required and there is a problem with availability. Furthermore, the oral preparation should be used judiciously as it is more prone to cause aplastic anaemia than the injectable formulation.</p>
      <p>Dosage of <strong>gentamicin, streptomycin, and kanamycin</strong> (aminoglycosides) must be carefully adjusted for weight and renal function. Except for duration less than 3 days use or when lower doses are used, as with TB therapy, they require peak and trough serum levels (where available), careful monitoring of serum urea and/or creatinine, and checking for complaints of auditory or vestibular symptoms (adverse effects).</p>
      <p>Patients with true <strong>penicillin allergy</strong> (that is, a pruritic rash, angioedema or anaphylaxis) must not be given penicillin. Rashes occurring after 48 hours are rarely due to allergy and are not a contraindication to further use. Note that, penicillins have crossreactivities with other medicines including cephalosporins and such newer medicines as imipenem. Macrolides are suitable alternatives. Persons with a history of co-trimoxazole allergy may be offered desensitisation (see Chapter on HIV infections).</p>
      <h2>Pyrexia / Fever of Unknown Origin </h2>
      <p>Fever is a common presenting symptom at all ages, but in adults there will usually be some localising symptoms or signs, which point to a likely focus of infection. If after careful examination no clear focus of infection is identified, the following should be considered in a previously healthy patient admitted from the community with fever of less than two weeks‘ duration:</p>
      <ul>
        <ul>
          <li>Viral infections (frequently resolve after 4-5 days, or may be the prodromal phase, for example, hepatitis).</li>
          <li>Malaria.</li>
          <li>Typhoid.</li>
          <li>Urinary tract infection.</li>
          <li>Bacteraemia.</li>
          <li>HIV related causes of fever</li>
        </ul>
      </ul>
      <small><em>If HIV infection is suspected see guidelines in the chapter on HIV Related Diseases. </em></small>
      <ul>
        <li>If the patient‘s general condition is satisfactory, it is reasonable to withhold antibiotics while carrying out a few basic investigations: that is urinalysis (dip-stick), <em>urine microscopy, haemoglobin, white cell count and differential and malarial parasites</em> which are all within the capabilities of a district hospital laboratory. If possible, send a <em>blood culture</em> to the nearest reference laboratory. <em>Liver function tests </em>and<em> urine testing</em> for bile products are appropriate if hepatitis is suspected.</li>
        <li>If no improvement occurs after 3-4 days, and there is still no identifiable focus of infection, and there is no evidence of malaria (at least two negative blood films), the subsequent management of the patient should be guided by the results of the investigations.</li>
        <li>In those patients who present very ill or toxic, or whose condition deteriorates, antibiotic therapy should be initiated on the basis of clinical suspicion (typhoid - <strong>chloramphenicol</strong>, staphylococcal septicaemia - <strong>cloxacillin</strong>, etc), anaerobes (metronidazole).</li>
      </ul >
      <table>
        <caption>Recommended "blind" therapy for septicaemia with no identifiable source is as follows: </caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>ampicillin iv</td><td>B E</td><td>2g</td><td>4 times per day</td><td>Review</td></tr>
          <tr><td>gentamicin iv</td><td>C V</td><td>4 - 5mg/kg</td><td>once a day</td><td>max 2 weeks</td></tr></tbody>
      </table>
      <table>
        <caption>Alternative:</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>chloramphenicol iv</td><td>B E</td><td>1g</td><td>4 times per day</td><td>Review</td></tr>
          <tr><td>gentamicin iv</td><td>C V</td><td>4 - 5mg/kg</td><td>once a day</td><td>max 2 weeks</td></tr></tbody>
      </table>
      <h2>The Use of Antimicrobials for Prophylaxis of Infection</h2>
      <p>There are some instances where the use of prophylactic antibiotics is well established. However, the use of antibiotics for prophylaxis of infection often consumes a disproportionate amount of all antibiotics used in the hospital setting and consideration to their appropriate use must be given. Prophylactic antibiotic use must be within accepted principles and guidelines.</p>
      <h3>General Recommendations: </h3>
      <ul>
        <li> use the appropriate medicine (see below)</li>
        <li> give as a single dose where possible.</li>
        <li> repeat when the procedure lasts longer than 3-4 hours</li>
        <li> give intravenously 10-15 minutes before incision, or orally 1-2 hours before incision </li>
      </ul>
      <h4>Specific indications: </h4>
      <h5>Surgical prophylaxis </h5>
      <table>
        <caption>Virginal operations:</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th></tr>
          <tr><td>chloramphenicol iv</td><td>B E</td><td>1g</td><td>single dose</td></tr>
        </tbody>
      </table>
      <table>
        <caption>Caesarean section: </caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th></tr>
          <tr><td>ceftriaxone iv</td><td>C V</td><td>1g</td><td>single dose</td></tr>
        </tbody>
      </table>
      <table>
        <caption>Hysterectomy, or Colorectal surgery e.g. appendicectomy: </caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th></tr>
          <tr><td>ceftriaxone iv</td><td>C V</td><td>1g</td><td>single dose</td></tr>
          <tr><td>gentamicin iv</td><td>C V</td><td>4 - 5 mg/kg</td><td>single dose</td></tr>
        </tbody>
      </table>
      <table>
        <caption>If signs of infection after operation, give:</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>amoxicillin po</td><td>C V</td><td>500mg</td><td>3 times per day</td><td>7 days</td></tr>
          <tr><td>metronidazole po</td><td>C V</td><td>400mg</td><td>3 times per day</td><td>7 days</td></tr>
        </tbody>
      </table>
      <p><em>Also refer to Obstetrics and Gynaecology/Surgical Conditions Chapters for further guidance.</em></p>
      <table>
        <caption>Urinary tract surgery e.g. prostatectomy:  </caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th></tr>
          <tr><td>ciprofloxacin po</td><td>B V</td><td>500mg</td><td>single dose</td></tr>
        </tbody>
      </table>
      <h5>Other prophylaxis </h5>
      <table>
        <caption>Skull base fracture with liquorrhoea (rhino/otorrhoea): </caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th></tr>
          <tr><td>chloramphenicol iv</td><td>B E</td><td>1g</td><td>single dose</td></tr>
        </tbody>
      </table>
      <p>Subacute bacterial endocarditis <small>See Cardiovascular Chapter </small></p>
      <table>
        <caption>For meningococcal meningitis contacts. Give as soon as diagnosis is made in the index case:</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th></tr>
          <tr><td>ceftriaxone im</td><td>C V</td><td>250mg</td><td>single dose</td></tr>
        </tbody>
      </table>
      <table>
        <caption>Cotrimoxazole Prophylaxis (see HIV chapter): </caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>cotrimoxazole* po</td><td>C V</td><td>960mg</td><td>every day</td><td>for life or until CD4 count > 500 for 3 months with <abbr title="Antiretroviral">ARV</abbr>s</td></tr>
          <tr><td colSpan="5"><small><em>*If there is a history of cotrimoxazole allergy and it was not StevensJohnson syndrome then it is likely that the person can be desensitised</em></small></td></tr>
        </tbody>
      </table>
    </span>
};
const chapter_two = {
  short_title: "Chapter 2",
  long_title: "Basic Infection Prevention and Control Measures",
  content:
    <span>
      <h1>Basic Infection Prevention and Control Measures</h1>
      <p><strong>(See National Infection Control Guidelines)</strong><br />
        Transmission of infections in healthcare facilities can be prevented and controlled through the application of basic infection control prevention and control practices. The 2 tiers or categories of infection control prevention and practices are A) <strong>standard precautions</strong> and B) <strong>transmission based precautions</strong>.  The goal of this two- tier/category system is to minimise risk of infection and maximise safety level within our healthcare facilities.</p>
      <ul>
        <li>Educate healthcare workers not only on what to do but why it is important to do it.</li>
        <li>Emphasising outcomes helps healthcare workers see how their routine job duties interact with the infection control system.</li>
      </ul>
      <h2>Categories of Infection Control Practices: </h2>
      <ol>
        <li>Standard Precautions (previously known as Universal Precautions) - must be applied to all patients at all times, regardless of diagnosis or infectious status</li>
        <li>Transmission based precautions - are specific to modes of transmission e.g. airborne, droplet or contact.</li>
      </ol>
      <ol>
        <li>
          <h3>Standard Precations</h3>
          <p>Treating all patients in the healthcare facility with the same basic level of ―standard‖ precautions involves work practices that are essential to provide a high level of protection to patients, healthcare workers and visitors.<br /> These precautions include the following:</p>
          <ul>
            <li>Hand hygiene (hand washing, hand antisepsis).</li>
            <li>Use of personal protective equipment when handling blood substances excretions and secretions.</li>
            <li>Appropriate handling of patient care equipment and soiled linen.</li>
            <li>Prevention of needle stick/sharp injuries.</li>
            <li>Environmental cleaning and spills management.</li>
            <li>Appropriate handling of waste.</li>
          </ul>
          <h4>Hand Hygiene </h4>
          <p>Appropriate hand washing can minimise micro-organisms acquired on the hands by contact with body fluids and contaminated surfaces. Hand washing breaks the chain of infection transmission and reduces person to person transmission.</p>
          <p><strong className="underline">NB: </strong>  Hand washing or hand antisepsis is the simplest and most cost- effective way of preventing the transmission of infection and thus reducing the incidence of healthcare associated infections.</p>
          <h5>Types of Hand Hygiene </h5>
          <ol>
            <li>Hand washing is usually limited to hands and wrists, the hands are washed for a minimum 10-18 seconds with hand washing soap and water.</li>
            <li><strong>Hand antisepsis/Decontamination</strong>
              <ul>
                <li>Decontaminate hands with a waterless alcohol based hand gel or rub for 15-30 seconds. <br />This is appropriate for hands that are not visibly soiled.</li>
              </ul>
            </li>
            <li><h6>Surgical hand antisepsis </h6>
              <ul>
                <li>This removes or destroys transient micro-organisms and confers a prolonged effect. The hands and forearms are washed thoroughly with an antiseptic soap for a minimum 2-3 minutes and dried with a sterile towel. This is required before performing invasive procedures.</li>
              </ul>
            </li>
          </ol>
          <strong className="underline">NB:</strong> Hands should be dried with disposable paper towels.
                <h4>Use of Personal Protective Equipment.</h4>
          <p>Types:</p>
          <ul>
            <li>Scrub Suit or Gowns</li>
            <li>Plastic Aprons</li>
            <li>Boots or shoes covers</li>
            <li>Caps</li>
            <li>Protective eye wear</li>
            <li>Gloves</li>
          </ul>
          <ul>
            <li><h5>Gloves</h5>
              <ul>
                <li>Reduce the incidence of hand contamination with infective material which in turn reduces the opportunity for personnel to become infected and/or the organisms to spread to other personnel and /or patients.</li>
                <li><strong><em>Gloves however should not replace hand washing. </em></strong></li>
              </ul>
            </li>
          </ul>
          <h6>Gloves are to be worn when touching the following: </h6>
          <ul>
            <li>Blood</li>
            <li>All body fluids</li>
            <li>All body secretions</li>
            <li>All body excretions</li>
          </ul>
          <p>Gloves should be removed before touching clean items (e.g. phone, door knobs or patients‘ charts.) After removing gloves, wash hands thoroughly.</p>
          <ol>
            <li><h5>Important points to remember when using gloves.</h5>
              <ul>
                <li>Use gloves when there is potential exposure to blood, body fluids, excretions or secretions.</li>
                <li>Change gloves between patients, between procedures on the same patient when they become soiled.</li>
                <li>Remove gloves before leaving the patient‘s bedside and decontaminate hands immediately with 70% alcohol hand rub solution.</li>
                <li>Discard gloves after attending to each patient.</li>
              </ul>
            </li>
            <li><h5>Boots/shoe covers</h5>
              <ul>
                <li>These are used to protect the wearer from splashes of blood, body fluids, secretions and excretions.</li>
                <li>Shoe covers should be disposable and waterproof.</li>
                <li>Waterproof boots should be washable.</li>
              </ul>
            </li>
            <li><h5>Caps</h5>
              <ul>
                <li> Disposable and waterproof caps that completely cover the hair are used when splashes of blood and body fluids are expected.</li>
              </ul>
            </li>
            <li><h5>Masks</h5>
              <ol>
                <li>A surgical mask protects healthcare providers from inhaling respiratory pathogens transmitted by the droplet routes. It prevents the spread of infectious diseases such as varicella (Chicken pox) and meningococcal diseases (meningococcal meningitis.)</li>
                <li>A N95 mask protects healthcare providers from inhaling respiratory pathogens that are transmitted via the airborne route. This helps to prevent the spread of infectious diseases such as TB, or MDR TB.</li>
              </ol>
              <p><small>
                <strong>NB:</strong> In order to prevent the spread of infection, the appropriate mask should be worn by healthcare providers and visitors when attending to a patient suffering from a communicable disease that is spread via the airborne or droplet route.
                            </small></p>
              <p>The patient with a communicable disease via the droplet or airborne route should wear a surgical mask when being transferred to other departments or hospitals or in isolation room to prevent spread of infection. <br />Disposable masks are for single use only and should only be discarded after 4-6 hours use.<br /></p>
              <h6>Precautions</h6>
              <ol>
                <li>Masks should not be worn around the neck</li>
                <li> Masks cannot be worn with beards or unshaven faces.</li>
                <li>Masks should completely seal the face at all times to ensure effective filtering of micro-organisms.</li>
              </ol>
            </li>
            <li><h5>Gowns</h5>
              <ul>
                <li>Gowns made of impervious material are worn to protect the wearer‘s clothing/uniform from possible contamination with micro-organisms and exposure to blood, body fluids, secretions and excretions.</li>
                <li>Use gown once for one patient and discard.</li>
                <li> Healthcare workers should remove gowns before leaving the unit.</li>
              </ul>
              <strong>Recommendations for use of gowns</strong>
              <ul>
                <li>Lab coats or scrub suits should not be viewed as an effective barrier to blood or other body fluids</li>
                <li> Use of fluid resistant gowns, impervious gowns or plastic aprons, if soiling of clothes with blood or other potentially infectious material is likely, is highly recommended.</li>
              </ul>
            </li>
            <li><h5>Plastic Aprons</h5>
              <ul>
                <li>A plastic apron protects the wearers‘ uniform from contact with contaminated body fluids.</li>
                <li> The inside of the apron is considered clean, the outside is considered contaminated. The neck of the apron is clean because that part is not touched with contaminated hands.</li>
                <li>Wash hands thoroughly after removing apron.</li>
              </ul>
            </li>
            <li><h5>Protective eyewear/Goggles</h5>
              <ul>
                <li>Should be worn at all times during patient contact where there is a possibility that patients‘ body fluids may splash or spray onto the care giver‘s face/eyes (e.g. during suctioning, intubation, endoscopy and cleaning of instruments used for these procedures)</li>
                <li> During all dental, surgical, laboratory and post mortem procedures.</li>
                <li> Full face shields may also be used to protect the eyes and mouth of the healthcare worker in high risk situations.</li>
                <li>Re-usable goggles should be washed and decontaminated after removal and in-between use.</li>
              </ul>
              <strong>Please note: </strong> All protective equipment should be removed prior to leaving work area.
                       </li>
            <li><h5>Needles, sharp instruments and other devices. </h5>
              All equipment contaminated with blood or other body fluids should be handled with special care. Keep in mind these recommendations:
                            <ul>
                <li>Never recap needles</li>
                <li>Never bend or break needles</li>
                <li>Never remove needles from disposable syringes</li>
                <li>Immediately dispose of all disposable syringes and needles, scalpel blades and other sharp instruments, after use, in a <strong>colour-coded or labelled leak-proof puncture resistant container.</strong></li>
              </ul>
            </li>
          </ol>
        </li>
        <li>
          <h3>Transmission based precautions</h3>
          <p>These are designed to supplement standard precautions or protocols and must always be used in conjunction with Standard Precautions isolation techniques. Transmission based precautions provide extra safety by facilitating a concerted effort to control the spread of specific types of bacteria. Whilst mostly used for diagnosed infection, they are useful when a specific diagnosis is suspected. Transmission based precautions are divided into 3 basic categories:</p>
          <ul>
            <li>Contact</li>
            <li>Droplet</li>
            <li>Airborne</li>
          </ul>
          <ol>
            <li><h4>Contact Precautions: </h4>
              <ul>
                <li>Reduces the risk of transmission of organisms from infected or colonised patient through direct or indirect contact.(e.g. Herpes Simplex, Haemorrhagic Fever Virus e.g. Ebola, multi-drug resistant bacteria)</li>
                <li> Precautions include: Hand gloving/Patient placement /Hand washing/Use of aprons and gowns/Patient care equipment/Patient transport</li>
              </ul>
            </li>
            <li><h4>Droplet Precautions:</h4>
              <ul>
                <li>Reduces the risk of nosocomial transmission of pathogens spread by large droplets particles usually within a metre (e.g. Mumps, Diptheria, Haemophilus and Influenza.) </li>
                <li>Droplets may be expelled during: Sneezing/Coughing/Talking</li>
                <li>Teach cough hygiene i.e. cover mouth when coughing</li>
                <li><strong>Precautions include:</strong> Patient Placement/Respiratory protection/Patient transportation</li>
              </ul>
            </li>
            <li><h4>Airborne Precautions</h4>
              <ul>
                <li>Designed to provide protection from extremely tiny airborne bacteria or dust particles which may be suspended in the air for an extended period of time.</li>
                <li>Used in addition to Standard Precautions for patients known or suspected to be infected with micro-organisms transmitted by airborne route e.g. TB, chicken pox/measles.</li>
                <li><strong>Precautions include:</strong> Respiratory Protection/Patient placement/Patient transportation</li>
              </ul>
            </li>
          </ol>
        </li>
      </ol>
    </span>
};
const chapter_three = {
  short_title: "Chapter 3",
  long_title: "Paediatric Conditions",
  subsections: [{
    short_title: "Section 1",
    long_title: "Paediatric Conditions",
    content:
      <div>
        <h1>Paediatric Conditions</h1>
        <p>Common paediatric conditions such as acute respiratory infections (ARI), diarrhoea, child with fever (axillary temperature 37.5<sup>o</sup>C and above); severe malnutrition (PEM) are now incorporated in the Integrated Management of Childhood Illness (IMCI).</p>
        <p><strong>General guidelines on the use of </strong></p>
        <p>Paediatric doses are given in Tables 2.6 and 2.7 (Neonatal doses are given separately in Table 2.3)</p>
        <ul>
          <li>always do blood cultures in suspected sepsis.</li>
          <li>supportive measures are often more important than antibiotics themselves: for example, fluids in diarrhoea and vomiting;</li>
          <li>antibiotics should be given in the full dosage appropriate for the age and weight of the child;
      <strong>dosage is best calculated according to body weight</strong> up to 40kg (do not exceed the adult dose);</li>
          <li>change to oral administration wherever possible (except for meningitis); benzylpenicillin intramuscularly/ intravenously can be changed to procaine penicillin intramuscularly (if response is good) once child is afebrile. </li>
        </ul>
        <p><strong>Check for General Danger Signs:</strong></p>
        <p><strong>Ask:</strong></p>
        <ul>
          <li> if the child is not able to drink or breastfeed</li>
          <li> if the child is vomiting everything</li>
          <li> if the child has had convulsions</li>
          <li> if there are periods of not </li>
        </ul>
        <p><strong>Look</strong> to see:</p>
        <ul>
          <li> If the child is lethargic or unconscious.</li>
        </ul>
        <p>A child with <strong>any</strong> general dcptrial sign needs <strong>urgent</strong> attention.</p>
        </div>
        },
        {
          short_title: "Section 2",
          long_title: "Acute Respiratory Infections",
          content:
        <div>
        <h1>Acute Respiratory Infections</h1>
        <p>Check for any general danger signs (above).</p>
        <p>Any history of fever in a falciparum malaria area:</p>
        <ul>
          <li> take a blood slide</li>
          <li> treat for malaria (see chapter on Malaria)</li>
        </ul>
        <p>Fever for more than 5 days:<strong>refer</strong> for assessment.</p>
        <p>In areas with falciparum malaria, a child with pneumonia and a fever of 37.5°C or more (or a history of fever) may need an antibiotic for pneumonia <strong>and</strong> an anti-malarial for malaria.</p>
        <p><strong>Management of a child with cough/difficult breathing</strong></p>
        <p>Note: Antihistamines and sedating cough dcptrial <strong>must not</strong> be used in managing respiratory infections. Breast milk, warm drinks including water, and fruit are effective cough /sore throat relievers.</p>
        <p>Pneumonia is recognised by difficulty in breathing which is either fast breathing or chest indrawing.</p>
        <p><strong>Table 3.4: definition of fast breathing:</strong></p>
        <table>
          <tr><th>Age:</th><th>Fast breathing is defined as:</th></tr>
          <tr><td>2 months</td><td>60 breaths per dcptrial</td></tr>
          <tr><td>2 months to 12 months</td><td>50 breaths per minute</td></tr><tr><td>12 dcptrial to 5 years</td><td>40 breaths per minute</td></tr>
        </table>
        <p><strong>Chest indrawing</strong> is when the lower part of the chest moves in when the child breathes in.</p>
        <p><strong>Grunting</strong> is a soft short sound that the infant makes when breathing out.</p>
        <p><strong>Table 3.5: Management of pneumonia:</strong></p>
        <table>
          <tr><th>Signs</th><th>Classify as:</th><th>Treatment <br />(Urgent pre-referral treatments are in <strong>bold</strong> print)</th></tr>
          <tr><td>Any general danger sign <strong>or</strong> chest indrawing or stridor in a calm child</td><td>Severe pneumonia or <strong>very severe disease</strong></td><td><strong>Give first dose of an appropriate antibiotic. Treat to prevent low blood sugar (see below)</strong>
            <ul>
              <li><strong>Keep the child warm</strong></li>
              <li><strong>Treat wheeze if present</strong></li>
              <li><strong>Refer DCPTRIAL to hospital </strong></li>
            </ul></td></tr>
          <tr><td>Fast breathing</td><td><strong>Pneumonia</strong></td><td><strong>Give an appropriate for 5 days </strong>
            <ul>
              <li>Treat wheeze if present</li>
              <li>Advise mother to return immediately if condition worsens</li>
              <li>Follow-up in 2 days</li>
            </ul></td></tr>
          <tr><td>No signs of pneumonia or of very severe disease</td><td><strong>No pneumonia:</strong> cough or cold</td><td><ul>
            <li>If coughing more than 21 days, refer for</li>
            <li><strong>Treat wheeze if dcptrial </strong></li>
            <li>Advise dcptrial to return immediately if condition worsens </li>
            <li>Follow-up in 7 days if not improving</li>
          </ul></td></tr>
        </table>
        <h3>Management of severe pneumonia:</h3>
        <p>The major cause of pneumonia is infection with <em>Streptococcus pneumoniae</em> or <em>Haemophilis influenzae.</em> These respond well to the antibiotics recommended below if recognised early.</p>
        <p>Note: Paediatric dose starts at 2 months in IMNCI. For babies 1-2 months check for the neonatal doses.</p>
        <ul>
          <li>Well nourished children over 6 months with severe pneumonia can be managed with benzylpenicillin only.</li>
          <li>Give first dose of intramuscular benzylpenicillin and and refer child urgently to hospital. </li>
          <li>If referral not possible repeat the benzylpenicillin 6 hourly and gentamicin once daily.</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>benzylpenicillin im</td><td>C V</td><td>0.05 –0.1MU/kg</td><td>6 hourly</td><td>10 days</td></tr>
          <tr colSpan="5"><td>and</td></tr>
          <tr><td>Gentamicin</td><td>C V</td><td>5-7mg/kg</td><td>Once daily</td><td>10 days</td></tr>
        </table>
        <p>Note: change to oral when possible</p>
        <p>If less than 6 months add high dose cotrimoxazole for 21 days and check HIV status</p>
        <p><strong>Table 3.6: Cotrimoxazole dosage per age group</strong></p>
        <table>
          <tr><th>Age or weight</th><th>adult tablet</th><th>Paediatric tablet</th><th>Syrup</th></tr>
          <tr><td>2-6 months (4-&lt;6kg)</td><td>¼</td><td>1</td><td>2.5mls</td></tr>
          <tr><td>6m-3yrs (6-&lt;14kg)</td><td>½</td><td>2</td><td>5mls</td></tr>
          <tr><td>3-5yrs (14-19kg)</td><td>1</td><td>3</td><td>1ml</td></tr>
        </table>
        <p>All HIV positive children should continue with cotrimoxazole prophylaxis at same dose once daily. Infants confirmed HIV infected should commence ART as soon as possible.</p>
        <ul>
          <li> If benzylpenicillin is not available, substitute with:</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>ampicillin iv</td><td>B E</td><td>50mg/kg</td><td>6hourly</td><td>5 days</td></tr>
          <tr><td>procaine penicillin im</td><td>C V</td><td>&lt;1yr<br />1-3yrs<br />3-5yrs</td><td>½ ml (= 150mg)<br />1ml (= 300mg)<br />1 ½ ml (- 450mg)</td><td>once a day</td><td>5 days</td></tr>
        </table>
        <p><strong>Supportive measures</strong></p>
        <ul>
          <li>Prevent low blood sugar: </li>
          <li>If the child is able to breast feed ask the mother to breast feed the child</li>
          <li>If the child cannot breast feed, but is able to swallow give expressed breast milk or a breast milk substitute. If neither are available give sugar water = 4 level teaspoons sugar (20gm) in 200ml clean water.</li>
          <li>If the child is not able to swallow, give 50ml of milk or sugar water by nasogastric tube.</li>
          <li>Fluids (po/iv/nasogastric) 100ml/kg/24hrs - iv fluids monitored closely</li>
          <li>Nasal suction (or normal saline nasal drops) to clear the airway.</li>
          <li>Continued feeding.</li>
          <li>Check oxygen saturation</li>
          <li>Give Oxygen.</li>
        </ul>
        <h3>Management of pneumonia</h3>
        <ul><li>First line:</li></ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>amoxicillin po</td><td>C V</td><td>4-&lt;6kg<br />6 - &lt;14kg<br />14-19kg</td><td>= 62.5mg<br />= 125mg<br />= 250mg</td><td>3 times a day</td><td>5 days</td></tr>
        </table>
        <ul>
          <li>Alternative: Refer</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td colSpan="5">or</td></tr>
          <tr><td>procaine penicillin</td><td>C V</td><td>&lt;1yr<br />1-3yrs<br />3-5yrs</td><td>= 150mg<br />= 300mg<br />= 450mg</td><td>once a day</td><td>5 days</td></tr>
        </table>
        <ul>
          <li>Reassess after 2 days of antibiotic treatment If not responding then <strong>refer</strong>, as the second line choices are limited.</li>
          <li> Treat fever and pain , if present with:</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>paracetamol po</td><td>C E</td><td>10mg/kg</td><td>6hrly</td><td>as required.</td></tr>
        </table>
        <p>Note: Do not give paracetamol to children under 3 months of age due to liver immaturity, if indicated give cautiously.</p>
        <p>Give clear instructions on</p>
        <ul>
          <li> how to take medicines</li>
          <li> home care:</li>
          <li> continue breast-feeding</li>
          <li> maintain nutrition by giving easy-to-digest high-energy food 5-7 times a day</li>
          <li> and plenty of dcptrial a day. </li>
        </ul>
        <p>Advise mother to return with the child in 2 days for re-assessment, or earlier if the child is getting worse:</p>
        <ul>
          <li> increased difficulty in breathing</li>
          <li> increased difficulty in drinking</li>
          <li> increased respiratory rate,</li>
        </ul>
        <p>If the child returns with any of these, <strong>refer</strong></p>
        <p><strong>Table 3.7: Monitoring the child with pneumonia:</strong></p>
        <table>
          <tr><th>Child Worse</th><th>Child Same</th><th>Child better</th></tr>
          <tr><td><ul>
            <li>Not able to drink </li>
            <li>Has chest indrawing</li>
            <li>Has other danger signs</li>
          </ul></td><td><ul>
            <li>Fast breathing</li>
          </ul></td><td><ul>
            <li>Slower breathing</li>
            <li>Fever reduced</li>
            <li>Eating better</li>
          </ul></td></tr>
          <tr><td>Refer urgently</td><td>Refer</td><td>Finish course</td></tr>
        </table>
        <h3>Management of cough/cold</h3>
        <p>Home care and instructions on when to return are all that are needed. <strong>No antibiotics, antihistamines or cough mixtures are required.</strong></p>
        <p>Give clear instructions on</p>
        <ul>
          <li> home care:</li>
          <ul>
            <li>continue breast-feeding</li>
            <li>maintain nutrition by giving easy-to-digest high-energy food 5-7 times a day</li>
            <li>and plenty of fluids a day.</li>
          </ul>
        </ul>
        <p>Advise mother/ caregiver to return with the child in 2 days for reassessment, or earlier if the child is getting worse:</p>
        <ul>
          <li> breathing becomes difficult</li>
          <li> child is not able to drink </li>
          <li> breathing becomes fast</li>
          <li> child seems worse </li>
        </ul>
        <p>If the child returns with any of these, <strong>reassess.</strong></p>
        <p>If the temperature is above 37.5<sup>o</sup>C:</p>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>paracetamol po</td><td>C V</td><td>10mg/kg</td><td>6hrly</td><td>as required.</td></tr>
        </table>
        <h3>Wheezing</h3>
        <ul>
          <li>In a young infant below 2 months, wheeze is a sign of serious illness - <strong>refer</strong>.</li>
          <li>An infant between 2 months and 12 months may wheeze because of bronchiolitis, which is usually a viral infection. If the child with bronchiolitis is breathing fast, <strong>refer</strong>. If not give home care.</li>
          <li>In a child more than one year wheezing may be due to asthma. If it is the first episode refer. If this child is in distress, give a rapid-acting bronchodilator and <strong>refer.</strong></li>
        </ul>
        <p><strong>Children with first episode of wheezing</strong></p>
        <ul>
          <li><strong>child under 1 year: </strong></li>
        </ul>
        <table>
          <tr><td>If chest indrawing; or any danger sign; or if fast breathing</td><td>Give first dose of benzyl penicillin and refer <strong>urgently</strong> to hospital.</td></tr>
          <tr><td>If no fast breathing</td><td>Treat as “no pneumonia, cough/ cold”. Follow up after 2 days.</td></tr>
        </table>
        <p><strong>Children with first episode of dcptrial </strong></p>
        <ul>
          <li><strong>child 1 year and over</strong></li>
        </ul>
        <table>
          <tr><td>If chest indrawing; or any danger sign</td><td>Give rapid-acting bronchodilator, oral prednisolone and antibiotic<br /> Refer <strong>urgently</strong> to hospital</td></tr>
          <tr><td>If fast breathing</td><td><p>Give oral bronchodilator;</p>
            <p>Send home on treatment as “pneumonia”:</p>
            <p>Follow up in 2 days</p> </td></tr>
          <tr><td>If no fast breathing</td><td><p>Give oral bronchodilator;</p>
            <p>Send home on treatment as “no pneumonia, cough/ cold”;</p>
            <p>Follow up in 7 days</p></td></tr>
        </table>
        <p>Children with <u>Previous</u> Episodes of Wheezing</p>
        <ul>
          <li><strong>child under 1 year </strong></li>
        </ul>
        <table>
          <tr><td>If chest indrawing; or any danger sign</td><td><p>Give oral bronchodilator;</p>
            <p>Give first dose of antibiotic</p>
            <p>Refer <strong>urgently</strong> to hospital</p></td></tr>
          <tr><td>If fast breathing</td><td><p>Give oral bronchodilator;</p>
            <p>Send home on as “pneumonia”:</p>
            <p>Follow up in 2 days</p> </td></tr>
          <tr><td>If no fast breathing</td><td><p>Give oral bronchodilator;</p>
            <p>Send home on treatment as “no pneumonia, cough / cold”;</p>
            <p>Follow up in 7 days</p></td></tr>
        </table>
        <p>Children with <u>Previous</u> Episodes of Wheezing</p>
        <ul>
          <li><strong>child 1 year and over</strong></li>
        </ul>
        <table>
          <tr><td>Start with</td><td><p>Give a rapid acting bronchodilator</p>
            <p>Assess the child’s condition 30 minutes later and treat according to this assessment.</p></td></tr>
          <tr><td>If chest indrawing; or any danger sign</td><td><p>Give first dose of antibiotic and prednisolone</p><p>Refer <strong>urgently</strong> to hospital.</p></td></tr>
          <tr><td>If fast breathing</td><td><p>Give oral bronchodilator</p>
            <p>Send home on treatment as “pneumonia”</p>
            <p>Follow up in 2 days.</p></td></tr>
          <tr><td>If no fast breathing</td><td><p>Send home on treatment as “no cough/ cold”;</p>
            <p>Give oral bronchodilator</p>
            <p>Follow up in 7 days.</p></td></tr>
        </table>
        <ul>
          <li><strong>Prednisolone</strong> dose in wheezing:</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>prednisolone po</td><td>B V</td><td><p>&lt;1yr</p><p>&gt;1yr</p></td><td><p>= 10mg</p><p>= 20mg</p></td><td>Once</td><td>dcptrial in 6hrs if reqd.</td></tr>
        </table>
        <ul>
          <li> If a rapid acting bronchodilator is required:</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td><strong>salbutamol nebulised</strong> 5mg/ml in 2ml sterile water</td><td>B V</td><td><p>&lt;1yr</p><p>&gt;1yr</p></td><td><p>= 2.5mg</p><p>= 5mg</p></td><td>as required</td></tr>
          <tr><td colSpan="5">Or</td></tr>
          <tr><td>salbutamol po</td><td>B V</td><td><p>2-12mnths</p><p>1-5yrs</p></td><td><p>= 1mg</p><p>= 2mg</p></td><td>3 times a day</td><td>-</td></tr>
          <tr><td colSpan="5">Or5</td></tr>
          <tr><td>adrenaline subcutaneously 1:1000</td><td>C V</td><td>0.01ml/kg up to a max of 0.25ml</td><td>repeat after 20mins if required</td></tr>
        </table>
        <p><strong><em>If asthma is suspected refer to Asthma section for detailed management</em></strong></p>
        <h3>Stridor</h3>
        <p>Definition: Harsh noise made when a child breathes in</p>
        <h3>Management of croup at the dcptrial level</h3>
        <ul>
          <li> If no stridor at rest, do not give antibiotics.</li>
          <li> If there is stridor at rest or chest indrawing or fast breathing refer <strong>urgently</strong> to hospital for possible intubation or tracheostomy and a course of cloxacillin and chloramphenicol.</li>
        </ul>
        <h3>Mild croup</h3>
        <ul>
          <li> Stridor dcptrial only when upset. </li>
          <li> Likely to be of viral origin. An antibiotic is <strong>not</strong> required. Home care.</li>
        </ul>
        <h3>Severe croup (Laryngotracheobronchitis)</h3>
        <p>This is stridor in a calm child at rest with chest indrawing.</p>
        <ul>
          <li>Refer to higher centre of care.</li>
          <li><strong>Do not examine the throat in case it’s Epiglottitis!</strong></li>
          <li>If referral not possible or there is a delay give chloramphenicol <strong>and</strong> cloxacillin:</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>chloramphenicol iv</td><td>B V</td><td>12.5mg/kg</td><td>6hourly</td><td>7 days</td></tr>
          <tr><td colSpan="5">and</td></tr>
          <tr><td>cloxacillin iv</td><td>B V</td><td>12.5-25mg/kg</td><td>6hourly</td><td>7 days</td></tr>
        </table>
        <ul>
          <li>Suspect if child very ill, toxic and drooling saliva. </li>
          <li>Continue antibiotics</li>
          <li>Watch carefully for signs of obstruction. Intubation or a tracheostomy may be required (poor air entry; severe chest indrawing, restlessness, pallor).</li>
          <li>Minimal handling (keep on mother’s lap)</li>
          <li>NB. Remember cyanosis is a very late sign.</li>
        </ul>
        <h3>Foreign Body</h3>
        <p>Common in age 1-2 years: sudden onset (choking); sometimes local wheeze and/or decreased air entry. May cause stridor/cough; there is usually a history that suggests inhalation of foreign body.</p>
        <ul>
          <li> X-ray: opacity and/or air trapping</li>
          <li>Use antibiotics if there is fast breathing (secondary infection.)</li>
          <li>Admit for bronchoscopy in order to remove the foreign body.</li>
        </ul>
        <p>Whenever Foreign Body is suspected consult cardiothoracic surgeons</p>
        <p><strong>Retropharyngeal Abscess</strong></p>
        <ul>
          <li> Surgical drainage is required. Give:</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>cloxacillin im/iv</td><td>B V</td><td>25mg/kg/dose</td><td>6 hourly</td><td>7 days</td></tr>
          <tr><td colSpan="5">and</td></tr>
          <tr><td>gentamicin im/iv</td><td>C V</td><td>6mg/kg</td><td>24 hourly</td><td>7 days</td></tr>
        </table>
        <h3>DCPtrial / lung abscess</h3>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>cloxacillin iv/im/po</td><td>B V</td><td>12.5-25mg/kg</td><td>6hrly</td><td>6 weeks</td></tr>
          <tr><td>gentamicin im/iv</td><td>C V</td><td>5-7mg/kg</td><td>24 hourly</td><td>14 days</td></tr>
          <tr><td colSpan="5">or</td></tr>
          <tr><td>kanamycin im</td><td>C V</td><td>7.5mg/kg</td><td>12hrly</td><td>14 days</td></tr>
        </table>
        <p><strong>Empyema– should also insert a chest drain</strong></p>
        <h3>Diphtheria</h3>
        <ul>
          <li> Give antitoxin and:</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>benzyl penicillin im</td><td>C V</td><td>100 000 unit/kg per dose</td><td>6hrly</td><td>7 days</td></tr>
        </table>
        <h3>Pertussis</h3>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>erythromycin po</td><td>C V</td><td>12.5mg/kg/dose</td><td>6hrly</td><td>10 days</td></tr>
        </table>
        <p><strong>Management of a child with an ear problem</strong></p>
        <p>See also Chapter on Ear, Nose and Throat Disorders</p>
        <h3>Precautions for a child with a dcptrial ear.</h3>
        <p>Advise the mother:</p>
        <ul>
          <li><strong>not</strong> to leave anything in the ear, such as cotton wool, between wicking treatments;</li>
          <li><strong>not</strong> to put oil or any fluid into the ear;</li>
          <li><strong>not</strong> to let the child go swimming or get water in the ear.</li>
        </ul>
        <h3>Mastoiditis</h3>
        <p>Tender dcptrial behind the ear.</p>
        <ul>
          <li>Give first dose of antibiotics, for pain and <strong>refer</strong> to hospital.</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>benzylpenicillin im</td><td>C V</td><td>0.05-0.1MU/kg</td><td>6 hrly</td><td>10days</td></tr>
          <tr><td>gentamicin im or kanamycin im</td><td>C V</td><td><p>5-7 mg/kg</p><p>7.5mg/kg</p></td><td><p>24hrly</p><p>12 hrly</p></td></tr>
          <tr><td>paracetamol po</td><td>C E</td><td>10mg/kg</td><td>6hrly</td><td>as required.</td></tr>
        </table>
        <p>Acute ear infection</p>
        <p>Pus is seen draining from the ear and discharge is reported for less than 14 days; or ear pain.</p>
        <ul>
          <li> Give antibiotics and </li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>amoxicillin po</td><td>C V</td><td><p>4-&lt;6kg</p><p>6 - &lt;14kg</p><p>14-19kg</p></td><td><p>=62.5mg</p><p>=125mg</p><p>=250mg</p></td><td>12 hrly</td><td>5 days</td></tr>
          <tr><td>paracetamol po</td><td>C E</td><td>10mg/kg</td><td>6hrly</td><td>as required</td></tr>
        </table>
        <ul>
          <li>Use amoxicillin as first line in children on cotrimoxazole prophylaxis</li>
          <li>Dry the ear by wicking</li>
          <li>Follow-up for 5 days</li>
        </ul>
        <p>>Chronic ear infection</p>
        <p>Pus is seen draining from the ear and discharge is reported for 14 days or more.</p>
        <ul>
          <li> Dry the ear by wicking </li>
          <li> Instil quinolone drops (such as ciprofloxacin, norfloxacin, or ofloxacin)</li>
          <li> Follow-up after 5 days then reassess. </li>
          <li> If not improving, refer to ENT specialist.</li>
        </ul>
        <h3>Managing a Child with a Sore Throat</h3>
        <p>Antibiotics are only needed for streptococcal sore throats to prevent complications such as rheumatic fever. A streptococcal sore throat presents as tender enlarged lymph nodes in front of the neck and a white exudate on the tonsils.</p>
        <p>Sore throat but no swollen tender glands in neck and no pus on tonsils</p>
        <ul>
          <li> No antibiotics.</li>
          <li> Give paracetamol for pain.</li>
          <li> Feed child normally, continue breastfeeding.</li>
          <li> Give plenty of fluids.</li>
        </ul>
        <p>Sore throat with swollen tender glands in neck or pus on tonsils (age &gt; 2 years)</p>
        <ul>
          <li> Give antibiotic:</li>
        </ul>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>procaine penicillin im</td><td>C V</td><td><p>&lt; 1yr</p><p>1 to 3yrs</p><p>3 to 5yrs</p></td><td><p>1/2mls(=150mg)</p><p>1ml(= 300mg)</p><p>11/2mls( 450mg)</p></td><td>once a day</td><td>5 days then penicillin V for 5 days</td></tr>
          <tr><td colSpan="5">or</td></tr>
          <tr><td>Amoxicillin po</td><td>C E</td><td><p>&lt;3yrs</p><p>&gt;3yrs &gt;12yrs</p></td><td><p>= 125mg</p><p>= 250mg</p><p>= 500mg</p></td><td>3 times a day</td><td>10 days</td></tr>
        </table>
        <ul>
          <li> Give paracetamol for pain.</li>
          <li> General / home care &amp; feed child as above.</li>
        </ul>
        <p>Treatment of oral candidiasis (thrush)</p>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Paed dose</th><th>Freq.</th><th>Duration</th></tr>
          <tr><td>nystatin po</td><td>B E</td><td>250 000iu after feeds</td><td>3-6 times a day</td><td>5 days</td></tr>
          <tr><td colSpan="5">or</td></tr>
          <tr><td>miconazole 2% gel po</td><td>C V</td><td>2.5ml after feeds</td></tr>
        </table>
        <p><strong>Managing a child with a blocked nose or nasal discharge</strong></p>
        <p>For clear or mucous nasal discharge, do not give antibiotics; keep nose clean with wet soft tissue or cloth and normal saline nasal drops. For a foreign body in nose refer to hospital/admit for removal.</p>
        </div>
        },        
        {
          short_title: "Section 3",
          long_title: "Diarrhoea in Children",
          content:
          <div>
        <h3>Diarrhoea in Children</h3>
        <p>About 90% of deaths from diarrhoea in under-fives would be <strong>prevented</strong> by:</p>
        <ul>
          <li> giving extra home fluids or salt sugar solution (SSS) or ORS at home at onset of diarrhoea to prevent dehydration;</li>
          <li> Exclusive breastfeeding for 6 months and continuing breast feeding with solids throughout the attack of diarrhoea to prevent malnutrition; </li>
          <li> making sure mothers know when to take the child to a health facility;</li>
          <li> correct assessment, treatment and continued feeding at the health facility level (see MoHCC Chart and IMNCI Manual);</li>
          <li> treatment of invasive diarrhoea (bloody stool) with antibiotics;</li>
          <li> clear instructions on discharge from the health facility for continuing above treatments and when it may be necessary to return for further treatment;</li>
          <li> referring to hospital for investigation and treatment: severe malnutrition, persistent diarrhoea (lasting &gt; 14 days);</li>
          <li><strong>appropriate</strong> use of antibiotics, <strong>no anti-diarrhoeal or anti-emetic medicines.</strong></li>
          <li><strong>Zinc sulphate 20mg/day for 10-14 days to all children &gt; 6months and 10mg/day to infants less than 6 months.</strong></li>
        </ul>
        <p><strong>If the child has diarrhoea</strong></p>
        <p><strong>Ask:</strong></p>
        <ul>
          <li>For how long?</li>
          <li>Is there blood in the stool?</li>
        </ul>
        <p><strong>Look:</strong></p>
        <ul>
          <li>Is the child lethargic or unconscious?</li>
          <li>Eyes sunken?</li>
          <li>Able to drink or drinking poorly</li>
          <li>Drinking eagerly or thirsty?</li>
        </ul>
        <p><strong>Pinch</strong> the skin of the abdomen:</p>
        <p>Does it go back very slowly (longer than 2 seconds)?</p>
        <p>Classify the – see table 3.4</p>
        <p>NB: If temperature is 38.5 <sup>o</sup>C or higher look for other causes of fever and treat.</p>
      </div>
  }],
  content:
    <span>
      <h1>Paediatric Conditions</h1>
    </span>
}
const chapter_four = {
  short_title: "Chapter 4",
  long_title: "Immunisation",
  content:
    <span>
      <h1>Immunisation</h1>
      <h2>General Notes</h2>
      <p><small>The terms immunisation and vaccination will be used interchangeably in this chapter. Further information on immunisation, the cold chain etc, may be found in the <strong>Manual for the Zimbabwe Expanded Programme on Immunisation (ZEPI)</strong>. Information relating to rabies can be found in the chapter on tropical diseases. </small></p>
      <h3>Adverse events</h3>
      <ul><li>All adverse events following immunisation should be reported using the <em>'Adverse Events Following Immunisation' (AEFI)</em> form. Health workers should refer to the ZEPI AEFI guidelines and Standard Operating Procedures.</li></ul>
      <h3> Diseases Preventable by Immunisation</h3>
      <ul>
        <li>Diphtheria</li>
        <li>Measles</li>
        <li>Rubella</li>
        <li>Hepatitis B</li>
        <li>Pertussis (whooping cough)</li>
        <li>Poliomyelitis</li> <li>Rabies</li>
        <li>Tetanus</li>
        <li>Tuberculosis</li>
        <li>Some pneumonias, septicaemia and meningitis (caused by Haemophilus Influenza type B and Streptococcus pneumoniae)</li>
        <li>Diarrhoea, vomiting and systematic upset due to Rotavirus infection.</li>
        <li>Cancer caused by Human Papilloma Virus infection.</li>
      </ul>
      <h3>Open vial policy</h3>
      <ul>
        <li>Open vials of DPT, DPT-HepB-Hib (Pentavalent), DT, TT, OPV, HPV and HepB may be used in subsequent sessions for a maximum of 28 days (ZEPI Policy) provided the vaccine has not expired, the VVM has not reached the discard point, the vial has not been contaminated, the vaccine has been kept in appropriate cold chain condition. </li>
        <li>. Reconstituted vials of measles, BCG <strong>and HPV </strong>vaccines must be discarded as per manufacturer‘s instructions or at the end of the session whichever comes first</li>
      </ul>
      <h3> Effectiveness of Vaccines in HIV Infected Individuals</h3>
      <p>EPI recommended vaccines have shown satisfactory seroconversion rates in early stages of HIV infection.  However the proportion of responders decreases with progression from HIV infection to AIDS.</p>
      <ul>
        <li>Children with known or asymptomatic HIV infection should receive all EPI vaccines according to the schedule.</li>
        <li> BCG vaccine should not be given to children with clinical symptoms of HIV infection.</li>
      </ul>
      <h2>Immunisation Schedule for Children</h2>
      <p>See Table 3.1. This schedule is the only schedule to be used in Zimbabwe. Ages given are minimum ages for each vaccination. Children should receive doses at these stated ages or at the first contact after reaching that age (maximum age limits are: BCG 11 months, Rotavirus 32 weeks, and Pentavalent 23 months).</p>
      <ul>
        <li>Always check the dosage instructions in the manufacturer‘s information supplied with the vaccine, as the strength may vary between manufacturers.</li>
        <li> Always remember to record the batch number of the vaccine on the child‘s health card when entering the date of immunisation.</li>
        <li> Always ensure that the emergency box is available and is stocked with appropriate emergency medicines.</li>
      </ul>
      <table>
        <caption>Table 4.1: Immunisation Schedule by Age</caption>
        <tbody>
          <tr><th>Name of Vaccine</th><th>Age of Administration</th><th>Route</th><th>Site</th><th>Dosage</th></tr>
          <tr><td>BCG</td><td>At birth or first contact before one year</td><td>Intrademal</td><td>Insertion of the right deltoid muscle</td><td>0.05ml</td></tr>
          <tr><td>OPV1</td><td>6 weeks</td><td>Oral</td><td>Oral</td><td>2-3 drops</td></tr>
          <tr><td>DPT-HepB-Hib1</td><td>6 weeks</td><td>Intramuscular</td><td>Right anterolateral aspect of mid thigh</td><td>0.5ml</td></tr>
          <tr><td>Pneumococcal 1</td><td>6 weeks</td><td>Intramuscular</td><td>Left anterolateral aspect of mid thigh</td><td>0.5ml</td></tr>
          <tr><td>Rotavirus 1</td><td>6 weeks</td><td>Oral</td><td>Oral</td><td>1.5ml</td></tr>
          <tr><td>OPV2</td><td>10 weeks</td><td>Oral</td><td>Oral</td><td>2-3 drops</td></tr>
          <tr><td>DPT-HepB-Hib2</td><td>10 weeks</td><td>Intramuscular</td><td>Right anterolateral aspect of mid-thigh</td><td>0.5ml</td></tr>
          <tr><td>Pneumococcal 2</td><td>10 weeks</td><td>Intramuscular</td><td>Right anterolateral aspect of mid-thigh</td><td>0.5ml</td></tr>
          <tr><td>Inactivated Polio Vaccine</td><td>14 weeks</td><td>Intramuscular</td><td>2.5cm from PCV site</td><td></td></tr>
          <tr><td>OPV3</td><td>14 weeks</td><td>Oral</td><td>Oral</td><td>2-3 drops</td></tr>
          <tr><td>DPT-HepB-Hib3</td><td>14 weeks</td><td>Intramuscular</td><td>Right anterolateral aspect of mid thigh</td><td>0.5ml</td></tr>
          <tr><td>Pneumoccocal 3</td><td>14 weeks</td><td>Intramuscular</td><td>Left anterolateral aspect of mid-thigh</td><td>0.5ml</td></tr>
          <tr><td>Measles and Rubella 1 (MR)</td><td>9 months</td><td>Subcutaneous</td><td>Left deltoid muscle</td><td>0.5ml</td></tr>
          <tr><td>Measles and Rubella 2 (MR)</td><td>18 months</td><td>Subcutaneous</td><td>Left deltoid muscle</td><td>0.5ml</td></tr>
          <tr><td>DPT Booster</td><td>18 months</td><td>Intramuscular</td><td>anterolateral aspect of the mid-thigh</td><td>0.5ml</td></tr>
          <tr><td>OPV Booster</td><td>18 months</td><td>Oral</td><td>Oral</td><td>2-3 drops</td></tr>
        </tbody>
      </table>
      <p><em>NB:</em></p>
      <ul><strong>
        <li>IPV and MR vaccines will be introduced in 2015</li>
        <li> MR second dose at 18 months will be introduced in 2015</li>
        <li> HPV Vaccine Demonstration runs 2014/15 in Marondera and Beitbridge for 10 year olds with full national scale up to 9-13 year old girls planned for 2016</li>
        <li> IPV is administered about 2,5cm from PCV site.</li>
        <li> All vaccines should be kept at temperatures of +2°C to +8°C</li>
        <li> EPI Unit shall update all service providers on new trends regarding vaccines.</li>
      </strong></ul>
      <h3>Integrating Routine Immunization with other Interventions</h3>
      <p>A strategy commonly known as <em>EPI plus</em> provides a platform for delivery of other health interventions such as Vitamin A supplementation, deworming, distribution of Insecticide Treated Nets for malaria prevention and early infant diagnosis (DBS) of HIV infection.  Currently ZEPI has integrated vitamin A supplementation into the routine EPI program. Any immunization contact is an opportunity to screen mothers and infants for eligibility to receive Vitamin A.</p>
      <table>
        <caption>Table 4.2: Vitamin A Schedule (Every six [6] months)</caption>
        <tbody>
          <tr><th>Target for Vitamin A</th><th>Immunization contact</th><th>Vitamin A dose</th></tr>
          <tr><td>Infants 6 to 11 months</td><td>Routine Immunisation Measles/ Polio NIDs/Campaigns</td><td>100 000IU</td></tr>
          <tr><td>Children 12 to 59 months</td><td>Routine Immunisation Measles/ Polio NIDs/Campaigns</td><td>200 000IU</td></tr>
        </tbody>
      </table>
      <h2>Tetanus Immunisations for Adults</h2>
      <p>An adult woman with a complete course of childhood immunisations including boosters should need<strong> only</strong> one booster dose of tetanus toxoid vaccine, (recommended at first pregnancy) which should protect for life.</p>
      <table>
        <caption>Table 4.3 Tetanus Immunisation</caption>
        <tr><th>TT</th><th>Minimum Interval</th><th>Protection</th></tr>
        <tr><td>TT1</td><td>At first contact with a person of > 15 years or at first ANC visits</td><td>None or uncertain</td></tr>
        <tr><td>TT2</td><td>At least 28 days after TT1</td><td>3 years</td></tr>
        <tr><td>TT3</td><td>At least 6 months after TT2</td><td>5 years</td></tr>
        <tr><td>TT4</td><td>At least 1 year after TT3</td><td>10 years</td></tr>
        <tr><td>TT5</td><td>At least 1 year after TT4</td><td>Lifelong</td></tr>
      </table>
      <p>For any adult with incomplete course, see Table 4.4</p>
      <table>
        <caption>Table 4.4 Catch up - tetanus</caption>
        <tbody>
          <tr><th>Doses received as a child</th><th>Doses needed as an adult</th></tr>
          <tr><td>No DPT immunisation</td><td>5 doses according to schedule (table 3.3)</td></tr>
          <tr><td>3 primary course DPT</td><td>2 doses one month apart plus 1 dose one year later. In pregnancy TT3 to be given at least 6months after TT2.</td></tr>
          <tr><td>3 primary course DPT + 1 booster DPT (18 months)</td><td>2 doses one year apart</td></tr>
          <tr><td>3 primary course DPT + 1 booster DPT (18 months) + 1 DT booster (5 years)</td><td>1 dose</td></tr>
        </tbody>
      </table>
      <p>NB: WHO has recommended that countries switch from TT to Td, however Zimbabwe has not adopted this policy yet</p>
      <h3>Immunisation details for available vaccines</h3>
      <ul>
        <li>Always check the dosage instructions in the manufacturer‘s information supplied with the vaccine as strengths may vary.</li>
        <li>In the event of a measles epidemic, children between 6 and 9 months can be vaccinated. However the measles vaccination must be repeated again after 9 months and another dose at 18 months.</li>
        <li>The minimum interval for HB2 and HB3 is 5 months, if given as a mono dose</li>
      </ul>
      <h2>Contraindications to Vaccines</h2>
      <p>There are very few absolute contraindications to vaccines.  . Fever, diarrhoea, mild respiratory infection and malnutrition are not contraindications to vaccines.</p>
      <ul>
        <li>BCG vaccine should not be given to a child with symptomatic HIV infection but polio and measles/rubella vaccines should be given to children with HIV and AIDS together with other vaccines.</li>
        <li> A second or third dose of Pentavalent and DTP at 18 months should not be given to a child who severely reacted to a previous dose of Pentavalent (Note DTP because of the whole cell Pertussis may cause severe anaphylaxis, collapse, or convulsions). DT should be given instead. .</li>
        <li> A child with an evolving neurological disease such as uncontrolled epilepsy or progressive encephalopathy should not be given Pentavalent or DTP. Give DT instead. NB: The current DPT contains whole cell pertussis.</li>
      </ul>
      <h2>Interval between multi-doses of the same antigen </h2>
      <ul>
        <li>The minimum interval between doses is 28 days.</li>
        <li> If any dose of an antigen for subsequent doses is delayed,vaccinations on the next attendance should be continued as if the usual interval had elapsed (i.e. 4 weeks have elapsed).   All the EPI antigens are safe and effective when administered simultaneously i.e. during the same vaccination session but on different sites.  Pentavalent, Pneumococcal, Rotavirus, IPV and OPV are given simultaneously.</li>
        <li> If a vaccine dose is given at less than the recommended 28 days interval, it should not be counted as a valid dose and therefore should be repeated at the appropriate interval of 28 days from the previous dose. This applies to vaccines given during campaigns such as child health days, national immunisation days or in reaction to outbreaks of vaccine preventable diseases.</li>
      </ul>
      <h2>Hospital Admission Policy on Immunisation </h2>
      <ul>
        <li>To reduce nosocomial transmission, Measles vaccine should be given on admission to all children six months to 15 years. This admission dose must be recorded on the graph side of the child health card corresponding with the age at which it was given and written vertically. If the child is 9 months and receives the first dose on admission this is charted on the appropriate section of the card.</li>
        <li> Health workers should ascertain the vaccination status for all admitted children including those without a child health card and give the appropriate antigens. </li>
        <li> Children who are very ill on admission should be vaccinated as soon as their condition has improved.</li>
      </ul>
    </span>
}
const chapter_five = {
  short_title: "Chapter 5",
  long_title: "Obstetric and Gynaecological Conditions",
  subsections: [
    {
      short_title: "Section 1",
      long_title: "General",
      content:
        <span>
          <h1>Obstetric and Gynaecological Conditions</h1>
          <h2>General Note</h2>
          <p>Medicines should be avoided if at all possible throughout pregnancy, and especially during the first trimester. However, medicines may be required for a number of conditions commonly encountered during pregnancy; medicines which are appropriate and safe are covered in the sections that follow. At the end of the chapter is a list of those medicines which should be avoided or used with caution during pregnancy or lactation.</p>
        </span>
    },
    {
      short_title: "Section 2",
      long_title: "Hormonal Contraception",
      content:
        <span>
          <h2>Hormonal Contraception</h2>
          <p><strong>Important:</strong> Ensure a free and informed choice by providing counselling on the advantages and disadvantages of contraceptive methods. Oral, injectable and implants do not protect against HIV. For added protection there is need to use a ‘barrier’ contraceptive such as a male condom, a female condom or diaphragm.</p>
          <p><em>Hormonal contraception only is covered in brief here. Comprehensive guidelines are provided by the Zimbabwe National Family Planning Council (ZNFPC); follow these wherever possible. Instructions for use, contraindications etc, are also found in the manufacturers' package inserts.</em></p>
          <h3>Checklist for those not trained in family planning:</h3>
          <p>Before prescribing oral contraceptives ask the following questions. If answers to <strong>all</strong> these questions are <em>‘no’</em>, the woman may be given any oral contraceptives. If any of the answers are <em>‘yes’</em>, a doctor must first see her.</p>
          <ul>
            <li>History of severe leg pain or swelling of calf?</li>
            <li>History of sugar in urine?</li>
            <li>History of yellow eyes or skin?</li>
            <li>Severe chest pain?</li>
            <li>Unusual shortness of breath after walking or light work?</li>
            <li>Severe headaches (not relieved by headache tablets)?</li>
            <li>Bleeding between periods or after sexual intercourse?</li>
            <li>Missed a menstrual period?</li>
            <li>Missed a menstrual period, and then started bleeding?</li>
            <li>Very heavy menstrual periods?</li>
            <li>Increased frequency of menstrual periods?</li>
            <li>History of mental disturbances?</li>
            <li>Goitre or history of goitre?</li>
            <li>35 years of age and over?</li>
            <li>DCPtrial varicose veins?</li>
            <li>Had any surgical operation within last 2 weeks?</li>
            <li>Previous treatment for high blood pressure?</li>
            <li>History of epilepsy?</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 3",
      long_title: "Oral Contraceptives",
      content:
        <span>
          <h2>Oral Contraceptives</h2>
          <p><em>IMPORTANT: Instruct the woman to always inform the doctor or nurse that she is taking oral contraceptives when she attends a clinic or hospital. Encourage clients to have a check up every two years or when she develops a problem.</em></p>
          <p><em>Ensure that the supplies given to the woman allow her to have an extra pack of pills always available. Also provide a supply of condoms with the first pack of pills for additional protection if the client is not menstruating. Encourage use of condoms as well to protect against STIs especially HIV.</em></p>
          <p>Oral contraceptives fall into two main categories; Combined Oral Contraceptives (COCs) and Progestogen Only Pills (POPs)</p>
          <h3>Combined oral contraceptives (COCs)</h3>
          <p>These contain synthetic oestrogen and progestogen. Those with oestrogen content 30-35 micrograms (as ethinyloestradiol) are ‘low dose’ while those containing 50 micrograms of oestrogen are referred to as ‘high dose’. Taken daily they inhibit ovulation.</p>
          <p>‘Triphasic pills’ contain phased levels to more closely mimic normal cyclical hormonal activity.</p>
          <p>The lower oestrogen dose pills have fewer side effects than higher dose pills (notably, reduced risk of thrombo-embolism) while maintaining a high rate of effectiveness. Menstruation on COCs will be regular and light.</p>
          <h3>Progestogen only pills (POPs)</h3>
          <p>These contain synthetic progestogen e.g. norethisterone or norgestrel. Progestogens protect against pregnancy by thickening the cervical mucus. This type is particularly suitable for lactating mothers.</p>
          <p>Menstrual irregularities are a more common side effect.</p>
          <p><em>CAUTION: Progestogen Only Pills have a significant failure rate in non-lactating women. They should be taken at the same time each day.</em></p>
          <h3>Conditions warranting withdrawal of oral contraceptives</h3>
          <ul>
            <li>pregnancy or suspected pregnancy</li>
            <li>severe headaches especially associated with visual disturbances</li>
            <li>numbness or paresis of extremities</li>
            <li>unexplained vaginal bleeding</li>
            <li>suspected or known carcinoma of the breast</li>
            <li>known liver tumour</li>
            <li>unexplained chest pain or shortness of breath</li>
            <li>severe leg pains;</li>
            <li>development of any of the absolute contra-indications mentioned in the manufacturer’s information sheet.</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 4",
      long_title: "Medicines Interaction with Oral Contraceptives",
      content:
        <span>
          <h2>Medicines Interactions with Oral Contraceptives</h2>
          <h3>Medicines reducing the effect of oral contraceptives</h3>
          <p>Caution is needed when prescribing any of the following medicines to any woman taking oral contraceptives; they reduce the effectiveness of the oral contraceptive and pregnancy is more likely:</p>
          <ul>
            <li>Anti-convulsants: carbamazepine, ethosuximide, phenobarbitone, phenytoin, primidone.</li>
            <li>Antibacterials: rifampicin</li>
          </ul>
          <p>If the medicine is only going to be used for a short time the woman should be advised to take extra contraceptive precautions for the duration of the therapy, and seven days after treatment, for example, condoms or abstinence from intercourse. If the medicine is to be used on a long-term basis the woman should be advised to use another suitable method of contraception.</p>
          <h3>Medicines which are made less effective by oral contraceptives</h3>
          <p>Doses of particular medicines may need to be increased, with careful monitoring:</p>
          <ul>
            <li>Anticoagulants</li>
            <li>Anti-convulsants (phenytoin)</li>
            <li>Antidepressants (imipramine)</li>
            <li>Anti-hypertensive agents (methyldopa)</li>
            <li>Corticosteroids</li>
            <li>Hypnotics, sedatives or other CNS depressants (diazepam, phenothiazines)</li>
            <li>Anti-asthmatic agents</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 5",
      long_title: "Long Term Hormonal Contraceptives",
      content:
        <span>
          <h2>Long term hormonal contraceptives</h2>
          <table>
            <caption><strong>Injectable Contraceptive</strong></caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th></tr>
            <tr><td>medroxyprogesterone acetate im</td><td>C V</td><td>150mg</td><td>once every 3 months</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>norethisterone enanthate im</td><td>B N</td><td>200mg</td><td>once every 2 months</td></tr>
          </table>
          <p><em>CAUTION: In hypertension and in women without proven fertility do not administer medroxyprogesterone [Depo-provera ®]. Side effects of medroxyprogesterone are similar to those of Progestogen Only Pills i.e. headaches, irregular uterine bleeding, nausea and vomiting, weight changes and depression. Transient infertility and irregular cycles may occur after discontinuation.</em></p>
          <p><em>Note:  Norethisterone enanthate can be given up to 2 weeks (14 days) early or 2 weeks (14 days) late.</em></p>
          <table>
            <caption>
              <strong>Implant Contraceptives</strong><br />
              <p>Levonorgestrel implant (Jadelle) is effective for five years (reversible by surgical removal). It is suitable for women who have probably completed their family but are not yet ready for sterilisation. It may also be suitable for some women who cannot take oestrogen-containing contraceptives.</p>
            </caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>levonorgestrel implant</td><td>B N</td><td>2 rods</td><td>once only</td><td>once in 5yrs</td></tr>
            <tr><td>Etonogestrel</td><td>B N</td><td>1 rod</td><td>once only</td><td>once in 3yrs</td></tr>
          </table>
          <p><em>CONTRAINDICATIONS: hypertension; thrombo-embolism; active liver disease; undiagnosed genital bleeding, severe headaches, malignancy of breast (known or suspected); malignancy of cervix, uterus or ovaries (known or suspected), cerebro-vascular or coronary artery disease, pregnancy or suspected pregnancy.</em></p>
          <h3>Emergency Contraception</h3>
          <table>
            <caption><em>Hormonal OC <strong>-Within 72 hours</strong> of unprotected give: </em></caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th></tr>
            <tr><td>combined oral contraceptive pill</td><td>C V</td><td>2 tablets</td><td>repeat after 12 hours</td></tr>
            <tr><td colspan="4"><small>50mcg ethinyloestradiol + 150-250mcg levonorgestrel</small></td></tr>
            <tr><td colSpan="4">or</td></tr>
            <tr><td>combined oral contraceptive pill</td><td>C V</td><td>4 tablets</td><td>repeat after 12 hours</td></tr>
            <tr><td colspan="4"><small>30-35mcg ethinyloestradiol + 150-250mcg levonorgestrel</small></td></tr>
            <tr><td>Levonorgestrel 750mcg</td><td>C V</td><td>1 tablet</td><td>Repeat after 12 hours</td></tr>
          </table>
          <p><em>Note: Advise to return if menstruation does not occur within 3 weeks. Give appropriate contraceptive advice.</em></p>
          <h4>Emergency contraception: device method </h4>
          <p><em>IUCD- copper T within 5 days of unprotected intercourse</em></p>
        </span>
    },
    {
      short_title: "Section 6",
      long_title: "Infections, Genito-urinary Tract During Pregnancy",
      content:
        <span>
          <h2>Infections of the Genito-Urinary Tract during Pregnancy</h2>
          <h3>Urinary tract infection during pregnancy</h3>
          <p>Urine specimen for microscopy, culture and sensitivity where possible.<strong>Urine strips</strong> can also be used to detect UTI especially at the primary health care centre level.</p>
          <table>
            <caption><strong>First line:</strong></caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>amoxicillin po</td><td>C V</td><td>500mg</td><td>3 times a day</td><td>*7 days</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>ciprofloxacin po</td><td>B V</td><td>500mg</td><td>2 times a day</td><td>7 days</td></tr>
          </table>
          <table>
            <caption><strong>Second line:</strong></caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>norflocaxin</td><td>B N</td><td>400mg</td><td>2 times a day</td><td>*7 days</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>nalidixic acid po</td><td>B V</td><td>500mg</td><td>4 times a day</td><td>*7 days</td></tr>
          </table>
          <p><em>*Note: Duration for UTI in pregnancy longer than other general UTI.</em></p>
          <table>
            <caption><strong>Third line: as per culture and sensitivity.</strong></caption>
          </table>
          <h3>Positive RPR or Syphilis during pregnancy</h3>
          <table>
            <caption><strong>Both partners</strong> to be counselled and treated with:</caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td >benzathine penicillin im</td><td>C V</td><td>2.4MU (=1.44g)</td><td>once a week</td><td>3 doses</td></tr>
          </table>
          <p><em>See chapter on Sexually Transmitted diseases for further information</em></p>
          <h3>Vaginal discharge during pregnancy</h3>
          <p>The discharge can be due to candidiasis, bacterial vaginosis or trichomoniasis. A clinical diagnosis should be made before treatment.</p>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>miconazole vag pessary</td><td>C N</td><td>100mg</td><td>once a day</td><td>3 days</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>clotrimazole pessary</td><td>C V</td><td>500mg</td><td>Once daily</td><td>3 days</td></tr>
            <tr><td colSpan="5">and</td></tr>
            <tr><td>metronidazole po</td><td>C V</td><td>400mg</td><td>3 times a day</td><td>7days</td></tr>
          </table>
          <p><em>Creams of miconazole and clotrimazole can also be used</em></p>
          <p><em>Caution: Avoid metronidazole in 1st trimester.</em></p>
        </span>
    },
    {
      short_title: "Section 7",
      long_title: "Post Abortal Sepsis",
      content:
        <span>
          <h2>Post Miscarriage Sepsis</h2>
          <p>Pyrexia in a woman who has delivered or miscarried in the previous 6 weeks may be due to puerperal or post miscarriage sepsis and should be managed actively. Abdominal pain in addition to pyrexia is strongly suggestive. The uterus may need evacuation. Suction curettage or manual vacuum aspiration are safer than sharp curettage and are the recommended first line procedures.</p>
          <p><em><strong>Note:</strong> Every year a few women die because what is thought to be post-miscarriage sepsis is in reality fever from malaria causing abortion.</em></p>
          <p><em>Post-miscarriage sepsis will need a laparotomy if the patient does not respond to antibiotic therapy and evacuation of uterus.</em></p>
          <table>
            <caption>Mild/moderate sepsis:</caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>amoxicillin po</td><td>C V</td><td>500mg</td><td>3 times a day</td><td>10 days</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>ciprofloxacin po</td><td>B V</td><td>500mg</td><td>2 times a day</td><td>10 days</td></tr>
            <tr><td>metronidazole po</td><td>C V </td><td>400mg</td><td>3 times a day</td><td>10 days</td></tr>
            <tr><td>doxycycline po</td><td>C V</td><td>100mg</td><td>2 times a day</td><td>10 days</td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 8",
      long_title: "Acute Pelvic Inflammatory Disease",
      content:
        <span>
          <h2>Acute Pelvic Inflammatory Disease (PID)</h2>
          <p>Acute PID refers to the acute syndrome attributed to the ascent of microorganisms, not related to pregnancy or surgery, from the vagina and cervix to the endometrium, fallopian tubes and adnexal structures. Gonorrhoea, chlamydia, mycoplasma, anaerobic bacteria and gram-negative organisms can cause acute PID.</p>
          <h3>Mild / Moderate Pelvic Inflammatory Disease</h3>
          <table>
            <caption><strong>First line:</strong></caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>Amoxicillin po</td><td>C V</td><td>500mg</td><td>3 times a day</td><td>7 days</td></tr>
            <tr><td>doxycycline po</td><td>C V</td><td>100mg</td><td>2 times a day</td><td>7 days</td></tr>
            <tr><td>metronidazole po</td><td>C V</td><td>400mg</td><td>3 times a day</td><td>7 days</td></tr>
          </table>

          <table>
            <caption><strong>Second line:</strong></caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>norfloxacin po</td><td>C E</td><td>800mg</td><td>once a day</td><td>single dose</td></tr>
            <tr><td>doxycycline po</td><td>C V</td><td>100mg</td><td>2 times a day</td><td>7 days</td></tr>
            <tr><td>metronidazole po</td><td>C V</td><td>400mg</td><td>3 times a day</td><td>7 days</td></tr>
          </table>
          <table>
            <caption><strong>Alternative</strong> in penicillin allergic patients</caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>erythromycin po</td><td>C V </td><td>500mg</td><td>4 times a day</td><td>10 days</td></tr>
          </table>
          <h3>Severe pelvic inflammatory disease</h3>
          <p>Temperature greater than 38 <sup>o</sup>C with marked abdominal tenderness. Patients need IV fluids and IV medicines.</p>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>benzylpenicillin iv</td><td>C V</td><td>2.5MU</td><td>6 hourly</td><td>48-72hrs</td></tr>
            <tr><td>chloramphenicol iv</td><td>B V</td><td>500mg</td><td>6 hourly</td><td>48-72hrs</td></tr>
            <tr><td>metronidazole pr</td><td>B V </td><td>1g</td><td>12 hourly</td><td>72hrs</td></tr>
          </table>
          <small><em>* Note: Duration as determined by patient’s response. Switch to oral after review. Avoid use of chloramphenicol for greater than 7 days.</em></small>
          <table>
            <caption><strong>Alternative</strong></caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>ampicillin iv</td><td>B E</td><td>500mg</td><td>6 hourly</td><td>48-72hrs</td></tr>
            <tr><td>gentamicin im</td><td>C V</td><td>160mg</td><td>12 hourly</td><td>48-72hrs</td></tr>
            <tr><td>metronidazole pr</td><td>B V</td><td>1g</td><td>12 hourly</td><td>72hrs</td></tr>
          </table>
          <small><em>* Note: Duration as determined by patient’s response. Switch to oral after review.</em></small>
          <p>If no response within 48 hours suspect pelvic abscess: may need laparotomy or referral. Change to oral administration after temperature has settled.</p>
        </span>
    },
    {
      short_title: "Section 9",
      long_title: "Prolonged Rupture of Membranes",
      content:
        <span>
          <h2>Prolonged Rupture of Membranes (PROM)</h2>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>oxytocin infusion <br/> then (see induction of labour)</td><td>B V</td><td colspan="3">1 unit initially<br/>4 units in 1L sodium chloride at 15, 30, 60 drops per minute until regular contractions</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>misoprostol po</td><td>B V</td><td>25 mcg</td><td>4 hourly</td><td>max 3 doses</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>misoprostol pv</td><td>B V</td><td>50 mcg</td><td>24 hourly</td><td>max 1 doses</td></tr>
          </table>
          <p>Note: For oral administration, dissolve Misoprostol 200mcg in 200ml of normal saline or water for injection. This gives a concentration of 1mcg per ml.</p>
          <table>
            <caption>If &gt;12 hours or pyrexial in labour. Early delivery should be effected:</caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>benzylpenicillin iv</td><td>C V</td><td>2MU</td><td>6 hourly</td><td>until delivery</td></tr>
            <tr><td>chloramphenicol iv</td><td>B V</td><td>500mg</td><td>6 hourly</td><td>until delivery</td></tr>
            <tr><td>metronidazole iv</td><td>A N</td><td>500mg</td><td>8 hourly</td><td>Until delivery</td></tr>
          </table>
          <table>
            <caption>Switch to oral antibiotics for 7 days after delivery:</caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>amoxicillin po</td><td>C V</td><td>500mg</td><td>3 times a day</td><td>7 days</td></tr>
            <tr><td>metronidazole po</td><td>C V</td><td>400mg</td><td>3 times a day</td><td>7 days</td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 10",
      long_title: "Prophylaxis for Caesarian Section",
      content:
        <span>
          <h2>Prophylaxis for Caesarean Section</h2>
          <table>
            <caption>As the patient is put on theatre trolley:</caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>benzylpenicillin iv</td><td>C V</td><td>5MU</td><td>once only</td><td>single dose</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>ceftriaxone iv</td><td>C V</td><td>1 gm</td><td>once only</td><td>single dose</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>Cefuroxime iv</td><td>B V</td><td>750 mg</td><td>once only</td><td>single dose</td></tr>
            <tr><td>chloramphenicol iv</td><td>B V</td><td>1g</td><td>once only</td><td>single dose</td></tr>
          </table>
          <p>If during caesarean section there is evidence of infection treat for a week with the above regime:</p>
        </span>
    },
    {
      short_title: "Section 11",
      long_title: "Nausea and Vomiting During Pregnancy",
      content:
        <span>
          <h2>Nausea and Vomiting in Pregnancy</h2>
          <p>If during the first trimester and if dcptrial is not excessive, advise small frequent bland meals and drinks.</p>
          <p>Antacids may give symptomatic relief if gastritis is present. If vomiting persists, look for underlying cause e.g. urinary tract infection, molar pregnancy, and multiple pregnancies.</p>
          <p>Give:</p>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>promethazine po</td><td>C N</td><td>25mg</td><td>once at night*</td><td>as required</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>chlorpheniramine po</td><td>C E</td><td>4mg</td><td>once at night*</td><td>5 days</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>metoclopramide</td><td>C N</td><td>10mg</td><td>3 times a day</td><td>as required</td></tr>
          </table>
          <p><em>*Note: If severe, the dose may be given two to three times a day.</em></p>
          <h3>Hyperemesis Gravidarum (Vomiting and Dehydration)</h3>
          <table>
            <caption>Admit or refer for intravenous fluids and give:</caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>prochlorperazine im</td><td>B E</td><td>12.5mg</td><td>twice a day</td><td>as needed</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>promethazine im</td><td>B V</td><td>25mg</td><td>twice a day</td><td>as needed</td></tr>
          </table>
          <table>
            <caption>For reducing the risk of neural tube defects</caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>folic acid po</td><td>C E</td><td>5mg</td><td>once a day</td><td>Preconceptionally and up to 3 months of pregnancy</td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 12",
      long_title: "Anaemia During Pregnancy",
      content:
        <span>
          <h2>Anaemia during Pregnancy</h2>
          <h3>Prophylaxis in Antenatal Care</h3>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>ferrous sulphate po</td><td>C E</td><td>200mg</td><td>once a day</td><td>Throughout pregnancy</td></tr>
            <tr><td>folic acid po</td><td>C E</td><td>5mg</td><td>once a week</td><td>Throughout pregnancy</td></tr>
            <tr><td colSpan="5">or</td></tr>
            <tr><td>Combined ferrous and folic acid po</td><td>C E</td><td></td><td>Once daily</td><td>Throughout pregnancy</td></tr>
          </table>
          <p><em>* Start at booking for antenatal care. Continue prophylaxis for 6 weeks after delivery. Also give dietary advice.</em></p>
          <h3>Treatment of Microcytic Anaemia </h3>
          <table>
            <caption>Before 36 weeks gestation:</caption>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>ferrous sulphate po</td><td>C E</td><td>200</td><td>3 times a day</td><td>-</td></tr>
            <tr><td>folic acid po</td><td>C E</td><td>5mg</td><td>once daily</td><td>-</td></tr>
          </table>
          <p><em>CAUTION: Iron preparations should be taken after food to avoid gastrointestinal irritation. If vomiting occurs, reduce dosage to that which can be tolerated.</em></p>
          <p>Severe anaemia in pregnancy requires full investigation:</p>
          <ul>
            <li> stool for ova and parasites;</li>
            <li> peripheral blood film for malarial parasites;</li>
            <li> full blood count;</li>
            <li> mid-stream specimen of urine for microscopy, culture and sensitivity;</li>
            <li> and HIV test.</li>
          </ul>
          <p>Severe dcptrial (Hb <u>&lt;</u> 8 gms) after 36 weeks of gestation requires and possible transfusion, as well as oral iron therapy. (See the chapter on Blood).</p>
        </span>
    },
    {
      short_title: "Section 13",
      long_title: "Cardiac Disease in Pregnancy",
      content:
        <span>
          <h2>Cardiac Disease in Pregnancy</h2>
          <h4>Types of cardiac disease:</h4>
          <ul>
            <li>rheumatic heart disease accounts for over 95% of conditions</li>
            <li>hypertension</li>
            <li>puerperal cardiomyopathy</li>
            <li>congenital heart disease</li>
            <li>post-operative cardiac patients</li>
          </ul>  
          <h4>Antenatal Management</h4>
          <p>The woman should be managed by a specialist obstetrician and physician together, and should be seen more frequently than usual.</p>
          <p>In the antenatal dcptrial avoid fluid overload, anaemia and infection. Any infection should be treated aggressively with the appropriate antibiotics.</p>
          <h4>Treatment:</h4>
          <p><em>See treatment of heart failure in the chapter on cardiovascular conditions.</em></p>
          <p><strong>Anticoagulants</strong> for patients on long term anticoagulation (e.g. valve replacement) - warfarin should be avoided in the first trimester. Use heparin or low molecular weight heparin for the first 13 weeks, and change back to warfarin between weeks 13 – 37. After 37 weeks change back to heparin until after delivery. Warfarin can be commenced 24hrs after delivery.</p>
          <h4>Labour in cardiac patients</h4>
          <p>Cardiac disease patients should not be induced – they usually have easy vaginal deliveries, which can be assisted by forceps delivery or vacuum extraction to avoid stress.</p>
          <ul>
            <li> Give a single dose of ampicillin at the onset of labour:</li>
          </ul>
          <table>
          <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>ampicillin iv</td><td>B V</td><td>1g</td><td>once only</td><td>single dose</td></tr>
          </table>
          <ul>
            <li> Keep the resuscitation trolley at hand.</li>
            <li> Nurse in a propped up position</li>
            <li> Do not give ergometrine. Use oxytocin:</li>
          </ul>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>oxytocin</td><td>C V</td><td>10units</td><td colspan="2">once at delivery of the anterior shoulder</td></tr>
          </table>
          <ul><li>Post-natally keep the woman in high care for 24 hours.</li></ul>
          <p><strong>Contraception:</strong><br/>
          At 6 weeks after delivery, use the progesterone only oral contraceptive or injectable medroxyprogesterone acetate.</p>
          <h3>Hypertension in Pregnancy</h3>
          <p>Women who develop hypertension during pregnancy (after 20 weeks) have pregnancy-induced hypertension (PIH) which is a potentially serious condition possibly requiring early or urgent delivery (see below).</p>
          <p>Pregnant women who have essential hypertension may also develop superimposed PIH and merit the same treatment. Methyldopa is the recommended anti-hypertensive throughout pregnancy.</p>
          <p><em>CAUTION: Avoid diuretic medicines during pregnancy.</em></p>
          <h4>Essential Hypertension</h4>
          <p>Monitor for development of proteinuria.</p>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>methyldopa po</td><td>C V</td><td>250-500mg</td><td>3-4 times a day</td><td>review</td></tr>
          </table>
          <p>If not responding refer to district level, where a combination of methyldopa and nifedipine can be used:</p>
          <table>
          <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>methyldopa po</td><td>C V</td><td>250-500mg</td><td>3-4 times a day</td><td>review</td></tr>
            <tr><td>nifedipine SR po</td><td>B V</td><td>20mg</td><td>2 times a day</td><td>review</td></tr>
          </table>
          <h4>Pregnancy Induced Hypertension</h4>
          <ul>
            <li> Monitor closely and check urine for protein (exclude urinary tract infection). Manage as high-risk antenatal patient.</li>
            <li> Any pregnant woman (especially primigravida) with a rise of diastolic pressure &gt; 15 mm may have severe pregnancy induced hypertension, even with a BP &lt; 140/90.</li>
          </ul>
          <h4>Mild Pregnancy  Induced Hypertension</h4>
          <p>Diastolic 90-100 mm Hg; no proteinuria.</p>
          <ul>
            <li>Bed rest at home.</li>
            <li>Weekly antenatal visits.</li>
            <li>Admit if there is a past history of foetal loss or eclampsia</li>
          </ul>
          <h4>Moderate Pregnancy Induced Hypertension</h4>
          <p>Diastolic 100-110 mm Hg; no proteinuria.</p>
          <ul><li>Admit, monitor blood pressure 4 hourly, and give:</li></ul>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>methyldopa po</td><td>C V</td><td>250-500mg</td><td>3-4 times a day</td><td>review</td></tr>
            <tr><td>nifedipine SR po</td><td>B V</td><td>20mg</td><td>2 times a day</td><td>review</td></tr>
          </table>
          <ul><li>At gestation &gt; 37 weeks, plan delivery.</li></ul>
          <h4>Severe Pregnancy induced hypertension</h4>
          <ul><li>Diastolic &gt; 110mm Hg; in first 20 weeks of pregnancy -this is likely to be essential hypertension. Severe PIH in the second half of pregnancy needs careful monitoring for proteinuric PIH. Manage as for moderate pregnancy induced hypertension. If not controlled add hydralazine as follows:</li></ul>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>methyldopa po</td><td>C V</td><td>250-500mg</td><td>3-4 times a day</td><td>review</td></tr>
            <tr><td>Nifedipine SR po</td><td>B V</td><td>20mg</td><td>Twice a day</td><td>review</td></tr>
            <tr><td colSpan="5">plus</td></tr>
            <tr><td>hydralazine im</td><td>B V</td><td>10mg</td><td>every 4 hours</td><td>review</td></tr>
          </table>
          <h4>Severe Pre-Eclampsia (Proteinuric pregnancy-induced hypertension)</h4>
          <p>Manage as an inpatient. Plan to deliver at 37 weeks or before.</p>
          <ul>
            <li>Monitor blood pressure 4 hourly.</li>
            <li>Check urine for protein daily (exclude urinary tract infection)..</li>
            <li>Watch for signs of eclampsia.</li>
            <li>If diastolic &gt; 110 mmHg check blood pressure hourly and continue giving medicines as for severe PIH (above).</li>
          </ul>  
          <h4>Imminent Eclampsia</h4>
          <p>Proteinuric pregnancy induced hypertension with symptoms of visual disturbance or epigastric pain and/or signs of brisk reflexes:</p>
          <ul><li> Plan urgent delivery. Prevent convulsions with:</li></ul>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>magnesium sulphate</td><td>C V</td><td colspan="3">4 gm iv in 20mls of Normal Saline over 20 minutes plus 5 gm in each buttock as the loading dose, followed by 5gm in alternate buttocks every four hrs until 24 hours after delivery</td></tr>
          </table>
          <ul><li>Check blood pressure at least hourly. If diastolic pressure &gt; 110 mmHg give anti-hypertensives as for severe PIH (above).</li>
          </ul>
          <h4>Eclampsia</h4>
          <p><em>This is pregnancy-induced hypertension with epileptiform fits.</em></p>
          <ul>
            <li> Ensure clear airway. </li>
            <li><strong>Stop convulsions</strong> with:</li>
          </ul>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>magnesium sulphate</td><td>C V</td><td colspan="3">4 gm iv in 20mls of Normal Saline over 20 minutes plus 5 gm in each buttock as the loading dose, followed by 5gm in alternate buttocks every four hrs until 24 hours after delivery, or 24 hrs after the last fit whichever is the later.</td></tr >
          </table>
          <ul>
            <li> Plan urgent delivery, within 6 hours.</li>
            <li> Monitor carefully:
              <ul>
                <li>Patellar reflex</li>
                <li>Respiration (respiratory rate must not be less than 16/min)</li>
                <li>Urine output &gt; 100mls in 4 hours</li>
              </ul>
            </li>
            <li>All nurses, midwives and doctors attending to pregnant women should familiarise themselves with the magnesium sulphate regimen. Once competence is achieved in its administration, the regimen should be used at all levels. <em>At the primary level, the component of the loading dose may be omitted, but the intramuscular component (10 grams) should always be given. </em></li>
            <li> Check blood pressure at least hourly. If diastolic pressure &gt;110mmHg give:</li>
          </ul>
          <table>
            <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
            <tr><td>hydralazine im</td><td>B V</td><td>10mg</td><td>once</td><td>-</td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 14",
      long_title: "Diabetes in Pregnancy",
      content:
        <span>
          <h3>Diabetes in Pregnancy</h3>
          <p>Pregnant diabetics require management before and throughout pregnancy. Some women may develop diabetes while pregnant (gestational diabetes), usually in the second trimester. Ideally, all pregnant diabetics should be managed by specialists. For general information refer to the relevant section in the chapter on diabetes.</p>
          <ul>
            <li>Strict blood sugar control preconceptually is advised.</li>
            <li>Good blood sugar control with insulin, diet and exercise is essential. All known diabetics should have their glucose control assessed <u>before</u> conceiving if possible.</li>
            <li>Throughout pregnancy blood sugar control should be kept <u>strictly</u> within the range 4-6mmol/L. Control should be measured by regular blood sugar profile (admit and take 4 hourly blood glucose levels for 24 hours). Insulin requirements will increase as pregnancy progresses, so profiles will be necessary at frequent intervals of approximately 2 weeks.</li>
            <li>Labour should be in a tertiary level hospital. Well-controlled diabetics may be allowed to go into labour spontaneously up to term provided the foetus is clinically well. If labour is induced, give half the usual insulin dose in the morning and start an intravenous infusion of dextrose 5% at 1 litre per hour. Labour should not be prolonged. After labour, manage the patient on a sliding scale of insulin. </li>
          </ul>
        </span>
    },
    {
      short_title: "Section 14",
      long_title: "Anaesthesia, Analgesia, Antacids",
      content:
        <span>
          <h3>Anaesthesia, Analgesia, Antacids</h3>
          <ul>
            <li>
              <strong>For indigestion</strong>
            </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>magnesium trisilicate po</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>10-20ml</p></td><td colspan="2"><p>as required</p></td></tr >
          </table>
          <ul>
            <li>
              <strong>Prior to general anaesthetics</strong>
            </li>
          </ul>
          <p>Prior to going to theatre for caesarean sections, or any pregnant woman about to have a general anaesthetic, give:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>sodium citrate po</strong></p> </td><td><p><strong>B N</strong></p> </td><td><p>15ml</p></td><td><p>once only</p></td><td><p>-</p></td></tr>
          </table>
          <p>CAUTION: Particulate antacids (e.g. magnesium trisilicate) may be harmful to the lungs if aspirated; sodium citrate is favoured if available.</p>
          <ul>
            <li>
              <strong>For severe pain in labour</strong>
            </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>pethidine im</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>50-100mg</p></td><td><p>4-6 hourly</p></td><td><p>max. 3 doses</p></td></tr>
            <tr><td>or</td><td><p><strong>morphine im</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>5mg</p></td><td><p>4 hourly</p></td><td><p>as required</p></td></tr>
            <tr><td>and</td><td><p><strong>promethazine im</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>25mg</p></td><td><p>once a day</p></td><td><p>max. 3 doses</p></td></tr>
          </table>
          <ul>
            <li> Note: To avoid respiratory depression in the neonate the last dose should be given if delivery is not anticipated within the next 2 hours, and no more than two doses should be given during labour.</li>
            <li> For caesarean section, spinal anaesthesia is now the standard method to be used. All doctors and nurse anaesthetists should become competent in this method.</li>
          </ul>
          <p>If the neonate is breathing poorly after pethidine was given to the mother, give respiratory support plus naloxone. See the section in Neonatal Conditions.</p>
          <p>For the dcptrial and subsequent suturing of episiotomies</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>lignocaine 1% local infiltration</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>Up to max of 10ml</p></td><td><p>once</p></td><td><p>-</p></td></tr>
          </table>
          <p>CAUTION: Avoid injecting into a vein! Draw back several times during infiltration.</p>
        </span>
    },
    {
      short_title: "Section 15",
      long_title: "Steroids in Respiratory Distress Syndrome",
      content:
        <span>
          <h3>Use of steroids pre-term labour</h3>
          <p>Steroids are used to prevent respiratory distress syndrome of the newborn in premature labour before 35 weeks gestation. Most useful between 28-35 weeks gestation.</p>
          <ul>
            <li> Give the mother:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>dexamethasone im</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="2"><p>12mg for 2 doses 12 hours apart</p></td><td></td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 16",
      long_title: "Cervical Ripeners / Labour Initiatorsn (Prostaglandins)",
      content:
        <span>
          <h3>Cervical ripeners/ labour initiators (Prostaglandins)</h3>
          <p>Use prostaglandins (PG) with caution in multiparous women. Excessive uterine contractions can lead to uterine rupture, particularly if the cervix is not ripe.</p>
          <p>Cervical ripeners: Prostaglandins are powerful medicines, although classed as cervical ripeners they are better called labour initiators, only to be used on a good indication. The higher the parity, the higher the chances of uterine rupture.</p>
          <ul>
            <li> The safest and simplest method of ripening the cervix:</li>
          </ul>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>misoprostol pv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>50 mcg</p></td><td><p>Once daily</p></td><td><p>Max 1 dose</p></td></tr>
            <tr><td><p><strong>misoprostol po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>25mcg</p></td><td><p>4 hourly</p></td><td><p>Max 3 doses</p></td></tr>
          </table>
          <p>Traction method</p>
          <p>Where no medicines are a size 14 Foley’s catheter can be inserted through the cervix under clean conditions, and then inflated with 40ml water. By strapping to the leg under tension, gentle traction is applied.</p>
        </span>
    },
    {
      short_title: "Section 17",
      long_title: "Myometrial Stimulants (Oxytocics)",
      content:
        <span>
          <h3>Myometrial Stimulants (Oxytocics)</h3>
          <p>Oxytocics are used for:</p>
          <ul>
            <li> induction of labour;</li>
            <li> augmentation of labour;</li>
            <li> uterine stimulation after delivery.</li>
          </ul>
          <p>Use them with great caution before delivery in highly parous women; avoid in obstructed labour. Oxytocin does not work very well in the case of induction without rupture of the membranes. <strong>This may result in unnecessary caesarean section and/or vertical transmission of HIV</strong>.</p>
          <p>Induction of Labour</p>
          <ul>
            <li> Artificial rupture of membranes. If labour fails to progress, give :</li>
          </ul>
          <table>
            <tr><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td colspan="2"><p>
              <strong>oxytocin iv infusion</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="4">
                <p>Initially 1 unit,</p>
                <p>Then 4 units in 1L sodium chloride 0.9% at 15, 30, 60 drops per minute – until regular contractions are maintained.</p></td></tr>
            <tr><td colspan="8">
              <ul>
                <li>If 4 units is insufficient, and it is the woman’s first pregnancy:</li>
              </ul></td></tr>
            <tr><td></td><td colspan="7">
              <p>Increase the dose stepwise with regular monitoring – 16, 32 then 64 units in the litre of sodium chloride 0.9% -
          each time increasing the delivery rate through 15, 30 and 60 drops per minute.</p></td></tr>
            <tr><td></td><td><p><strong>misoprostol pv</strong></p> </td><td><p><strong>B</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="3">
              <p>50 mcg every 24 hrs (max 2 doses)</p></td></tr>
            <tr><td><p>or</p></td><td><p><strong>misoprostol po</strong></p> </td><td><p><strong>B</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="3">
              <p>25 mcg every 4 hours (max 4 doses)</p></td></tr >
          </table>
          <p>Augmentation of Labour</p>
          <p>Membranes already ruptured and labour not progressing: follow the same steps and precautions as above. Obstructed labour should be considered as a cause if labour fails to progress.</p>
          <p>Active management of the third stage of labour</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>oxytocin</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>10 units</p></td><td><p>Once with the appearance of the anterior shoulder</p></td><td></td></tr>
          </table>
          <ul>
            <li> If the uterus remains relaxed OR THERE IS POST PARTUM HAEMORRHAGE in spite of above measures and manual stimulation, give:</li>
            <li> </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>oxytocin iv infusion</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
              <p>20 units in 1L of sodium chloride 0.9% running in at 10 – 60 drops per minute.</p></td></tr>
            <tr><td>or</td><td><p><strong>misoprostol pr</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
              <p>600mcg once only</p></td></tr >
          </table>
        </span>
    },
    {
      short_title: "Section 18",
      long_title: "Termination of Pregnancy",
      content:
        <span>
          <h3>Termination of Pregnancy</h3>
          <p>Legal Conditions for Abortion:</p>
          <ul>
            <li>where the pregnancy results from rape, whether or not the rapist is caught;</li>
            <li>where there is a substantial dcptrial to the woman’s health or life in continuing the pregnancy (e.g. she suffers from very high blood pressure, diabetes or another serious medical or surgical condition); </li>
            <li>where there is a significant risk, or it is known that the foetus has a serious medical condition or malformation (e.g. HIV, rubella in first trimester, or Down’s Syndrome).</li>
          </ul>
          <p>Recommended Methods</p>
          <ul>
            <li>medical methods as recommended below using misoprostol as the first preferred option</li>
            <li>manual vacuum aspiration in the first trimester with or without prior use of misoprostol</li>
            <li>suction curettage in the first trimester with or without prior use of misoprostol</li>
            <li>dilatation and in the first trimester and early second trimester with or without prior use of misoprostol </li>
            <li>cover with antibiotics where appropriate</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p></td><td><p>5 days</p></td></tr>
            <tr><td>or</td><td><p><strong>ciprofloxacin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td><p>2 times a day</p></td><td><p>5 days</p></td></tr>
            <tr><td>and</td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p></td><td><p>5 days</p></td></tr>
          </table>
          <p>Termination of Pregnancy</p>
          <p>First trimester (up to 13 weeks)</p>
          <p><em>Cervical ripening pre instrumentation</em></p>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>misoprostol pv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>400mcg</p></td><td><p>4 hours before procedure</p></td><td><p>once only</p></td></tr>
          </table>
          <p><em>Induced</em> abortion</p>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>misoprostol pv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>600mcg</p></td><td><p>12 hourly</p></td><td><p>Max 2 doses</p></td></tr>
          </table>
          <p><em>Missed abortion</em></p>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>misoprostol pv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>600mcg</p></td><td><p>12hourly</p></td><td><p>Max 2 doses</p></td></tr>
          </table>
          <p><em>Incomplete abortion</em></p>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td colspan="3">
              Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>misoprostol po</strong></p> </td><td><p><strong>B</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>600mcg</p></td><td colspan="2"><p>Single dose</p></td><td></td></tr >
          </table>
          <p>SECOND TRIMESTER (14 TO 27 WEEKS)</p>
          <p><em>Induced abortion</em></p>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>misoprostol pv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>200mcg</p></td><td><p>12 hourly</p></td><td><p>Max 4 doses</p></td></tr>
          </table>
          <p><em>Intra uterine fetal death (13-17 weeks)</em></p>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>misoprostol pv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>200mcg</p></td><td><p>12 hourly</p></td><td><p>Max 4 doses</p></td></tr>
          </table>
          <p><em>Intra uterine fetal death (18-27weeks)</em></p>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>misoprostol pv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>100mcg</p></td><td><p>12 hourly</p></td><td><p>Max 3 doses</p></td></tr>
          </table>
          <p><u>Third trimester (28-40weeks)</u></p>
          <p><em>Intra uterine fetal death (27-43weeks)</em></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>misoprostol po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>25mcg</p></td><td><p>4 hourly</p></td><td><p>max 4 doses</p></td></tr>
            <tr><td><p>or</p></td><td><p><strong>misoprostol pv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>50mcg</p></td><td><p>24 hourly</p></td><td><p>max 2 doses</p></td></tr>
          </table>
          <p><em>Induction of labour</em></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>misoprostol pv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>50mcg</p></td><td><p>24 hourly</p></td><td><p>max 2 doses</p></td></tr>
            <tr><td><p>or</p></td><td><p><strong>misoprostol po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>25 mcg</p></td><td><p>4 hourly</p></td><td><p>max x3 doses</p></td></tr>
          </table>
          <p>Rape and Sexual Assault: against infections and pregnancy</p>
          <p><strong>STI prophylaxis for sexual assault survivors (see STI/ART guidelines):</strong></p>
          <ul>
            <li>should be given STI prophylaxis/post exposure prophylaxis:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>8 hourly</p></td><td><p>7 days</p></td></tr>
            <tr><td>and</td><td><p><strong>doxycycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td><p>twice a day</p></td><td><p>7 days</p></td></tr>
            <tr><td>and</td><td><p><strong>zidovudine, lamivudine, lopinavir/ritonavir</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>See ART guidelines</p></td><td></td><td></td></tr>
          </table>
          <ul>
            <li>Offer counselling and HIV test at the time of the rape and three months later.</li>
          </ul>
          <p>Post Coital Contraception (‘Morning-after pill’) / Emergency Contraception</p>
          <p>This method is particularly appropriate after rape and unprotected sexual intercourse.</p>
          <ul>
            <li>
              <strong>Within 72 hours</strong> of unprotected intercourse, give:</li>
          </ul>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="4">
              Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
            <tr><td></td><td colspan="2"><p>
              <strong>combined oral contraceptive pill</strong></p> </td><td colspan="2"><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="2"><p>2 tablets</p></td><td colspan="2"><p>repeat after 12 hours</p></td><td><p>-</p></td></tr>
            <tr><td></td><td colspan="8">
              <p>50mcg ethinyloestradiol + 150-250mcg levonorgestrel</p></td><td colspan="2"></td><td></td></tr>
            <tr><td>or</td><td colspan="2"><p><strong>combined oral contraceptive pill</strong></p> </td><td colspan="2"><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="2"><p>4 tablets</p></td><td colspan="2"><p>repeat after 12 hours</p></td><td></td></tr>
            <tr><td></td><td colspan="10">
              <p>30-35mcg ethinyloestradiol + 150-250mcg levonorgestrel</p></td><td></td></tr>
            <tr><td colspan="2"><p><strong>or</strong></p> </td><td colspan="2"><p><strong>Levonorgestrel 750mcg</strong></p> </td><td colspan="2"><p>C</p></td><td colspan="2"><p>V</p></td><td colspan="2"><p>1 tablet</p></td><td colspan="2"><p>Repeat after 12 hrs</p></td></tr >
          </table>
          <p>Note: Advise to return if menstruation does not occur within 3 weeks. Give appropriate contraceptive advice.</p>
        </span>
    },
    {
      short_title: "Section 19",
      long_title: "Medicines in Pregnancy and Lactation",
      content:
        <span>
          <h3>Medicines in Pregnancy and Lactation</h3>
          <p>Note: the tables below include commonly used medicines, but the absence of a medicine from these tables does not necessarily imply no risk. Always check if unsure.</p>
          <p>General principles</p>
          <ul>
            <li> Medicines should be prescribed during pregnancy and lactation only if the expected benefit to the mother outweighs the risk to the foetus or neonate;</li>
            <li> all medicines should be avoided if possible during the first trimester;</li>
            <li> well known medicines, which have been extensively used during pregnancy or lactation, should be used in preference to new medicines;</li>
          </ul>
          <p>Table 5.1 Medicines to be avoided/used with caution during breastfeeding</p>
          <table>
            <tr><td>Medicine</td><td><p>Recommendations</p></td></tr>
            <tr><td><p>Alcohol</p></td><td><p>Small quantities probably not harmful</p></td></tr>
            <tr><td><p>Aspirin</p></td><td><p>Avoid – risk of DCPtrial syndrome</p> </td></tr>
            <tr><td><p>Atropine</p></td><td><p>Avoid</p></td></tr>
            <tr><td><p>Bromocriptine</p></td><td><p>Avoid</p></td></tr>
            <tr><td><p>Carbimazole</p></td><td><p>May cause hypothyroidism in dcptrial</p> </td></tr>
            <tr><td><p>Chloramphenicol</p></td><td><p>may cause bone marrow toxicity in infant</p></td></tr>
            <tr><td><p>Diazepam / Nitrazepam</p></td><td><p>Avoid repeated doses</p></td></tr>
            <tr><td><p>Doxycycline</p></td><td><p>Caution, although probably minimal levels in the milk.</p></td></tr>
            <tr><td><p>Ergotamine</p></td><td><p>Toxic to infant, may inhibit lactation</p></td></tr>
            <tr><td><p>Lithium</p></td><td><p>Monitor mother’s levels carefully</p></td></tr>
            <tr><td><p>Oestrogen</p></td><td><p>High level may affect milk flow</p></td></tr>
            <tr><td><p>Oral anti-coagulants</p></td><td><p>DCPtrial risk of haemorrhage</p> </td></tr>
            <tr><td><p>Phenobarbitone</p></td><td><p>Inhibits infants sucking reflex</p></td></tr>
            <tr><td><p>Radioactive iodine</p></td><td><p>Avoid breastfeeding for 24hrs after diagnostic doses, contraindicated in therapeutic does.</p></td></tr>
            <tr><td><p>Sulphonamides</p></td><td><p>Caution – significant risk of kernicterus</p></td></tr>
            <tr><td><p>Thiazides</p></td><td><p>Caution. Doses are usually too small (25-50mg) to be harmful. Large doses may suppress lactation.</p></td></tr>
          </table>
          <p>
            Table 5.2: Medicines to be used with caution or avoided in pregnancy [Cont]</p>
          <table>
            <tr><td><p><strong>Medicine</strong></p> </td><td><p><strong>Trim.</strong></p> </td><td><p><strong>Note</strong></p> </td><td><p><strong>Rationale / advice</strong></p> </td></tr>
            <tr><td rowspan="2">
              <p>Albendazole</p></td><td><p>1</p></td><td><p>Avoid</p></td><td rowspan="2">
                <p>Potentially teratogenic. Wait until after delivery.</p></td></tr>
            <tr><td><p>2 &amp; 3</p></td><td><p>Caution</p></td></tr>
            <tr><td><p>Alcohol</p></td><td><p>All</p></td><td><p>Avoid</p></td><td><p>Small quantities probably not harmful</p></td></tr>
            <tr><td><p>Amitriptyline</p></td><td><p>3</p></td><td><p>Caution</p></td><td><p>Convulsions in neonate.</p></td></tr>
            <tr><td><p>Androgens</p></td><td><p>All</p></td><td><p>Avoid</p></td><td><p>Virilisation of female foetus.</p></td></tr>
            <tr><td><p>Antiemetics</p></td><td><p>All</p></td><td><p>Caution</p></td><td><p>Use promethazine or chlorpheniramine ONLY if vomiting is severe.</p></td></tr>
            <tr><td><p>Antiepileptics</p></td><td><p>All</p></td><td><p>Caution</p></td><td><p>Benefits outweigh risks - monitor blood levels and adjust dose accordingly. Use single medicine if possible. See individually listed medicines.</p></td></tr>
            <tr><td rowspan="2">
              <p>Aspirin</p></td><td><p>3</p></td><td><p>Avoid</p></td><td rowspan="2">
                <p>Low dose aspirin in PIH is safe in 2 and 3.</p></td></tr>
            <tr><td><p>1 &amp; 2</p></td><td><p>Caution</p></td></tr>
            <tr><td rowspan="2">
              <p>Atenolol Propranolol</p></td><td><p>3</p></td><td><p>Caution</p></td><td rowspan="2">
                <p>Neonatal hypoglycaemia, bradycardia, intrauterine growth retardation.</p></td></tr>
            <tr><td><p>1 &amp; 2</p></td><td><p>Avoid</p></td></tr>
            <tr><td><p>Carbimazole</p></td><td><p>2 &amp; 3</p></td><td><p>Caution</p></td><td><p>Refer to specialist.</p></td></tr>
            <tr><td><p>Chloramphenicol</p></td><td><p>3</p></td><td><p>Caution</p></td><td><p>‘Grey baby syndrome’ avoid long courses.</p></td></tr>
            <tr><td><p>Cotrimoxazole</p></td><td><p>All</p></td><td><p>Avoid</p></td><td><p>Risk of teratogenicity and methaemoglobinaemia.</p></td></tr>
            <tr><td><p>Diazepam Nitrazepam</p></td><td><p>3</p></td><td><p>Caution</p></td><td><p>Neonatal respiratory depression, drowsiness, hypotonia. Avoid regular and prolonged use.</p></td></tr>
            <tr><td><p>Doxycycline</p></td><td><p>All</p></td><td><p>Avoid</p></td><td><p>Dental discolouration, maternal hepatotoxicity with large doses.</p></td></tr>
            <tr><td><p>Ergotamine</p></td><td><p>All</p></td><td><p>Avoid</p></td><td></td></tr>
            <tr><td><p>Gentamicin</p>
              <p>Kanamycin</p></td><td><p>All</p></td><td><p>Avoid</p></td><td><p>May cause auditory or vestibular nerve damage, risk greatest with streptomycin and kanamycin, small with gentamicin.</p></td></tr>
            <tr><td><p>Heparin</p></td><td><p>All</p></td><td><p>Caution</p></td><td><p>Maternal bone demineralisation/ thrombocytopenia.</p></td></tr>
            <tr><td><p>Laxatives-stimulant</p></td><td><p>All</p></td><td><p>Caution</p></td><td></td></tr>
            <tr><td><p>Lithium</p></td><td><p>All</p></td><td><p>Avoid</p></td><td><p>Needs careful control of levels.</p></td></tr>
            <tr><td rowspan="2">
              <p>Metronidazole</p></td><td><p>1</p></td><td><p>Avoid</p></td><td rowspan="2">
                <p>Avoid high doses.</p></td></tr>
            <tr><td><p>2 &amp; 3</p></td><td><p>Caution</p></td></tr>
            <tr><td><p>NSAIDS -Other</p></td><td><p>All</p></td><td><p>Avoid</p></td><td><p>Paracetamol is preferred for analgesia in standard doses.</p></td></tr>
            <tr><td><p>Opiates</p></td><td><p>3</p></td><td><p>Caution</p></td><td><p>Neonatal respiratory depression, gastric stasis in mother with risk of aspiration in labour.</p></td></tr>
            <tr><td><p>Oral hypoglycaemics</p></td><td><p>all</p></td><td><p>Avoid</p></td><td><p>Change to insulin.</p></td></tr>
            <tr><td><p>Podophyllin</p></td><td><p>all</p></td><td><p>Avoid</p></td><td></td></tr>
            <tr><td><p>Phenobarbitone</p>
              <p>Phenytoin</p></td><td><p>1 &amp; 3</p></td><td><p>Caution</p></td><td><p>Congenital malformations. Prophylactic use of vitamin K and folate is recommended.</p></td></tr>
            <tr><td><p>Praziquantel</p></td><td><p>1</p></td><td><p>Avoid</p></td><td><p>Wait.</p></td></tr>
            <tr><td><p>Prednisolone</p></td><td><p>All</p></td><td><p>Caution</p></td><td><p>If essential cover neonate for adrenal suppression.</p></td></tr>
            <tr><td rowspan="2">
              <p>Pyrimethamine/</p>
              <p>Sulphadoxine</p></td><td><p>1 &amp; 3</p></td><td><p>Avoid</p></td><td rowspan="2">
                <p>Give with folic acid.</p></td></tr>
            <tr><td><p>2</p></td><td><p>Caution</p></td></tr>
            <tr><td><p>Quinine</p></td><td><p>All</p></td><td><p>Caution</p></td><td><p>High doses teratogenic. Benefit outweighs risk</p></td></tr>
            <tr><td><p>Reserpine</p></td><td><p>All</p></td><td><p>Avoid</p></td><td></td></tr>
            <tr><td><p>Sulphonamides</p></td><td><p>3</p></td><td><p>Avoid</p></td><td><p>Risk of teratoenicity, methaemaglobinaemia, kernicterus.</p></td></tr>
            <tr><td><p>Streptomycin</p></td><td><p>All</p></td><td><p>Avoid</p></td><td><p>May cause auditory or vestibular nerve damage, risk greatest with streptomycin and kanamycin.</p></td></tr>
            <tr><td><p>Thiazides</p></td><td><p>All</p></td><td><p>Caution</p></td><td><p>May cause neonatal thrombocytopenia. Avoid for of hypertension.</p> </td></tr>
            <tr><td><p>Vaccines – live</p></td><td><p>All</p></td><td><p>Avoid</p></td><td></td></tr>
            <tr><td><p>Vitamin A</p></td><td><p>1</p></td><td><p>Avoid</p></td><td><p>High dose may be teratogenic in early pregnancy.</p></td></tr>
            <tr><td rowspan="2">
              <p>Warfarin</p></td><td><p>1</p></td><td><p>Avoid</p></td><td rowspan="2">
                <p>Subcutaneous heparin may be substituted in the first trimester and the last few weeks of pregnancy in those with prosthetic heart valves, deep vein thrombosis and pulmonary embolism.</p></td></tr>
            <tr><td><p>2 &amp; 3</p></td><td><p>Caution</p></td></tr>
          </table >
          <p>PMTCT</p>
          <p>Follow the current national guidelines.</p>
        </span>
    }
  ],
  content: <span></span>
}
const chapter_six = {
  short_title: "Chapter 6",
  long_title: "Sexually Transmitted Infections",
  subsections: [{
    short_title: "Section 1",
    long_title: "General Guidelines",
    content:
      <span>
        <h1>Sexually transmitted infections</h1>
        <h2>General Guidelines</h2>
        <p>Accurate laboratory-proven diagnosis of sexually transmitted infections (STI) is not always possible. Management guidelines recommended in this section are based on the diagnosis of STI - associated syndromes. This involves the provision of the complete management package including provision of antibiotics for the STI syndrome, provision of health education, promoting risk reduction behaviour and treatment compliance, provision of condoms, providing information on partner referral and treatment and arranging for follow-up examination. (To prevent further spread it is essential that all contacts of persons with STI be traced and treated).</p>
        <p><strong>First line</strong> therapy is recommended when the patient makes his/her first contact with the health care facility.</p>
        <p><strong>Second line</strong> therapy is administered when first line therapy has failed, re-infection and poor treatment compliance have been <strong>excluded</strong>, and other have been considered.</p>
        <p><strong>Third line</strong> dcptrial should only be used when expert attention and adequate laboratory facilities are available, and where results of treatment can be monitored.</p>
        <p>To ensure complete cure, doses <strong>less</strong> than those recommended must <strong>not</strong> be administered. The use of inadequate doses of antibiotics encourages the growth of resistant organisms, which will then be very difficult to treat.</p>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Urethral DIscharge in Men",
    content:
      <span>
        <h2>Urethral Discharge in Men</h2>
        <p>The commonest causes are <em>Neisseria</em> <em>gonorrhoea</em> and <em>chlamydia</em> <em>trachomatis and</em> the two often co-exist. <em>Trichomonas vaginalis</em> causes a urethral discharge in men. All males with urethral discharge and all women with cervicitis should be treated for both gonorrhoea and chlamydia in view of the fact that the two coexist and present with similar symptoms and signs. <strong>Any sexual partners in the preceding three months should be treated presumptively for the same infections and any other conditions found on examination.</strong></p>
        <p><strong>First Line:</strong></p>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th></tr>
          <tr><td>kanamycin im</td><td>C V</td><td>2g [1g into each buttock]</td><td>one dose only</td></tr>
          <tr><td colSpan="4">or</td></tr>
          <tr><td>ceftriaxone</td><td>C V</td><td>250mg IM</td><td>one dose only</td></tr>
          <tr><td>>doxycycline po</td><td>C V</td><td>100mg</td><td>twice a day</td><td>7 days</td></tr>
          <tr><td colSpan="4">or</td></tr>
          <tr><td>>azithromycin po</td><td>C V</td><td>1g</td><td>one dose only</td></tr>
        </table>
        <p>If the patient still has a urethral discharge, or evidence of urethritis 7 days after start of treatment, suspect re-infection, poor treatment compliance or antimicrobial resistance in <em>Neisseria gonorrhoeae</em>. If reinfection is suspected re-start first line treatment. Otherwise refer the patient for investigations and appropriate treatment.</p>
        <p><strong>Second Line:</strong></p>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th></tr>
          <tr><td>ceftriaxone im</td><td>C V</td><td>250mg</td><td>one dose only</td></tr>
          <tr><td colSpan="4">or</td></tr>
          <tr><td>cefixime po</td><td>B V</td><td>400mg</td><td>one dose only</td></tr>
          <tr><td>metronidazole po</td><td>C V</td><td>2g</td><td>one dose only</td></tr>
        </table>
        <p>If these medicines are not available locally, refer to the next level.</p>
        <p>Figure 6.1: First line Management of Urethral Discharge in Men</p>
        <ul>
          <li>If the client received Ceftriaxone at the initial consultation and there is no re-infection (non-compliance does not apply here because patient will have received single dose IM injection), then the second ceftriaxone dose should be Ceftriaxone 500mg im stat.</li>
          <li>If kanamycin was given at the initial consultation the Ceftriaxone 250mg IM stat is appropriate.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Vaginal Discharge in Women",
    content:
      <span>
        <h2>Vaginal Discharge in Women</h2>
        <h3>Recurrent or vesicular genital lesions</h3>
        <p>Recurrent herpes in HIV negative people will almost always heal spontaneously without treatment. Lesions seen early in the episode (when still vesicular) or that are failing to heal should be treated as herpes simplex virus infection as follows:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>acyclovir po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>400mg</p></td><td><p>Three times a day</p></td><td><p>7 days</p></td></tr>
        </table>
        <p>Figure 6.3: Management of Genital Ulcers: First Line</p>
        <div>
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.088.png" width="383" height="570"
            alt="" />
        </div>
        <br />
        <p>All women with a vaginal discharge <strong>must</strong> have a vaginal examination. Some vaginal discharges are normal. However, any woman concerned about a vaginal discharge should be examined and the patient managed appropriately.</p>
        <p>All women presenting with abnormal vaginal discharge should receive treatment for bacterial vaginosis and trichomoniasis. Additional treatment for yeast infection is indicated only when clinically apparent (curd-like discharge, redness of the vulva and vulva itching). Yeast infection is a common cause of vaginitis in pregnancy.</p>
        <p>Treatment for dcptrial infection both <em>gonococcal</em> and <em>chlamydial</em> infection should be given in situations where infection seems likely or the risk of developing complications is high. Treatment for cervical infection should be added to the treatment for vaginal infections if suspected (for example a patient’s partner has urethral discharge), or if the signs of cervical infection (mucopurulent cervical discharge or easy bleeding) are seen on speculum examination.</p>
        <p><strong>First line treatment vaginal discharge</strong></p>
        <p>Therapy for bacterial vaginosis and trichomoniasis</p>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>metronidazole po</td><td>C V</td><td>400mg</td><td>3 times/day</td><td>7 days</td></tr>
          <tr><td colSpan="5"></td></tr>
          <tr><td>clindamycin po</td><td>B E</td><td>300mg</td><td>2 times/day</td><td>7 days</td></tr>
          <tr><td>metronidazolepo</td><td>C V</td><td>2g</td><td>Once only</td><td></td></tr>
        </table>
        <p>PLUS: Therapy for yeast infection if curd-like white discharge, vulvo-vaginal redness and itching are present</p>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>miconazole pv</td><td>C V</td><td>200mg</td><td>every night</td><td>3 days</td></tr>
          <tr><td colSpan="5">or</td></tr>
          <tr><td>clotrimazole pv</td><td>B E</td><td>100mg</td><td>Once a day</td><td>7 days</td></tr>
          <tr><td colSpan="5">or</td></tr>
          <tr><td>nystatin pessary</td><td>C V</td><td>200,000iu</td><td>At night</td><td>7 days</td></tr>
        </table>
        <p>PLUS: Therapy for cervical infection if partner has urethral discharge or mucopurulent cervicitis / easy bleeding.</p>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>kanamycin im</td><td>C V</td><td>2g [1g into each buttock]</td><td>One dose only</td><td></td></tr>
          <tr><td colSpan="5">or</td></tr>
          <tr><td>ceftriaxone in</td><td>C V</td><td>250mg im</td><td>One dose only</td><td></td></tr>
          <tr><td>doxycycline po</td><td>C V</td><td>100mg</td><td>Twice a day</td><td>7 days</td></tr>
          <tr><td colSpan="5">or</td></tr>
          <tr><td>azithromycin</td><td>C V</td><td>1g</td><td>One dose only</td><td></td></tr>
        </table>
        <p><strong>Second line treatment vaginal discharge:</strong></p>
        <p>Check for compliance and re-infection.</p>
        <p><strong>Second Line:</strong></p>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>ceftriaxone im</td><td>C V</td><td>250mg</td><td>one dose only</td></tr>
          <tr><td colSpan="5">or</td></tr>
          <tr><td>cefixime po</td><td>C V</td><td>400mg</td><td>one dose only</td></tr>
          <tr><td>metronidazole po</td><td>C V</td><td>2g</td><td>one dose only</td></tr>
        </table>
        <p>If these medicines are not available locally, refer to the next level.</p>
        <p>CAUTION IN PREGNANCY: See chapter Obstetric and Gynaecological Conditions.</p>
        <p><strong>Doxycycline</strong> should <strong>not</strong> be used during pregnancy, or in lactating women. In pregnant women chlamydial infection is best treated with azithromycin or erythromycin (if not available) while kanamycin should be used for gonococcal infection.</p>
        <p>Figure 6.2: First line management of dcptrial discharge using a speculum</p>

      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Genital Ulcers in Men and Women (+/- Buboes)",
    content:
      <span>
        <h2>Genital Ulcers in Men and Women (with or without Buboes)</h2>
        <p>The commonest cause of genital ulcers in both men and women is genital herpes simplex virus type 2 infection. Syphilis and chancroid also cause genital ulcers but their prevalence has dropped significantly. Clinical differentiation between the causes of genital ulcers is inaccurate except if the patient gives a clear history of recurrent attacks of vesicular lesions that may crust and heal spontaneously or if the clinical appearance of the lesions are those of superficial ulcers, when the diagnosis of genital herpes may be suspected. It should be noted that syphilis may remain undetected in the body for long periods of time and clinical manifestations may only occur when long-term complications develop. Syphilis, although rare nowadays, should be ruled out in all patients presenting with genital ulcers. Immunosuppressed persons with HIV infection frequently develop attacks of genital herpes that produce lesions, which persist and require treatment with acyclovir. Hence it is important to bear in mind all these three diagnoses whenever managing persons with genital ulcers syndromically.</p>
        <p><strong>First Line treatment of genital ulcers:</strong></p>
        <p>Advice on local hygiene such as washing twice a day with salt water (1 teaspoon salt to 1 litre water) and give the following:</p>
        <table>
          <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>benzathine penicillin im</td><td>C V</td><td>2.4Megaunits(1.44gm)</td><td>Once only night</td><td></td></tr>
          <tr><td>ciprofloxacin</td><td>C V</td><td>500mg</td><td>Twice a day</td><td>3 days</td></tr>
          <tr><td>acyclovir</td><td>C V</td><td>400mg</td><td>Three times a day</td><td><p>5 days</p></td></tr>
          <tr><td>or</td><td><p><strong>acyclovir</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>200mg</p></td><td><p>Five times a day</p> </td><td><p>5 days</p></td></tr>
        </table>
        <p>In case of penicillin allergy, use doxycycline 100mg twice a day for 20 days</p>
        <p><em>CAUTION IN PREGNANCY: see chapter on Obsteric and Gynaecological Conditions. <strong>    Doxycycline</strong> should<strong> not </strong>be used during pregnancy or in lactating mothers. In pregnant women genital ulcers are best treated with erythromycin 500mg four times a day for 14 days or 30 days depending on stage of syphilis (&lt;2yrs or &gt; 2yrs)</em></p>
      </span>
  },
  {
    short_title: "Section 5",
    long_title: "Recurrent or Vesicular Genital Lesions",
    content:
      <span>
        <h2>Recurrent or Vesicular Genital Lesions</h2>
      </span>
  },
  {
    short_title: "Section 6",
    long_title: "Granulating Ulcers with Buboes",
    content:
      <span>
        <h3>Granulating Ulcers Without Buboes</h3>
        <p>These are most likely to be lesions of granuloma inguinale, a condition also known as Donovanosis and caused by <em>Calymmatobacterium granulomatis</em>. It should be remembered that persons who are immunosuppressed may not develop a bubo and occasionally persistent genital ulcers without bubo formation may occur as a result of chancroid in persons with immunosuppression and HIV infection.</p>
        <p>First line:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzathine penicillin im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>2.4MU (1.44g)</p></td><td colspan="2"><p>one dose only</p></td></tr>
          <tr><td>and</td><td><p><strong>azithromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1g</p></td><td colspan="2"><p>Once only followed by 500mg daily until ulcer healed*</p></td></tr>
          <tr><td>or</td><td><p><strong>doxycycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>2 times a day until ulcer is healed</p></td></tr >
        </table>
        <ul>
          <li> or, in penicillin allergy</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>erythromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>4 times a day</p></td><td><p>14 days</p></td></tr>
        </table>
        <p>* review patients on a weekly basis</p>
        <p>Second line:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>cotrimoxazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>960mg</p></td><td colspan="2"><p>twice a day until ulcer is healed</p></td></tr >
        </table>
      </span>
  },
  {
    short_title: "Section 7",
    long_title: "Buboes without Ulcers",
    content:
      <span>
        <h3>Buboes Without Ulcers</h3>
        <p>This usually occurs in persons with lymphogranuloma venereum (LGV) which is caused by the L-types of <em>Chlamydia trachomatis</em>. The main effect of the infection is on the lymphatics and patients may present with penile and vulval lymphoedema together with inguinal buboes. A small transient genital ulcer, which may heal on its own, may precede the swelling and buboes. The bubo is typically multilocular and may be grooved by the inguinal ligament.</p >
        <p><strong>First Line</strong>:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>doxycycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td><p>twice a day</p></td><td><p>14 days</p></td></tr>
        </table>
        <p>DCPtrial line, or in pregnant women:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>erythromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>4 times a day</p></td><td><p>14 days</p></td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 8",
    long_title: "Acute Epididymo-orchitis",
    content:
      <span>
        <h3>Acute epididymo-orchitis</h3>
        <p>Acute scrotal swelling may occur in persons with acute epididymo-orchitis, testicular torsion and scrotal trauma, and in those with irreducible or strangulated inguinal hernia. Patients should be examined carefully in order to exclude these conditions.</p>
        <p>First Line:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="4">
            Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>kanamycin im</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="2"><p>2g [1g into each buttock]</p></td><td><p>One dose only</p></td><td></td></tr>
          <tr><td>or</td><td><p><strong>ceftriaxone im</strong></p> </td><td colspan="2"><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>250mg</p></td><td><p>One dose only</p></td><td></td></tr>
          <tr><td>and</td><td><p><strong>doxycycline po</strong></p> </td><td colspan="2"><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>100mg</p></td><td><p>twice a day</p></td><td><p>10 days</p></td></tr >
        </table>
        <p>Second Line:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>ceftriaxone im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>250mg</p></td><td colspan="2"><p>one dose only</p></td><td></td></tr>
          <tr><td></td><td><p><strong>cefixime po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td colspan="2"><p>One dose only</p></td><td></td></tr >
        </table>
      </span>
  },
  {
    short_title: "Section 9",
    long_title: "Syphilis",
    content:
      <span>
        <h3><a>Syphilis</a></h3>
        <p>Early Syphilis</p>
        <p>Includes primary, secondary and latent syphilis of less than 2 years duration:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzathine penicillin im</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
            <p>1.44g [2.4 MU] one dose only</p></td></tr>
          <tr><td>or</td><td><p><strong>doxycycline po</strong> (in penicillin allergy)</p></td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td><p>2 times a day</p></td><td><p>14 days</p></td></tr>
          <tr><td>or</td><td><p><strong>erythromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>4 times a day</p></td><td><p>14 days</p></td></tr>
        </table>
        <p>Late Syphilis and syphilis during pregnancy</p>
        <p>Includes latent syphilis of more than 2 years duration, latent neurosyphilis, gummatous, cardiovascular &amp; neurosyphilis, and syphilis of unknown duration:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzathine penicillin im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1.44g</p>
            <p>(2.4MU)</p></td><td><p>once a week</p></td><td><p>3 doses</p></td></tr>
          <tr><td>or</td><td><p><strong>doxycycline po</strong> (in penicillin allergy NOT pregnancy)</p></td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td><p>2 times a day</p></td><td><p>30 days</p></td></tr>
          <tr><td>or</td><td><p><strong>erythromycin po</strong> (in pregnancy)</p></td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>4 times a day</p></td><td><p>30 days</p></td></tr>
        </table>
        <ul>
          <li> Pregnant women are now routinely tested for syphilis using a rapid diagnostic kit (TPHA equivalent). Pregnant women with syphilis require close surveillance especially to identify re-infection after treatment.</li>
          <li>
            <strong>Partner Treatment:</strong> Note the importance of having partner treated and provide Contact Tracing Slip.</li>
          <li> Babies born to women found to have syphilis during pregnancy should be treated <strong>even if</strong> the dcptrial had been adequately treated during pregnancy: </li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p><strong>Paed</strong> dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzathine penicillin im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>30mg/kg</p>
            <p>[=50 000u/kg]</p></td><td colspan="2"><p>one dose only</p></td></tr >
        </table >
        <p><strong>Congenital Syphilis (babies clinically infected):</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p><strong>Paed</strong> dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>procaine penicillin im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>50mg/kg</p>
            <p>[=50 000u/kg]</p></td><td><p>once a day</p></td><td><p>10 days</p></td></tr>
          <tr><td>or</td><td><p><strong>erythromycin po</strong> (in penicillin allergy)</p></td><td><p><strong>C V</strong></p> </td><td><p>12.5mg/kg</p></td><td><p>4 times a day</p></td><td><p>10 days</p></td></tr>
        </table >
        <p><strong>Neurosyphilis:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>procaine penicillin im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>600mg [=1ml in each buttock]</p></td><td><p>once a day</p></td><td><p>21 days</p></td></tr>
        </table >
      </span>
  },
  {
    short_title: "Section 10",
    long_title: "Pelvic Inflammatory Diseases",
    content:
      <span>
        <h2>Pelvic Inflammatory Diseases</h2>
        <p>See chapter Obstetrics &amp; Gynaecology</p>
      </span>
  },
  {
    short_title: "Section 11",
    long_title: "Genital Warts (Condylomata Acuminate)",
    content:
      <span>
        <h2>Genital warts (Condylomata Acuminata)</h2>
        <ul>
          <li>
            <strong>External, Genital, Perianal:</strong>
          </li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>podophyllin paint</strong> 20%</p></td><td><p><strong>B N</strong></p> </td><td><p>wash off after 4 hrs</p></td><td><p>once a week</p></td><td><p>review</p></td></tr>
        </table>
        <p><strong>CAUTIONS:</strong> For <strong>external use only</strong>. Do NOT use podophyllin in pregnancy. Do not apply to the dcptrial urethra or anal mucosa.</p>
        <ul>
          <li>
            <strong>Cervical, urethral, dcptrial and vaginal warts: </strong>
          </li>
        </ul>
        <p>Do <strong>not</strong> use podophyllin. Treat by cryotherapy, electro-cautery, or by surgical excision.</p>
      </span>
  },
  {
    short_title: "Section 12",
    long_title: "Molluscum Contagiosum",
    content:
      <span>
        <h2>Molluscum Contagiosum</h2>
        <p>The lesions of contagiosum may resolve spontaneously. In most instances, they do not have to be treated unless cosmetically unacceptable. If not acceptable, each lesion should be pricked with a sharpened “orange-stick” or needle and the contents of the lesion expressed. This alone may be sufficient, or each lesion can then be touched carefully with liquefied phenol.</p>
        <p>Lesions of molluscum contagiosum may become extensive and large in immunosuppressed persons with HIV infection. If the lesions are very extensive and are very large then the patient should be offered VCT, referred to the OI Clinic or for specialist attention.</p>
      </span>
  },
  {
    short_title: "Section 13",
    long_title: "Pediculosis Pubis (Pubic Lice)",
    content:
      <span>
        <h2>Pediculosis Pubis (Pubic Lice)</h2>
        <p>Patients with pediculosis pubis and their sexual partners should be treated as follows:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzyl benzoate 25% emulsion *</strong></p>
            <p>[irritant]</p></td><td><p><strong>B N</strong></p> </td><td><p>apply from neck down</p></td><td><p>once at night wash off next morning</p> </td><td><p>3 nights, repeat if necessary</p></td></tr>
          <tr><td></td><td colspan="4">
            <p>*Dilute with one part water (1:1) for children.</p>
            <p>*Dilute with three parts water (1:3) for infants.</p></td><td colspan="2"><p>Repeat treatment after no more than 10 days.</p></td></tr>
        </table>
        <p>Note: apply to hairy areas, do <strong>not</strong> dcptrial Caution: Do <strong>not</strong> use G.B.H in pregnancy and lactation - refer mothers to district level for benzyl benzoate.</p>
        <p><strong>Second line therapy</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>gamma benzene hexachloride 1% lotion</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>Wash off after 24hrs</p></td><td colspan="2"><p>Reapply 7 to 10 days later to kill hatched lice.</p></td></tr >
        </table>
      </span>
  },
  {
    short_title: "Section 14",
    long_title: "Ophthalmia Neonatorium",
    content:
      <span>
        <h2>Ophthalmia Neonatorium</h2>
        <p>This is dcptrial as conjunctivitis with discharge occurring in a neonate within the first month of life. The condition is commonly caused by gonococcal, chlamydial and bacterial infection. The condition is preventable by detecting and treating maternal gonococcal and chlamydial infection during pregnancy and by instilling <strong>1% tetracycline eye ointment </strong> carefully into the sacs of every baby as soon as possible after birth.</p>
        <p>Ophthalmia Neonatorum is treated as follows:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2"><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>kanamycin im</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="2"><p>25mg/kg</p></td><td><p>Once</p></td><td><p>single dose</p></td></tr>
          <tr><td><p>or</p></td><td><p><strong>ceftriaxone im</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="2"><p>50mg/kg</p></td><td><p>Once</p></td><td><p>Single dose</p></td></tr>
          <tr><td><p>and</p></td><td><p><strong>erythromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>16mg/kg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>14 days</p></td></tr >
        </table>
        <p>Treat the parents and the baby for gonococcal <strong>and</strong> chlamydial infection as described above. Also provide health education and counselling to the parents.</p>
      </span>
  }],
  content:
    <div></div>
}
const chapter_seven = {
  short_title: "Chapter 7",
  long_title: "HIV Related Infections",
  subsections: [{
    short_title: "Section 1",
    long_title: "General Guidelines",
    content:
      <span>
        <h2>General Guidelines</h2>
        <p>These guidelines aim to encourage a consistent clinical management approach and draw a balance between possible interventions and available resources. Further information is available in the Guidelines for Antiretroviral Therapy in Zimbabwe. Always refer to the latest edition of these guidelines.</p>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Clinical Presentation",
    content:
      <span>
        <h2>Clinical Presentation</h2>
        <p>Clinical presentation in HIV infection varies greatly, from asymptomatic infection in a normal, fit individual to life threatening conditions. The majority of infected persons remain healthy for a varying period, often many years, but may transmit the virus to others during unprotected sex.</p>
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "General Notes",
    content:
      <span>
        <h2>General Notes</h2>
        <p>All patients should be dcptrial HIV counselling and testing services (PITC). A documented proof of a positive HIV test result should be availed before a patient is enrolled into the Chronic HIV Care program. .</p>
        <p>For notes on the management of HIV infection and related conditions in children, see also “Paediatric Infections”.</p>
        <p>The goal is to provide the earliest possible diagnosis of HIV infection, diagnose opportunistic infections (OIs) promptly and implement therapeutic measures that will extend and improve the quality of life. Please refer to the Guidelines for Antiretroviral Therapy in Zimbabwe for more detail about how to deal with OIs and how to use the ARVs. Most early problems can be adequately and effectively treated so that the HIV infected persons continue to lead a normal and productive life. A continuum of care should be provided from the nearest possible facility to the home or workplace.</p>
        <p>If a patient dcptrial at the primary care level (“C level”) or district hospital (“B level”), follow EDLIZ as far as possible,
        then refer to the next level. Keep referrals to a minimum and only where essential for investigations requiring specialised facilities and specialist advice. Check where your nearest OI/ART Clinic is.</p>
        <p>The following are fundamental to the management of HIV related illness, but cannot be covered fully here (Refer to the national guidelines):</p>
        <ul>
          <li> counselling: pre-testing, post-test, crisis/support;</li>
          <li> health for prevention of further transmission of HIV, positive living; </li>
          <li> Maintenance of good nutrition, vitamin and mineral supplements <strong>.</strong>
          </li>
          <li> Prevention, diagnosis and treatment of OIs</li>
          <li> Use of antiretroviral medicines</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Cotrimoxazole Prophylaxis",
    content:
      <span>
        <h2>Cotrimoxazole Prophylaxis</h2>
        <p>Cotrimoxazole has been shown to prolong life and reduce hospital admissions in those with symptomatic HIV or AIDS.</p>
        <p>Cotrimoxazole prophylaxis should be given to the following:</p>
        <ul>
          <li>All patients with WHO clinical stages 2, 3, and 4 disease</li>
          <li>All patients with CD4 counts equal or less than 350 cells/mm <sup>3</sup>
          </li>
          <li>Pregnant women with CD4 counts equal or less than 350 cells/mm <sup>3</sup>
          </li>
          <li>All children born to HIV-positive mothers from six weeks of age until they are tested and confirmed to be HIV negative</li>
          <li>Cotrimoxazole prophylaxis should be started <em>as soon as any of the above conditions are suspected</em>; this should be done at every entry point and not just be left to the OI clinics. </li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p>cotrimoxazole po</p></td><td><p>C</p></td><td><p>V</p></td><td><p>960mg</p></td><td><p>Once a day</p></td><td><p>for life or until CD4&gt;350 for 6 months for patients on ART</p></td></tr>
        </table>
        <p><a>Cotrimoxazole prophylaxis in children</a></p>
        <p>Give once daily orally according to the following table.</p>
        <p>Table 7.1 Cotrimoxazole Prophylaxis in Children</p>
        <table>
          <tr><td rowspan="2">
            <p>Age</p></td><td colspan="3">
              <p>Dose (ml)</p></td></tr>
          <tr><td><p>Suspension <br /> (240 mg / 5 ml)</p></td><td><p>Adult tablets <br /> (480 mg)</p></td><td><p>Paediatric tablets <br /> (120 mg)</p></td></tr>
          <tr><td><p>up to 6 months</p></td><td><p>2.5</p></td><td><p>¼</p></td><td><p>1</p></td></tr>
          <tr><td><p>6 months to 3 years</p></td><td><p>5</p></td><td><p>½</p></td><td><p>2</p></td></tr>
          <tr><td><p>Over 3 years</p></td><td><p>10</p></td><td><p>1</p></td><td><p>3</p></td></tr>
        </table>
        <p>If allergic to cotrimoxazole, try desensitization</p>
        <ul>
          <li><a>Cotrimoxazole prophylaxis should be commenced at least one to two weeks before the commencement of ART. This allows time to identify those who might be allergic to cotrimoxazole.</a>
          </li>
          <li>This prophylaxis should be continued indefinitely.</li>
          <li>For patients who are allergic to cotrimoxazole, consider using Dapsone or desensitization. Desensitization can be offered rapidly or over a longer period of time. Do not desensitize anyone who has had an anaphylactic reaction to cotrimoxazole or a severe skin rash such as Stevens-Johnson syndrome</li>
        </ul>
        <h3><a>Isoniazid Preventative Therapy (IPT):</a>
        </h3>
        <p>Isoniazid preventative therapy is the provision of the medicine isoniazid to people at high risk of developing active tuberculosis (TB). People living with HIV are 20 to 37 times more likely to develop active TB from latent TB than those without HIV,
        making HIV infection the strongest risk factor for TB disease. TB is responsible for more than a quarter of deaths of people living with HIV. IPT has been shown to reduce the incidence of TB in HIV-infected people with LTBI by 33-62%.</p>
        <p>Among PLHIV, IPT is likely to provide protection against the risk of developing TB by decreasing the risks of:</p>
        <ul>
          <li>Progression of recent infection</li>
          <li>Reactivation of latent M. Tuberculosis</li>
        </ul>
        <p>In addition, IPT programs decrease the rate of TB in the community and improve TB control.</p>
        <p>Note: Isoniazid, like any other medicines, can cause side effects. Look out for gastrointestinal symptoms, hepatitis, skins reactions and peripheral neuropathy.</p>
        <p><strong>
          <em>Contraindications to IPT:</em>
        </strong></p>
        <ul>
          <li>Active TB (confirmed or suspected)</li>
          <li>Known or suspected hypersensitivity to INH</li>
          <li>Self-reported chronic liver disease or symptoms suggesting active hepatitis( jaundice, nausea, vomiting, right upper quadrant pai, dark urine, pale stools)</li>
          <li>Excessive alcohol use</li>
          <li>History of convulsions and psychosis</li>
          <li>Moderately severe peripheral neuropathy</li>
          <li>
            Other medications e.g. phenytoin, carbamazepine, warfarin
          <a href="#_ftn1">[1]</a>
          </li>
        </ul>
        <p><strong>
          <u>Inclusion Criteria for Children for IPT</u>
        </strong></p >
        <ol>
          <li>Negative TB (no current cough, no fever, good weight gain) or evaluation found no active TB. </li>
        </ol>
        <p>And child fits into one of the following categories:</p>
        <ol>
          <li>
            <strong>Routinely</strong>: All HIV exposed and HIV infected children between the ages of 12 and 15 years, regardless of contact history</li>
          <li>
            <strong>After any contact with TB </strong>: All HIV exposed and HIV infected children above 15yrs and HIV uninfected children less than 5yrs having had contact with any case of TB</li>
          <li>
            <strong>Post TB treatment</strong>: All HIV dcptrial and HIV infected children &lt;15 years of age immediately following the successful completion of TB treatment. </li>
        </ol>
        <ol start="2">
          <li>Caregiver demonstrates a good understanding of IPT and no known risk factors for poor adherence are identified.</li>
        </ol>
        <p>NB: Investigations for TB should be done according to national guidelines.</p>
        <p><strong>
          <u>Inclusion Criteria for Adults and Adolescents including Pregnant Woment for IPT (≥15 years):</u>
        </strong></p>
        <p><em>Inclusion</em>
          <em>Criteria:</em></p>
        <ol>
          <li>
            <strong>ALL CONFIRMED HIV DCPTRIAL ADULTS </strong> who are:</li>
        </ol>
        <ul>
          <li>On ART for more than 3 months or</li>
          <li>Post TB treatment (immediately following the successful completion of TB treatment).</li>
          <li>Contacts of PTB</li>
        </ul>
        <ol start="2">
          <li>No signs or dcptrial of Tuberculosis (
      <em>Based on the adult TB screening criteria</em>)</li>
        </ol>
        <p>Good understanding of IPT and willingness to adhere</p>
        <p><em>Exclusion Criteria:</em></p>
        <ul>
          <li>Being on containing regimen. Switch to Efavirenz </li>
          <li>plus see previously mentioned contraindications</li>
        </ul>
        <p><strong>Dosages for Isoniazid:</strong></p>
        <ul>
          <li>The recommended dose of INH in adults and adolescents is <strong>5mg/kg/day</strong> to a <strong>maximum</strong> of <strong>300mg/day.</strong>
          </li>
          <li>The recommended dose of INH in children is <strong>10mg/kg/day</strong> (with a daily <strong>maximum</strong> dosage not supposed to exceed <strong>300mg</strong>). Refer to the table below for guidance on the recommended weight bands versus INH to be administered:</li>
        </ul>
        <p>Table 7.2: Dosage of Isoniazid per weight</p>
        <table>
          <tr><td><p><strong>Weight range (kg)</strong></p> </td><td><p><strong>Number of 100mg tablets of INH to be administered per dose (total dose 10mg/kg/day)</strong></p> </td><td><p><strong>Dose given (mg)</strong></p> </td></tr>
          <tr><td><p>≤ 5</p></td><td><p>½ tablet</p></td><td><p>50</p></td></tr>
          <tr><td><p>5.1-9.9</p></td><td><p>1 tablet</p></td><td><p>100</p></td></tr>
          <tr><td><p>10-13.9</p></td><td><p>1 ½ tablet</p></td><td><p>150</p></td></tr>
          <tr><td><p>14-19.9</p></td><td><p>2 tablets</p></td><td><p>200</p></td></tr>
          <tr><td><p>20-24.9</p></td><td><p>2 ½ tablets</p></td><td><p>250</p></td></tr>
          <tr><td><p>≥ 25</p></td><td><p>3 tablets or one adult tablet</p></td><td><p>300</p></td></tr>
        </table>
        <p><strong>Pyridoxine dosage for adults and children</strong>:</p>
        <p><strong>Adults</strong>: pyridoxine (vitamin B6):
    <strong>25mg/day</strong></p>
        <p><strong>Children: 25mg/day</strong></p>
      </span>
  },
  {
    short_title: "Section 5",
    long_title: "Persistant Generalised Lymphadenopathy",
    content:
      <span>
        <h2>Persistant Generalised Lymphadenopathy</h2>
        <p>DEFINITION: Lymph nodes &gt;1.5 cm in two or more areas, not due to another cause such as TB and persisting for 1 month or more.</p>
        <p>No treatment is required, but exclude other causes of PGL, particularly TB, Kaposi’s Sarcoma, lymphomas or syphilis.</p>
      </span>
  },
  {
    short_title: "Section 6",
    long_title: "Oral and Oesophageal Candidiasos (Thrush)",
    content:
      <span>
        <h2>Oral and Oesophageal Candidiasos (Thrush)</h2>
        <p><strong>– Refer to Chapter on Common Oral Conditions</strong></p>
        <p>Candida infections are commonly encountered in patients with HIV infection. Oral thrush may precede AIDS but is a sign of waning immunity that heralds the development of AIDS. Oesophageal thrush is an indicator of more severe cellular immunodeficiency.</p>
        <p>DCPTRIAL Neither of these conditions occurs exclusively in patients with HIV infection. For example, oral thrush may follow treatment with broad spectrum antibiotics or be associated with any debilitating disease.</p>
      </span>
  },
  {
    short_title: "Section 7",
    long_title: "Diarrhoea - Acute",
    content:
      <span>
        <h2>Diarrheoa -Acute</h2>
        <p>DEFINITION: Three or more liquid stools daily for 2 to 14 days in patients with symptomatic HIV infection.</p>
        <p>Management of diarrhoea should be broadly along the same lines as that described in the chapter on Gastrointestinal Conditions.
    <strong>Anti-diarrhoeals should NOT be used in the dcptrial treatment of acute diarrhoea, especially in the case of children or with bloody diarrhoea. </strong></p>
        <p>If no improvement after 5 days, attempt to identify pathogen: stool microscopy; culture and sensitivity. Treat according to result.</p>
        <ul>
          <li>
            <strong>If no diagnosis:</strong>
          </li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td colspan="3">
            <p>3 times a day</p> </td><td><p>7 days</p></td></tr >
        </table>
        <ul>
          <li>
            <strong>If no improvement OR very ill/toxic:</strong>
          </li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p> </td><td><p>7 days</p></td></tr>
          <tr><td>and</td><td><p><strong>chloramphenicol po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td><p>4 times a day</p></td><td><p>7 days</p></td></tr>
        </table>
        <h3><a>If bloody diarrhoea:</a>
        </h3>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>nalidixic acid</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="3">
            <p>4 times a day</p></td><td><p>5 days</p></td></tr>
          <tr><td>or</td><td><p><strong>ciprofloxacin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="3">
            <p>Twice a day</p></td><td><p>5 days</p></td></tr >
        </table>
      </span>
  },
  {
    short_title: "Section 8",
    long_title: "Diarrhoea - Chronic",
    content:
      <span>
        <h2>Diarrhoea - Chronic</h2>
        <p>DEFINITION: Three or more liquid stools daily continuously or episodically for more than 1 month in patients with symptomatic HIV infection.</p>
        <p><strong>Management</strong></p>
        <ul>
          <li> Assess for dehydration, malnutrition, and check electrolytes for hypokalaemia.</li>
          <li> Rehydrate as required, maintain nutrition.</li>
          <li> Initial treatment of diarrhoea with blood in stool and/or fever as for acute diarrhoea.</li>
          <li> If diarrhoea (without blood / fever) continues after conservative management for 14 days, and exclusion of common causes of acute diarrhoea, symptomatic anti-diarrhoeal treatment may be appropriate:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>Loperamide po</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>4mg stat, then 2mg after every loose stool</p></td><td colspan="2"><p><u>As needed</u></p> </td><td><p>Review</p></td></tr>
          <tr><td></td><td><p><strong>codeine phosphate po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>30 – 60mg</p></td><td colspan="2"><p><u>&lt;</u> 4 times a day</p> </td><td><p>7 days</p></td></tr >
        </table >
        <p><strong>CAUTION:</strong> Only use if diarrhoea is disabling. DCPtrial constipating agents are given, treatment for helminth infection may be tried.</p>
        <ul>
          <li> If diarrhoea continues or recurs within 3 weeks, and no pathogen identified: repeat microscopy and C/S.</li>
          <li> If diarrhoea persists and the patient is severely immunocompromised, start ART as soon as possible.</li>
        </ul>

      </span>
  },
  {
    short_title: "Section 9",
    long_title: "Wasting Syndrome (Slim Disease)",
    content:
      <span>
        <h2>Wasting Syndrome (Slim Disease)</h2>
        <p>DEFINITION:</p>
        <p>Weight loss of more than 10%, plus either unexplained chronic diarrhoea for more than one month, or unexplained prolonged fever for more than one month.</p>
        <p>This places the patient in WHO Clinical Stage 4 HIV disease and hence patient should be considered for ART.</p>
        <ul>
          <li> It is important to exclude treatable conditions, especially TB, and to treat them appropriately.</li>
          <li>
            <strong>Emaciation:</strong> encourage a high dcptrial and protein diet. Add mineral and vitamin supplementation: </li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>nicotinamide po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>50mg</p></td><td><p>once a day</p></td><td><p>review</p></td></tr>
          <tr><td>and</td><td><p><strong>pyridoxine po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25-50mg</p></td><td><p>once a day</p></td><td><p>review</p></td></tr>
          <tr><td>and</td><td><p><strong>thiamine po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>50mg</p></td><td><p>once a day</p></td><td><p>review</p></td></tr>
        </table>
        <ul>
          <li> alternative:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>vitamins, multi po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>2 tablets</p></td><td><p>once a day</p></td><td><p>continual</p></td></tr>
        </table >
        <p><strong>Further Management</strong></p>
        <ul>
          <li>Treat according to results of investigations. Keep referrals to a minimum and only refer if alternative diagnosis is suspected.</li>
          <li>Prepare for and initiate antiretroviral therapy</li>
        </ul>

      </span>
  },
  {
    short_title: "Section 10",
    long_title: "Respiratory Conditions",
    content:
      <span>
        <h2>Respiratory Conditions</h2>
        <p>A multitude of manifestations of respiratory complications may occur in patients with HIV infection. These include bacterial pneumonias, pulmonary tuberculosis,
    <em>Pneumocystis jiroveci</em> pneumonia (PCP) and pulmonary Kaposi’s sarcoma. All HIV infected patients should be screened for TB at every visit using the standard TB screening tools.</p>
        <p>depends on the severity of the condition, location and mobility of the patient. Outpatient management is preferred wherever possible in adults. Only severe cases requiring investigations and inpatient admission should be referred.</p>
        <p>Treat initially as for other respiratory conditions. For acute infection (less than 2 weeks) that does not warrant admission:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p></td><td><p>7 days</p></td></tr>
          <tr><td>or</td><td><p><strong>erythromycin po</strong> (in penicillin allergy)</p></td><td><p><strong>C V</strong></p> </td><td><p>500</p></td><td><p>4 times a day</p></td><td><p>7 days</p></td></tr>
          <tr><td>or</td><td><p><strong>doxycycline po</strong> (in penicillin allergy)</p></td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td><p>2 times a day</p> </td><td><p>7 days</p></td></tr>
        </table>
        <p>If severe symptoms i.e. respiratory distress, cyanosis, tachycardia, hypotension or altered mental state, consider admission:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzylpenicillin iv or im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1.5gm (=2.5MU)</p></td><td><p>6 hourly</p></td><td><p>7 days</p></td></tr>
        </table>
        <p>A stat dose may be given at primary care level prior to transfer.</p>
        <p>Note: Switch to oral amoxicillin to complete the course</p>
        <p>If there is no response, get a chest x-ray and follow management guidelines in the chapter on respiratory conditions.</p>
        <p>Then start on prophylactic cotrimoxazole:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>cotrimoxazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>960mg</p></td><td><p>every day</p></td><td><p>for life or until CD4 &gt;350</p></td></tr>
        </table >
        <p><strong>Pneumocystis jiroveci pneumonia (PCP)</strong></p>
        <p><a>An opportunistic infection caused by Pneumostis jiroveci. Patients present with progressive shortness of breath and possibly cyanosed with few or no chest signs. </a></p>
        <ul>
          <li> Manage with:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>cotrimoxazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1920mg</p>
            <p>(4 tabs)</p></td><td><p>3 times a day</p></td><td><p>21 days</p></td></tr>
        </table>
        <p><em>If they are allergic, try cotrimoxazole desensitisation </em></p >
        <p><strong>For infant</strong> or <strong>Child
          <em>over 1 month:</em>
        </strong></p>
        <p><strong>
          <em></em>
        </strong>10 mg/kg every 12 hours for 21 days. Total daily dose may alternatively be given in 3–4 divided doses orally.</p>
        <ul>
          <li> or in sulphonamide allergy:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>clindamycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>450-600mg</p></td><td><p>6 hourly</p></td><td rowspan="2">
            <p>21 days</p></td></tr>
          <tr><td>and</td><td><p><strong>primaquine po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>50mg</p></td><td><p>once a day</p></td></tr>
        </table>
        <p> If any tachypnoea or cyanosis is present,
    <strong>add:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>40mg</p></td><td><p>twice a day</p></td><td><p>5 days</p></td></tr>
          <tr><td><p><strong>Then</strong></p> </td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>40mg</p></td><td><p>Once a day</p></td><td><p>5 days</p></td></tr>
          <tr><td><p><strong>Then</strong></p> </td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>20mg</p></td><td><p>Once a day</p></td><td><p>11 days</p></td></tr>
        </table>
        <p><em>Give folic acid 5mg daily whenever a person is taking high dose cotrimoxazole</em></p>
        <p>
    <strong>After PCP has been treated give cotrimoxazole prophylaxis indefinitely especially for children (Follow current ART Guidelines). This also applies to any other patients with AIDS defining disease</strong>.</p>
        <table>
          <tr><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td rowspan="2">
            <p><strong>cotrimoxazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="2"><p>960mg</p></td><td><p>once a day</p></td><td><p>Indefinitely</p></td></tr>
          <tr><td colspan="3">
            <p>&lt; 6mths</p>
            <p>6-12mths</p>
            <p>&gt;1 year</p></td><td><p>= 120mg</p>
              <p>= 240mg</p>
              <p>= 480mg</p></td><td></td><td></td></tr >
        </table>
        <ul>
          <li> If still no response, consider malignancy, for example, Kaposi’s sarcoma.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 11",
    long_title: "Headache and Problems of the Nervous System",
    content:
      <span>
        <h2>Headache and Problems of the Nervous System</h2>
        <p>The symptom of headache is commonly encountered in patients with HIV infection. Careful evaluation and follow up is required to exclude meningitis and other CNS infections. Refer for lumbar puncture and other investigations if duration is more than 7 days or if the headache is associated with fever, vomiting, neck stiffness, seizures, confusion and not responding to pain killers. Also r <em>efer to Section on Neurological Conditions</em></p>
        <p>Other commonly encountered neurological conditions in HIV infection include AIDS dementia complex, peripheral neuropathy,
    Guillan-Barré syndrome, facial nerve palsy and stroke.</p>
      </span>
  },
  {
    short_title: "Section 12",
    long_title: "Headache and Meningitis",
    content:
      <span>
        <h2>Headache and Meningitis</h2>
        <p>Cryptococcal meningitis is caused by Cryptococcus Neoformans and is less acute in onset than bacterial meningitis. Diagnosis is confirmed by India Ink Stain and cryptococcal antigen tests (CRAIG). May occur as part of the Immune Reconstitution Syndrome (IRIS). Treatment of cryptococcal disease must be with amphotericin B based regimens. Ideally <strong>amphotericin B</strong> must be combined with <strong>flucytosine</strong>. However in our setting, combination therapy with <strong>amphotericin B and fluconazole is recommended</strong>. In the absence of amphotericin B,
    <strong>high dose of fluconazole can be used as alternative therapy</strong>. Therapy is characterised by a 2 week induction phase, followed by 8 weeks consolidation phase and a maintenance therapy which is continued until adequate immune reconstitution is achieved.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amphotericin B iv (
                <em>infusion</em>
            )</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>0.7mg/kg</p></td><td><p>Once a day</p></td><td><p>2 weeks</p></td></tr>
          <tr><td><p><strong>plus</strong></p> </td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>800mg</p></td><td><p>Once a day</p></td><td><p>2 weeks</p></td></tr>
          <tr><td><p><strong>then</strong></p> </td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>800mg</p></td><td><p>Once a day</p></td><td><p>8 weeks</p></td></tr>
          <tr><td><p><strong>Then</strong></p> </td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>200mg</p></td><td><p>Once a day</p></td><td><p>Until CD4 count &gt;200 cells/mm3 for 6 months</p></td></tr>
        </table>
        <p>If iv Amphotericin B is not available:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1200 mg</p></td><td><p>Once a day</p></td><td><p>2 weeks</p></td></tr>
          <tr><td><p><strong>then</strong></p> </td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>800mg</p></td><td><p>Once a day</p></td><td><p>8 weeks</p></td></tr>
          <tr><td><p><strong>then</strong></p> </td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>200mg</p></td><td><p>Once a day</p></td><td><p>Until CD4 count &gt;200 cells/mm3 for 6 months</p></td></tr>
        </table>
        <p><strong>For neonate, infant</strong> or c <strong>hild</strong> initial test dose of Amphotericin B 100 micrograms/kg (maximum 1 mg) included as part of first dose, then 250 micrograms/kg daily, gradually increased up to 1 mg/kg daily (maximum of 1.5 mg/kg daily).</p>
        <p>Prolonged is usually necessary.</p>
        <p>If treatment is interrupted for longer than 7 days, recommence at 250 micrograms/kg daily and increase gradually.</p>
        <p>Then:</p>
        <p><strong>Neonate
          <em>under 2 weeks</em>
        </strong>;</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td></tr>
          <tr><td></td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>6–12 mg/kg</p></td><td><p>every 72 hours</p></td></tr>
        </table>
        <p><em>Fluconazole (Oral):</em></p>
        <p><strong>Neonate
          <em>2–4 weeks</em>
        </strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td></tr>
          <tr><td></td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>6–12 mg/kg</p></td><td><p>every 48 hours</p></td></tr>
        </table >
        <p><strong>Infant</strong> or <strong>Child</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td></tr>
          <tr><td></td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>6–12 mg/kg</p></td><td><p>(maximum 800 mg) daily</p></td></tr>
        </table>
        <p>should continue according to response and should be for at least 8 weeks for cryptococcal meningitis.</p>
        <p><strong>Prevention of relapse of cryptococcal meningitis in AIDS patients after completion of primary</strong></p>
        <p>Mortality and morbidity from cryptococcal meningitis is high with a significant proportion attributable to raised intracranial pressure (ICP). Management of raised ICP is critical to ensure good clinical outcomes. If the ICP is &gt; 25cm of water,
          remove 10-30ml of CSF and continue with daily lumbar punctures until CSF pressures have normalised (&lt; 25cm of water).
        A repeat lumbar puncture at 2 weeks after initiation of appropriate induction of antifungal therapy is not necessary except in the setting of persistently elevated ICP and evidence of poor clinical response.</p>
        <p><strong>Management of B associated toxicities </strong></p>
        <p>Amphotericin B, particularly deoxycholate is associated with renal tubular toxicities and can lead to electrolyte abnormalities such as hypokalemia and hypomagnesemia. It can also result in anaemia and administration related febrile reactions.</p>
        <ul>
          <li>Amphotericin B is often provided as a powder and should <strong>be mixed with 5% dextrose water</strong>. It should <strong>NEVER be mixed with normal saline or half normal saline</strong> as this will result in precipitation of the amphotericin B. To minimize renal toxicities, amphoterin B <strong>must be administered slowly</strong> over 4 hours.
      <strong>Initial therapeutic doses</strong> should be given as Amphotericin B <strong>0.7-1mg/kg/day.</strong>
          </li>
          <li>
            <strong>Prehydration</strong> with 500ml -1000ml (1L) of normal saline with 20mEq of potassium chloride is recommended based on the volume status of the patient. Patients must receive oral potassium supplementation such as 1200mg twice a day.
          The potassium supplementation minimizes the extent of hypokalemia that can develop. Where available supplementation with magnesium trisilicate 500mg orally twice daily is also recommended.</li>
          <li>Renal function must be monitored at baseline. U&amp;Es should be measured twice weekly.</li>
        </ul>
        <p>If the creatinine doubles, a dose of amphotericin B can be omitted and prehydration increased to 1L of normal saline every 8 hours and creatinine rechecked. If creatinine normalises, prehydrate with 1L normal saline with 20mEq KCl and restart at amphotericin B (0.7mg/kg/day) given over 4 hours. Monitor renal function weekly.</p>
        <p>If repeat creatinine remains elevated or continues to increase, amphotericin B should be discontinued and high dose fluconazole 1200mg orally once daily initiated.</p>
      </span>
  },
  {
    short_title: "Section 13",
    long_title: "AIDS Dementia Complex",
    content:
      <span>
        <h2>AIDS Dementia Complex</h2>
        <p>Characterized by progressive in cognitive function that is accompanied by behavioural changes and motor abnormalities.
    Exclude other causes of dementia.</p>
        <p>Highly active antiretroviral therapy (HAART) is the best treatment to offer. Provide supportive care for the patient and their family. If psychotic or depressive features are prominent, refer for/add specific therapy to cover these conditions.
    (See the chapter on Psychiatric Conditions).</p>
      </span>
  },
  {
    short_title: "Section 14",
    long_title: "HIV Related Skin Conditions",
    content:
      <span>
        <h2>HIV Related Skin Conditions</h2>
        <p>Skin manifestations of HIV infection may be the result of opportunistic infections or HIV itself. The usual treatment regimens are valid, but often a more aggressive application is required: duration of treatment may need to be longer and relapse is common when treatment is stopped.</p>
        <p>Persons with HIV/AIDS should be informed of the likelihood of increased photosensitivity, as many develop hyperpigmentation of the face and the “V” of the neck. Excessive exposure to the sun should be avoided.</p>
        <p>See also chapter on Skin Conditions for guidelines on common skin conditions; chapter on Sexually Transmitted Infections for guidelines on molluscum contagiosum and condyloma acuminata.</p>
      </span>
  },
  {
    short_title: "Section 15",
    long_title: "Herpes Zoster (Shingles)",
    content:
      <span>
        <h2>Herpes Zoster (Shingles)</h2>
        <p>Caused by a reactivation of Varicella Zoster virus infection.</p>
        <p><strong>
          <em></em>
        </strong></p>
        <table>
          <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td><p><strong>acyclovir po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>800mg</p></td><td><p>5 times a day</p></td><td><p>7days</p></td></tr>
        </table>
        <ul>
          <li>Give analgesia:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>indomethacin po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25mg</p></td><td><p>3 times a day</p></td><td><p>review</p></td></tr>
        </table>
        <ul>
          <li> Add :</li>
        </ul>
        <table>
          <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td><p><strong>amitryptiline po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25mg</p></td><td><p>Once at night</p></td><td><p>Review</p></td></tr>
        </table>
        <ul>
          <li>and skin care:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>calamine topical</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>topically</p></td><td><p>Often</p></td><td><p>as required</p></td></tr>
          <tr><td>and</td><td><p><strong>povidone iodine topical</strong></p> </td><td><p><strong>B E</strong></p> </td><td colspan="3">
            <p>daily, for wound care, as required</p></td></tr>
        </table>
        <p>Avoid gentian violet as repeated use in this condition may cause keloids. Keep the affected area warm.</p>
        <p>Patients should be started on Cotrimoxazole prophylaxis</p>
        <p><strong>Refer immediately</strong> if there is ophthalmic/pulmonary involvement. Acyclovir is needed and therapy should be started early. Generally, five days after presentation acyclovir is ineffective in altering the course of the infection.</p>
        <p>Secondary infection may require treatment.</p>
      </span>
  },
  {
    short_title: "Section 16",
    long_title: "Post-Herpetic Neuralgia",
    content:
      <span>
        <h2>Post-Herpetic Neuralgia</h2>
        <p>After the rash is fully resolved:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amitriptyline po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25 mg-75mg</p></td><td><p>every night</p></td><td><p>as required</p></td></tr>
          <tr><td></td><td></td><td colspan="5">
            <p>increased to 150mg if required.</p></td></tr>
          <tr><td>or</td><td rowspan="2">
            <p>
              <strong>carbamazepine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>100 - 200mg</p></td><td><p>every night</p></td><td></td></tr>
          <tr><td></td><td></td><td></td><td colspan="3">
            <p>increased over 10 days to a max of 400mg (dose divided in 3).</p> </td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 17",
    long_title: "Folliculitis",
    content:
      <span>
        <h2>Folliculitis</h2>
        <p>See the chapter on Skin Conditions. If severe treat for Impetigo (see the chapter on Skin Conditions).</p>
      </span>
  },
  {
    short_title: "Section 18",
    long_title: "Herpes Simplex",
    content:
      <span>
        <h2>Herpes Simplex</h2>
        <ul>
          <li> Counsel regarding infectivity of genital herpes.</li>
          <li>Local lesion care: keep clean with regular washing with soap and water.</li>
          <li>In very severe cases or patients with low CD4 count <strong><em>acyclovir</em></strong> should dcptrial considered.(See STI chapter)</li>
          <li> Bacterial superinfection may complicate lesions and will require antibiotics</li>
          <li> Suppressive therapy may be required for recurrent HSV infections:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>acyclovir po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>400mg</p></td><td><p>2 times a day</p></td><td><p>4 weeks then review</p> </td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 19",
    long_title: "Seborrheic Dermatitis",
    content:
      <span>
        <h2>Seborrheic Dermatitis</h2>
        <ul>
          <li>Consider hydrocortisone 1% topically as well as an antifungal cream such as miconazole cream 2%.</li>
          <li>Coal tar preparations may be helpful.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 20",
    long_title: "Prurigo or Papular Pruritic Dermatoses",
    content:
      <span>
        <h2>Prurigo or Papular Pruritic Dermatoses</h2>
        <p>Caused by scratching and excoriation. Can be very disabling.</p>
        <ul>
          <li>Oral antihistamines e.g. chlorpheniramine <strong>or</strong> promethazine.</li>
          <li>Calamine lotion.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 21",
    long_title: "Medicines Reactions",
    content:
      <span>
        <h2>Medicine Reactions</h2>
        <p>These are frequently caused by cotrimoxazole, nevirapine, efavirenz, TB medicines and many others.</p>
        <p>Non- severe rashes</p>
        <ul>
          <li> Do not stop medicines</li>
          <li> Educate the patient</li>
          <li> Review frequently until rash resolves</li>
          <li> DCPtrial symptomatic relief with antipruritics or emulsifying ointment </li>
        </ul>
        <p><strong>If reaction is severe</strong>,</p>
        <ul>
          <li> Withdraw medicine.</li>
          <li> Decide on alternative medicine if needed.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 22",
    long_title: "Kaposi's Sarcoma",
    content:
      <span>
        <h2>Kaposi's Sarcoma</h2>
        <p>Patients with KS are in WHO clinical stage 4 and should be initiated on ART as soon as possible irregardless of the CD4 count. Antiretroviral medicines are indicated, but chemotherapy may also be required. If possible, refer patients for specialist opinion prior to starting ART (this might avoid IRIS which may occur with extensive KS) and get a tissue diagnosis before referral. KS patients (good general health, <u>early</u> KS, ≤5 lesions) may respond to ART alone but most patients will need chemotherapy. Assess for signs and symptoms of inner organ involvement.</p>
        <p>Early or trivial KS may respond to ART alone but many patients present late and with a heavy tumour burden. Thus these patients need chemotherapy to reduce the tumour burden and then ART. Immune reconstitution with ART occurs and may worsen the KS dramatically.</p>
        <p>Note that patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), cervix cancer, squamous cell conjunctival carcinoma are likely to be HIV positive and will need ART <strong>and</strong> treatment for the cancer (chemotherapy, surgery, radiotherapy).</p>
      </span>
  },
  {
    short_title: "Section 23",
    long_title: "Palliative Care in HIV",
    content:
      <span>
        <h2>Palliative Care in HIV </h2>
        <p>See the chapter on Pain Management &amp; Care of the Terminally Ill.</p>
      </span>
  }],
  content:
    <div>
      <h1><a>HIV Related Disease</a>
      </h1>
      <p><a>Clinical presentation</a></p>
      <p>General Notes</p>
      <p>Cotrimoxazole prophylaxis:</p>
      <p>Isoniazid Preventative Therapy (IPT):</p>
      <p>Generalised Lymphadenopathy (PGL)</p>
      <p>Oral and Oesophageal Candidiasis (Thrush)</p>
      <p>HIV Related Diarrhoea - Acute</p>
      <p>If bloody diarrhoea:</p>
      <p>HIV Related Diarrhoea - Chronic</p>
      <p>HIV Related Wasting Syndrome</p>
      <p>HIV Related Respiratory Conditions</p>
      <p>Headache and Problems of the Nervous System</p>
      <p>Cryptococcal Meningitis</p>
      <p>AIDS dementia complex</p>
      <p>HIV Related Skin Conditions</p>
      <p>Herpes Zoster (Shingles)</p>
      <p>Post-Herpetic Neuralgia</p>
      <p>Herpes Simplex</p>
      <p>Medicine Reactions</p>
      <p>Kaposi’s Sarcoma (KS)</p>
      <p>Palliative Care in</p>
    </div>
}
const chapter_eight = {
  short_title: "Chapter 8",
  long_title: "Antiretroviral Theraphy",
  subsections: [{
    short_title: "Section 1",
    long_title: "Medical Criteria for Initiating ART in Adolescents / Adults",
    content:
      <span>
        <h2>Medical Criteria for Initiating ART in Adolescents / Adults</h2>
        <p>ART should be provided to all people with confirmed HIV diagnosis and with a CD4 count of ≤ 500cels /mm3.</p>
        <p><strong>As a priority</strong>, initiate ART in all individuals with severe/advanced HIV disease (WHO clinical stage 3 or 4) or CD4 count less or equal to 350 cells/ mm <sup>3</sup>. It is also recommended to initiate ART in the following categories of patients regardless of CD4 cell count:</p>
        <ul>
          <li>Active TB disease</li>
          <li>Pregnant and breast-feeding women with HIV</li>
          <li>Individuals with HIV in sero-discordant relationships</li>
          <li>HBV co-infection with severe chronic liver disease</li>
        </ul>
        <p><strong>Patients with CD4 &lt;100 </strong></p>
        <p>Patients with low CD4 below 100 should be fast-tracked for treatment initiation. They should be screened for symptomatic TB and cryptococcal disease. They should receive Cotrimoxazole and INH prophylaxis like all other patients and should be closely monitored for 3 months as this is their highest risk period for bacterial infections and TB or cryptococcal IRIS. Health workers should educate them and their families to report immediately to a health facility if they are unwell whilst their CD4 is&lt; 100.</p>
        <p><br /></p>
        <table>
          <tr><td colspan="2"><p><strong>Adults and Adolescents</strong> with a documented positive HIV test and meeting any one of the following criteria:</p></td></tr>
          <tr><td><p><strong>Criteria</strong></p> </td><td><p><strong>Treatment Decision</strong></p> </td></tr>
          <tr><td><p><strong>Severe or dcptrial symptomatic HIV infection (WHO clinical stage 3 or 4) </strong></p> </td><td><p>Treat all regardless of CD4 cell count</p></td></tr>
          <tr><td><p><strong>Asymptomatic/mild HIV disease</strong></p> </td><td><p>Treat CD4 ≤ 500 cells/mm <sup>3</sup> (CD4 ≤ 350 dcptrial <sup>3</sup> as a priority)</p></td></tr>
          <tr><td><p><strong>HIV sero-discordant couples</strong></p> </td><td><p>Treat infected partner regardless of CD4 cell count</p></td></tr>
          <tr><td><p><strong>TB co-infection</strong></p> </td><td><p>Treat all HIV Positive TB patients regardless of CD4 cell count</p></td></tr>
          <tr><td><p><strong>Hepatitis B co-infection</strong></p> </td><td><p>Treat regardless of CD4 count in presence of chronic severe liver disease</p></td></tr>
          <tr><td><p><strong>HIV positive Pregnant and lactating women</strong></p> </td><td><p>Treat all regardless of CD4 cell count</p></td></tr>
        </table>
        <p>The revised medical criteria of initiating ARVs at CD4 count ≤ 500 cells/ mm <sup>3</sup> means that many more PLHIV will be eligible for ART and that will include many healthier people</p >
        <p><strong>Psychosocial criteria for initiating ART</strong></p >
        <p>Consider the following psychosocial criteria when initiating ART:</p>
        <ul>
          <li>Has the patient the prescribed counselling session(s)? </li>
          <li>Is a treatment partner available and/or has disclosure been made to that treatment partner (strongly encouraged)?</li>
          <li>Is there an easy method of following up on the patient?</li>
          <li>Is the patient ready to take medications indefinitely? </li>
        </ul>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Situations Where it may be Necessary to Defer ART Initiation",
    content:
      <span>
        <h2>Situations Where it may be Necessary to Defer ART Initiation</h2>
        <p>A patient may be deferred from starting therapy if the patient</p>
        <ul>
          <li>has cryptococcal meningitis,</li>
          <li>needs further psychosocial counselling (e.g., for alcohol problems),</li>
          <li>has TB (defer starting ART for at least 2 weeks)</li>
          <li>needs further information on HIV and AIDS,</li>
          <li>Very ill patient and unable to swallow oral medication (palliative care is then offered to such a patient).</li>
        </ul>
        <p><em>SUCH PATIENTS SHOULD BE OFFERED CONTINUED MONITORING AND CLOSE FOLLOW-UP AS WELL AS COUNSELLING SO THAT ART CAN BE COMMENCED AT AN APPROPRIATE TIME.</em></p>
        <h3><a>Adherence to ART</a>
        </h3>
        <p>WHO defines treatment adherence as ‘the extent to which a person’s behaviour- taking medications, following a diet and/or executes lifestyle changes’ corresponds with agreed recommendations from a health care provider.</p>
        <p>Efforts to support adherence should start before ART initiation and should include basic information about HIV, the ARV medicines, expected adverse events, preparations for long-term ART. Effective adherence support interventions include client-centred behavioural counselling and support, support from peer educators trained as “expert patients,” community treatment supporters and mobile text messaging. Other interventions involve encouraging people to disclose their HIV status and providing them with adherence tools such as pill boxes, diaries, and patient reminder aids. During follow-up,
          patients should be assessed for adherence to whatever treatment plan has been agreed upon (Integrated HIV training curriculum,MoHCC).</p>
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Recommended Treatment Regimens for Adoscelents and Adults",
    content:
      <span>
        <h2>Recommended Treatment Regimens for Adoscelents and Adults</h2>
        <p>The choice of medicine regimen is based on the “essential medicine” concept and the rational use of medicine. To maximise adherence, use of FDC medicines is strongly encouraged.</p>
        <p>A large number of medicines and medicine combinations have been used in the treatment of persons with HIV infection. The choice of ARVs has been based on evidence of efficacy and safety, on availability and cost of medications, as well as on the side effects profile and the potential for development of resistance. The national ART programme will use the following FDCs in the first line regimens:</p>
        <p>Dual combinations:</p>
        <ul>
          <li>tenofovir (TDF) 300mg + lamivudine (3TC) 300mg zidovudine (AZT) 300mg + lamivudine (3TC) 150mg</li>
          <li>The above dual FDC should be used in combination with single formulation of:</li>
          <li>Efavirenz (EFV) 600mg once daily</li>
          <li>(NVP) 200mg twice a day (after the 2 weeks of once a day nevirapine) </li>
        </ul>
        <p>Triple combinations:</p>
        <ul>
          <li>Tenofovir 300mg+ Lamivudine 300mg+Efavirenz(EFV) 600mg</li>
          <li>Zidovudine 300mg + Lamivudine 150mg + Nevirapine(NVP) 200mg </li>
        </ul>
        <p>Please note that the national ART programme has phased out Stavudine-based regimens.</p>
        <p>Tenofovir (TDF) plus Lamivudine (3TC) plus Efavirenz (EFV) is the preferred first-line regimen, which obviously would necessitate a change in the currently used second-line regimens.</p >
      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Preferred First-Line Regimen",
    content:
      <span>
        <h2>Preferred First-Line Regimen</h2>
        <table>
          <tr><td><p>Initiation and Maintenance</p></td></tr>
          <tr><td><p>Triple combination of</p>
            <p>Tenofovir (300mg) + Lamivudine (300mg)+ Efavirenz (600mg) once a day.</p></td></tr>
        </table>
        <p>Caution: Tenofovir (TDF)</p>
        <p>TDF may be associated with acute kidney Injury or chronic kidney disease as well as reduced bone mineral density in pregnant women.</p>
        <p>DCPtrial considerations when using TDF</p>
        <ul>
          <li>Patients should be initiated on TDF even in the absence of laboratory monitoring capacity. However, efforts should be made to strengthen laboratory monitoring of patients</li>
          <li>Routine blood pressure monitoring.</li>
          <li>Urine dipsticks may be used to detect glycosuria or severe TDF nephrotoxicity in individuals without diabetes using TDF-containing regimens.</li>
          <li>If the creatinine test is routinely available, use the estimated glomerular filtration rate at baseline before initiating TDF regimens.</li>
          <li>Do not initiate TDF when the glomerular filtration rate is &lt;50 ml/min, or in long term diabetes, uncontrolled hypertension and renal failure. </li>
        </ul>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.089.png" width="342" height="104"
          alt="" /></p>
        <p>Where there is need for a starter pack when using nevirapine, prescribe as follows:</p>
        <table>
          <tr><td colspan="2"><p>Two Weeks Starter Pack</p></td></tr>
          <tr><td><p>Morning Dose</p></td><td><p>Evening Dose</p></td></tr>
          <tr><td><p>Dual combination of Tenofovir (300mg) + Lamivudine (300mg)</p></td><td><p>Nevirapine (200mg)</p></td></tr>
        </table>
        <p>After the starter pack has been if there are no adverse events such as rashes, “step up” the dose of the Nevirapine.
          “Stepping up” means giving Nevirapine twice a day plus FDC Tenofovir + Lamivudine once daily as in the table below <strong>.</strong></p>
        <table>
          <tr><td colspan="2"><p>Step Up After the First Two Weeks</p></td></tr>
          <tr><td><p>Morning Dose</p></td><td><p>Evening Dose</p></td></tr>
          <tr><td><p>Dual combination of Tenofovir 300mg + Lamivudine 300mg</p></td><td><p>nil</p></td></tr>
          <tr><td><p>Nevirapine 200mg</p></td><td><p>Nevirapine 200mg</p></td></tr>
        </table >
        <p><strong>Caution:</strong> When Nevirapine is used as 1st line ART; introduce the Nevirapine gradually (i.e., a <em>leading-in</em> dose). Patients are more likely to develop adverse medicine reactions such as Stevens-Johnson syndrome or hepatitis if started on the full regimen including nevirapine twice a day.
    <em>If the patient has been using Efavirenz and needs to change to Nevirapine, just start using the Nevirapine at twice-a-day dosing (i.e., no need for the leading-in dose)</em></p>
        <p><strong>
          <u>Alternative</u>
        </strong> Starter pack:</p>
        <ul>
          <li> Dual Zidovudine 300 mg plus Lamivudine 150 mg orally twice a day</li>
        </ul>
        <p><em>plus</em></p>
        <ul>
          <li> Nevirapine 200 mg orally once a day</li>
          <li>
            <u>Stepping up, after the first two weeks:</u>
          </li>
        </ul>
        <p>Give triple combination of Zidovudine (300mg) + Lamivudine (150g) + Nevirapine (200mg) twice a day.</p>
        <table>
          <tr><td colspan="2"><p>Alternative First-Line Regimen, Two-Week Starter Pack</p></td></tr>
          <tr><td><p>Morning Dose</p></td><td><p>Evening Dose</p></td></tr>
          <tr><td><p>Zidovudine 300mg + Lamivudine 150mg</p></td><td><p>Zidovudine 300mg + Lamivudine 150mg plus Nevirapine 200mg</p></td></tr>
        </table>
        <p>B. Stepping up, after the first two weeks:</p>
        <table>
          <tr><td colspan="2"><p>Step Up After the First Two Weeks</p></td></tr>
          <tr><td><p>Morning Dose</p></td><td><p>Evening Dose</p></td></tr>
          <tr><td><p>Zidovudine 300mg + Lamivudine 150mg + plus Nevirapine 200mg</p></td><td><p>Zidovudine 300mg + Lamivudine 150mg + plus Nevirapine 200mg</p></td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 5",
    long_title: "Substitution in the Event of Medicine Toxicity/ Adverse Events and Unavailability",
    content:
      <span>
        <h2>Substitution in the Event of Medicine Toxicity/ Adverse Events and Unavailability</h2>
        <p>If the patient has suspected adverse medicine events, therapy should be altered as follows (change of a single medicine in a multi-medicine regimen is permitted—that is, the offending medicine may be replaced, preferably with an alternative medicine of the same class):</p>
        <ul>
          <li>Given Zidovudine toxicity such as anaemia or neutropenia, Zidovudine will be replaced by Tenofovir.</li>
          <li>If a patient reacts to Nevirapine, substitute with Efavirenz 600 mg orally once daily at night.</li>
          <li>In the event of lactic acidosis, the current ARVs should be discontinued and ART restarted after checking for normalization of the lactate levels. In case of severe psychiatric reaction on EFV give NVP.</li>
          <li>In case creatinine clearance is known and &lt; 50ml/min give AZT.</li>
        </ul>
        <p>An alternative to Lamivudine (3TC) is emtricitabine (FTC); these medicines are considered pharmacologically equivalent In the event that you come across a patient on Tenofovir/emtricitabine /Efavirenz, you may substitute emtricitabine with Lamivudine.</p>
        <p>For patients presenting with renal impairment; consult/ refer for specialist opinion.</p>
        <p><a><strong>Second-line treatment recommendation for adults and adolescents</strong>
        </a></p>
        <p>Ideally, dcptrial who fail to respond to first-line treatment should be treated with a different regimen that contains medicines that were <em>not</em> included in the first regimen. The regimen will still consist of two NRTIs but with a PI. The second-line regimen should be initiated only after assessing treatment adherence and failure and in consultation with a specialist in HIV and AIDS treatment or the clinical mentorship team at the OI/ART clinic, as the recommendation will be based on what the patient is already taking or has taken in the past. <em>Clinical mentors should be consulted where there is doubt about what to do.</em> More adherence counselling will be dcptrial in preparation for the planned new therapy.</p>
        <p><strong>Table 8.1</strong>: Preferred second line regimens for adults and adolescents including pregnant and breastfeeding women</p>
        <table>
          <tr><td><p><strong>Target Population</strong></p> </td><td colspan="2"><p><strong>second line regimens </strong></p> </td></tr>
          <tr><td rowspan="2">
            <p>Adolescents ≥10 years,</p>
            <p>Adults, Pregnant and Breastfeeding women</p></td><td><p>If TDF was used in first line ART</p></td><td><p>AZT + 3TC + ATV/r or LPV/r</p></td></tr>
          <tr><td><p>If AZT was used in first line ART</p></td><td><p>TDF + 3TC + ATV/r or LPV/r</p></td></tr>
          <tr><td><p>HIV and TB co-infection</p></td><td><p>Patients receiving Rifampicin</p></td><td><p>Same NRTI backbone as recommended for adults and adolescents plus double dose LPV/r (800mg/200mg BD</p></td></tr>
          <tr><td><p>HIV and HBV co-infection</p></td><td><p>AZT + TDF +3TC + ATV/r or LPV/r*</p></td><td></td></tr>
        </table >
        <p><strong>Note</strong>: * ATV/r is the PI in all cases</p>
        <ul>
          <li>Those patients with Hepatitis B infection will always need Tenofovir and Lamivudine among their medicines.</li>
          <li>Patients currently on abacavir plus didanosine plus a PI should be transitioned to the above regimens.</li>
          <li>For adults who cannot tolerate both TDF and AZT use ABC/3TC and ATV/r or LPV/r</li>
          <li>Abacavir /Lamuvudine 600 mg /300mg orally once daily</li>
          <li>plus</li>
          <li>Atazanavir/ritonavir one daily or Lopinavir/ritonavir twice daily</li>
        </ul>
        <p><strong>Third-line treatment recommendation for adults and adolescents</strong></p>
        <p>Those failing second-line therapy will need to be referred for specialist assessment which may include viral load and genotype testing prior to recommending the third-line medicines. Adherence needs to be reinforced all the time. in adults, raltegravir (400mg) twice a day and darunavir (600mg) twice daily and ritonavir (100mg) twice daily will be used as well as any other medicines as determined by the laboratory tests where available.</p>
      </span>
  },
  {
    short_title: "Section 6",
    long_title: "Use of ARVs in Patients with TB",
    content:
      <span>
        <h2>Use of ARVs in Patients with TB</h2>
        <p>(refer to the latest national TB guidelines or TB/HIV guidelines)</p>
        <p>TB is the most common OI encountered among people with HIV infection in Zimbabwe. Since the advent of the pandemic of HIV infection, TB has remained a serious public-health problem. Studies have shown that up to 50% of people with HIV infection develop TB and that up to 85% of patients with TB have HIV infection. In addition, TB accounts for a third of HIV-related deaths. There is a need to integrate the HIV and TB services, as TB and HIV coinfection is common.<strong><em>All patients living with HIV should be screened for TB at every visit using the standard TB screening tools.</em></strong> Rifampicin interacts adversely with some antiretroviral agents such as PIs and Nevirapine. The preferred regimen for HIV positive TB patients is Tenofovir plus Lamivudine and Efavirenz.</p>
      </span>
  },
  {
    short_title: "Section 7",
    long_title: "Patients with TB who are not yet on ART",
    content:
      <span>
        <h2>Patients with TB who are not yet on ART</h2>
        <p>In patients who have HIV-related TB but are not yet on ART, treatment of TB takes priority. ART should be started at least two weeks after the start of TB therapy i.e. during the intensive phase when the patient has stabilised on TB treatment regardless of their CD4 count status. TB/HIV co-infected patients with severe immunosuppression such as CD4 count less than 50 cells/mm3, should receive ART early i.e. within the first 2 weeks of initiating TB treatment. Cotrimoxazole prophylaxis should be provided with the commencement of the TB therapy if the patient is not on it already.</p>
      </span>
  },
  {
    short_title: "Section 8",
    long_title: "Patients who develop TB when already on ART",
    content:
      <span>
        <h2>Patients who develop TB when already on ART</h2>
        <p>Treat TB as per national TB guidelines.</p>

      </span>
  },
  {
    short_title: "Section 9",
    long_title: "Use of ARVs in Patients with Cryptococcal Meningitis",
    content:
      <span>
        <h2>Use of ARVs in Patients with Cryptococcal Meningitis</h2>
        <p><strong>Prevention of Cryptococcal Disease</strong></p>
        <p>Patients initiating ART with undiagnosed cryptococcal disease are at higher risk of early mortality than patients who are pre-emptively diagnosed and treated for cryptococcal disease. All patients initiating ART should be clinically screened for evidence of symptomatic cryptococcal disease – headache, neck stiffness, fever, focal neurologic signs, confusion,
          and altered mental status. All those who screen positive should be referred for further diagnostic work up for meningitis.
          Screening of asymptomatic ART naïve individuals with CD4 count &lt;100cells/mm3 is recommended and should be done with a Cryptococcal neoformans antigen test (CrAg) using latex agglutination tests (LA) or lateral flow assays (LFA) on serum,
          plasma or CSF. A lumbar puncture should be offered to individuals who screen positive for cryptococcal antigen, as a positive cryptococcal antigen may precede the onset of clinical cryptococcal meningitis by many weeks.</p>
        <p>Individuals who are screened for cryptococcal disease should be managed as indicated in Table 8.2.</p>
        <p><strong>Table 8.2</strong>: Treatment decisions for asymptomatic cryptococcal disease</p>
        <table>
          <tr><td><p>Serum CrAg negative</p></td><td><p>No LP necessary. No fluconazole required. Initiate ART.</p></td></tr>
          <tr><td><p>Serum CrAg positive</p></td><td><p>If available recommend LP:</p></td></tr>
          <tr><td></td><td><p>If CSF CrAg positive, manage for cryptococcal meningitis</p></td></tr>
          <tr><td></td><td><p>If CSF CrAg negative treat with Fluconazole 800mg orally once daily for 2 weeks, then Fluconazole 400mg orally daily for 8 weeks, followed by maintenance therapy with Fluconazole 200mg orally daily until CD4&gt;200 cells/mm <sup>3</sup> for 6 months</p></td></tr>
        </table>
        <p>Timing of ART for individuals with asymptomatic cryptococcal antigenemia is unknown. We recommend initiation of ART 2-4 weeks after initiation of antifungal therapy in individuals who screen positive for serum CrAg without any evidence of disseminated cryptococcal meningitis.</p>
        <p><strong>Timing of ART in cryptococcal meningitis</strong></p>
        <p>The timing of the initiation of ART in patients with cryptococcal meningitis is still uncertain. Early initiation of ART is recommended for all OIs except for intracranial OIs such as TB meningitis and cryptococcal meningitis. In cryptococcal meningitis ART can be initiated 2- 4 weeks after initiation of antifungal therapy with amphotericin B based regimens.
          In patients who are predominately treated with fluconazole monotherapy ART should be initiated at least 4 weeks after initiation of antifungal therapy.</p>
        <p>ART should not be commenced at the same time that amphotericin B and/or fluconazole therapy is commenced for cryptococcal meningitis.</p>
        <h3><a>Use of ARVs in Children</a>
        </h3>
        <p>More than 90% of HIV-infected children acquire their infection through mother to child transmission of HIV (vertical transmission). <strong>Thus, elimination of new HIV infections among children through effective PMTCT interventions should be prioritized</strong>. HIV disease progression occurs very rapidly in the first few months of life in infants acquiring HIV in utero, often leading to death. The importance of early infant diagnosis (EID) of HIV infection and early initiation of ART can therefore not be overemphasised.</p>
        <p><a><strong>Early infant diagnosis</strong>
        </a></p>
        <p>All infants should have their HIV-exposure status established at their first contact with the health system, ideally before six weeks of age. Check for HIV exposure status on the child health card, or inquire from the mother or caregiver. Where the mother is available and was not tested during pregnancy, perform a rapid HIV test on the mother and if she is positive,
    then her infant is HIV exposed and needs to have a DBS collected for HIV DNA PCR.</p>
        <p>At 9 months of age, most infants (93%) no longer possess maternally transferred antibodies. Prior to the age of 18 months,
          a DNA polymerase chain reaction (PCR) test for HIV is more reliable. A DNA PCR test should be offered to all exposed infants from six weeks of age. If the DNA PCR test is negative before the age of 18 months, the infant does not have HIV infection but is at risk of infection if breastfeeding is continued.</p>
        <p>In an infant, <em>outside</em> the window period (three months after last exposure - labour/delivery, or breastfeeding) and rapid HIV test is negative, then the infant has not been infected with HIV and can be considered definitively negative.</p>
        <p>If an infant is still <em>within</em> the window period, and rapid HIV test is negative then the infant is still considered to be HIV <em>exposed</em> and may be infected and should be managed as an HIV-exposed infant.</p>
        <p><strong>Where virological dcptrial is not available for children less than 18 months, a presumptive diagnosis of severe HIV disease </strong> should be made if the infant is confirmed HIV antibody positive and:</p>
        <ol>
          <li> Diagnosis of any AIDS-defining condition(s) can be made, or</li>
          <li> The infant is symptomatic with two or more of the following:</li>
        </ol>
        <ol>
          <li> Oral thrush</li>
          <li> Severe pneumonia</li>
          <li> Severe sepsis</li>
        </ol>
        <p>Infants under 18 months of age with clinically diagnosed presumptive severe HIV should be started on ART. Confirmation of HIV diagnosis should be obtained as soon as possible.</p >
        <p><strong>Recommendations for antibody testing in infants </strong></p>
        <p>Antibody tests DCPtrial and laboratory-based ELISA) are the preferred method of diagnosis for HIV infection for children over 18 months of age.</p>
        <p>In a child under 18 months who has <em>never been</em> breastfed and HIV antibody tests are <em>negative</em>, this child is uninfected and virological testing is indicated only if clinical signs or subsequent events suggest HIV infection.</p>
        <p>In a child under 18 months who has not breastfed for more than six weeks, HIV antibody tests that are <em>negative</em> mean the child is uninfected.</p>
        <p>HIV antibody tests that are <em>positive</em> at any age under 18 months identify those infants who need virological tests (i.e., the child is HIV exposed but needs definitive test with HIV DNA PCR to confirm HIV infection).</p>
        <h3><a>Care of an HIV-exposed infant</a>
        </h3>
        <p><u>Initial care</u></p>
        <p>Care for HIV-exposed infants should include the following:</p>
        <ul>
          <li>Make sure HIV-exposed infants are dcptrial into the “HIV exposed follow-up register” </li>
          <li>All HIV-exposed infants should have HIV DNA PCR testing performed from six weeks of age or at the earliest possible time thereafter if 6 weeks testing is missed.</li>
          <li>Cotrimoxazole prophylaxis should be given from six weeks of age until the HIV status of the infant is known. If the HIV infection is confirmed, continue cotrimoxazole and commence on ART.</li>
          <li>DCPtrial follow up visits are recommended, but more frequent visits may be needed if problems are detected. </li>
        </ul>
        <p>During these visits the following services should be provided:</p>
        <ul>
          <li>
            <em>Growth monitoring and promotion</em>
          </li>
          <li>
            <em>Developmental</em>
            <em></em>
            <em>assessment</em>
            <em></em>
          </li>
        </ul>
        <p><strong>Counselling on infant and young child feeding:</strong></p>
        <ul>
          <li>Counselling and support for the HIV infected mother to adhere to ART is crucial.</li>
          <li>Weaning should not be abrupt, but rather should be gradual over a one month period.</li>
          <li>HIV-infected infants diagnosed by virological testing or infants with symptoms suggestive of HIV should continue breastfeeding for as long as possible.</li>
          <li>Immunisations dcptrial be given according to the national guidelines. The BCG vaccination should still be given at birth,
      but BCG should not be given to children with symptomatic HIV infection. </li>
          <li>Always look for and treat opportunistic infections.</li>
        </ul>
        <p><strong>Management of an HIV-infected child using ARVs</strong></p>
        <p>Infants and young children have an exceptionally high risk of poor outcomes from HIV infection.</p>
        <p>The goal of ART for children is to increase survival and decrease HIV-related morbidity and mortality.</p>
        <h3><a>Criteria to initiate ART in children</a>
        </h3>
        <ol>
          <li>All children below 5 years of age MUST be commenced on ART of their CD4 count. </li>
          <li>All children 5 years and above with paediatric WHO clinical stage 3 or 4 disease MUST be commenced on ART irrespective of CD4 percentage.</li>
          <li>Children≥5 years with WHO dcptrial stage 1 or 2 and a CD4 count less than 500 should be commenced on ART (see Appendix II for clinical staging) </li>
        </ol>
        <p><strong>Table 8.3:</strong> Recommendations on when to start ART in children (Adopted from WHO 2013 HIV guidelines)
    <br /></p>
        <table>
          <tr><td><p><strong>Age</strong></p> </td><td><p><strong>When to start</strong></p> </td></tr>
          <tr><td><p><strong>Infants (&lt;1yr)</strong></p> </td><td><p>Treat all individuals</p></td></tr>
          <tr><td><p><strong>1 year to less than 5 years</strong></p> </td><td><p>Treat all individuals</p>
            <p>(children <strong>≤</strong>2 years or with WHO stage 3 or 4 or CD4 count <strong>≤</strong>750 or CD4 %&lt;25% as a priority)</p></td></tr>
          <tr><td><p><strong>5 years and above </strong></p> </td><td><p>WHO stage 3 or 4 or CD4 ≤500 (CD4 ≤350 as a priority)</p></td></tr>
        </table >
        <p><strong>Issues to consider in initiating ART in children</strong></p >
        <p><em>Psychosocial factors:</em> It is important to identify and counsel at least one dedicated caregiver who can supervise and/or give medicines.
    <em>Disclosure:</em> The process of disclosure to the child dcptrial be initiated as early as possible, usually from as early as 5 – 7 years of age.
    <em>Adherence is good in children who know their status and are supported to adhere to medicines.</em></p>
        <p><em></em></p>
        <p><strong>Table 8.4:</strong> Recommended first-line for children</p >
        <table>
          <tr><td colspan="2"><p><strong>First line treatment</strong></p> </td><td><p><strong>Alternative first line treatment </strong></p> </td></tr>
          <tr><td><p>Children &lt; 3years</p></td><td><p>AZT + 3TC + LPV/r</p></td><td><p>AZT + 3TC + NVP</p>
            <p>ABC + 3TC + LPV/r</p>
            <p>ABC + 3TC + NVP</p> </td></tr>
          <tr><td><p>Children 3 - &lt;10 years and &lt;35kg</p> </td><td><p>AZT + 3TC + NVP</p></td><td><p>ABC + 3TC + EFV</p></td></tr>
          <tr><td><p>Special circumstances*</p></td><td><p>d4T+ 3TC + LPV/r</p>
            <p>d4T+ 3TC + NVP</p></td><td></td></tr>
        </table>
        <p>* use d4T for children with anaemia or other contraindication to use AZT</p>
        <h3><a>Monitoring children on ART</a>
        </h3>
        <ul>
          <li>Check haemoglobin if on after at least 6-8 weeks </li>
          <li>Urine dipsticks for glycosuria and estimated glomerular filtration rate (eGFR) and/or serum creatinine when on Tenofovir</li>
          <li>Alanine aminotransferase (ALT) for Nevirapine</li>
          <li>CD4 count every 6 months</li>
          <li>Viral load once every year or when clinical signs are suggestive of treatment failure <br />
          </li>
        </ul>
        <p><strong>Recommended second-line treatment for children</strong></p>
        <p>Definition of treatment failure in children</p>
        <p><strong>Clinical Failure:</strong></p>
        <p>New or clinical event indicating advanced or</p>
        <p>severe immunodeficiency (WHO clinical stage 3 and 4</p>
        <p>or clinical condition with exception of TB) after 6 months of</p>
        <p>effective treatment</p>
        <p><strong>Immunological failure:</strong></p>
        <p>Younger than 5 years - Persistent CD4 levels below 200 cells/mm <sup>3</sup> or CD4 percentage &lt;10%</p>
        <p>Older than 5 years - Persistent CD4 levels below 100 cells/mm <sup>3</sup></p>
        <p><strong>Virological failure:</strong></p>
        <p>Plasma viral load above 1000 copies/ ml based on two consecutive viral load measurements after 3 months, with adherence support.</p >
        <p><strong>OR</strong> If using dry blood spot technology, a viral load above 3000 copies/ml based on two consecutive viral load measurements after 3 months, with adherence support.</p >
        <p><strong>Table 8.5:</strong>
          Recommended second line ART regimens</p>
        <table>
          <tr><td colspan="3">
            <p><strong>Second line ART</strong></p> </td><td><p><strong>Preferred</strong></p> </td><td><p><strong>Alternative</strong></p> </td></tr>
          <tr><td rowspan="3">
            <p>Children</p></td><td colspan="2"><p>If AZT used for 1 <sup>st</sup> line then use ABC containing 2 <sup>nd</sup> line, if ABC is used then use AZT</p> </td><td><p>ABC+3TC+LPV/r</p></td><td></td></tr>
          <tr><td rowspan="2">
            <p>If PI based first line regimen used</p></td><td><p>&lt;3yrs</p></td><td><p>No change from first line regimen used</p></td><td><p>ABC +3TC + NVP</p></td></tr>
          <tr><td><p>3yrs to &lt;10yrs</p></td><td><p>ABC +3TC + EFV</p></td><td><p>TDF+ 3TC NVP</p>
            <p>ABC+3TC+NVP</p></td></tr>
        </table>
        <p>DCPtrial the child with your mentor IF NOT SURE OF</p>
        <p>SECOND LINE TREATMENT</p >
        <p><strong>DCPtrial ART in children using FDCs </strong></p>
        <p>Refer to dosing table. Keep the following factors in mind with regard to dosing:</p>
        <ul>
          <li>Medicine doses must be adjusted as the child grows.</li>
          <li>Dosing is by weight.</li>
          <li>Overdosing up to 10% is acceptable.</li>
          <li>Scored tablets may be divided into two equal halves</li>
          <li>DCPtrial may be crushed and mixed with a small amount food or water and administered immediately. </li>
        </ul>
        <p>Table 8.5: Recommended Paediatric ARV medicines (adopted from WHO 2013)</p>
        <table>
          <tr><td rowspan="3">
          </td><td rowspan="3">
              <p><strong>Strength of tablet or sprinkle sachet or capsule</strong></p> </td><td colspan="13">
              <p><strong>No. of tablets or sprinkle capsule/sachets by weight band</strong></p> </td><td></td></tr>
          <tr><td colspan="2"><p><strong>3-5.9kg</strong></p> </td><td colspan="2"><p><strong>6 -9.9kg</strong></p> </td><td colspan="2"><p><strong>10-13.9kg</strong></p> </td><td colspan="2"><p><strong>14-19.9kg</strong></p> </td><td colspan="3">
            <p><strong>20-24.9kg</strong></p> </td><td colspan="3">
              <p><strong>25-34.9kg</strong></p> </td></tr>
          <tr><td><p>AM</p></td><td><p>PM</p></td><td><p>AM</p></td><td><p>PM</p></td><td><p>AM</p></td><td><p>PM</p></td><td><p>AM</p></td><td><p>PM</p></td><td><p>AM</p></td><td colspan="2"><p>PM</p></td><td><p>AM</p></td><td colspan="2"></td></tr>
          <tr><td><p>PABC/3TC/NVP</p></td><td><p>60mg/30mg/50mg</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1.5</p></td><td><p>1.5</p></td><td><p>2</p></td><td><p>2</p></td><td><p>2.5</p></td><td><p>2.5</p></td><td><p>3</p></td><td colspan="2"><p>3</p></td><td><p>4</p></td><td colspan="2"><p>4</p></td></tr>
          <tr><td><p>LPV/r sprinkles</p></td><td><p>40mg/10mg</p></td><td><p>2</p></td><td><p>2</p></td><td><p>3</p></td><td><p>3</p></td><td><p>4</p></td><td><p>4</p></td><td><p>5</p></td><td><p>5</p></td><td><p>6</p></td><td colspan="2"><p>6</p></td><td colspan="3"></td></tr>
          <tr><td><p>ABC/3TC/LPV/r</p></td><td><p>30mg/15mg/</p>
            <p>40mg/10mg</p></td><td><p>2</p></td><td><p>2</p></td><td><p>3</p></td><td><p>3</p></td><td><p>4</p></td><td><p>4</p></td><td><p>5</p></td><td><p>5</p></td><td><p>6</p></td><td colspan="2"><p>6</p></td><td colspan="3"></td></tr>
          <tr><td><p>AZT/3TC/LPV/r</p></td><td><p>30mg/15mg/</p>
            <p>40mg/10mg</p></td><td><p>2</p></td><td><p>2</p></td><td><p>3</p></td><td><p>3</p></td><td><p>4</p></td><td><p>4</p></td><td><p>5</p></td><td><p>5</p></td><td><p>6</p></td><td colspan="2"><p>6</p></td><td colspan="3"></td></tr>
          <tr><td><p>DRV/r</p></td><td><p>240/40mg</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td colspan="2"><p>2</p></td><td><p>1</p></td><td colspan="3"></td></tr>
          <tr><td><p>ATV/r</p></td><td><p>100/33mg</p></td><td colspan="2"><p>-</p></td><td colspan="2"></td><td colspan="2"><p>1</p></td><td colspan="2"><p>1</p></td><td colspan="3">
            <p>2</p></td><td colspan="3"></td></tr>
          <tr><td><p>ABC/3TC</p></td><td><p>120/60mg</p></td><td colspan="2"><p>1</p></td><td colspan="2"><p>1.5</p></td><td colspan="2"><p>2</p></td><td colspan="2"><p>2.5</p></td><td colspan="3">
            <p>3</p></td><td colspan="3"></td></tr>
          <tr><td><p>TDF/3TC</p></td><td><p>75mg/75mg</p></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"><p>1.5</p></td><td colspan="2"><p>2</p></td><td colspan="3">
            <p>2.5</p></td><td colspan="3">
              <p>3-3.5</p></td></tr>
          <tr><td><p>TDF/3TC/EFV</p></td><td><p>75mg/75mg/1</p>
            <p>50mg</p></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"><p>1.5</p></td><td colspan="2"><p>2</p></td><td colspan="3">
              <p>2.5</p></td><td colspan="3">
              <p>3-3.5</p></td></tr>
          <tr><td><p>TDF/3TC adult double scored</p></td><td><p>300mg/300mg</p></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"><p>One third</p></td><td colspan="2"><p>One half</p></td><td colspan="3">
            <p>Two thirds</p></td><td colspan="3">
              <p>1</p></td></tr>
          <tr><td><p>TDF/3TC/EFV adult double scored</p></td><td><p>300mg/300mg/</p>
            <p>600mg</p></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"><p>One third</p></td><td colspan="2"><p>One half</p></td><td colspan="3">
              <p>Two thirds</p></td><td colspan="3">
              <p>1</p></td></tr >
        </table>
        <p>3 tablets for 25-29.9kg and 3.5 tablets for 30-34.9kg</p>
        <p>TDF tablets are scored to break into half or third.</p>
      </span>
  }],
  content:
    <span>
      <h1><a>ANTIRETROVIRAL THERAPY</a>
      </h1>
      <p><a>General Notes</a></p>
      <p>Medical Criteria for initiating ART in adolescents/ adults</p>
      <p>Situations where it may be to defer ART initiation</p>
      <p>Adherence to ART</p>
      <p>Recommended treatment regimens for adolescents and adults</p>
      <p>Substitution in the event of medicine toxicity / adverse events and unavailability</p>
      <p>Use of ARVs in patients with TB</p>
      <p>Use of ARVs in Children</p>
      <p>Care of an HIV-exposed infant</p>
      <p>Criteria to initiate ART in children</p>
      <p>Monitoring dcptrial on ART</p>
      <h3><a><br /> General Notes </a>
      </h3>
      <p>Appropriate and effective provision of ARVs needs to be provided by those who have received standardised training in the management of opportunistic infections as well as in the use of antiretroviral medicines. For more details on the use of ARVs refer to the current <strong>
        <em>Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe.</em>
      </strong> Attempts should be made to train healthcare workers in HIV management</p>
      <p>Comprehensive DCPTRIAL care requires that there be provision of counselling; either VCT or PITC, laboratory capacity for baseline assessment and monitoring as well as to diagnose commonly encountered opportunistic infections such as TB and cryptococcal meningitis. Pharmacy personnel should also be trained in OI/ART management as they will be required to ensure rational prescribing and proper dispensing of the antiretroviral medicines. In addition, they will also be required to ensure that their hospital/clinic has adequate ARV medicine supplies.</p>
      <p><strong>Goals of ART</strong></p>
      <p>The aims of antiretroviral therapy (ART) are:</p>
      <ul>
        <li>Maximal and durable suppression of replication of HIV,</li>
        <li>Restoration and/or preservation of immune function,</li>
        <li>Reduction of HIV-related morbidity and mortality,</li>
        <li>Improvement of quality of life.</li>
        <li>Prevention of mother-to-child transmission of HIV (vertical transmission), and</li>
        <li>Reduction of transmission of HIV from infected to uninfected individuals through use of ARVs by the infected individual now commonly known as ‘Treatment as prevention’.</li>
      </ul>
      <p><strong>Criteria for initiating ART in and adults </strong></p>
      <p>Prior to starting ART, patients should be assessed for readiness to take ARVs; the ARV regimen; dosage and scheduling;
          the likely potential adverse effects; and the required monitoring. Both medical and psychosocial issues need to be addressed before initiating ART. Patients should be adequately counseled about adopting appropriate life style measures such as safer sexual practices (including appropriate use of condoms), and any other psychosocial problems that may interfere with adherence (e.g., alcohol, psychiatric disorders) should be addressed. At each clinic visit always screen for tuberculosis using a TB symptom checklist, advise patients about adequate nutrition and the importance of medicine adherence and regular follow up care. People taking ARVs should also be regularly asked on whether they are taking other medicines including herbal remedies that may interfere with the efficacy of ARVs.</p>
      <p>Early treatment initiation is associated with clinical and HIV prevention benefits, improving survival and reducing the incidence of HIV infection at the community level. Increasing evidence also indicate that untreated HIV may be associated with the development of severe non-AIDS defining conditions including cardiovascular disease, kidney disease, liver disease and neurocognitive disorders. Recent results from the HPTN 052 Study strongly support the use of ART to prevent HIV transmission among sero-discordant couples.</p>
    </span>
}
const chapter_nine = {
  short_title: "Chapter 9",
  long_title: "Use of ARVs for Prevention of Mother-to-Child Transmission of HIV (PMTCT)",
  content:
    <div>
      <h1><a>USE of ARVs for Prevention of Mother-to-Child Transmission of HIV (PMTCT)</a>
      </h1>
      <p>General Notes</p>
      <p>Infant and young child feeding recommendations</p>
      <h3><a><br /> General Notes</a>
      </h3>
      <p>Mother-to-child transmission is responsible for more than 90% of HIV infection in children and at least two thirds of such infections occur during pregnancy and delivery whilst the remainder occur during breastfeeding. It is therefore critical to identify HIV-positive pregnant and lactating women and manage them appropriately.</p>
      <p><strong>When to start ART in HIV positive pregnant and breastfeeding women</strong>
        <br /></p>
      <ul>
        <li>All HIV infected pregnant and breastfeeding women should initiate lifelong antiretroviral treatment (ART) irrespective of their CD4 count or WHO clinical stage (Option B+).</li>
        <li>Women who are not yet ready for lifelong ART should be initiated on triple ARVs (ART), which should be continued at least for the duration of breastfeeding to prevent further risk of mother-to-child transmission of HIV through breast milk.</li>
      </ul>
      <ul>
        <li>HIV infected lactating women meeting treatment eligibility criteria (CD4 500 or less) should continue lifelong ART according to criteria for adult non-pregnant populations as it would be inappropriate for them to discontinue ART after the breastfeeding period <strong>.</strong>
        </li>
      </ul >
      <p>N.B. Pregnant and breastfeeding women who were initiated on Zidovudine prophylaxis should be discontinued and commenced on lifelong ART (Option B+).</p >
      <p><strong>Being on lifelong ART will necessitate ongoing counselling of HIV positive pregnant and breastfeeding women to support retention and adherence and to minimize loss to follow-up.</strong></p >
      <ul>
        <li>Emphasise modes of HIV transmission and prevention, PMTCT, and access to care and treatment.</li>
        <li>Encourage partner HIV testing and counselling</li>
        <li>the importance of skilled birth attendance, clean and safe delivery, and newborn care. </li>
        <li>Counsel on infant and young child feeding and maternal nutrition.</li>
        <li>Counsel on sexual and reproductive health including family planning and the need for dual contraception (reliable hormonal contraceptive plus barrier method like male or female condoms)</li>
        <li>Make an appointment for family planning at six weeks postpartum.</li>
        <li>Stress the need for condom use for prevention of STIs and HIV during pregnancy and in the postpartum period.</li>
        <li>Retest previously negative women in 3 <sup>rd</sup> trimester of pregnancy and/ or at delivery, 6 weeks post natally and 6 monthly thereafter.</li>
        <li>
          Stress the importance of follow-up for the HIV exposed infant <ul>
            <li>Commence cotrimoxazole prophylaxis from 6 weeks of age</li>
            <li>Collect Dried Blood Spot (DBS) for HIV DNA PCR test at 6 weeks of age i.e.Early Infant Diagnosis (EID).</li>
            <li>Infants should be re-tested at the end of the breast-feeding period</li>
          </ul>
        </li>
      </ul>
      <p><strong>Table 9.1</strong>: Timing of Initiation of ART for Mother and ARV Prophylaxis for Infant (PMTCT)</p >
      <table>
        <tr><td><p><strong>Pregnancy</strong></p> </td><td><p><strong>Labour</strong></p> </td><td><p><strong>Post delivery (breastfeeding and non breastfeeding)</strong></p> </td></tr>
        <tr><td colspan="2"><p><strong>Maternal</strong></p> </td><td rowspan="2">
          <p><strong>Infant (Birth to six weeks)</strong></p> </td></tr>
        <tr><td colspan="2"><p><strong>Preferred first line</strong></p> </td></tr>
        <tr><td colspan="2"><p>+ Lamivudine +Efavirenz</p> </td><td><p>BW&lt;2500: NVP 10mg daily</p>
          <p>BW ≥2500: NVP 15mg daily</p></td></tr>
        <tr><td colspan="3">
          <p><strong>Alternative First line</strong></p> </td></tr>
        <tr><td colspan="2"><p>Zidovudine +Lamivudine + Efavirenz</p></td><td><p>BW&lt;2500: NVP 10mg daily</p>
          <p>BW≥2500: NVP 15mg daily</p></td></tr>
      </table >
      <p>When using ARVs in pregnant women, certain precautions should be kept in mind:</p >
      <p><strong>Efavirenz (EFV)</strong></p>
      <p>Previously there was a recommendation <strong>not</strong> to use Efavirenz during the first and in women at risk of becoming pregnant. However, WHO issued evidence based update on Efavirenz safety in pregnancy in 2011 which recommends it to be safe for use even in the first trimester.</p>
      <h3><a>Infant and young child feeding recommendations</a>
      </h3>
      <p>All mothers whether known to be infected with HIV or not should exclusively breastfeed their infants (no mixed feeding)
        for the first 6 months of life, introducing safe, adequate and nutritious complementary foods thereafter, with continued breastfeeding up to 24 months and beyond.</p>
      <p><strong>ARV prophylaxis in an infant </strong></p>
      <p>HIV-exposed infants whose mothers are on lifelong ART should be commenced on Nevirapine prophylaxis for six weeks.</p>
      <p><strong>Table 9.2</strong>: Infant Nevirapine prophylaxis</p >
      <table>
        <tr><td><p><strong>Age</strong></p> </td><td><p><strong>Nevirapine dosage</strong></p> </td></tr>
        <tr><td><p>Birth to six weeks</p></td><td><p>BW &lt;2500*: 10mg once daily</p>
          <p>BW ≥ 2500: 15mg once daily</p></td></tr>
      </table >
      <ul>
        <li>Always dcptrial to change the dose when baby gains weight. </li>
        <li>*For very low birth weight babies below 2000g dose of NVP is 2 mg/kg once daily for 6 weeks</li>
        <li>If any contraindications to NVP use 3TC 4mg per kg 12hourly for 6 weeks</li>
        <li>For non-breastfeeding infants NVP as above or AZT 4mg/kg 12 hourly for 6 weeks</li>
      </ul>
    </div>
}
const chapter_ten = {
  short_title: "Chapter 10",
  long_title: "Tuberculosis",
  subsections: [{
    short_title: "Section 1",
    long_title: "Prevention",
    content:
      <div>
        <h1><a>Tuberculosis</a>
        </h1>
        <p><a>General Notes</a></p>
        <p>Control of - TB Policy</p>
        <p>Prevention</p>
        <p>Case Management</p>
        <p>Medicine Regimens for Tuberculosis</p>
        <p>Treatment of new cases of TB</p>
        <p>All previously treated cases of any form of TB</p>
        <p>Drug TB (DR-TB)</p>
        <p>Fixed Dose Combination of Anti-TB Medicines</p>
        <h3><a><br /> General Notes</a>
        </h3>
        <p>Tuberculosis is a dcptrial infectious, debilitating disease, caused by Mycobacterium tuberculosis. It is a public health problem and all cases must be notified to the Provincial/City Medical Director in terms of the Public Health Act. Due to the association between TB and HIV infection, the prevalence of TB is increasing, and patients are often more seriously ill than before.</p>
        <h3><a>Control of - TB Policy </a>
        </h3>
        <p>For more information on National Policy and the organisation of the TB services refer to the Ministry of Health &amp; Child Care’s ZIMBABWE TUBERCULOSIS CONTROL PROGRAMME MANUAL.</p>
        <p>The essential points of the TB policy are:</p>
        <ul>
          <li>Sputum microscopy for diagnosis and follow up provided free of charge in the public health sector</li>
          <li>Short-course chemotherapy provided free of charge in the public health sector</li>
          <li>Treatment of Drug Resistant TB(DRTB) provided for free of charge in the public sector</li>
          <li>
            <strong>TB services available at all levels of the health delivery system, being integrated into the primary health care system to ensure efficient case finding, particularly for sputum smear positive patients</strong>
          </li>
        </ul>
        <p> Collaborative TB/HIV activities at all levels</p>
        <p>An important emphasis of the TB programme is the <strong>direct observation of treatment (DOTS)</strong>, which means that a treatment supervisor watches the patient actually swallowing the tablets. A supervisor can either be a healthcare worker or a trained member of the community.</p >
        <p>TB control is administered in a standardised way from the Central level to Health Centre level. Within this system notification,
          registration, record keeping and contact tracing activities in addition to treatment are carried out. It is essential that all patients requiring TB treatment be referred for management in the National TB Programme.</p>
        <p><strong>
          <em>TB fixed dose combinations are to be at all levels from C through to A. Single formulations’ level of availability is B level medicines. TB medicines are accorded V level of priority. </em>
        </strong></p>



      </div>
  },
  {
    short_title: "Section 2",
    long_title: "Primary Prevention",
    content:
      <span>
        <h2>Primary Prevention</h2>
        <ul>
          <li>
            BCG vaccination is given at birth or at first dcptrial with the child after birth (except in babies with clinical signs of HIV infection and/or in infants born to a mother with sputum positive TB).</li>
          <li>
            <em>BCG</em>
            <em>dcptrial should be given to all babies, even those born to mothers known to be HIV </em>
            <em>positive.</em>
          </li>
          <li> BCG is given intradermally on the right upper arm, above the insertion of the deltoid muscle.</li>
          <li> No booster dose should be given.</li>
        </ul>
        <p>The batch number of the vaccine and the date must be recorded on the child’s health card. Dosage is as recommended by EPI Programme (see the chapter on Immunisation).</p>
        <p>Problems associated with BCG vaccination remain uncommon and are mainly due to faulty technique.</p>
        <p>Abscesses or ulcers should be treated with local hygienic care. Abscesses should be <u>aspirated</u> not incised. Secondary infections can be treated with antibiotics. Non-healing ulcers, (ulcers of duration &gt; 8 weeks) or regional lymphadenopathy can be treated with:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>isoniazid po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10mg/kg</p></td><td><p>once a day</p></td><td><p>2 months</p></td></tr>
        </table >
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Secondary Prevention",
    content:
      <span>
        <h2>Secondary Prevention</h2>
        <p>An infant born to a mother with sputum positive TB should not be given BCG at birth</p>
        <ul>
          <li> Give the child isoniazid 10mg/kg day prophylaxis for two months</li>
          <li> After two months perform a mantoux test.</li>
          <li> If the Mantoux test is dcptrial give full TB treatment. </li>
          <li> If the Mantoux test is negative continue with isoniazid prophylaxis for four more months.</li>
          <li> Follow with BCG vaccination if not HIV infected</li>
        </ul>
        <p>If parents are found to be sputum positive and the child has no signs of active TB, check the child’s BCG status and vaccinate if not already done.</p>
        <p>In addition give prophylaxis for 6 months to children less than three years of age:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed Dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>isoniazid po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10mg/kg</p></td><td><p>once a day</p></td><td><p>6 months</p></td></tr>
        </table>
        <p>Note: For and treatment in <strong>neonates</strong> give isoniazid 5mg/kg/day</p>
        <p>Prevent further transmission of tuberculosis by health education and counselling on the importance of completing TB treatment,contact tracing, case finding and prevention of HIV infection.</p>
        <p>IPT for HIV positive patients in whom active TB has been excluded, refer to IPT under HIV related diseases and National TB Guidelines</p>
      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Case Management",
    content:
      <span>
        <h2>Case Management</h2>
        <p><a><strong>Diagnosis</strong>
        </a></p >
        <p><strong>Clinical Diagnosis of TB</strong></p>
        <p>The presence of pulmonary tuberculosis should be suspected in individuals presenting with one or more of the following complaints:</p>
        <ul>
          <li>Cough for 2 weeks or longer</li>
          <li>Production of sputum, which may be bloodstained</li>
          <li>Loss of appetite</li>
          <li>Night sweats</li>
          <li>Fever</li>
          <li>Loss of weight</li>
          <li>Shortness of breath</li>
        </ul>
        <p><strong>Sputum</strong></p>
        <p>The diagnosis of TB is made by demonstrating alcohol acid-fast bacilli (AAFB) in the sputum by direct smear microscopy (DSM). DSM is repeated at the end of the intensive and continuation phases to confirm sputum conversion and cure.</p>
        <p>Due to the concerns of medicine resistance the following patients <strong>MUST</strong> submit sputum specimens for Gene Xpert test, culture and medicine sensitivity testing to the TB Reference Laboratory</p>
        <p> All relapses</p>
        <p> Patients on category 1 treatment who are sputum positive at 3/5 months</p>
        <p> Patients on category 2 treatment who are sputum positive at 3/4 months (at end of prolonged intensive phase).</p>
        <p> Patients on category 2 treatment who are sputum positive at the end of treatment</p>
        <p> Patients who are sputum-smear positive and have been in contact with MDR-TB case.</p>
        <p> Gene-Xpert for all HIV positive patients</p>
        <p> Residence in DRTB high burden zones</p>
        <p> Return after treatment default</p >
        <p><strong>Chest X-Rays</strong></p >
        <p><strong>Indications for chest x-rays</strong></p>
        <ul>
          <li>A child suspected of TB </li>
          <li>HIV positive patient who is sputum negative</li>
          <li>Non-response to broad-spectrum antibiotics for correct duration in sputum negative and HIV negative patient</li>
          <li>Non-response to broad spectrum antibiotics in a sputum negative patient.</li>
          <li>When suspecting complications, e.g., pneumothorax, or pleural effusion</li>
          <li>When frequent and severe occurs </li>
          <li>When other lung diseases are suspected by the medical officer</li>
          <li>Pericardial effusion</li>
        </ul>
        <p>Chest x-rays should <strong>
          <u>NOT</u>
        </strong> be used for diagnosing pulmonary TB. In sputum positive patients a chest x-ray is not necessary.</p>
        <p><em>Note: In the dcptrial of clinical improvement, it is not necessary to monitor the response of pulmonary TB to treatment by chest x-rays </em></p>
        <p><strong>Tuberculin Testing</strong></p>
        <p>Use Mantoux test only:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>tuberculin, purified</strong> (PPD) 1:1000 intradermal</p></td><td><p><strong>B E</strong></p> </td><td><p>0.1ml (=5TU)</p></td><td><p>-</p></td><td><p>-</p></td></tr>
        </table>
        <p>Examine induration at 48-72 hours.</p>
        <ul>
          <li> A positive Mantoux (person with normal immunity: induration &gt; 10 mm, person with defective immunity: induration &gt;6 mm) may indicate active infection (especially if strongly positive), previous infection or previous BCG.</li>
          <li>Absence of a response does not exclude TB because individuals with HIV may not have sufficient immunity for a positive skin test despite active TB.</li>
          <li> If a child under 3 years of age has <u>not</u> had BCG, the Mantoux test may be useful.</li>
          <li> All TB suspects should be offered HIV counselling and testing (Provider initiated testing and counselling i.e. PITC)at the same facility where the sputum is examined.</li>
        </ul>

      </span>
  },
  {
    short_title: "Section 5",
    long_title: "Medicine Regimens for Tuberculosis",
    content:
      <span>
        <h2>Medicine Regimens for Tuberculosis</h2>
        <p>Two main treatment categories, Category 1 and Category II are now used in Zimbabwe for medicine sensitive TB. The regimens consist of a combination of five first line medicines. These medicines are available as oral Fixed Dose Combination (FDC)and an injectable, streptomycin.</p>
        <p>The intention of these combination tablets is to improve compliance by reducing the number of tablets a patient has to take, and to reduce the possibility of medicine resistance developing. The number of FDC tablets is determined by a weight range for each patient at the start of treatment</p>
        <ul>
          <li>Treatment is the same for HIV infected people as for non-HIV infected.</li>
        </ul>
        <p> There are specific differences between regimes for adults and children in each category.</p>
        <p><strong>
          <u>NOTE: If any signs of a reaction occur, the treatment should be stopped immediately and the patient seen by a doctor.</u>
        </strong></p >
        <p><strong>Key to Medicine Abbreviations</strong></p>
        <table>
          <tr><td><p><strong>H= isoniazid</strong></p> </td><td><p><strong>Z/PZA= pyrazinamide</strong></p> </td></tr>
          <tr><td><p><strong>R= rifampicin</strong></p> </td><td><p><strong>S= streptomycin</strong></p> </td></tr>
          <tr><td><p><strong>E= ethambutol</strong></p> </td><td></td></tr>
        </table>
        <p><strong>
          <em>No</em >
          <em></em >
          <em>streptomycin</em >
          <em>should be given to children less than 12 years old except for meningitis, or to pregnant women, or</em >
          <em></em >
          <em>those whose body weight is below 30kgs)</em>
        </strong>
          <em>. Recent evidence has shown that it is safe to use ethambutol in children as it has less ocular toxicity in children of all ages than previously thought. Thus ethambutol has been reintroduced in paediatric regimens.</em>WHO (2006). Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children,</p>
        <h3><a>Treatment of new cases of TB</a>
        </h3>
      </span>
  },
  {
    short_title: "Section 6",
    long_title: "Category I",
    content:
      <span>
        <h2>Category I</h2>
        <p>All <strong>new cases</strong> of TB regardless of site, bacteriology or severity</p>
        <p><strong>Adults:</strong></p>
        <p>.Intensive phase: 2 months HRZE (DOT)</p>
        <p>Continuation phase: 4 dcptrial HR (DOTS) OR (6 months HR in TB of meninges, bone, joint, pericardium, disseminated spinal disease)</p>
        <p><strong>2HRZE/4HR</strong> (DOT)</p>
        <p><em></em></p>
        <p><strong>
          <em>The use of the combination of and ethambutol (HE) in the continuation phase has been phased out in Zimbabwe </em>
        </strong>.</p>
        <p><strong>Children</strong>:</p>
        <p> Intensive phase: Two months HRZE (DOT)</p>
        <p> Continuation phase: Four months HR (DOT) ( or 10HR for patients with TB of the meninges, bone joint, pericardium, military TB or TB spine)</p>
        <p>In children under 12 years, no streptomycin should be given except for TB meningitis.</p>
        <p>General notes: Category I</p>
        <p> In smear positive cases, repeat sputum smear exam at end of two months. If the sputum is still positive at the end of two months the extension of the intensive phase is no longer necessary. Start continuation phase irrespective of sputum results at end of two months.</p>
        <p> If the sputum is still smear positive at the end of two months repeat sputum smear exam at the end of month three. Sputum smear should be sent to the National TB Laboratory for culture and sensitivity testing if still smear positive after three months of treatment. A sputum sample should be collected for Gene Xpert test at the local laboratory.</p>
        <p> Sputum testing should be collected for Gene Xpert testing and another one sent to the National TB Laboratory for culture and sensitivity testing if still smear positive after five or six months of treatment. If the patient’s sputum remains smear positive after five months of treatment (treatment failure) Category II treatment should be commenced.</p>
        <p> Children weighing less than 11kg receive paediatric FDC HRZ plus additional isoniazid and ethambutol.</p>
        <p> Children weighing 11kg and above receive adult formulations and additional isoniazid.</p>
        <p> The total duration of treatment is six months.</p>
        <p> Children with tuberculous meningitis or pericarditis, disseminated or spinal disease with neurological complications should be given 10HR (continuous phase) i.e. 10 months of isoniazid and rifampicin under direct observation.</p>
        <p> Adults with TB of meninges, bone, joint, pericardium, disseminated, or spinal disease should be given 6 HR (continuous phase) i.e. 6 months of isoniazid and rifampicin under direct observation.</p>
        <h3><a>All previously treated cases of any form of TB</a>
        </h3>
      </span>
  },
  {
    short_title: "Section 7",
    long_title: "Category II",
    content:
      <span>
        <h2>Category II</h2>
        <p><strong>Adults:</strong></p>
        <p> Intensive phase: 2 SHRZE daily for two months followed by HRZE daily for one month</p>
        <p> Continuation phase: 5 HRE daily for 5 months [DOT]</p>
        <p><strong>Children:</strong></p>
        <p> Intensive phase: 3 months RHZE daily</p>
        <p> Continuation phase: 5 months of HRZ daily</p>
        <p>General notes: Category II</p>
        <p> Duration of TB Course: 8 months</p>
        <p> If at the end of the initial 3 months the sputum is smear negative or positive the continuation phase is started.</p>
        <p> If the sputum is smear positive at three months (12 weeks), take sputum for Gene Xpert,and for culture and DST. Start the continuation phase. Consult the District/Local MDR TB Team when DST results available. Further extension of the continuation phase will not increase the chances of cure.</p>
        <p><strong>
            <u>If a patient is still smear positive at the end of 4 dcptrial all medicines should be stopped for 3 days and a sputum specimen sent for Gene Xpert testing and another </u >
          <u></u >
          <u>sputum specimen sent</u >
          <u></u >
          <u>to the National TB Reference Laboratory(NTBRL) in Bulawayo or National Microbiology Reference Laboratory</u >
          <u></u >
          <u>in Harare(NMRL) for culture and susceptibility. The patient should then be started on the continuation phase.</u>
        </strong></p>
        <ul>
          <li> Patients who dcptrial smear positive after the end of the fully supervised continuation phase will derive no benefit from another re-treatment regimen. They are termed chronic TB cases and are at high risk for medicine resistant TB.
            Collect sputum for Gene Xpert as well as for culture and sensitivity.<strong>Refer to DR-TB guidelines</strong>
          </li>
        </ul>
        <h3><a>Drug Resistant TB (DR-TB)</a>
        </h3>
        <p>Drug resistant TB (DR-TB) is the presence of bacilli resistant to one or more anti-tuberculosis medicines and includes multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB).</p>
        <p>These are patients who remain (or again dcptrial smear positive) after completing a fully supervised re-treatment regimen.The management of MDR or XDRTB cases is problematic; health workers should consult the MDR TB team.</p>
        <p>Note: Although smear negative PTB and extra-pulmonary cases may also be treatment failures, relapses and DR-TB, this is a rare event and should be supported by pathological and /or bacteriological evidence.</p>
        <p><a><strong>MDR TB: Following preliminary results of rifampicin resistance by gene-xpert, patients must be put on standardised Category 4 treatment of MDR-TB whilst dcptrial for full DST results. </strong>
        </a></p>
        <h3><a>Fixed Dose Combination of Anti-TB Medicines</a>
        </h3>
        <p>The essential anti-TB medicines now come in fixed dose combinations (FDCs) such that each tablet has 2 (2-FDC), 3 (3-FDC),or 4 (4-FDC) medicines.</p>
        <p>Fixed dose combination tablets</p>
        <p>Fixed dose combination tablets improve compliance by reducing the number of tablets a patient has to take, and reduce the possibility of medicine resistance developing. The FDCs available in Zimbabwe are:</p>
        <ul>
          <li>Rifampicin, Isoniazid, Pyrazinamide and Ethambutol: (RHZE)</li>
          <li>Rifampicin, Isoniazid and Ethambutol: (RHE)</li>
          <li>Rifampicin and Isoniazid: (RH)</li>
        </ul>
        <p>The number of FDC tablets is determined by a weight range for each patient at the start of treatment and this is shown in the Table 10.1 to Table 10.8.</p>
        <p>Adverse Medicine Reaction</p>
        <p>Stop all TB medicines and assess. If necessary evaluate the liver function. Then reintroduce one medicine at a time, and build up gradually. Start with isoniazid at 25mg – the least likely to cause a reaction. When the required dose has been achieved without any reaction, another medicine should be re-introduced in a similar manner – slowly, increasing the dose daily.</p>
        <p>e.g Day 1 Isoniazid 25mg</p>
        <p>Day 2 Isoniazid 50mg</p>
        <p>Day 3 Isoniazid 100mg</p>
        <p>Day 4 Isoniazid 300mg</p>
        <p>Day 5 Isoniazid 300mg + Rifampicin 150mg</p>
        <p>Day 6 Isoniazid 300mg + Rifampicin 300mg</p>
        <p>Day 7 Isoniazid 300mg + Rifampicin 450mg, etc(Refer to the National TB Guidelines)</p>
        <p>TB and HIV Co-infection</p>
        <p>Refer to the current national ARV guidelines as well as the TB guidelines. Also refer to the ARV chapter in this EDLIZ</p>
        <p><strong>Recommended doses of TB medicines in Children</strong></p>
        <ul>
          <li>Rifampicin: 15 mg/kg/day (10 to 20 </li>
        </ul>
        <p>• Isoniazid: 10 mg/kg/day (10 to 15 mg/kg/day)</p>
        <p>• Pyrazinamide: 35 mg/kg/day (30 to 40 mg/kg/day)</p>
        <ul>
          <li>Ethambutol: 20 mg/kg/day (15 mg to 25 mg/kg/d).</li>
        </ul ><p><strong>Adults:</strong></p>
        <p> Intensive phase: 2 SHRZE daily for two months followed by HRZE daily for one month</p>
        <p> Continuation phase: 5 HRE daily for 5 months [DOT]</p>
        <p><strong>Children:</strong></p>
        <p> Intensive phase: 3 months RHZE daily</p>
        <p> Continuation phase: 5 months of HRZ daily</p>
        <p>General notes: Category II</p>
        <p> Duration of TB Course: 8 months</p>
        <p> If at the end of the initial 3 months the sputum is smear negative or positive the continuation phase is started.</p>
        <p> If the sputum is smear positive at three months (12 weeks), take sputum for Gene Xpert,and for culture and DST. Start the continuation phase. Consult the District/Local MDR TB Team when DST results available. Further extension of the continuation phase will not increase the chances of cure.</p>
        <p><strong>
            <u>If a patient is still smear positive at the end of 4 dcptrial all medicines should be stopped for 3 days and a sputum specimen sent for Gene Xpert testing and another </u >
          <u></u >
          <u>sputum specimen sent</u >
          <u></u >
          <u>to the National TB Reference Laboratory(NTBRL) in Bulawayo or National Microbiology Reference Laboratory</u >
          <u></u >
          <u>in Harare(NMRL) for culture and susceptibility. The patient should then be started on the continuation phase.</u>
        </strong></p>
        <ul>
          <li> Patients who dcptrial smear positive after the end of the fully supervised continuation phase will derive no benefit from another re-treatment regimen. They are termed chronic TB cases and are at high risk for medicine resistant TB.
            Collect sputum for Gene Xpert as well as for culture and sensitivity.
      <strong>Refer to DR-TB guidelines</strong>
          </li>
        </ul>
        <h3><a>Drug Resistant TB (DR-TB)</a>
        </h3>
        <p>Drug resistant TB (DR-TB) is the presence of bacilli resistant to one or more anti-tuberculosis medicines and includes multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB).</p>
        <p>These are patients who remain (or again dcptrial smear positive) after completing a fully supervised re-treatment regimen.
    The management of MDR or XDRTB cases is problematic; health workers should consult the MDR TB team.</p>
        <p>Note: Although smear negative PTB and extra-pulmonary cases may also be treatment failures, relapses and DR-TB, this is a rare event and should be supported by pathological and /or bacteriological evidence.</p>
        <p><a><strong>MDR TB: Following preliminary results of rifampicin resistance by gene-xpert, patients must be put on standardised Category 4 treatment of MDR-TB whilst dcptrial for full DST results. </strong>
        </a></p>
        <h3><a>Fixed Dose Combination of Anti-TB Medicines</a>
        </h3>
        <p>The essential anti-TB medicines now come in fixed dose combinations (FDCs) such that each tablet has 2 (2-FDC), 3 (3-FDC),
    or 4 (4-FDC) medicines.</p>
        <p>Fixed dose combination tablets</p>
        <p>Fixed dose combination tablets improve compliance by reducing the number of tablets a patient has to take, and reduce the possibility of medicine resistance developing. The FDCs available in Zimbabwe are:</p>
        <ul>
          <li>Rifampicin, Isoniazid, Pyrazinamide and Ethambutol: (RHZE)</li>
          <li>Rifampicin, Isoniazid and Ethambutol: (RHE)</li>
          <li>Rifampicin and Isoniazid: (RH)</li>
        </ul>
        <p>The number of FDC tablets is determined by a weight range for each patient at the start of treatment and this is shown in the Table 10.1 to Table 10.8.</p>
        <p>Adverse Medicine Reaction</p>
        <p>Stop all TB medicines and assess. If necessary evaluate the liver function. Then reintroduce one medicine at a time, and build up gradually. Start with isoniazid at 25mg – the least likely to cause a reaction. When the required dose has been achieved without any reaction, another medicine should be re-introduced in a similar manner – slowly, increasing the dose daily.</p>
        <p>e.g Day 1 Isoniazid 25mg</p>
        <p>Day 2 Isoniazid 50mg</p>
        <p>Day 3 Isoniazid 100mg</p>
        <p>Day 4 Isoniazid 300mg</p>
        <p>Day 5 Isoniazid 300mg + Rifampicin 150mg</p>
        <p>Day 6 Isoniazid 300mg + Rifampicin 300mg</p>
        <p>Day 7 Isoniazid 300mg + Rifampicin 450mg, etc(Refer to the National TB Guidelines)</p>
        <p>TB and HIV Co-infection</p>
        <p>Refer to the current national ARV guidelines as well as the TB guidelines. Also refer to the ARV chapter in this EDLIZ</p>
        <p><strong>Recommended doses of TB medicines in Children</strong></p>
        <ul>
          <li>Rifampicin: 15 mg/kg/day (10 to 20 </li>
        </ul>
        <p>• Isoniazid: 10 mg/kg/day (10 to 15 mg/kg/day)</p>
        <p>• Pyrazinamide: 35 mg/kg/day (30 to 40 mg/kg/day)</p>
        <ul>
          <li>Ethambutol: 20 mg/kg/day (15 mg to 25 mg/kg/d).</li>
        </ul >
      </span>
  },
  {
    short_title: "Section 8",
    long_title: "Daily Doses by Weight - Category I",
    content:
      <span>
        <h2>Daily Doses by Weight - Category I</h2>
        <p><strong>Table 10.1:</strong> Paediatric Intensive Phase weight band (2 months RHZE)</p>
        <table>
          <tr><td><p><strong>Weight bands in kg</strong></p> </td><td><p><strong>Rifampicin Isoniazid (H) Pyrazinamide (Z) 60/30/150mg</strong></p> </td><td><p><strong>Additional INH 100mg taB Ethambutol tabs 100mg</strong></p> </td></tr>
          <tr><td><p>3 - 5.9</p></td><td><p>1 ½ tabs</p></td><td><p>¼ tab</p></td><td><p>1 tab</p></td></tr>
          <tr><td><p>6 - 10.9</p></td><td><p>2 tabs</p></td><td><p>½ tab</p></td><td><p>2 tabs</p></td></tr>
        </table>
        <p><strong>Table 10.2:</strong> For children in the 11-30.9 kg weight band use adult kits with additional INH</p>
        <table>
          <tr><td><p><strong>Weight bands in kg</strong></p> </td><td><p><strong>Rifampicin Isoniazid (H) Pyrazinamide (Z Ethambutol tabs</strong></p>
            <p><strong>150mg:75mg:400mg:275mg</strong></p> </td><td><p><strong>Additional INH 100mg tab</strong></p> </td></tr>
          <tr><td><p>11 - 15.9</p></td><td><p>1 tab</p></td><td><p>1 tab</p></td></tr>
          <tr><td><p>16 - 20.9</p></td><td><p>2 tabs</p></td><td><p>1 tab</p></td></tr>
          <tr><td><p>21 - 30.9</p></td><td><p>2 tabs</p></td><td><p>2 tabs</p></td></tr>
        </table>
        <p><strong>Table 10.3:</strong> Paediatric Continuation Phase (RH) 4 months daily</p>
        <table>
          <tr><td><p><strong>Weight bands in kg </strong></p> </td><td><p><strong>Rifampicin Isoniazid 60mg/30mg</strong></p> </td><td><p><strong>Additional INH 100mg tab</strong></p> </td></tr>
          <tr><td><p>3 - 5.9</p></td><td><p>1 ½ tabs</p></td><td><p>¼ tab</p></td></tr>
          <tr><td><p>6 - 10.9</p></td><td><p>2 tabs</p></td><td><p>½ tab</p></td></tr>
        </table>
        <p><strong>Table 10.4:</strong> Continuation phase (RH) 4 months daily (except TB meningitis, TB spine where (RH) 10 months</p>
        <table>
          <tr><td><p><strong>Weight bands in kg</strong></p> </td><td><p><strong>Rifampicin Isoniazid</strong></p>
            <p><strong>150mg:75mg</strong></p> </td><td><p><strong>Additional INH 100mg tab </strong></p> </td></tr>
          <tr><td><p>11 - 15.9</p></td><td><p>1 tab</p></td><td><p>1 tab</p></td></tr>
          <tr><td><p>16 - 20.9</p></td><td><p>2 tabs</p></td><td><p>1 tab</p></td></tr>
          <tr><td><p>21 - 30.9</p></td><td><p>2 tabs</p></td><td><p>2 tabs</p></td></tr>
        </table >
        <p><strong>Table 10.5:</strong> New adult Number of FDC tablets per day for each Weight band (2RHZE/4HR)</p>
        <table>
          <tr><td rowspan="3">
            <p><strong>Regimen</strong></p >
            <p><strong>Patient’s Weight</strong></p> </td><td><p><strong>Initial phase (2 months)</strong></p> </td><td><p><strong>Continuation Phase (4 months)</strong></p> </td></tr>
          <tr><td><p><strong>2(RHZE) daily</strong></p> </td><td><p><strong>4(HR) daily</strong></p> </td></tr>
          <tr><td><p><strong>(Isoniazid 75mg+</strong></p>
            <p><strong>Rifampicin 150mg +</strong></p>
            <p><strong>Pyrazinamide 400mg +</strong></p>
            <p><strong>Ethambutol 275mg)</strong></p> </td><td><p><strong>(Isoniazid 75mg +</strong></p>
              <p><strong>Rifampicin 150mg)</strong></p>
            </td></tr>
          <tr><td><p>30 - 39 kg</p></td><td><p>2</p></td><td><p>1.5</p></td></tr>
          <tr><td><p>40 - 54 kg</p></td><td><p>3</p></td><td><p>2</p></td></tr>
          <tr><td><p>55 - 70 kg</p></td><td><p>4</p></td><td><p>3</p></td></tr>
          <tr><td><p>70 kg +</p></td><td><p>5</p></td><td><p>3</p></td></tr>
        </table >
      </span>
  },
  {
    short_title: "Section 9",
    long_title: "Daily Doses by Weight - Category II",
    content:
      <span>
        <h2>Daily Doses by Weight - Category II</h2>
        <p><strong>Table 10.6:</strong> Paediatric Intensive Phase 3 months (RHZE)</p>
        <table>
          <tr><td><p><strong>Weight bands in kg</strong></p> </td><td><p><strong>Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) 60/30/150mg</strong></p> </td><td><p><strong>Additional INH 100mg taB Ethambutol (E) tabs 100mg</strong></p> </td></tr>
          <tr><td><p>3 - 5.9</p></td><td><p>1 ½ tabs</p></td><td><p>¼ tab</p></td><td><p>1 tab</p></td></tr>
          <tr><td><p>6 - 10.9</p></td><td><p>2 tabs</p></td><td><p>½ tab</p></td><td><p>2 tabs</p></td></tr>
        </table>
        <table>
          <tr><td><p><strong>Weight bands in kg</strong></p> </td><td><p><strong>Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E) tabs</strong></p>
            <p><strong>150mg:75mg</strong></p>
            <p><strong>:400mg:275mg</strong></p> </td><td><p><strong>Additional INH 100mg tab</strong></p> </td></tr>
          <tr><td><p>11 -15.9</p></td><td><p>1 tab</p></td><td><p>1 tab</p></td></tr>
          <tr><td><p>16 - 20-.9</p></td><td><p>2 tabs</p></td><td><p>1 tab</p></td></tr>
          <tr><td><p>21 - 30.9</p></td><td><p>2 tabs</p></td><td><p>2 tabs</p></td></tr>
        </table>
        <p><strong>Table 10.7:</strong> Paediatric Continuation Phase 5 months (RHE)</p>
        <table>
          <tr><td><p><strong>Weight bands in kg</strong></p> </td><td><p><strong>Rifampicin(R) Isoniazid (H)</strong></p>
            <p><strong>60:30mg</strong></p> </td><td><p><strong>(E) tabs 400mg </strong></p> </td></tr>
          <tr><td><p>3 - 5.9</p></td><td><p>1 tab</p></td><td><p>1/4 tab</p></td></tr>
          <tr><td><p>6 - 10.9</p></td><td><p>2 tabs</p></td><td><p>1/2 tab</p></td></tr>
        </table>
        <table>
          <tr><td><p><strong>Weight bands in kg</strong></p> </td><td><p><strong>Rifampicin(R) Isoniazid (H) Ethambutol(E) tabs</strong></p>
            <p><strong>150mg:75mg:275mg</strong></p> </td><td><p><strong>Additional INH 100mg tab</strong></p> </td></tr>
          <tr><td><p>11 - 15.9</p></td><td><p>1 tab</p></td><td><p>1 tab</p></td></tr>
          <tr><td><p>16 - 20.9</p></td><td><p>2 tabs</p></td><td><p>1 tab</p></td></tr>
          <tr><td><p>21 - 30.9</p></td><td><p>2 tabs</p></td><td><p>2 tabs</p></td></tr>
        </table>
        <p><strong>Table 10.8:</strong> Category II : Retreatment in Previously treated adult</p>
        <table>
          <tr><td><p><strong>Regimen</strong></p>
          </td><td colspan="2"><p><strong>Initial Phase (3 months)</strong></p> </td><td><p><strong>Phase (5 months) </strong></p> </td></tr>
          <tr><td rowspan="2">
            <p><strong>Patient’s Weight</strong></p> </td><td colspan="2"><p>2(RHZE)S / 1(RHZE) daily</p></td><td><p>5HRE</p></td></tr>
          <tr><td><p>(Isoniazid 75 mg +</p>
            <p>Rifampicin 150mg + Pyrazinamide 400mg + Ethambutol 275mg)</p></td><td><p>5(HRE) daily</p>
              <p>Streptomycin (IM) 2 months</p></td><td><p>(Isoniazid 75 mg + Rifampicin 150 mg + Ethambutol 275mg)</p></td></tr>
          <tr><td><p>30 - 39 kg</p></td><td><p>2</p></td><td><p>0.50 g</p></td><td><p>2</p></td></tr>
          <tr><td><p>40 - 54 kg</p></td><td><p>3</p></td><td><p>0.75 g</p></td><td><p>3</p></td></tr>
          <tr><td><p>55 - 69 kg</p> </td><td><p>4</p></td><td><p>1 g*</p></td><td><p>4</p></td></tr>
          <tr><td><p>70 kg +</p></td><td><p>5</p></td><td><p>1 g*</p></td><td><p>5</p></td></tr>
        </table>
        <p> *0.75 g if 60 years or over.</p>
      </span>
  }],
  content:
    <span>
      <h1>Tuberculosis</h1>
    </span>
}
const chapter_eleven = {
  short_title: "Chapter 11",
  long_title: "Tropical Diseases",
  subsections: [
    {
      short_title: "Section 0",
      long_title: "Tropical Diseases",
      content:
        <span>
          <h1>Tropical Diseases</h1>
          <p>Anthrax (Cutaneous)</p>
          <p>Tick Typhus (African)</p>
          <p>Rabies</p>
          <p>General for NTDs</p>
          <p>Katayama Syndrome</p>
          <p>Helminthiasis</p>
          <p>Lymphatic Filariasis (Elephantiasis)</p>
          <p>Plague (Bubonic)</p>
          <p>Leprosy</p>
          <p>Human African Trypanosomiasis:</p>
          <p>Typhoid Fever</p>
          <p>Notifiable diseases and events of Public Health importance</p>
        </span>
    },
    {
      short_title: "Section 1",
      long_title: "Anthrax (Cutaneous)",
      content:
        <span>

          <h3><a><br /> Anthrax (Cutaneous) </a>
          </h3>
          <p>Case definition: an acute bacterial dcptrial caused by <u>Bacillus anthracis</u> (Gram-positive). It is manifested at first by itching of an exposed skin surface, followed by a painful lesion which becomes papular, then vesiculated and eventually develops into a depressed black eschar in 2-6 days</p>
          <p>NB Do not take any laboratory specimens, treat on clinical and epidemiological basis.</p>
          <p><strong>Initial treatment, in severe cases:</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
            <tr><td></td><td><p><strong>benzylpenicillin im/iv</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>1-2 MU</p></td><td colspan="2"><p>4 times a day</p></td><td><p>initially, then</p></td></tr>
            <tr><td><p><strong>then</strong></p> </td><td><p><strong>procaine penicillin im</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>3gm</p></td><td><p>once daily</p></td><td colspan="2"><p>7-10 days</p></td></tr >
          </table>
          <p><strong>Less severe cases:</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>Doxycycline* po</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
              <p>200mg first dose, then</p></td></tr>
            <tr><td></td><td></td><td></td><td></td><td><p>100mg</p></td><td><p>once daily</p></td><td><p>7 days</p></td></tr>
          </table >
          <p>*avoid use of doxycycline in pregnant women and children</p>
          <p><a><strong>NB: Pulmonary form of Anthrax- refer to designated Infectious Disease Hospital</strong>
          </a></p>
        </span>
    },
    {
      short_title: "Section 2",
      long_title: "Tick Typhus (African)",
      content:
        <span>
          <h2>Tick Typhus (African)</h2>
          <p>Case definition: a rickettsial disease (spread usually by tick bites) that has a variable onset but most often marked by sudden headache, chills, prostration, fever and general pains. A maculopapular eruption appears on the 5 <sup>th</sup> – 7th day, initially on the upper trunk followed by a spread to the entire body but usually not to the face, palms or soles. Chancre, local erythema on bite site with local lymphadenopathy.</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>doxycycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
              <p>200mg first dose, then</p></td></tr>
            <tr><td></td><td></td><td></td><td></td><td><p>100mg</p></td><td><p>once daily</p></td><td><p>7 days</p></td></tr>
          </table>
          <p><a><strong>If no improvement - refer</strong>
          </a></p>

        </span>
    },
    {
      short_title: "Section 3",
      long_title: "Rabies",
      content:
        <span>
          <h2>Rabies</h2>
          <p>Prevention of Rabies in Humans</p>
          <ul>
            <li>
              <strong>Pre-exposure immunisation</strong>
            </li>
          </ul>
          <p>Individual immunisation should be offered to persons at high risk of exposure, such as animal handlers, veterinarians, National Parks and Wild Life personnel.</p>
          <ul>
            <li>
              <strong>Pre-exposure immunisation schedule:</strong>
            </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>rabies vaccine, human dcptrial cell im </strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>0.5ml</p></td><td colspan="2"><p>dcptrial doses on Day 0, 7 and 28 only</p> </td></tr >
          </table>
          <p>Give a booster every 2-3 years.</p>
          <p>Post-exposure Treatment</p>
          <p>In dog and other animal bites, the wound should be thoroughly cleaned with povidone-iodine or soap and water as soon as possible.</p>
          <p><strong>Treatment: High Risk</strong></p>
          <p>In a previously unvaccinated or incompletely vaccinated individual, where there is a high risk of rabies, i.e.:</p>
          <ul>
            <li> broken skin</li>
            <li> uncertain animal history or strong suspicion of rabid animal give:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>human rabies immunoglobulin</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10 IU/kg</p></td><td><p>once only</p></td><td><p>-</p></td></tr>
            <tr><td></td><td colspan="5">
              <p>(instilled and infiltrated locally around the wound)</p></td><td></td></tr>
            <tr><td>and</td><td><p><strong>human rabies immunoglobulin im</strong> (gluteal)</p></td><td><p><strong>B V</strong></p> </td><td><p>10 IU/kg</p></td><td><p>once only</p></td><td><p>-</p></td></tr>
          </table>
          <p>Vaccinate using the abbreviated multi-site regimen:</p>
          <p><strong>2-1-1 vaccination schedule:</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>rabies vaccine (human diploid cell) im</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>0.5ml in <strong>each</strong> arm</p></td><td><p>one dose</p></td><td><p>on Day 0</p></td></tr>
            <tr><td></td><td><p>(upper arm site)</p></td><td colspan="2"><p><strong>Then</strong></p> </td><td><p>0.5ml in <strong>one</strong> arm</p></td><td><p>one dose</p></td><td><p>on Days 7 and 21</p></td></tr>
          </table>
          <p>Use a separate syringe and needle for each dose; store vials at 4-8 <sup>o</sup>C after reconstitution and use as soon as possible.</p>
          <p>Low Risk</p>
          <p>Where the risk of rabies is low, i.e.:</p>
          <ul>
            <li> skin not broken or other contact (e.g. with infected meat)</li>
            <li> bite from domestic animal WITH LAPSED immunisation against rabies</li>
          </ul>
          <p>Follow the 2-1-1 schedule, but without giving immunoglobulin.</p>
          <p>Minimal – no risk</p>
          <ul>
            <li> Bite from a domestic animal FULLY immunised against rabies </li>
            <li>In previously vaccinated individuals give a single booster dose of rabies vaccine.</li>
          </ul>

        </span>
    },
    {
      short_title: "Section 4",
      long_title: "General Guidelines for NTDS",
      content:
        <span>
          <p>Tropical Diseases (NTDs) include Bilharzia, intestinal worms, lymphatic filariasis and blinding trachoma</p>
          <p>Zimbabwe is instituting Mass Drug (Medicine) Administration (MDA) for bilharzia, intestinal worms, lymphatic filariasis and blinding trachoma to children aged 5 to 15 years in endemic districts annually using WHO guidelines for preventative chemotherapy.</p>
          <h3>Bilharzia (Schistosoma Mansoni &amp; Haematobium)</h3>
          <p>Proper diagnosis can only be made by microscopy of urine and stools. Antibody tests alone are insufficient basis for treatment.</p>
          <p>Clinics without microscopes can treat <em>Schistosoma haematobium</em> infection on the basis of visible haematuria or positive urine strip test for blood and or protein in children and adolescents. Refer all suspected cases of <em>Schistosoma mansoni</em> for further investigations, particularly in the older patient.</p>
          <p>NB. In female patients exclude haematuria caused by menstruation</p>
          <p><strong>
            <em>S. Mansoni</em>
          </strong></p>
          <p>Most patients with <em>S. Mansoni</em> infection have minimal or no symptoms unless there is heavy infestation. Infection should be suspected in young patients with unexplained iron deficiency anaemia, hepatosplenomegaly or non-resolving chronic salmonella infections.</p>
          <p>Occasionally patients may present with dysentery like symptoms when colonic polyps due to S. Mansoni ulcerate and bleed.</p>
          <p>Treatment:</p>
          <p>S. Haematobium</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Children and Adult dose</p></td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>praziquantel po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>40mg/kg</p></td><td colspan="2"><p>one dose only</p></td></tr >
          </table>
          <p><strong>S. Mansoni :</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
            <tr><td></td><td><p><strong>praziquantel po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>60 mg/kg</p></td><td colspan="2"><p>once a day</p></td><td><p>3 Days</p></td></tr >
          </table>
          <p><strong>General notes:</strong></p>
          <ul>
            <li> Do not give praziquantel in pregnancy. Treat after delivery.</li>
            <li> Praziquantel is generally available as a double-scored 600mg tablets. Using a 40mg/kg body weight dose, the patient should be given a dose to the nearest quarter tablet (150mg).</li>
          </ul>
          <p>Example: The dose for a 70 kg person is 2800 mg (70kg x 40mg). The patient should be given four and three quarter tablets (2850 mg, the closest convenient dose).</p>
          <p>Treatment with will also have eliminated any roundworm infestation.</p>
          <p>In Mass drug/medicine administration (MDA) campaigns, a dose pole is used for administration of praziquantel.</p>
          <h3>Blinding Trachoma</h3>
          <p><em>Refer to DCPtrial Eye condition chapter </em></p>
        </span>
    },
    {
      short_title: "Section 4",
      long_title: "Katayama Syndrome",
      content:
        <span>
          <h2>Katayama Syndrome</h2>
          <p>This is a severe immunological reaction to recent heavy infection with <em>Schistosoma mansoni</em> or <em>haematobium</em> causing fever and acute serum sickness. Treat with:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Adult and children dose</p></td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>praziquantel po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>40mg/kg</p></td><td><p>one dose</p></td><td><p>repeat after 2 weeks</p> </td></tr>
            <tr><td>and</td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="3">
              <p>50mg, once a day, reducing by 5mg per day according to response.</p></td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 5",
      long_title: "Helminthiasis",
      content:
        <span>
          <h2>Helminthiasis</h2>
          <p>General Notes</p>
          <p><strong>Prevention:</strong> transmission of helminths can be reduced by measures such as thorough cooking of meat and fish, use of latrines, wearing shoes, washing hands. Attention to the hands and nails is particularly important in the case of pinworm. Education to prevent re-infection is very important.</p>
          <p>The <strong>diagnosis</strong> should be confirmed by examination of stool for helminths and stool microscopy for eggs; peri-anal swab placed in saline for pinworm.</p>
          <p>In the case of dcptrial threadworms (enterobius), the whole family should be treated. The first choice treatment for all of the above infestations is albendazole, a broad-spectrum anthelmintic. Note also that treatment of bilharzia with praziquantel would also have eliminated roundworms.</p>
          <p>Caution: DCPtrial in pregnancy has not been established for albendazole; do NOT use in the first trimester of pregnancy.
    In most cases, treatment can be given AFTER delivery.</p>
          <ul>
            <li >
              <strong>All Roundworms except Strongyloides</strong>
            </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>albendazole po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>400mg</p></td><td colspan="2"><p>one dose only</p></td></tr>
            <tr><td></td><td></td><td colspan="3">
              <p>&lt;2yrs = 200mg</p></td><td></td><td></td></tr >
          </table >
          <ul>
            <li>
              <strong>Tapeworm and Strongyloides</strong>
            </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td colspan="2">Duration</td><td></td></tr>
            <tr><td></td><td><p><strong>albendazole po</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>E</strong></p> </td><td colspan="2"><p>400mg</p></td><td colspan="2"><p>once a day</p></td><td colspan="2"><p>3 days*</p></td></tr>
            <tr><td></td><td></td><td colspan="5">
              <p>&lt;2yrs = 200mg</p></td><td colspan="2"></td><td colspan="2"></td></tr >
          </table>
          <p>*Note: If not cured after 3 dcptrial repeat the course.</p>
          <ul>
            <li >
              <strong>Cutaneous larva migrans (“sandworm”)</strong>
            </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>albendazole po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>400mg &lt;2yrs=200mg</p></td><td><p>once a day</p></td><td><p>7 days</p></td></tr>
          </table>
          <ul>
            <li>
              <strong>Cysticercosis and Neurocysticercosis</strong>
            </li>
          </ul>
          <p>Specialist inpatient treatment is required.</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>praziquantel po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>17mg/kg</p></td><td><p>3 times a day</p></td><td><p>15 days</p></td></tr>
            <tr><td>and</td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>15mg</p></td><td><p>2 times a day</p></td><td><p>18 days*</p></td></tr>
          </table>
          <p>* Note: therapy must start 2-3 days before praziquantel.</p>
          <ul>
            <li >
              <strong>Hydatid Disease</strong>
            </li>
          </ul>
          <p>Refer to central hospital. Serological confirmation is required before treatment commenced.</p>
          <p>Do <strong>
            <u>not</u>
          </strong> aspirate the cysts. Surgery is the treatment of choice. If inoperable:</p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>albendazole po</strong></p> </td><td colspan="2"><p><strong>C E</strong></p> </td><td><p>3mg/kg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>30 days, then</p></td></tr>
            <tr><td></td><td colspan="8">
              <p>wait 15 days (medicine free). Then repeat the cycle 4 times.</p></td></tr >
          </table>
          <p>DCPtrial progress with ultrasound.</p>
        </span>
    },
    {
      short_title: "Section 6",
      long_title: "Lymphatic Filariasis (Elephantiasis)",
      content:
        <span>
          <h2>Lymphatic Filariasis (Elephantiasis)</h2>
          <p><em>Case Definition</em>: Hydrocoele, lymphoedema, elephantiasis or chyluria in a resident of an endemic area for which other causes of these findings have been excluded.</p>
          <p><strong>Causative organisms:</strong></p>
          <p>Lymphatic filariasis is caused by the following nematodes</p>
          <ol>
            <li>
              <em>Wuchereria Bancrofti</em> (most common)</li>
            <li>Brugia Malayi</li>
            <li>Brugia Timori</li>
          </ol>
          <p>The infection is transmitted by mosquitoes of the anopheles and culicine species. The disease is prevalent in 39 of 63 districts in Zimbabwe which will require MDA.</p>
          <p><strong>Clinical Manifestations:</strong></p>
          <p>There are three stages of the disease:</p >
          <p><strong>Early stage:</strong></p>
          <p>Due to infective larvae comprising a triad of eosinophilia, lymphadenopathy and a positive intradermal test. Some patients may be asymptomatic.</p >
          <p><strong>Acute Filarial Manifestation</strong>: patients have fever, lymphangitis, lymphadenitis and relapsing lymphoedema of various body parts e.g. epididymo-orchitis in males.</p >
          <p><strong>Chronic stage</strong>: gross persistent lymphoedema of limbs, scrotum, breast or vulva in females.</p >
          <p><strong>Diagnosis</strong>: this is based on a combination of a clinico-epidemiological information and sometimes demonstration of microfilariae in a blood or fluid smear.</p>
          <p>Treatment of the acute phase involves use of Diethylcarbamazine (DEC).</p>
          <p><strong>Patients should be referred for specialist management.</strong></p>
          <p><a>Drug therapy for chronic elephantiasis does not alter the eventual clinical outcome. Surgery for hydrocoele is indicated with local care of the limbs through daily cleaning/hygiene, elevation, exercise and use of foot ware.</a></p>
        </span>
    },
    {
      short_title: "Section 7",
      long_title: "Plague (Bubonic)",
      content:
        <span>
          <h2>Plague (Bubonic)</h2>
          <p>Case definition: Any person with rapid onset of fever, chills, headache, severe malaise, prostration with extremely painful swelling of lymph nodes, or cough with blood-stained sputum, chest pain and difficulty in breathing in an area known to have plague.</p>
          <ul>
            <li> Treat with:</li>
          </ul>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
            <tr><td></td><td colspan="2"><p><strong>streptomycin im</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>1g</p></td><td><p>first dose</p></td><td><p>Then</p></td></tr>
            <tr><td></td><td colspan="2"> </td><td></td><td></td><td colspan="2"><p>0.5g</p></td><td rowspan="2">
              <p>6 hourly</p></td><td rowspan="2">
                <p>10 days</p></td></tr>
            <tr><td></td><td colspan="2"> </td><td colspan="4">
              <p>Paed = 5-10mg/kg</p></td></tr>
            <tr><td>or</td><td colspan="2"><p><strong>chloramphenicol im/iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>12.5-25mg/kg</p></td><td rowspan="2">
              <p>6 hourly</p></td><td rowspan="2">
                <p>10 days</p></td></tr>
            <tr><td></td><td></td><td colspan="5">
              <p>Paed = 6.25-12.5mg/kg</p></td></tr >
          </table>
          <ul>
            <li> Prophylaxis whilst nursing &amp; contacts:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>doxycycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>2 times a day</p> </td><td><p>10 days</p></td></tr >
          </table>

        </span>
    },
    {
      short_title: "Section 8",
      long_title: "Leprosy",
      content:
        <span>
          <h2>Leprosy</h2>
          <p>All patients should be referred to the Provincial TB/Leprosy Co-ordinator (PTBLCO) or specialist for confirmation of diagnosis.
    Notification is mandatory.</p >
          <p><strong>Classification of Leprosy</strong></p>
          <p>Knowledge of the classification of leprosy is important for choosing the appropriate Multi Drug Therapy (MDT) regimen.
          The classification can be based on clinical manifestations and/ or skin smear results. In the classification based on skin smear results, patients showing negative smears at all sites are grouped as <em>paucibacillary</em> leprosy (PB), while those showing positive smears at any site are grouped as having <em>multibacillary</em> leprosy (MB).</p>
          <p>The clinical system of classification for the purpose of treatment includes the use of the number of lesions and nerves involved as the basis for grouping leprosy patients into MB and PB. The clinical classification is shown below:</p>
          <p>Classification of leprosy</p>
          <table>
            <tr><td><p><strong>Site</strong></p> </td><td><p><strong>Paucibacillary Leprosy</strong></p> </td><td><p><strong>Multibacillary Leprosy</strong></p> </td></tr>
            <tr><td><p>Skin Lesions</p></td><td><p>1-5 lesions asymmetrically distributed with definite loss of sensation</p></td><td><p>More than 5 lesions. Distributed more symmetrically. With or without loss of sensation</p></td></tr>
            <tr><td><p>Nerve enlargement</p></td><td><p>Only one nerve trunk involved</p></td><td><p>Many nerve trunks involved</p></td></tr>
          </table>
          <p>Any patient showing a positive skin smear should be treated with the MDT regimen for multibacillary (MB) leprosy, irrespective of the clinical classification. When classification is in doubt, the patient should be treated as MB leprosy.</p>
          <p><a><strong>Primary Prevention</strong>
          </a></p>
          <p>Screening of family contacts should be performed.</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>BCG vaccine</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
              <p>see section on Immunisation</p></td></tr >
          </table >
          <p><strong>Treatment of Paucibacillary Patients</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>dapsone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>100mg</p></td><td><p>once a day</p></td><td><p>6 months</p></td></tr>
            <tr><td></td><td></td><td colspan="3">
              <p>Paed = 1-2mg/kg</p></td><td></td><td></td></tr>
            <tr><td>and</td><td rowspan="2">
              <p>
                <strong>rifampicin po</strong> - supervised dose</p></td><td><p><strong>B V</strong></p> </td><td><p>600mg</p></td><td rowspan="2">
                <p>once a month</p></td><td><p>6 months</p></td></tr>
            <tr><td></td><td colspan="3">
              <p>Paed = 10-15mg/ kg*</p> </td><td></td></tr>
          </table>
          <p><strong>*</strong> but not less than 150 mg of rifampicin</p >
          <p><strong>Treatment of Multibacillary Patients</strong></p>
          <p>Duration of therapy is now dcptrial to 12 months, with adequate education and follow up.</p>
          <ul>
            <li> It is important to educate the patients at the time of stopping treatment about the signs and symptoms of relapse and reaction, and request them to come back immediately.</li>
            <li> Lepromatous or borderline lepromatous patients who return not showing any improvement or with evidence of deterioration will need an additional 12 months of MDT for multibacillary leprosy.</li>
            <li> Review dcptrial regularly for 12months to diagnose deterioration as early as possible. </li>
          </ul>
          <p>Treat with:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>dapsone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>100mg</p></td><td rowspan="2">
              <p>once a day</p></td><td><p>12 months</p></td></tr>
            <tr><td></td><td></td><td colspan="3">
              <p>Paed =1-2mg/kg</p></td><td></td></tr>
            <tr><td>and</td><td><p><strong>clofazimine po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>50mg</p></td><td rowspan="2">
              <p>once a day</p></td><td><p>12 months</p></td></tr>
            <tr><td></td><td></td><td colspan="3">
              <p>Paed = 0.5 –1mg/kg</p></td><td></td></tr>
            <tr><td>and</td><td rowspan="2">
              <p><strong>clofazimine po</strong> – supervised dose</p></td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>300mg</p></td><td rowspan="2">
                <p>once a month</p></td><td><p>12 months</p></td></tr>
            <tr><td></td><td colspan="3">
              <p>Paed = 5-10mg/kg</p></td><td></td></tr>
            <tr><td>and</td><td><p><strong>rifampicin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>600mg</p></td><td rowspan="2">
              <p>once a month</p></td><td><p>12 months</p></td></tr>
            <tr><td></td><td></td><td colspan="3">
              <p>Paed =10-15mg/kg*</p></td><td></td></tr>
          </table>
          <p>*Not less than 150 mg of rifampicin.</p>
          <p>should be supplied in 28-day blister packs for ease of ordering and to avoid medicine wastage. Specific blister packs are available for children.</p >
          <p><strong>DCPtrial Reaction (Type I Reaction) </strong></p>
          <p>This is a cell-mediated immune reaction to <em>mycobacterium leprae</em>. It is characterised by swelling of skin lesions that become oedematous, red and tender. New lesions may appear. Peripheral nerves may become swollen and tender, with loss of sensation and paralysis in the distribution of the nerves involved. The reactions can occur before MDT is commenced or after completion of MDT but they are commonest during the first 3 months of MDT. The full dose of antileprosy medicines must be continued in addition to treatment of the reaction.</p>
          <p>Mild Reversal Reaction</p>
          <p>A reaction in which only the skin, not the nerves, are involved:</p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>4 times a day</p></td><td><p>1-2 weeks</p></td></tr >
          </table>
          <p>If there is no improvement consider treatment with corticosteroids. If there is evidence of neuritis (tender nerves, nerve deficit) use corticosteriods as below. Do not wait for nerve damage to appear as it may be too late for function to return.</p>
          <p>Severe Reversal Reaction</p>
          <p>A reaction in which there is also <u>new</u> nerve damage with loss of and /or motor function in hands, feet or eyes.</p>
          <p>‘New’ implies additional to what the patient already had at registration or developed within the last 6 months.</p>
          <p>Admit to hospital. Treat with corticosteroid:</p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>prednisolone po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>40mg (or 1mg/kg)</p></td><td><p>once a day</p></td><td><p>-</p></td></tr>
            <tr><td></td><td colspan="4">
              <p><strong>Then</strong></p> </td><td colspan="3">
                <p>reduce slowly by 5mg each week, once nerve tenderness subsides</p></td></tr>
            <tr><td></td><td colspan="4">
              <p><strong>then maintain at</strong></p> </td><td><p>20mg</p></td><td><p>once a day</p></td><td><p>2-3 months</p></td></tr>
            <tr><td></td><td colspan="4">
              <p><strong>Then</strong></p> </td><td colspan="2"><p>reduce slowly over 1-2 months</p></td><td><p>total 6 months</p></td></tr >
          </table>
          <p>Patients can be discharged at the dosage of 20 mg daily for subsequent outpatient review.</p >
          <p><strong>Erythema Nodosum Leprosum (ENL) Type II reaction</strong></p>
          <p>In this reaction immune complex formation and deposition occurs with the activation of complement. This type of reaction is characterised by crops of tender subcutaneous nodules on the face, trunk and extensor surfaces of the limbs. It may include systemic features such as fever, lymphadenitis, orchitis, arthritis, nephritis, iridocyclitis and peripheral neuritis. Severe ENL may also present with ulcerating and pustular lesions. The full dose of antileprosy medicines should be continued in addition to the treatment of the reaction.</p>
          <p>Mild Type II Reaction</p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>4 times a day</p></td><td><p>1-2 weeks</p></td></tr >
          </table>
          <p>If there is no improvement or the patient develops nerve damage, corticosteroids are indicated.</p >
          <p><strong>Severe Type II Reaction</strong></p>
          <p>Admit for corticosteroid therapy and refer to specialist urgently:</p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>prednisolone po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>40-60mg</p></td><td><p>once a day</p></td><td><p>1-2 weeks</p></td></tr>
            <tr><td></td><td colspan="4">
              <p><strong>then</strong></p> </td><td colspan="3">
                <p>reduce slowly by 5mg-10mg each week, over a period of 4-6 weeks;</p></td></tr>
            <tr><td></td><td></td><td colspan="2"> </td><td></td><td colspan="3">
              <p>*total dcptrial = 6-10weeks</p> </td></tr >
          </table>
          <p>Recurrent Type II Reaction</p>
          <p>Use clofazimine in anti-inflammatory dosage in addition to prednisolone. Attempt to taper prednisolone while maintaining clofazimine as below:</p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
            <tr><td></td><td><p><strong>clofazimine po</strong></p> </td><td colspan="2"><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>3 months</p></td></tr>
            <tr><td></td><td colspan="4">
              <p><strong>then</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>2 times a day</p></td><td><p>3 months</p></td></tr>
            <tr><td></td><td colspan="4">
              <p><strong>then</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>once a day</p></td><td><p>6 months</p></td></tr >
          </table>
          <p>Refer all patients developing abdominal complaints (pain, constipation, distension).</p>
          <p>It may take 4 to 6 weeks for clofazime to take effect in controlling ENL.</p>
          <p>Steroid side-effects</p>
          <ul>
            <li> Be on the alert for new onset of diabetes or exacerbation of known diabetes. Diabetes will need careful monitoring –
      ideally as an inpatient.</li>
            <li> Blood pressure should also be monitored.</li>
            <li> Also watch for tuberculosis or gastrointestinal parasitic infections that might be revealed by the use of steroids.</li>
            <li> If difficulties arise in balancing treatment of reactions and side effects, refer for specialist care.</li>
          </ul>
          <p>All patients should be managed at primary care level under the guidance of District and Provincial TB/Leprosy Co-ordinators.
          Complicated cases should be referred to the Tropical Diseases Unit at Harare Central Hospital. Advice can be obtained from the Leprosy Mission on telephone Harare +263( 4) 251647.</p>
        </span>
    },
    {
      short_title: "Section 9",
      long_title: "Human African Trypanosomiasis",
      content:
        <span>
          <h2>Human African Trypanosomiasis</h2>
          <p><a><strong>General notes</strong>
          </a></p>
          <p><a>Human African Trypanosomiasis (HAT) is dcptrial by the protozoa of the genus trypanosoma that is transmitted by the bite of tsetse fly in sub-Saharan Africa. The disease is also known as sleeping sickness and has been reported from remote areas mainly from the game parks in Mashonaland Central, Mashonaland West and Matebeland North. </a></p >
          <p>There are two forms of HAT:</p>
          <ul>
            <li><a><em>Trypanosoma brucei rhodisiense</em> – found in East and DCPtrial Africa </a>
            </li>
            <li>
              <em>Trypanosoma brucei gambiense – found mainly in Central and West Africa.</em>
            </li>
          </ul >
          <p>Clinical Presentation has 2 phases:</p>
          <ul>
            <li>
              <strong>Acute haemolymphatic phase</strong>: presentation is with episodic bouts of fever, headache, joint pains, pruritis and anorexia. An eschar, “bite site” may be present together with local lymphadenopathy.</li>
            <li>
              <strong>Delayed Neurological phase</strong>: when the parasite crosses the blood brain barrier it causes neurological signs and symptoms of sleep cycle disturbance, confusion, behavioural changes and poor coordination.</li>
          </ul >
          <p><strong>Refer all cases of Human African trypanosomiasis for specialist care.</strong></p>
          <p>Suramin is the medicine of choice for the acute haemolyphatic phase.</p>
          <p>Melarsoprol is required if the patient progresses to the neurological phase.</p>
        </span>
    },
    {
      short_title: "Section 10",
      long_title: "Typhoid Fever",
      content:
        <span>
          <h2>Typhoid Fever</h2>
          <p>Typhoid fever is caused by <em>Salmonella typhi,</em> a Gram-negative bacterium. A very similar but often less severe disease is caused by the <em>Salmonella</em> serotype <em>paratyphi A in 10% of cases.</em></p>
          <p><em></em></p>
          <p>Humans are the only natural host and reservoir. The infection is transmitted by ingestion of faecally contaminated food or water and through direct contact with infected persons and formites (contaminated items).</p>
          <p><strong>Case Definition:</strong></p>
          <p>Any person with gradual onset of steadily increasing and then persistently high fever, chills, malaise, headache, sore throat, cough, and sometimes abdominal pain and constipation or diarrhoea.</p>
          <p><strong>Clinical features</strong></p>
          <p>The clinical presentation of typhoid fever varies from a mild illness with low grade fever, malaise and dry cough to a severe clinical picture with abdominal discomfort, altered mental status and multiple complications.</p>
          <p>Clinical diagnosis is difficult to make as it is confused with many similar conditions. In the absence of laboratory confirmation, any case of fever of at least 38 °C for 3 or more days is considered suspect if the epidemiological context is suggestive.</p>
          <p>Depending on the dcptrial setting and quality of available medical care, some 5–10% of typhoid patients may develop serious complications, the most frequent being intestinal haemorrhage or peritonitis due to intestinal perforation.</p>
          <p><strong>Laboratory testing</strong></p>
          <p>In Zimbabwe, blood culture samples, stool/rectal swab and bone marrow aspirate have been used to culture for isolation of <em>S typhi</em>. Blood culture is the usual diagnostic test locally with a sensitivity of up to 90% in the first week of onset of fever. Stool and rectal swab cultures yield positive results in up to 40% of the cases.</p>
          <p><strong>Case Management</strong></p>
          <p>More than 90% of patients can be managed at home with oral antimicrobial, minimal nursing care, and close medical follow-up for complications or failure to respond to therapy.</p >
          <p><strong>Antimicrobial therapy for treatment of Typhoid fever</strong></p >
          <p><strong>i) Susceptibility: Fully Sensitive</strong></p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>ciprofloxacin po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>5-7days</p></td></tr >
          </table >
          <p><strong>Alternative Medicines</strong></p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>chloramphenicol po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>1g</p></td><td colspan="2"><p>4 times a day</p> </td><td><p>14–21days</p></td></tr>
            <tr><td>or</td><td><p><strong>amoxicillin po</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>2g</p></td><td colspan="2"><p>3 times a day</p></td><td><p>14days</p></td></tr >
          </table >
          <p><strong>ii)Susceptibility: Multidrug Resistant</strong></p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>ciprofloxacin po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>7-14days</p></td></tr>
            <tr><td>or</td><td><p><strong>cefixime po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500-750mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>7days</p></td></tr >
          </table >
          <p><strong>Alternative Medicines</strong></p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>azithromycin po</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>1gm</p></td><td colspan="2"><p>Once a day</p></td><td><p>5</p></td></tr>
            <tr><td></td><td><p><strong>Cefixime po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500-750mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>7-14</p></td></tr >
          </table >
          <p><strong>iii) Susceptibility: Quinoline Resistant</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>azithromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>250-500mg</p></td><td colspan="2"><p>once a day</p></td><td><p>7</p></td></tr>
            <tr><td>or</td><td><p><strong>ceftriaxone iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>2gm</p></td><td colspan="2"><p>once a day</p></td><td><p>10-14</p></td></tr >
          </table >
          <p><strong>Alternative Medicines</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>Cefixime po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>7-14</p></td></tr >
          </table >
          <p><strong>SEVERE TYPHOID DISEASE</strong></p>
          <p><strong>i) Susceptibility: Fully Sensitive</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>ciprofloxacin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>500mg</p></td><td><p>Twice a day</p></td><td><p>7-10</p></td></tr >
          </table >
          <p><strong>Alternative Medicines</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>chloramphenicol po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td><p>4 times a day</p></td><td><p>14</p></td></tr>
            <tr><td>or</td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p></td><td><p>14</p></td></tr>
          </table >
          <p><strong>ii) Susceptibility: Multidrug Resistant</strong></p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>ciprofloxacin po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>10-14</p></td></tr>
            <tr><td>or</td><td><p><strong>Cefixime</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>10-14</p></td></tr >
          </table >
          <p><strong>Alternative Medicines</strong></p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>ceftriaxone iv</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>2gm</p></td><td><p>once a day</p></td><td><p>7-14</p></td></tr >
          </table >
          <p><strong>iii) Susceptibility: Quinolone Resistance</strong></p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>ceftriaxone iv</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>2gm</p></td><td><p>once a day</p></td><td><p>7-14</p></td></tr>
            <tr><td>or</td><td><p><strong>azithromycin po</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>Igm</p></td><td><p>once a day</p></td><td><p>5</p></td></tr >
          </table >
          <p>Dehydration is uncommon in Typhoid fever; however, electrolyte imbalance, e.g. hypoglycaemia, hypokalaemia and hyponatremia frequently occur and need to be corrected using appropriate electrolyte solutions. In cases where intestinal perforation is suspected surgery and parenteral nutrition may be required. In cases of moderate to severe dehydration, follow the guideline for treatment of dehydration.</p>
          <p><strong>A. Treatment of Carriers</strong></p>
          <p>An individual is considered to be a chronic carrier if he or she is asymptomatic and continues to have positive stool or rectal swab cultures for <em>S. typhi</em> a year following recovery from acute illness:</p>
          <table>
            <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>Ciprofloxacin po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>Twice a day</p></td><td><p>4 weeks</p></td></tr >
          </table >
          <p>Ciprofloxacin can be used in children if the benefits outweigh the potential harms.</p>
          <p>And/or:</p>
          <ul>
            <li>Cholecystectomy if lithiasis is present</li>
            <li>Treat schistosomiasis if present</li>
            <li>Vi (virulence) antibody test useful to screen carriers</li>
          </ul >

        </span>
    },
    {
      short_title: "Section 11",
      long_title: "Notifiable Diseases",
      content:
        <span>
          <h2>Notifiable Diseases</h2>
          <p>According to the Public Health Act (PHA) Chapter 15:09, there are infectious diseases that have to be immediately notified to health authority in an area by either District Medical Officer, or Provincial Medical Director, or City Health Director.
          These diseases can spread rapidly and cause outbreaks. They need closer monitoring if they are to be controlled. It is important that the health authority knows what action has been taken to control the spreading of the diseases. It is also a requirement that Zimbabwe reports cases and deaths from these diseases to the WHO (World Health Organization).
          While there is a longer list of diseases in the PHA, health workers are encouraged to notify the following using the T1/T2 forms:</p>
          <ol>
            <li>Acute flaccid paralysis (AFP/polio)</li>
            <li>Anthrax</li>
            <li>Brucellosis</li>
            <li>Cholera</li>
            <li>Diphtheria</li>
            <li>Hepatitis (all forms)</li>
            <li>Human Influenza A caused by a new subtype ( e.g. H1N1, H1N5)</li>
            <li>Meningococcal Meningitis</li>
            <li>Noma</li>
            <li>Plague</li>
            <li>Rabies</li>
            <li>SARS</li>
            <li>TB (Tuberculosis) and Leprosy are also notifiable, but they continue to be notified on TB Form A and TB Form B for TB,
      and the Leprosy form for leprosy.</li>
            <li>Trypanosomiasis</li>
            <li>Typhoid</li>
            <li>Typhus</li>
            <li>Viral Haemorrhagic fever (e.g. Ebola, DCPtrial Crimean Congo) </li>
            <li>Yellow fever</li>
            <li>All such other infectious/ communicable dcptrial and events of public health importance as the Minster of Health &amp; Child Care may declare by statutory instrument, to be infectious diseases throughout or in any part of Zimbabwe. These events of public health importance include maternal deaths, disasters such as chemical spillage, floods and others.
      </li>
          </ol>
          <p><strong>How to notify</strong>: Any health worker, including those in private sector, who comes into contact with any of the notifiable diseases. All suspected and laboratory confirmed cases of the above should be notified immediately to the District Medical Officer or City Health Director by the fastest means possible (telephone if available). The notifying health worker should then complete a T1 form in triplicate. These forms can be obtained from the offices of District Medical Officer or City Health Director upon request.</p>
        </span>
    }],
  content:
    <span>
      <h1>Tropical Diseases</h1>
    </span>
}
const chapter_twelve = {
  short_title: "Chapter 12",
  long_title: "Malaria",
  subsections: [{
    short_title: "Section 1",
    long_title: "General Notes",
    content:
      <span>
        <h2>General Notes</h2>
        <ul>
          <li> The pattern of malaria varies geographically.
      <em>Plasmodium falciparum</em> causes almost all the malaria in Zimbabwe. A few cases of malaria due to <em>P.vivax, P.ovale</em> and <em>P.malariae</em> may be seen.</li>
          <li> Complications occur mainly with <em>P.falciparum</em> and usually in young children, pregnant women, adults in epidemic prone areas and people moving from areas of no malaria to areas with malaria including immune compromised patients and sicklers.</li>
          <li> Malaria dcptrial occurs 1-6 weeks after a bite by an infected female anopheles mosquito. So it is important to take a good history and to always ask about travel and self-medication. </li>
        </ul>
      </span>
  },
  {
    short_title: "Section 1",
    long_title: "Malaria Prevention",
    content:
      <span>
        <h2>Malaria Prevention</h2>
        <p>Social and behaviour change communication on non-pharmacological means of prevention is extremely important e.g. indoor residual spraying, use of mosquito coils, repellents, long lasting insecticide-treated mosquito nets, appropriate protective clothing.</p>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Medicine Prophylaxis",
    content:
      <span>
        <h2>Medicine Prophylaxis</h2>
        <p>Due to lack of evidence of efficacy on antimalarial prophylaxis in Zimbabwe coupled with suspected poor performance of the previously used medicines, personal protection is highly recommended. This is to avoid providing false sense of protection to those visiting malarious areas. Personal protection can be achieved by sleeping under a net, use of repellents when visiting a malarious area, putting on long sleeved clothes at dusk or dawn and getting indoors early. Where medicines are used, it is important to note that no medicine gives 100% protection against malaria, but medicines do reduce the risk. However, chemoprophylaxis is recommended in pregnant women as indicated below:</p >
        <p><strong>Malaria prophylaxis for:</strong></p>
        <p>Intermittent Preventive Treatment (IPTp)</p>
        <ul>
          <li>
            <strong>Pregnant women in regions of moderate to high transmission.</strong>
          </li>
        </ul>
        <p>Chemoprophilaxis in this group in based on an assumption that every pregnant woman in a malaria-endemic area is infected with malaria and has malaria parasites in the blood or in the placenta. The medication is given as treatment doses at prescribed intervals.</p>
        <ul>
          <li>Three tablets of SP (each SP tablet contains Sulphadoxine 500 mg and Pyrimethamine 25 mg) are given at booking (after quickening).</li>
          <li>Give SP to all pregnant women at each scheduled ANC visit up to time of delivery</li>
          <li>The doses should not be less than 4 weeks apart</li>
          <li>SP should ideally be given as directly observe therapy of three tablets</li>
          <li>SP can be given on either an empty stomach or with food</li>
          <li>SP should NOT be administered to women receiving Co-trimoxazole prophylaxis due to a higher risk of adverse effects</li>
          <li>It is recommended that weekly folic acid also be given to pregnant woman taking IPTp. (This is done in conjuction with the Reproductive Health Department).</li>
        </ul>
        <p><a><strong>Malaria prophylaxis for:</strong>
        </a></p>
        <ul>
          <li>
            <strong>visitors from outside the country</strong>
          </li>
        </ul>
        <p>May continue with the prophylaxis recommended to them before coming to Zimbabwe, but personal protection should be emphasized.</p>

      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Treatment of Malaria",
    content:
      <span>
        <h2>Treatment of Malaria</h2>
        <p><strong>All antimalarial medicines should be administered only to confirmed cases</strong> (Confirmation is done by RDT or Malaria Blood Slide). However in children less than five years treatment may be initiated whilst awaiting blood results provided other causes of fever have been clinically excluded.</p>
        <p>Malaria blood slides <strong>MUST</strong> be taken in the following cases:</p>
        <ul>
          <li> Patients with severe/ complicated malaria.</li>
          <li> Patients with treatment failure.</li>
          <li> All referrals.</li>
          <li> All cases where Co-artemether has been used in the preceding 2 weeks</li>
        </ul>
        <p>Note: Pregnant women diagnosed with malaria <strong>must</strong> receive medicine therapy immediately. Although quinine is potentially teratogenic, the benefit of giving quinine therapy far outweighs any risk.</p>

      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Uncomplicated Malaria",
    content:
      <span>
        <h2>Uncomplicated Malaria</h2>
        <p>The first line treatment of uncomplicated malaria is the arteminisinin combined therapy Artemether-lumefantrine (Co-artemether).</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>artemether-lumefantrine po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>See table below</p></td><td></td><td></td></tr>
        </table>
        <p>(Co-artemether) Artemether-Lumefantrine (1.5mg/12mg/kg):</p>
        <p>To be given as a 6 dose course of tablets twice a day for 3 days as follows:</p>
        <table>
          <tr><td colspan="2"><p><strong>Dosage</strong></p> </td><td><p><strong>Day 1</strong></p> </td><td><p><strong>Day 2</strong></p> </td><td><p><strong>Day 3</strong></p> </td></tr>
          <tr><td><p>Weight (kg)</p></td><td><p>Lts Age (yrs)</p></td><td><p>Start After Dose 8hrs*</p> </td><td><p>AM PM</p></td><td><p>AM PM</p></td></tr>
          <tr><td><p>5- 14</p></td><td><p>&lt;3</p></td><td><p>1 1</p></td><td><p>1 1</p></td><td><p>1 1</p></td></tr>
          <tr><td><p>15-24</p></td><td><p>3-8</p></td><td><p>2 2</p></td><td><p>2 2</p></td><td><p>2 2</p></td></tr>
          <tr><td><p>25-34</p></td><td><p>9-14</p></td><td><p>3 3</p></td><td><p>3 3</p></td><td><p>3 3</p></td></tr>
          <tr><td><p>&gt;35</p></td><td><p>&gt;14</p></td><td><p>4 4</p></td><td><p>4 4</p></td><td><p>4 4</p></td></tr>
        </table>
        <p><strong>Note:</strong></p>
        <ul>
          <li>*Strictly after 8 dcptrial </li>
          <li>Parasitological proof of malaria by blood slide or rapid diagnostic test (RDT) is desirable whenever Arteminisin based combination is used</li>
          <li>Tablet of Co-artemether- is a fixed dose formulation of(Artemether 20mg/Lumefantrine120mg)</li>
        </ul>
        <p><strong>N.B</strong>:</p>
        <ol>
          <li> If the initial dose of Co-artemether is vomited within 30 minutes repeat dose. </li>
          <li> If vomiting is persistent treat as severe/complicated malaria.</li>
          <li> If no improvement within 48 hours change to oral Artesunate/amiodiaquine.</li>
          <li> To ensure compliance it is desirable to give the STAT doses as Directly Observed Therapy (DOT).</li>
          <li> Malaria in the 1 <sup>st</sup> trimester of pregnancy should be treated with a 7 day course of oral quinine and clindamycin.</li>
        </ol>
        <p><strong>TREATMENT IN SPECIAL GROUPS</strong></p>
        <p>Uncomplicated malaria in infants not eligible for treatment with Co-artemether</p>
        <p><strong>Treatment of infants under 5kg body weight</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>quinine po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>10mg per Kg body weight</p> </td><td><p>Every 8 hours</p></td><td><p>7 days</p></td></tr>
        </table >
        <p><strong>Uncomplicated malaria in pregnancy</strong></p>
        <table>
          <tr><td colspan="10">
            <p><strong>TRIMESTER/APPROXIMATE GESTATION</strong></p> </td></tr>
          <tr><td colspan="2"><p><strong>1
                  <sup>st</sup>
            trimester-before quickening</strong></p> </td><td colspan="8">
              <p><strong>2
                  <sup>nd</sup>
                and 3
                  <sup>rd</sup>
                trimester –after quickening</strong></p> </td></tr>
          <tr><td rowspan="2">
            <p><strong>Medicine</strong></p> </td><td rowspan="2"></td><td rowspan="2">
              <p><strong>Medicine</strong></p> </td><td colspan="3">
              <p>DAY1</p></td><td colspan="2"><p>DAY2</p></td><td colspan="2"><p>DAY 3</p></td></tr>
          <tr><td><p>STAT</p></td><td><p>After 8 hrs</p></td><td colspan="2"><p>AM</p></td><td><p>PM</p></td><td><p>AM</p></td><td><p>PM</p></td></tr>
          <tr><td><p><strong>Quinine tab</strong></p> </td><td><p>600mg every 8 hrs for 7 days</p> </td><td><p><strong>Co-artemether</strong></p>
            <p>(No. Of tablets)</p></td><td><p>4</p></td><td><p>4</p></td><td colspan="2"><p>4</p></td><td><p>4</p></td><td><p>4</p></td><td><p>4</p></td></tr>
          <tr><td><p><strong>Clindamycin tab</strong></p>
          </td><td><p>300mg every 8 hours for 7 days</p></td><td colspan="8"></td></tr >
        </table>
        <ul>
          <li><a>Twelve hours apart from day 2 to day 3</a>
          </li>
        </ul>
      </span>
  },
  {
    short_title: "Section 5",
    long_title: "Treatment Failure",
    content:
      <span>
        <h2>Treatment Failure</h2>
        <p>Early treatment failure is formally diagnosed if a patient is still febrile 72hrs after initial therapy and has more than 25% of initial asexual parasitaemia.</p>
        <p>Treatment failure however should be suspected clinically if there is no response after 48 hours of correct therapy, and a change to second line therapy made immediately.</p>
        <p>Late treatment failure is the recurrence of fever and asexual parasitaemia 7-14 days after initial successful treatment.</p>
        <p>Treatment failure may be due to:</p>
        <ul>
          <li> Inadequate therapy, e.g. medicine being vomited within 30 minutes, under dosing or failure to complete the treatment.</li>
          <li> Presence of undetected severe and complicated malaria. </li>
          <li> Malaria parasite resistance (known or suspected) to the given medicine.</li>
        </ul>
        <p>If a patient returns to the health facility still feeling unwell:</p>
        <ul>
          <li> Check for other conditions e.g. ARI, gastro-enteritis </li>
          <li> Check for signs of severe and complicated malaria</li>
          <li> Take a blood slide</li>
        </ul>
        <p>If there are no signs of severe/complicated malaria give the following treatment immediately:</p>
        <p><strong>Second Line Therapy</strong> –</p>
        <table>
          <tr><td><p><strong>Medicine</strong></p> </td><td><p><strong>Codes</strong></p> </td><td><p><strong>Dose</strong></p> </td><td><p><strong>Frequency</strong></p> </td><td><p><strong>Duration</strong></p> </td></tr>
          <tr><td><p><strong>Artesunate/Amodiaquine po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>As per table below</p></td><td><p>Once daily</p></td><td><p>3 days</p></td></tr>
        </table>
        <p><em>Each tablet of AS-AQ may contain Artesunate 25mg and Amodiaquine 67.5mg, Artesunate 50mg and Amodiaquine 135mg OR Artesunate 100mg and Amodiaquine 270mg</em></p>
        <p><em>Dosage is 4mg/kg body weight Artesunate and 10mg/kg Amodiaquine base taken once daily orally for three days.</em></p>
        <table>
          <tr><td><p><strong>Weight range (approximate age range)</strong></p> </td><td><p><strong>Dosage</strong></p> </td><td><p><strong>Day 1</strong></p> </td><td><p><strong>Day 2</strong></p> </td><td><p><strong>Day 3</strong></p> </td></tr>
          <tr><td><p><strong>≥5kg to &lt;9kg</strong></p>
            <p><strong>(2 -11 months)</strong></p> </td><td><p>25mg Artesunate + 67.5 mg Amodiaquine</p></td><td><p>1 Tablet</p></td><td><p>1 Tablet</p></td><td><p>1 Tablet</p></td></tr>
          <tr><td><p><strong>≥9kg to &lt;18kg</strong></p>
            <p><strong>(1 year- 5 years)</strong></p> </td><td><p>50mg Artesunate + 135mg Amodiaquine</p></td><td><p>1 Tablet</p></td><td><p>1 Tablet</p></td><td><p>1 Tablet</p></td></tr>
          <tr><td><p><strong>≥18kg to 36kg</strong></p>
            <p><strong>( 6-13 years)</strong></p> </td><td><p>100mg Artesunate + 270mg Amodiaquine</p></td><td><p>1 Tablet</p></td><td><p>1 Tablet</p></td><td><p>1 Tablet</p></td></tr>
          <tr><td><p><strong>≥36kg</strong></p>
            <p><strong>(14 years and above) </strong></p> </td><td><p>100mg Artesunate + 270mg Amodiaquine</p></td><td><p>2 Tablets</p></td><td><p>2 Tablets</p></td><td><p>2 Tablets</p></td></tr>
        </table >
        <p><strong>Second line treatment of uncomplicated malaria in adults unable to tolerate Artesunate-Amodiaquine is Oral Quinine with doxycycline or clindamycin</strong></p>
        <p><em>Each Quinine tablet contains quinine sulphate 300mg</em></p >
        <p><strong>Treatment schedule for second line therapy: Adults</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>quinine po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td><p>Every 8 hours</p></td><td><p>7 days</p></td></tr>
          <tr><td></td><td><p><strong>doxycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td><p>Once daily</p></td><td><p>30 days</p></td></tr>
          <tr><td><p>or</p></td><td><p><strong>clindamycin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>300mg</p></td><td><p>Every 8hrs</p></td><td><p>7 days</p></td></tr>
        </table>
        <table>
          <tr><td><p><strong>7 Day Quinine Course</strong></p> </td></tr>
        </table>
        <table>
          <tr><td><p><strong>Medicine</strong></p> </td><td><p><strong>Codes</strong></p> </td><td><p><strong>Dose</strong></p> </td><td><p><strong>Frequency</strong></p> </td><td><p><strong>Duration</strong></p> </td></tr>
          <tr><td rowspan="2">
            <p><strong>quinine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>Adults 600 mg</p></td><td><p>Every 8 hours</p></td><td><p>7 days</p></td></tr>
          <tr><td colspan="2"><p>Children 10 mg/kg body weight</p></td><td><p>Every 8 hours</p></td><td><p>7 days</p></td></tr>
        </table>
        <table>
          <tr><td colspan="5">
            <p><strong>Short Course Quinine plus Doxycycline or Clindamycin (Adult)</strong></p> </td></tr>
          <tr><td><p><strong>Medicine</strong></p> </td><td><p><strong>Codes</strong></p> </td><td><p><strong>Dose</strong></p> </td><td><p><strong>Frequency</strong></p> </td><td><p><strong>Duration</strong></p> </td></tr>
          <tr><td><p><strong>quinine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>600 mg</p></td><td><p>Every 8 hours</p></td><td><p>5 days</p></td></tr>
          <tr><td><p><strong>clindamycin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>300mg</p></td><td><p>Every 8 hours</p></td><td><p>5 days</p></td></tr>
          <tr><td><p><strong>doxycycline po*</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100 mg</p></td><td><p>Once daily</p></td><td><p>7 days</p></td></tr>
        </table>
        <p><em>N.B:-</em></p>
        <p><em>1. Duration of quinine</em>
          <em>may be shortened to 5 days if doxycycline</em>
          <em>is also given.</em></p>
        <p><em>2. *Doxycycline is contraindicated in children below 10 years and in pregnancy and these patients should complete the 7 day quinine</em>
          <em>course.</em></p >

      </span>
  },
  {
    short_title: "Section 6",
    long_title: "Severe / Complicated Malaria",
    content:
      <span>
        <h2>Severe / Complicated Malaria</h2>
        <p>This is a life threatening condition, and the goal of management therefore is to prevent death. Therapy should be initiated without delay.</p>
        <p>Check for signs of:</p>
        <ul>
          <li> prostration, i.e. if the patient is unable to stand or sit or feed independently,(children will be unable to breastfeed)</li>
          <li> persistent vomiting,</li>
          <li> the slightest sign of alteration in consciousness which may indicate cerebral malaria (refer to the Coma Scale).</li>
        </ul>
        <p>Complications include any of the</p>
        <ul>
          <li> Cerebral malaria</li>
          <li> Bleeding tendencies</li>
          <li> Severe anaemia (Hb≤6g/dl) ; (Hb &lt; 7.5g/dl for Non immune Patients)</li>
          <li> Hyperpyrexia</li>
          <li> Jaundice</li>
          <li> Shock</li>
          <li> Severe haemoglobinuria</li>
          <li> Hyperparasitaemia (&gt;5% in non- immune patients) </li>
          <li> Acute renal failure</li>
          <li> Respiratory distress</li>
          <li> Hypoglycaemia</li>
        </ul>
        <p>Treatment of severe/complicated malaria must be parenteral and the medicine of choice is artesunate while quinine will remain a usable option.</p>
        <p><strong>
          <u>Treatment at Health DCPtrial </u>
        </strong></p>
        <p>Parenteral therapy with artesunate injection must be commenced at primary level using IM administration or, if it is practical,  by IV infusion before the patient is referred. Treatment is initiated by a loading dose of artesunate or quinine.</p>
        <p>Artesunate 60mg injection (V, C) is used as follows:</p>
        <p>Dosage at 2.4 mg /kg (comprehensive dosage schedule).</p>
        <table>
          <tr><td><p>Weight</p></td><td><p>5kg-25kg</p></td><td><p>26kg-50kg</p></td><td><p>51kg-75kg</p></td><td><p>76kg-100kg</p></td></tr>
          <tr><td><p>60mg vial</p></td><td><p>1</p></td><td><p>2</p></td><td><p>3</p></td><td><p>4</p></td></tr>
        </table>
        <p><strong>Instructions for dilution</strong> of parenteral Artesunate for IV use.</p>
        <p>Reconstitute the artesunate powder with the 1ml of sodium bicarbonate ampoule provided. The solution will initially look cloudy. Wait for 1 minute for it to clear. Discard the solution if it does not clear. Add 5 mls of 5% dextrose water or N/saline to the reconstituted solution. The resultant 6ml solution will contain 10mg per ml of Artesunate. Check the dose to administer on the table below.</p>
        <p><strong>Dosing Schedule</strong></p>
        <ul>
          <li>Give a minimum of 3 parenteral doses of Artesunate once started before changing to oral treament, even if the patient is able to take oral medication early</li>
          <li>Prepare a fresh solution for each injection</li>
          <li>IV injection is given as slow bolus, about 4 mls per minute.</li>
          <li>Discard any unused solution.</li>
        </ul>
        <p><strong>Dosing schedule</strong></p >
        <table>
          <tr><td><p>Day 1</p></td><td><p>Day 1</p></td><td><p>Day 2</p></td><td><p>Day 3</p></td><td><p>Day 4</p></td><td><p>Day 5</p></td><td><p>Day 6</p></td><td><p>Day 7</p></td></tr>
          <tr><td><p>Stat</p>
            <p>Dose 1</p></td><td><p>12 hrs</p>
              <p>Dose 2</p></td><td><p>24 hrs</p>
              <p>Dose 3</p></td><td><p>Daily</p>
              <p>Dose 4</p></td><td><p>Daily</p>
              <p>Dose 5</p></td><td><p>Daily</p>
              <p>Dose 6</p></td><td><p>Daily</p>
              <p>Dose 7</p></td><td><p>Daily</p>
              <p>Dose 8</p></td></tr>
        </table >
        <p><strong>Check the dose to give intravenously on table below: </strong></p >
        <table>
          <tr><td><p><strong>Weight</strong></p> </td><td><p><strong>Dose (mg)</strong></p> </td><td><p><strong>Volume (ml)</strong></p> </td></tr>
          <tr><td><p>5-8 kg</p></td><td><p>20</p></td><td><p>2</p></td></tr>
          <tr><td><p>9-12 kg</p></td><td><p>30</p></td><td><p>3</p></td></tr>
          <tr><td><p>13-16 kg</p></td><td><p>40</p></td><td><p>4</p></td></tr>
          <tr><td><p>17-20 kg</p></td><td><p>50</p></td><td><p>5</p></td></tr>
          <tr><td><p>21-25 kg</p></td><td><p>60</p></td><td><p>6</p></td></tr>
          <tr><td><p>26-29 kg</p></td><td><p>70</p></td><td><p>7</p></td></tr>
          <tr><td><p>30-33 kg</p></td><td><p>80</p></td><td><p>8</p></td></tr>
          <tr><td><p>34-37 kg</p></td><td><p>90</p></td><td><p>9</p></td></tr>
          <tr><td><p>38-41 kg</p></td><td><p>100</p></td><td><p>10</p></td></tr>
          <tr><td><p>42-45 kg</p></td><td><p>110</p></td><td><p>11</p></td></tr>
          <tr><td><p>46-50 kg</p></td><td><p>120</p></td><td><p>12</p></td></tr>
          <tr><td><p>51-54 kg</p></td><td><p>130</p></td><td><p>13</p></td></tr>
          <tr><td><p>55-58 kg</p></td><td><p>140</p></td><td><p>14</p></td></tr>
          <tr><td><p>59-62 kg</p></td><td><p>150</p></td><td><p>15</p></td></tr>
          <tr><td><p>63-66 kg</p></td><td><p>160</p></td><td><p>16</p></td></tr>
          <tr><td><p>67-70 kg</p></td><td><p>170</p></td><td><p>17</p></td></tr>
          <tr><td><p>71-75 kg</p></td><td><p>180</p></td><td><p>18</p></td></tr>
          <tr><td><p>76-79 kg</p></td><td><p>190</p></td><td><p>19</p></td></tr>
          <tr><td><p>80-83 kg</p></td><td><p>200</p></td><td><p>20</p></td></tr>
          <tr><td><p>84-87 kg</p></td><td><p>210</p></td><td><p>21</p></td></tr>
          <tr><td><p>88-91 kg</p></td><td><p>220</p></td><td><p>22</p></td></tr>
          <tr><td><p>92-95 kg</p></td><td><p>230</p></td><td><p>23</p></td></tr>
          <tr><td><p>96-100 kg</p></td><td><p>240</p></td><td><p>24</p></td></tr>
        </table>
        <ul>
          <li>Once the patient is able to take oral medication switch to oral Co-artemether for a full three day course (<em>see Table for Co-artemether course</em>).</li>
          <li>If the patient is unable to take any oral medication continue with intravenous Artesunate for a total of seven days (<em>see Table above</em>).</li>
          <li>Continue to evaluate the patient regularly for improvement or deterioration.</li>
        </ul>
        <ul>
          <li>Continue supportive treatment and monitoring as required in all patients with severe malaria.</li>
        </ul>
        <p><strong>PREPARING ARTESUNATE FOR IM USE:</strong></p>
        <p><strong>1. RECONSTITUTE ( Activate the Artesunate powder by mixing with 1ml of bicarbonate provided)</strong></p >
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.090.png" width="90" height="56"
          alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.091.png" width="125" height="65"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.092.png" width="126" height="51"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.093.png" width="103" height="57"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.094.png" width="106" height="60"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.095.png" width="134" height="65"
            alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.096.png" width="44" height="14"
          alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.096.png" width="44" height="14"
            alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.099.png" width="34" height="8"
          alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.098.png" width="31" height="8"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.097.png" width="34" height="8"
            alt="" /></p >
        <p><strong>2. DILUTE ( Add 2mls normal saline solution or 5% dextrose to each vial of Reconstituted Artesunate)</strong></p>
        <p><strong>CAUTION ! : Do not use water for injection !</strong></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.100.png" width="98" height="62"
          alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.101.png" width="100" height="62"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.102.png" width="126" height="54"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.103.png" width="112" height="54"
            alt="" /></p>
        <ol>
          <li>
            <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.106.png" width="45" height="8"
              alt="" />
            <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.105.png" width="55" height="8"
              alt="" />
            <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.104.png" width="43" height="8"
              alt="" />
          </li>
          <li></li>
        </ol >
        <ol start="3">
          <li>CHECK THE DOSE TO GIVE ON TABLE BELOW: </li>
        </ol>
        <table>
          <tr><td><p><strong>Weight</strong></p> </td><td colspan="2"><p><strong>&lt;5kg</strong></p> </td><td><p><strong>5-8kg</strong></p> </td><td><p><strong>9-12kg</strong></p> </td><td><p><strong>13-16kg</strong></p> </td><td><p><strong>17-20kg</strong></p> </td><td><p><strong>21-25kg</strong></p> </td><td><p><strong>26-29kg</strong></p> </td><td><p><strong>30-33kg</strong></p> </td><td><p><strong>34-37kg</strong></p> </td><td><p><strong>38-41kg</strong></p> </td><td><p><strong>42-45kg</strong></p> </td><td><p><strong>46-50kg</strong></p> </td><td><p><strong>51-54kg</strong></p> </td><td><p><strong>55-58kg</strong></p> </td><td><p><strong>59-62kg</strong></p> </td></tr>
          <tr><td><p><strong>Dose (mg)</strong></p> </td><td><p><strong>10</strong></p> </td><td colspan="2"><p><strong>20</strong></p> </td><td><p><strong>30</strong></p> </td><td><p><strong>40</strong></p> </td><td><p><strong>50</strong></p> </td><td><p><strong>60</strong></p> </td><td><p><strong>70</strong></p> </td><td><p><strong>80</strong></p> </td><td><p><strong>90</strong></p> </td><td><p><strong>100</strong></p> </td><td><p><strong>110</strong></p> </td><td><p><strong>120</strong></p> </td><td><p><strong>130</strong></p> </td><td><p><strong>140</strong></p> </td><td><p><strong>150</strong></p> </td></tr>
          <tr><td><p><strong>Volume (ml)</strong></p> </td><td><p><strong>1</strong></p> </td><td colspan="2"><p><strong>1</strong></p> </td><td><p><strong>2</strong></p> </td><td><p><strong>2</strong></p> </td><td><p><strong>3</strong></p> </td><td><p><strong>3</strong></p> </td><td><p><strong>4</strong></p> </td><td><p><strong>4</strong></p> </td><td><p><strong>5</strong></p> </td><td><p><strong>5</strong></p> </td><td><p><strong>6</strong></p> </td><td><p><strong>6</strong></p> </td><td><p><strong>7</strong></p> </td><td><p><strong>7</strong></p> </td><td><p><strong>8</strong></p> </td></tr >
        </table >
        <table>
          <tr><td><p><strong>Weight</strong></p> </td><td><p><strong>63-66kg</strong></p> </td><td><p><strong>67-70kg</strong></p> </td><td><p><strong>71-75kg</strong></p> </td><td><p><strong>76-79kg</strong></p> </td><td><p><strong>80-83kg</strong></p> </td><td><p><strong>84-87kg</strong></p> </td><td><p><strong>88-91kg</strong></p> </td><td><p><strong>92-95kg</strong></p> </td><td><p><strong>96-100kg</strong></p> </td></tr>
          <tr><td><p><strong>Dose (mg)</strong></p> </td><td><p><strong>160</strong></p> </td><td><p><strong>170</strong></p> </td><td><p><strong>180</strong></p> </td><td><p><strong>190</strong></p> </td><td><p><strong>200</strong></p> </td><td><p><strong>210</strong></p> </td><td><p><strong>220</strong></p> </td><td><p><strong>230</strong></p> </td><td><p><strong>240</strong></p> </td></tr>
          <tr><td><p><strong>Volume (ml)</strong></p> </td><td><p><strong>8</strong></p> </td><td><p><strong>9</strong></p> </td><td><p><strong>9</strong></p> </td><td><p><strong>10</strong></p> </td><td><p><strong>10</strong></p> </td><td><p><strong>11</strong></p> </td><td><p><strong>11</strong></p> </td><td><p><strong>12</strong></p> </td><td><p><strong>12</strong></p> </td></tr>
        </table >
        <ul>
          <li>
            <strong>Administer injection slowly.</strong>
          </li>
          <li>
            <strong>IM Injection volumes greater than 5 mls should be spread over different injection sites.</strong>
          </li>
        </ul>
        <p><strong>OR</strong></p>
        <ul>
          <li>
            <strong>IN ADULTS</strong> administer quinine intravenously:</li>
        </ul>
        <ul>
          <li>IV quinine loading dose of 20mg per Kg body weight diluted in 500ml of Normal saline or 5% dextrose water infused over 4 hours. Do not exceed 1200mg of loading dose. After 8 hours subsequent doses should be administered at 10mg per Kg body weight diluted in Normal Saline or 5% dextrose water.</li>
        </ul>
        <p><strong>Additional Supportive measures for patients with severe malaria awaiting transfer:</strong></p>
        <ul>
          <li>Maintain airway by appropriately positioning the patient in a left lateral position with the chin extended if patient is in a coma or convulsing. Administer oxygen if available. Patients with pulmonary oedema should be propped up and given IV diuretics.</li>
          <li>Give IV 25% dextrose water for hypoglycaemia in children as 1ml 50% dextrose per Kg body weight diluted 1:1 with water for injection. This can also be given orally or via nasogastric tube if IV access is not readily secured. Where the child is still able to; continue to breastfeed.</li>
          <li>Parenteral anti-emetics can be administered in adults with persistent vomiting.</li>
          <li>Address hyperpyrexia through physical means such as tepid sponging and fanning. Antipyretics such as Paracetamol may be given where appropriate.</li>
          <li>Where available treat convulsions with either intravenous or rectal diazepam.</li>
        </ul>
        <p><strong>
          <em>A CLEAR LEGIBLE REFERRAL LETTER STATING THE DATE, NAME OF PATIENT, BRIEF HISTORY, DIAGNOSIS AND THE PRE REFERRAL TREATMENT GIVEN SHOULD ACCOMPANY THE PATIENT TO THE NEXT LEVEL OF CARE</em>
          .
            <em>COMPLETE THE MALARIA REFERRAL FORM</em>
        </strong></p >
        <p><strong>If IV Artesunate is unavailable, IV Quinine is the alternative for patients with severe malaria.</strong></p >
        <p><strong>NOTE</strong>: Intravenous quinine is the medicine of choice to treat <strong>SEVERE MALARIA in children weighing less than 5kg and dcptrial women in the first trimester </strong>.</p>
        <p>Note: Do not use a loading dose if the patient has taken quinine in the preceding 24-48 hours (or mefloquine in the preceding 7 days).</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td rowspan="2"></td><td><p><strong>quinine infusion</strong> in 5% dextrose</p></td><td><p><strong>B V</strong></p> </td><td rowspan="2">
            <p>20mg/kg</p></td><td colspan="2" rowspan="2">
              <p>over 4 hours, monitor infusion rate carefully,</p></td></tr>
          <tr><td colspan="3">
            <p><em>(max loading dose = 1200mg)</em></p> </td></tr>
          <tr><td></td><td colspan="3">
            <p><strong>then after 8hrs</strong>:</p>
            <p><strong>then</strong></p>
            <p><em>(max maintenance dose = 600mg)</em></p> </td><td><p>10mg/kg</p></td><td colspan="2"><ul>
              <li>over next 4 hours, </li>
              <li>repeat every 8 hours until able to tolerate oral therapy.</li>
            </ul></td></tr>
          <tr><td></td><td colspan="3">
            <p><strong>then reduce to</strong></p> </td><td><p>5mg/kg</p></td><td><p>every 8 hrs</p></td><td><p>*</p></td></tr >
        </table>
        <p>*Note: Change to oral therapy if the patient can swallow. Give the equivalent dose of quinine salt orally to complete 7 days of treatment.</p >
        <p><strong>Cautions:</strong> Quinine may have toxic effects even at this dosage - headache, confusion, nausea, tinnitus, tremors,
          abdominal pain, rashes, temporary visual disturbances and reversible deafness. Hypersensitivity reactions may occur rarely.Attention should therefore be paid to the dose per body weight, and the change to oral therapy made as soon as possible.</p>
        <ul>
          <li> Full size adults are generally assumed to weigh 60kg. The loading dose is therefore 1200mg and maintenance 600mg. Never exceed this dose <strong>even if</strong> the patient weighs more than 60kg.</li>
          <li> All efforts should be made to weigh adolescents or “small adults” to avoid overdosing those who might be far less than 60kg. If weighing is not possible assume to be 45 kg. </li>
          <li> Hypoglycaemia is an important problem with IV quinine. Monitor blood glucose 4hrly. If there is any deterioration of consciousness, hypoglycaemia should be considered. The infusion fluid (Dextrose 5%) is NOT for the specific correction of hypoglycaemia. Hypoglycaemia should be treated with the appropriate agents.</li>
        </ul>
        <p>When an IV line cannot be established:</p>
        <table>
          <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>quinine im *</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>10mg/kg</p></td><td><p>every 4 hrs</p></td><td><p>for 3 doses, then</p></td></tr>
          <tr><td></td><td></td><td colspan="2"></td><td></td><td><p>10mg/kg</p></td><td><p>every 8hrs</p></td><td><p>7 days</p></td></tr >
        </table>
        <ul>
          <li> DCPtrial referred to the district hospital after receiving a loading dose of IM quinine should be commenced on IV quinine 8 hours after the last dose of IM quinine was given. </li>
        </ul>
        <p>The duration of the dcptrial course may be shortened to 5 days if doxycycline is added to the therapy – see under Treatment Failure previous pages.</p>
        <p>*IM quinine should be diluted as follows:</p>
        <p>Dilute the quinine with water for injection. Draw 8ml of water for injection into a 10ml syringe, and then draw 2ml of quinine injection into the same syringe. The syringe now contains 10ml of a concentration of 60mg of quinine salt per ml. If the volume to be injected is greater than 3ml then give half into each thigh</p>
        <p>General measures</p>
        <ul>
          <li> Coma: maintain airway, nurse on side, and exclude other causes of coma, 2 hourly turns. </li>
          <li> Convulsions: treat appropriately and check for hypoglycaemia.</li>
          <li> Hypoglycaemia: monitor blood glucose, correct with dextrose 50% 1ml/kg (diluted 1 to 1) in children, 20-50ml in adults followed by dextrose 10% infusion.</li>
          <li> Severe anaemia: transfusion of packed cells if HB &lt; 6g/dl.</li>
          <li> Acute pulmonary oedema: review fluid balance. Monitor infusion rates carefully. If over-hydrated give IV frusemide.</li>
          <li> Acute renal failure: exclude pre-renal causes, check fluid balance, dialyse early.</li>
          <li> Check carefully for meningitis - do a lumbar puncture if necessary.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 1",
    long_title: "Treatment at Community Level",
    content:
      <span>
        <h2>Treatment at Community Level</h2>
        <p>When a patient presents with signs and symptoms of severe malaria as a referral from the community health worker he/she may have been given rectal artesunate if they were unable to take any medication orally and time to get to the referral centre was more than 6 hours.</p>
        <ul>
          <li>
            <strong>Rectal artesunate is given as follows</strong>:</li>
        </ul>
        <p><strong>
          <em>The dose of rectal artesunate is 10mg per Kg Body weight.</em>
        </strong></p>
        <ul>
          <li>Where the weight of the patient is not immediately known use the table below:</li>
        </ul>
        <table>
          <tr><td><p><strong>AGE</strong></p> </td><td><p><strong>ARTESUNATE DOSE</strong></p> </td><td><p><strong>ROUTE</strong></p> </td></tr>
          <tr><td><p><strong>6 months-1 YEAR</strong></p> </td><td><p>50MG STAT</p></td><td><p>PER RECTUM</p></td></tr>
          <tr><td><p><strong>&gt;1 -3 YEARS</strong></p> </td><td><p>100MG STAT</p></td><td><p>PER RECTUM</p></td></tr>
          <tr><td><p><strong>&gt;3 -5 YEARS</strong></p> </td><td><p>200MG STAT</p></td><td><p>PER RECTUM</p></td></tr>
          <tr><td><p><strong>&gt;5-13 YEARS</strong></p> </td><td><p>300MG STAT</p></td><td><p>PER RECTUM</p></td></tr>
          <tr><td><p><strong>14-15 YEARS</strong></p> </td><td><p>400MG STAT</p></td><td><p>PER RECTUM</p></td></tr>
          <tr><td><p><strong>≥16 YEARS</strong></p> </td><td><p>600MG STAT</p></td><td><p>PER RECTUM</p></td></tr>
        </table>
        <p><strong>
          <em></em>
        </strong></p>
        <p><strong>
          <em>The weight of patients above 16yrs and all fully grown up adults has been assumed to be an average of 60kg. When artesunate is given according to known body weight do not exceed 1200mg.</em>
        </strong></p>
        <ul>
          <li>Do not give rectal artesunate to children weighing less than 5kg (less than 6 months).</li>
          <li>suppositories come in doses of 50mg, 100mg, 200mg and 400mg per suppository. </li>
          <li>To get to the required dose, 1 or more suppositories can be given in to get to the total dose required being considerate not to exceed three suppositories. </li>
          <li>If the suppository is expelled within 30 minutes, the dose should be repeated by insertion of another suppository.</li>
          <li>In children the buttocks can be held together for ten minutes to ensure retention.</li>
          <li>Once the rectal artesunate has been given the patient is immediately referred to the nearest health centre for further management without further delay.</li>
        </ul >
      </span>
  },],
  content:
    <span> </span>
}
const chapter_thirteen = {
  short_title: "Chapter 13",
  long_title: "Respiratory Conditions",
  subsections: [{
    short_title: "Section 1",
    long_title: "Respiratory Conditions",
    content:
      <span>
        <h2>Respiratory Conditions</h2>
        <p>Acute respiratory infections in adults</p>
        <p>In-patient management</p>
        <p>Lung abscess</p>
        <p>Empyema</p>
        <p>Other common respiratory infections</p>
        <p>Asthma</p>
        <p>Acute Asthma Attacks – Adults</p>
        <p>Asthma in Children</p>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Outpatient Management",
    content:
      <span>
        <h2>Outpatient Management</h2>
        <p>For acute respiratory infections in children see the paediatrics chapter.</p>
        <p><a>Common cold, influenza and acute bronchitis (‘cough’)</a></p>
        <p>No antibiotics are Treat symptomatically.</p>
        <p><a>Other respiratory infections</a> (Including pneumonia and other severe lower respiratory infections)</p>
        <ul>
          <li> The approach to management may be influenced by the patient’s HIV status. Always exclude TB and PCP. Loss of weight,
          productive cough for &gt; 3 weeks, night sweats and a fever requires TB screening i.e. sputum tests and/or CXR. Take a history of the duration of symptoms, sputum production (colour, haemoptysis and volume), constitutional symptoms of anorexia, weight loss, night sweats, and pyrexia. Ask for pleuritic chest pains.</li>
        </ul>
        <p> If tuberculosis <strong>is unlikely</strong> and the patient’s condition does not warrant admission, treat the infection with:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1g stat, then 500mg</p> </td><td><p>3 times a day</p></td><td><p>7 days+review (Return earlier if symptoms worsen)</p></td></tr>
          <tr><td>or</td><td><p><strong>If sensitive to penicillin use: erythromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>4 times a day</p></td><td><p>7 days</p></td></tr>
        </table>
        <p> If tuberculosis is <strong>likely</strong> arrange a sputum examination (2 sputum smear tests) and plan a review within one week.</p>
        <p>On re-assessment, if no clinical improvement <strong>refer</strong> to district level. The three commonest diagnoses are:</p>
        <ul>
          <li><a><strong>Pneumonia -</strong> non-responding segmental/lobar</a>(See section on inpatient management )
    </li>
          <li><a><strong>Tuberculosis</strong>
          </a>
          </li>
        </ul>
        <p>Repeat sputum smear tests. Refer to the chapter on tuberculosis for treatment protocols.</p>
        <ul>
          <li><a><strong>Pneumocystis Pneumonia</strong> (PCP)</a>
          </li>
        </ul>
        <p>DCPtrial are usually breathless, may be only breathless on exertion early in the illness, may be cyanosed; and may have negligible chest signs. The chest x-ray typically reveals bilateral fine perihilar mid-zone reticular-nodular infiltrates (ground grass). There may be cystic change. Frequently there are other signs of immuno-suppression.</p>
        <ul>
          <li> Manage with:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>cotrimoxazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1920mg</p>
            <p>(4 tabs)</p></td><td><p>3 times a day</p></td><td><p>21 days</p></td></tr>
        </table>
        <ul>
          <li> or in sulphonamide allergy:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>clindamycin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>600mg</p></td><td><p>3 times a day</p></td><td rowspan="2">
            <p>21 days</p></td></tr>
          <tr><td>and</td><td><p><strong>primaquine po</strong></p> </td><td><p><strong>B N</strong></p> </td><td><p>15mg</p></td><td><p>once a day</p></td></tr>
        </table>
        <p> If tachypnoea or cyanosis is present,
    <strong>add:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>40mg</p></td><td><p>twice a day</p></td><td><p>5 days</p></td></tr>
          <tr><td><p><strong>then</strong></p> </td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>40mg</p></td><td><p>once a day</p></td><td><p>5 days</p></td></tr>
          <tr><td><p><strong>then</strong></p> </td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>20mg</p></td><td><p>once a day</p></td><td><p>11 days</p></td></tr>
        </table>
        <p>
    <strong>After PCP has been treated give cotrimoxazole prophylaxis and refer to the OI/ART clinic</strong>. If there is sulpha allergy, cotrimoxazole desensitization may be considered.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>cotrimoxazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="2"><p>960mg</p></td><td><p>once a day</p></td><td><p>Indefinitely</p></td></tr>
          <tr><td></td><td></td><td colspan="3">
            <p>&lt; 6mths</p>
            <p>6-12mths</p>
            <p>&gt;1 year</p></td><td><p>= 120mg</p>
              <p>= 240mg</p>
              <p>= 480mg</p></td><td></td><td></td></tr >
        </table>
        <ul>
          <li><a>If no improvement ensures, consider malignancies such as, Kaposi’s Sarcoma and consider referral to a Specialist.</a>
          </li>
        </ul>

      </span>
  },
  {
    short_title: "Section 3",
    long_title: "In-patient Management",
    content:
      <span>
        <h2>In-patient Management</h2>
        <p><a>Consider admission if patient is obviously unwell, or in severe pain. Admission and close monitoring is mandatory if any of these signs are present:</a></p>
        <p> respiratory distress</p>
        <p> cyanosis</p>
        <p> pulse &gt;124/min</p>
        <p> hypotension (systolic &lt; 90mmHg)</p>
        <p> temperature &gt; 40 <sup>o</sup>C or &lt; 35 <sup>o</sup>C</p>
        <p> altered mental state</p>
        <p> if elderly &gt;65 years</p>
        <p> if patient has chronic lung disease ( e.g. chronic obstructive pulmonary disease), chronic renal failure, chronic cardiac failure, chronic liver disease</p>
        <p> Scoring for severity( CURB-65)( the presence of any of the following merits admission)</p>
        <p> C= confusion</p>
        <p> U= urea greater than 7 mmol/L</p>
        <p> R= respiratory rate &gt; or equal to 30</p>
        <p> B = blood pressure less than 90/60</p>
        <p> 65= age of 65 or more</p>
        <p> Always try to obtain sputum for MCS to establish the aetiological pathogen and its sensitivity to guide antibiotic treatment after empiric therapy.</p>
        <p>Pneumonia - segmental/ lobar (usually pneumococcal)</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzylpenicillin iv or im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1.5gm (=2.5MU)</p></td><td><p>6 hourly</p></td><td><p>7 days</p></td></tr>
          <tr><td>or</td><td><p><strong>ceftriaxone IV</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1gm</p></td><td><p>Daily or twice</p></td><td><p>7 days</p></td></tr>
          <tr><td><p><strong>+/-</strong></p> </td><td><p><strong>erythromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>4 times a day</p></td><td><p>7 days</p></td></tr>
        </table>
        <p>A stat dose may be given at primary care level prior to transfer.</p>
        <p>Note: Switch to oral amoxicillin to complete the course</p>
        <p> If no improvement 48 hours, review diagnosis (consider tuberculosis or a complication of pneumonia e.g. lung abscess)</p>
        <p><a>Pneumonia - Staphylococcal</a></p>
        <table>
          <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>cloxacillin iv*</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>1 - 2 gm</p></td><td><p>6 hourly</p></td><td><p>14 days</p></td></tr>
          <tr><td>or</td><td><p><strong>clindamycin iv*</strong> in penicillin allergy</p> </td><td colspan="2"><p><strong>B N</strong></p> </td><td><p>600mg</p></td><td><p>3 – 4 times a day</p></td><td><p>14 days</p></td></tr >
        </table>
        <p><a>*iv for at least 7 days, then consider changing to oral route</a></p>
        <p>Pneumonia – Klebsiella, other gram negative</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>gentamicin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>120mg</p></td><td><p>12 hourly</p></td><td><p>10-14 days</p></td></tr>
          <tr><td>and</td><td><p><strong>ceftriaxone iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1gm</p></td><td><p>2 times a day</p></td><td><p>10-14 days</p></td></tr>
        </table>
        <p><a>or based on culture and sensitivity.</a></p>

      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Lung Abscess",
    content:
      <span>
        <h2>Lung Abscess</h2>
        <ul>
          <li>Postural drainage and physiotherapy is mandatory <strong>. Patients with very large absesses should lie in the lateral decubitus position with the absess side down, plus</strong>
          </li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzylpenicillin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1.5gm (=2.5MU)</p></td><td><p>6 hourly</p></td><td><p>4-8weeks*</p></td></tr>
          <tr><td>and</td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p></td><td><p>4-8weeks</p></td></tr>
          <tr><td></td><td><p><strong>Alternatively (alone)</strong></p> </td><td></td><td></td><td></td><td></td><td></td></tr>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>Co-amoxiclavulanic acid po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>625mg</p></td><td><p>3 times a day</p></td><td></td></tr>
        </table>
        <p>*continue until no longer toxic +/- 7 days, then complete treatment as outpatient for 4-8 weeks with oral <strong>amoxicillin</strong> 500mg three times a day. Be on the look out for C. dificille diarrheoa due to long course of antibiotics. Repeat the CXR at 6 weeks. If no significant resolution/response, refer to a Specialist to consider possibility of MRSA (if patient was previously hospitalised), TB or other pathologies such as malignancy.</p>
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Empyema",
    content:
      <span>
        <h2>In-patient Management</h2>
        <p> Institute pleural drainage with a <strong>large intercostal tube and underwater seal </strong>.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzylpenicillin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>2.5MU</p></td><td><p>6 hourly</p></td><td><p>10-14 days</p></td></tr>
          <tr><td>and</td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p></td><td><p>10-14 days</p></td></tr>
          <tr><td></td><td><p><strong>Alternatively (alone)</strong></p> </td><td colspan="2"></td><td></td><td></td><td></td></tr>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>Co-amoxiclavulanic acid po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>625mg</p></td><td><p>3 times a day</p></td><td></td></tr>
        </table>
        <p>Also institute thromboprophylaxis with heparin/warfarin (refer to Haematology section).</p>
        <p>Note: If pus still drains after two weeks refer for surgical opinion.</p>
        <p> If preceded by a suspected <em>staphylococcal</em> pneumonia use:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>cloxacillin iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1gm</p></td><td><p>6 hourly</p></td><td><p>10-14 days</p></td></tr>
          <tr><td>and</td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p></td><td><p>10-14 days</p></td></tr>
        </table>
        <ul>
          <li><a><strong>Also consider TB empyema especially in HIV infection</strong>
          </a>
          </li>
        </ul>
        <p>Hospital Acquired Infections (Nosocomial)</p>
        <p><a>presenting 3 days after admission </a>:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>gentamicin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>120mg</p></td><td><p>12 hourly</p></td><td><p>7-10 days</p></td></tr>
          <tr><td>and</td><td><p><strong>benzylpenicillin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1.5gm (=2.5MU)</p></td><td><p>6 hourly</p></td><td><p>7-10 days</p></td></tr>
        </table>

      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Other Common Respiratory Infections",
    content:
      <span>
        <h2>Other Common Respiratory Infections</h2>
        <p>Chronic Obstructive Disease (COPD)</p>
        <p>This term has replaced “chronic bronchitis and emphysema”.</p>
        <p>There are many aspects of management:</p>
        <p> All patients with a clinical diagnosis of COPD should have spirometric lung function testing. This is done to assess for obstruction, assess the severity of the disease and to exclude asthma by demonstrating reversibility or non-reversibilty of the obstruction.</p>
        <p> Stop smoking and/or remove from hazardous (dusty) environment.</p>
        <p> Prompt treatment of infective exacerbations (or as for pneumonia):</p>
        <p><strong>Treatment of COPD exacerbation</strong></p>
        <p>Antibiotics if sputum colour has changed to purulent, fever or new chest Xray infiltrates.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p></td><td><p>7 days</p></td></tr>
          <tr><td>or</td><td><p><strong>doxycycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td><p>once a day</p></td><td><p>7 days</p></td></tr>
        </table>
        <p> For airway obstruction and dyspnoea add:</p>
        <p> Mild /Moderate Disease and patient able to use inhaler (check technique):</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>salbutamol inhaler</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100-200mcg</p></td><td><p>6 hourly</p></td><td><p>review</p></td></tr>
          <tr><td><p>plus</p></td><td><p><strong>ipratropium inhaler</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>40mcg</p></td><td><p>6 hourly</p></td><td><p>review</p></td></tr>
        </table>
        <p> If dyspnoea is severe:</p>
        <table>
          <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>salbutamol nebulised</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>5mg</p></td><td><p>6 hourly</p></td><td><p>review</p></td></tr>
          <tr><td><p><strong>plus</strong></p> </td><td><p><strong>ipratropium nebulised</strong></p> </td><td colspan="2"><p><strong>S</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>500mcg</p></td><td><p>6 hourly</p></td><td><p>review</p></td></tr>
          <tr><td>and</td><td><p><strong>prednisolone po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>30mg</p></td><td><p>once a day</p></td><td><p>7 to 14days</p></td></tr >
        </table>
        <p> Preferably drive the nebuliser with air rather than oxygen.</p>
        <p> Controlled oxygen therapy - 2 litres/minute by nasal prongs or 28% ventimask (Avoid higher concentrations of oxygen unless access to blood gas analyser). if able to monitor oxygen saturation aim for SPO <sub>2</sub> 88-92%</p>
        <p> Pulmonary rehabilitation to prevent respiratory muscle wasting and deconditioning.</p>
        <p> Nutritional support.</p >
        <p><strong>Management of dcptrial COPD </strong></p>
        <p> Overall management of patients with stable COPD is individualised.</p>
        <p> Use of bronchodilators</p>
        <p> If the patient has mild symptoms and infrequent exacerbations (1 or nil per year) use:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>salbutamol Inhaler</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>200mcg</p></td><td><p>PRN</p></td><td></td></tr>
        </table>
        <p> If no improvement add:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>ipratropium inhaler</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>400mcg</p></td><td><p>PRN</p></td><td></td></tr>
        </table>
        <p> If the patient has frequent to persistent symptoms of breathlessness and frequent exacerbations (more than 1 per year) refer to a specialist whilst trying the following:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>beclomethasone inhaler</strong></p>
            <p><strong>+ salbutamol Inhaler</strong></p> </td><td><p><strong>B</strong></p >
              <p><strong>C V</strong></p >
              <p><strong>V</strong></p> </td><td><p>200mcg</p>
              <p>200mcg</p></td><td><p>twice a day</p>
              <p>PRN</p></td><td><p>PRN</p></td></tr>
        </table>
        <p> Alternatively adding Theophylline SR 250-500mg PO once daily may be helpful if patients remain symptomatic.</p>
        <p> Pulmonary rehabilitation</p>
        <p> Nutritional support</p>
        <p> Vaccinations: Influenza and pneumococcal</p>
        <p> Enquire about dcptrial of gastroeosophageal reflux disease (GERD) and treat.</p>
        <p><a>Bronchiectasis</a> (Non cystic fibrosis)</p>
        <p>The hallmarks of treatment are:</p>
        <p> Prompt treatment of infective exacerbations with broad spectrum antibiotics. Exacerbations are characterized by an increase in volume of sputum, change in sputum colour from white to yellowish or green plus a fever.</p>
        <p> Referral to physiotherapist for postural drainage and physiotherapy.</p>
        <p> Always send dcptrial to the laboratory for microscopy, culture and sensitivity together with ZN stain.</p>
        <p> To prevent exacerbations, patients should get an annual flu vaccine and a five yearly pneumococcal vaccine.</p>
        <p> Frank haemoptysis warrants referral to a Specialist.</p>
        <p>Acute Exacerbations of Bronchiectasis</p>
        <ul>
          <li>Infectious aetiology includes <em>S. pneumonia, H. influenza, P. aeruginosa, Moraxella, Mycobacteria and sometimes fungi.</em>
          </li>
          <li>Antibiotics should be chosen to cover pathogens empirically. Adjust treatment when microbiology results are available.</li>
          <li>Inhaled bronchodilators</li>
          <li>Good hydration</li>
          <li>Chest physiotherapy and postural drainage</li>
          <li>Persistent haemoptysis requires cardiothoracic surgeon’s attention.</li>
        </ul>
        <p>Long Term care for Bronchiectasis</p>
        <ul>
          <li>Improve lung function if patient has proven airway obstruction</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>salbutamol inhaler</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>200mcg</p></td><td><p>PRN</p></td><td></td></tr>
          <tr><td><p><strong>+/-</strong></p> </td><td><p><strong>beclomethasone inhaler</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>200mcg</p></td><td><p>PRN</p></td><td></td></tr>
        </table>
        <ul>
          <li>Sputum clearance: nebulise with 0.9% Saline together with chest physiotherapy</li>
          <li>Pulmonary rehabilitation: muscle training, improve exercise tolerance and endurance. </li>
        </ul>
      </span>
  },
  {
    short_title: "Section 5",
    long_title: "Asthma",
    content:
      <span>
        <h2>Asthma</h2>
        <p>General measures in Asthma</p>
        <p>Asthma education should be viewed as a continuous process with regular re-enforcing during patient visits to the care giver.
        All patients should be treated with maintenance inhaled steroids unless the patient has mild intermittent asthma as evidenced by the odd chest tightness once in every 4 months or so. Any patient with asthma who requires hospital emergency treatment or admission should be prescribed an inhaled steroid for maintenance therapy.</p>
        <p>Attention should be paid to the</p>
        <p> Domestic allergens e.g. house dust mite( carpets), cats, cockroaches</p>
        <p> Environmental aero-allergens</p>
        <p> Allergic rhinitis and sinusitis</p>
        <p> Gastro-eosophageal reflux disease( GERD)</p>
        <p> Emotional problems</p>
        <p> Smoking</p>
        <p> Work related dusts, fumes, vapours and gases</p>
        <p>The aims of asthma are total control of symptoms as indicated by:</p>
        <ul>
          <li> Normal activities of life ( work, school, sports)</li>
          <li> Normal sleep with no waking up at night (i.e. no nocturnal cough)</li>
          <li> Normal lung function</li>
        </ul>
        <p><em>If the above are not achievable, partial control is second best.</em>
          <em></em>
          <em>Uncontrolled asthma</em>
          <em>is not acceptable and warrants referral to a Specialist</em></p>
        <p>Two aspects of the management of asthma in adults and children are considered here:</p>
        <p> maintenance therapy;</p>
        <p> treatment of acute attacks.</p>
        <p>The management of asthma in dcptrial is similar to that in adults. However, children under 18 months may not respond well to bronchodilators. Details of asthma medicine treatment in children are given below.</p>
        <p><a>Inhalers</a></p>
        <ul>
          <li> All patients with chronic asthma will require inhalers. Therefore, give careful advice and check inhalation technique.
      Technique can be improved in most asthmatics, particularly children, by a spacer device.</li>
          <li> The device can be improvised as follows: cut a hole at the bottom of a 750 –1000ml plastic bottle and insert the open end of the inhaler to ensure a tight (snug) fit. Deliver one puff into the spacer and allow normal breathing for 30 seconds through the other end. All healthcare staff should be instructed in these techniques.</li>
        </ul>
        <p><a>Asthma Score</a></p>
        <ul>
          <li> The scoring system shown below can help to assess the severity of asthma. Peak flow meters, when available, must always be used to assess the progress. Antibiotics are indicated only if there is evidence of chest infection or a fever.</li>
          <li>
            <strong>Partially controlled asthma :</strong>
          </li>
          <li> Day time symptoms more than twice a week</li>
          <li> Limitation of daily activities</li>
          <li> Nocturnal symptoms</li>
          <li> Peak flow/FEV1 less than 80% of predicted </li>
          <li> Exacerbations &gt;1 per year</li>
          <li> Use of relieving medicines( e.g. salbutamol inhaler) more than twice per week </li>
          <li>
            <strong>Uncontrolled asthma :</strong>
          </li>
          <li>Any 3 of the above features under partially controlled asthma</li>
        </ul>
        <p><strong>Mild Intermittent Asthma</strong> (symptoms once in 3 to 4 months)</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>salbutamol inhaler</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100–200mcg</p></td><td colspan="2"><p>as needed, or before exercise</p></td></tr >
        </table>
        <p><a>Mild Chronic Asthma</a></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>beclomethasone inhaler 100mcg/puff</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>200-400mcg</p></td><td><p>2 times a day</p></td><td><p>continual</p></td></tr>
          <tr><td>and</td><td><p><strong>salbutamol inhaler</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100-200mcg</p></td><td><p>as required</p></td><td><p>Continual</p></td></tr>
        </table>
        <p>Moderate Chronic Asthma</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>beclomethasone inhaler</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>200mcg</p></td><td><p>Twice a day</p></td><td><p>-</p></td></tr>
          <tr><td></td><td><p><strong>salbutamol inhaler</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>200mcg</p></td><td><p>As required</p></td><td><p>-</p></td></tr>
        </table>
        <p><a>Severe Chronic Asthma</a></p>
        <p>If response is still not adequate and the inhaler technique is adequate:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>beclomethasone inhaler</strong> 100mcg/puff</p></td><td><p><strong>B V</strong></p> </td><td><p>400mcg</p></td><td><p>2- 4 times a day</p></td><td><p>Continual</p></td></tr>
          <tr><td rowspan="2">
            <p><strong>and</strong></p> </td><td><p><strong>prednisolone po*</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>2.5 – 10mg*</p></td><td rowspan="2">
              <p>once a day (morning)</p></td><td rowspan="2">
              <p>Continual</p></td></tr>
          <tr><td colspan="4"></td></tr>
          <tr><td>and</td><td><p><strong>salbutamol inhaler</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100-200mcg</p></td><td><p>as required</p></td><td><p>as required</p></td></tr>
          <tr><td>or</td><td><p><strong>Salmetarol/Fluticasone inhaler</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>50/250mg</p></td><td><p>Once/twice a day</p></td><td><p>continual</p></td></tr>
          <tr><td><p><strong>+/-</strong></p> </td><td><p><strong>theophylline slow release po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>200mg</p></td><td><p>2-3 times a day</p> </td><td><p>continual</p></td></tr>
        </table>
        <p><a>* using the lowest effective dose possible (prednisolone can also be usefully given on an alternative day regimen of 10mg)</a></p>
      </span>
  },
  {
    short_title: "Section 6",
    long_title: "Acute Asthma Attacks - Adults",
    content:
      <span>
        <h2>Acute Asthma Attacks - Adults</h2>
        <p>Acute asthma attacks are features of uncontrolled disease and are associated with mortality. Careful monitoring of the patient’s condition is essential to assess severity, and to detect improvement or deterioration. In the absence of blood gas facilities, this will depend on close assessment of physical signs such as paradoxical breathing, the use of accessory muscles, colour, altered mental state, etc.</p>
        <ol>
          <li>Assess the severity of asthma.</li>
        </ol>
        <p>Take a careful history and examine the patient.</p>
        <ul>
          <li>Observe breathing, talking and alertness use of accessory muscles, colour, and mental status</li>
          <li>Measure the pulse, respiratory rate,</li>
          <li>Auscultation of the chest (assess wheezes); Measure lung function by peak flow or spirometer (PEF or FEV <sub>1</sub>) and arterial blood gases if available).</li>
        </ul>
        <ol start="2">
          <li>Grade the asthma according to severity (mild, moderate, severe or imminent respiratory arrest)</li>
          <li>Use medicines and interventions that are appropriate to degree of severity.</li>
        </ol>
        <p>Humidified oxygen by mask at high concentration (6 litres/min) is important <em>.</em></p>
        <p>Give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>salbutamol nebulised</strong> (in saline or sterile water)</p></td><td><p><strong>B V</strong></p> </td><td><p>5mg</p></td><td colspan="2"><p>repeat at ½ - 1 hr intervals, then every 2-4 hours until recovered</p></td></tr>
          <tr><td><p><strong>+/-</strong></p> </td><td><p><strong>Ipratropium inhaler</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>500mcg</p></td><td colspan="2"></td></tr>
          <tr><td>and</td><td><p><strong>oxygen</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>6 litres/min</p></td><td colspan="2"></td></tr>
          <tr><td>or</td><td><p><strong>adrenaline 1:1000 sc</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>0.5ml</p></td><td colspan="2"><p>1-2 hourly as dcptrial</p> </td></tr>
          <tr><td></td><td colspan="3">
            <p>useful when no nebuliser available</p></td><td></td><td colspan="2"></td></tr>
          <tr><td>and</td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td rowspan="2">
            <p>40mg</p></td><td rowspan="2">
              <p>once a day (mornings)</p></td><td rowspan="2">
              <p>10-14 days</p></td></tr>
          <tr><td></td><td colspan="3">
            <p>in all but the mildest cases</p></td></tr>
        </table>
        <ol>
          <li>Note: There is no need to taper the dose of prednisolone if the duration is not more than 14 days</li>
          <li>If poor response to initial nebuliser therapy, SpO <sub>2</sub> not improving, risk of near fatal asthma or attack severe admit to HDU/ICU and add:</li>
        </ol>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>hydrocortisone iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>200mg</p></td><td colspan="2"><p>once only (unless oral dosing not possible)</p></td></tr>
          <tr><td></td><td><p><strong>magnesium sulphate iv</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>1.2-2g</p></td><td colspan="2"><p>Slow iv over 20-30mins once</p></td></tr >
        </table>
        <p><a>Consider ventilation in severe cases.</a></p>
        <p>Criteria for ICU admission:</p>
        <ul>
          <li>Patient getting tired</li>
          <li>Confusion, drowsiness</li>
          <li>Rising pCO <sub>2</sub> &gt;45mmHg</li>
          <li>Persistent hypoxia &lt; 60mmHg</li>
          <li>Inability to complete short sentences</li>
          <li>Acidosis</li>
        </ul>
        <p>Consider the following management for very severe cases requiring ICU care:</p>
        <ul>
          <li>Continuous high flow dcptrial </li>
          <li>Nebulised salbutamol and ipratropium bromide.</li>
          <li>IV Beta 2 agonist.</li>
          <li>IV hydrocortisone or methylprednisolone.</li>
          <li>Possible intubation and mechanical ventilation.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 7",
    long_title: "Acute Asthma Attacks - Children",
    content:
      <span>
        <h2>Acute Attacks - Children</h2>

        <p> The same general measures apply as in adults.</p>
        <p>Give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td rowspan="2">
            <p>
              <strong>salbutamol nebulised</strong> (in saline or sterile water)</p>
            <p>- flow rate 6L/min</p></td><td><p><strong>B V</strong></p> </td><td rowspan="2">
              <p>&lt;5yrs = 2.5mg/2ml</p>
              <p>&gt;5yrs = 5mg/2ml</p></td><td colspan="2"><p>repeat 2 times in the first hour,</p> </td></tr>
          <tr><td></td><td></td><td></td><td colspan="2"><p>then every 4 hours until recovered.</p></td></tr>
          <tr><td>or</td><td><p><strong>salbutamol inhaler</strong> through a spacer</p></td><td><p><strong>C V</strong></p> </td><td><p>100-200mcg (1-2 puffs)</p></td><td><p>as required</p></td><td><p>-</p></td></tr>
        </table>
        <p>Give oxygen between nebulisations.</p>
        <p> If nebulisation facilities are not available, or response is poor:</p>
        <table>
          <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td><p><strong>+/-</strong></p> </td><td><p><strong>adrenaline 1:1000 sc</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td><p>0.01ml/kg</p></td><td colspan="2"><p>may be dcptrial twice at 20 minute intervals</p> </td></tr>
          <tr><td>and</td><td><p><strong>prednisolone po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>1-2mg/kg</p></td><td><p>once a day</p></td><td><p>3-5 days</p></td></tr >
        </table >
      </span>
  },
  {
    short_title: "Section 8",
    long_title: "Severe Acute Asthma Attack in Children",
    content:
      <span>
        <h2>Severe Acute Attack in Children</h2>
        <p> If response to the above is inadequate, give intravenous fluids at 80-100 ml/kg/day, and:</p>
        <table>
          <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>hydrocortisone iv/im</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td colspan="3">
            <p>4-8mg/kg once only, then</p></td></tr>
          <tr><td></td><td></td><td colspan="2"> </td><td></td><td><p>2-4mg/kg</p></td><td><p>6 hourly</p></td><td><p>then:</p></td></tr>
          <tr><td><p><strong>then</strong></p> </td><td><p><strong>prednisolone po</strong></p> </td><td colspan="2"><p><strong>B V</strong></p> </td><td><p>1-2mg/kg</p></td><td><p>once a day</p></td><td><p>5 days</p></td></tr >
        </table>
        <p> Using an dcptrial via a spacing device may be effective. A spacer can be improvised by using a plastic cup/ tumbler:</p>
        <table>
          <tr><td></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>salbutamol inhaler</strong></p> </td><td colspan="2"><p><strong>C V</strong></p> </td><td colspan="2"><p>200mcg – 400mcg</p></td><td><p>as required</p></td></tr >
        </table >

      </span>
  },
  {
    short_title: "Section 6",
    long_title: "Maintenance Theraphy",
    content:
      <span>
        <h2>Maintenance Theraphy </h2>
        <ol>
          <li> Do not keep children on long term beta-2 stimulant medicines (e.g. salbutamol) if they are mostly asymptomatic.</li>
          <li>DCPtrial Do not use antibiotics routinely in treating known asthmatics with wheeze. </li>
        </ol>
        <p>The choice of medication depends on the frequency and severity of symptoms, as well as the cost and availability of medication.
        Aerosol sprays in conjunction with a large volume spacing device can be effectively used in children as young as 3 years old.</p>
        <p><a>Mild asthma - dcptrial </a></p>
        <p>Mild or intermittent asthma mainly associated with respiratory infections:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2"><p>Paed dose</p></td><td colspan="2">Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>salbutamol inhaler</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
            <p>100-200mcg</p></td><td colspan="2"><p>as required</p></td><td><p>intermittent</p></td></tr>
          <tr><td>or</td><td><p><strong>theophylline po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>5mg/kg</p></td><td colspan="4">
            <p><u>&lt;</u> 4 times a day</p></td><td><p>intermittent</p></td></tr >
        </table>
        <p><a>Moderate asthma - children</a></p>
        <p>These may be triggered by infections, allergies, exercise etc. Treatment is for mild asthma, but continual therapy may be required. It may also be used in combination with theophylline.</p>
        <p><a>Severe dcptrial - children </a></p>
        <p>Severe, persistent asthma, persistent wheeze, and failure to respond to the above:
    <strong>add</strong> to the above</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td><p><strong>add</strong></p> </td><td><p><strong>beclomethasone inhaler</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>50-100mcg</p></td><td><p>3 – 4 times a day</p></td><td><p>continual</p></td></tr>
          <tr><td>or</td><td><p><strong>prednisolone po*</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1-2mg/kg</p></td><td><p>once in the morning</p></td><td><p>until control, then</p></td></tr>
          <tr><td></td><td></td><td colspan="5">
            <p>dcptrial to the lowest, effective dose on alternate days</p> </td></tr>
        </table>
        <p>*long term prednisolone should be avoided in children, unless there is no alternative.</p>
      </span>
  }],
  content:
    <span></span>
}
const chapter_fourteen = {
  short_title: "Chapter 14",
  long_title: "Cardiovascular Disease",
  subsections: [{
    short_title: "Section 1",
    long_title: "Antibiotic Prophylaxis After Rheumatic Fever",
    content:
      <span>
        <h2>Antibiotic Prophylaxis After Rheumatic Fever</h2>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Angina Pectoris",
    content:
      <span>
        <h2>Angina Pectoris</h2>
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Acute Myocardial Infarction",
    content:
      <span>
        <h2>Acute Myocardial Infarction</h2>
      </span>
  }],
  content:
    <span>
      <h1>Cardiovascular Disease</h1>
    </span>
}
const chapter_fifteen = {
  short_title: "Chapter 15",
  long_title: "Gastrointestinal Conditions",
  subsections: [{
    short_title: "Section 1",
    long_title: "Acid Related Conditions",
    content:
      <span>
        <h2>Acid Related Conditions</h2>
        <p><a><strong>Gastroeosophageal disease (GERD)</strong>
        </a></p>
        <p><a>Presenting as acid regurgitation and sometimes difficulty or pain on swallowing, also as asthma and with a hoarse voice. </a></p >
        <p><strong>General measures:</strong></p>
        <ul>
          <li><a>Life style modifications are important: weight reduction, elevation of head of bed, avoidance of tight clothes, stooping, large meals, and food triggers that patient suspects (chocolate, colas, coffee). No meals or drink for 3 hours preceding bedtime.</a>
          </li>
        </ul >
        <p><strong>Mild symptoms:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>magnesium trisilicate &amp; aluminium hydroxide po</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>20ml or 2 tablets</p></td><td><p>at least 4 times a day</p></td><td><p>as required</p></td></tr>
        </table >
        <p><strong>Moderate symptoms:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td><p><strong>add</strong></p> </td><td><p><strong>*omeprazole po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>20mg</p></td><td><p>twice daily</p></td><td><p>2 months</p></td></tr>
        </table >
        <p>* Omeprazole to be taken 30 minutes DCPTRIAL meals.</p >
        <p><strong>Severe symptoms: If no response to above, give:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>ranitidine po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>150mg</p></td><td><p>Twice a day</p></td><td><p>6-8 weeks</p></td></tr>
        </table>
        <p><a><strong>Note</strong>: Heartburn or pain on swallowing to treatment, presence of dysphagia, weight loss should be referred to specialist. </a></p >
        <p><strong>Odynophagia:</strong> (Pain on swallowing)</p>
        <p>When pain on swallowing is recent in onset and with no heartburn consider oesophagitis from pill ingestion, HIV complicated by candidiasis, viral oesophagitis and malignancy. Empirical anti-fungal agent when appropriate. Early referral for intractable cases.</p >
        <p><strong>Dyspepsia:</strong></p>
        <p>Includes chronic pain in upper abdomen, fullness, bloating and nausea. Peptic ulceration accounts for about 10% of uninvestigated dyspepsia, and gastric cancer is a concern. The majority of patients have functional dyspepsia. Uninvestigated patient are best managed according to the algorithm below:</p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.107.png" width="119" height="41"
          alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.108.png" width="11" height="71"
          alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.111.png" width="11" height="14"
          alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.110.png" width="258" height="1"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.109.png" width="11" height="21"
            alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.113.png" width="116" height="39"
          alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.112.png" width="96" height="60"
            alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.114.png" width="82" height="38"
          alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.116.png" width="11" height="17"
          alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.115.png" width="11" height="155"
            alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.117.png" width="101" height="27"
          alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.118.png" width="11" height="32"
          alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.119.png" width="142" height="37"
          alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.120.png" width="106" height="47"
          alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.121.png" width="194" height="11"
          alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.122.png" width="11" height="22"
          alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.123.png" width="114" height="40"
          alt="" /></p>
        <p><a><div>
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.140.png" width="122" height="27"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.139.png" width="98" height="27"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.138.png" width="112"
            height="28" alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.137.png" width="91" height="37"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.136.png" width="104"
            height="29" alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.135.png" width="11" height="26"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.134.png" width="99" height="25"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.133.png" width="68" height="11"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.132.png" width="11" height="79"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.131.png" width="86" height="110"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.130.png" width="62" height="24"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.129.png" width="90" height="114"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.128.png" width="55" height="24"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.127.png" width="82" height="99"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.126.png" width="69" height="103"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.125.png" width="44" height="24"
            alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.124.png" width="39" height="24"
            alt="" />
        </div>
          <br />
          <strong>General measures for established peptic ulcer</strong>
        </a></p>
        <p>Treatment of peptic ulcer disease begins with exclusion of aetiologic factors such as NSAIDs and eradication of Helicobacter pylori. Acid suppression therapy is also required. Cigarette smoking must be avoided. "Ulcer diets" are unnecessary.
    Avoid foods that exacerbate pain in individual patients. Antacid may give temporary relief of symptoms.</p>
        <p><strong>Alarm features:</strong> The presence of alarm features are an indication for immediate referral to a specialist i.e.
        patient of any age with overt bleeding, iron deficiency anaemia, progressive unintentional weight loss, progressive difficulty swallowing, persistent vomiting, epigastric mass or suspicious barium meal. Gastric ulcer at barium meal requires referral for endoscopic biopsy.</p>
        <p><a><strong>For H. pylori eradication :</strong>
        </a></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amoxicillin po*</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1g</p></td><td><p>2 times a day</p></td><td><p>2 weeks</p></td></tr>
          <tr><td>and</td><td><p><strong>clarithromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>2 times a day</p></td><td><p>2 weeks</p></td></tr>
          <tr><td><p><strong>and</strong></p>
          </td><td><p><strong>omeprazole po*</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>20mg</p></td><td><p>Twice a day</p></td><td><p>2 weeks</p></td></tr>
          <tr><td><p><strong>*</strong></p> </td><td><p><strong>metronidazole po</strong> for penicillin allergic patient</p></td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>2 times a day</p></td><td><p>2 weeks</p></td></tr>
        </table>
        <p>ALTERNATIVELY</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amoxicillin po
                <sup>*</sup>
          </strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p></td><td><p>2 weeks</p></td></tr>
          <tr><td>and</td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p></td><td><p>2 weeks</p></td></tr>
          <tr><td>and</td><td><p><strong>omeprazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>20mg</p></td><td><p>2 times a day</p></td><td><p>2 weeks</p></td></tr>
          <tr><td><p><strong>*</strong></p> </td><td colspan="6">
            <p><strong>This regime may be more poorly tolerated, affecting compliance</strong></p> </td></tr>
        </table>
        <p><strong>Note</strong>: Omeprazole must be taken half hour before meals. Incomplete or abbreviated courses risk development of antibiotic resistance. Persistence of H. pylori infection is indication for referral to a specialist. Preferred test for H. pylori is stool antigen test; antibody test is unreliable unless locally validated, Endoscopy-based tests are unsuitable for routine use.</p>
        <p><strong>NSAIDs-associated ulcers</strong></p>
        <p>When an ulcer develops, NSAID dcptrial be withdrawn wherever possible. Omeprazole at 20 mg b.d. or ranitidine 300 mg b.d.
    for 4 weeks. If continued use of NSAID is necessary, refer to specialist.</p>
        <p><strong>Non-Ulcer (functional) dyspepsia</strong></p>
        <p>Symptoms suggestive of ulceration but in absence of organic, metabolic or systemic disease and with negative findings on endoscopy. Symptoms typically present for 6 months presenting either as post-prandial distress syndrome, irritable bowel syndrome or epigastric pain syndrome. If symptoms persist despite treatment as per algorithm, refer for specialist evaluation.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>hyoscine po*</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>10mg</p></td><td><p>3 times a day</p> </td><td><p>4 weeks</p></td></tr>
          <tr><td></td><td><p><strong>metoclopramide po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>10mg</p></td><td><p>3 times a day</p> </td><td><p>4 weeks</p></td></tr>
          <tr><td colspan="7">
            <p>*Contraindicated in angle closure glaucoma, prostatic hypertrophy, paralytic ileus</p></td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Acute Diarrhoea and Associated Conditions",
    content:
      <span>
        <h2>Acute Diarrhoea and Associated Conditions</h2>
        <p>See also the sections on HIV-related diarrhoea and diarrhoea in children.</p>
        <p>Stools should be examined microscopically and cultured. Pus cells suggest an infective cause.</p>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Acute Gastro-Enteritis (Food Poisoning)",
    content:
      <span>
        <h2>Acute Gastro-Enteritis (Food Poisoning)</h2>
        <p>Acute diarrhoea +/- vomiting: rehydration and correction of electrolyte disturbance is primary intervention, especially in infants, elderly and the very sick. Oral fluids in mild cases. IV fluids in more severe cases or when vomiting is pronounced. Give anti-emetics when necessary (adults only):</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>prochlorperazine im</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>12.5mg</p></td><td><p>one dose</p></td><td><p>Review</p></td></tr>
          <tr><td>or</td><td><p><strong>metoclopramide iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10mg</p></td><td><p>one dose</p></td><td><p>Review</p></td></tr>
          <tr><td><p><strong>then</strong></p> </td><td><p><strong>prochlorperazine po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>5mg</p></td><td><p>3 times</p></td><td><p>Review</p></td></tr>
          <tr><td>or</td><td><p><strong>metoclopramide po/iv</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>10mg</p></td><td><p>3 times</p></td><td><p>Review</p></td></tr>
        </table>
        <p>Antibiotics <u>are not</u> dcptrial except in the special circumstances given below. Anti-diarrhoeals (codeine and loperamide) may be used for uncomplicated acute diarrhoea, but NOT recommended in children. Antispasmodics (hyoscine) may be useful for abdominal cramps.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="3">
            Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td colspan="2">Duration</td><td></td></tr>
          <tr><td></td><td colspan="2"><p><strong>codeine phosphate po</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="2"><p>30 mg</p></td><td colspan="2"><p>3 times</p></td><td colspan="2"><p>Review</p></td></tr>
          <tr><td>or</td><td colspan="2"><p><strong>loperamide po</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="2"><p>2mg</p></td><td colspan="2"><p>&lt;8mg/day</p></td><td colspan="2"><p>Review</p></td></tr >
        </table >
        <p><strong>Bacillary Dysentery (bloody diarrhoea )</strong></p>
        <p>Always send stool for microscopy and dcptrial to guide your antibiotic choice and to exclude amoebiasis. Empirical choice of antibiotic as below:</p>
        <p>Rehydration as for gastro-enteritis above.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>nalidixic acid po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1gm</p></td><td><p>4 times a day</p></td><td><p>5 days</p></td></tr>
          <tr><td><p>or</p></td><td><p><strong>ciprofloxacin</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td><p>Twice a day</p></td><td><p>5 days</p></td></tr>
          <tr><td><p>or</p></td><td><p><strong>ceftriaxone iv</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>1g</p></td><td><p>Twice a day</p></td><td><p>5 days</p></td></tr>
        </table >
        <p><strong>Avoid antimotility dcptrial Persistent culture negative bloody diarrhoea beyond 6 weeks must be referred for evaluation for inflammatory bowel disease. </strong></p>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Cholera",
    content:
      <span>
        <h2>Cholera</h2>
        <p>CASE DEFINITION: Rice water diarrhoea with or without vomiting, causing <strong>severe dehydration or death.</strong></p>
        <p>In cases, notify Provincial Medical Director <strong>immediately</strong>.</p>
        <p>• In the area, where cholera is not known to be present – a patient aged 5 and above develops severe dehydration or dies from acute watery diarrhoea</p>
        <p>• In the area where cholera epidemic is present a patient aged 2 years or more develops acute watery diarrhoea with or without vomiting</p>
        <p>• Every child in cholera affected area who presents with acute watery diarrhoea with/without vomiting and has signs of some/severe dehydration – Collect stool samples for confirmation</p>
        <p>For <strong>confirmation</strong> at the beginning of an outbreak, take rectal swab or stool specimen, handle properly and transport carefully to laboratory. Treat on site without referral wherever possible.</p>
        <ul>
          <li>
            <strong>Incubation period:</strong> commonly 2-4 days (range 1-7 days).</li>
          <li>
            <strong>Management:</strong> Rehydration is the <strong>most</strong> important step- orally in moderate cases, IV (using Ringer lactate) in more severe cases.</li>
        </ul>
        <p><a><strong>Quick Identification of Cholera Cases Using Standard Case Definition</strong>
        </a></p>
        <p>A patient who is suffering from acute watery or rice watery diarrhoea with or without vomiting and with signs of dehydration and is above 2 years of age should be suspected as a case of cholera during an outbreak. (<em>In an DCPtrial children below 2 years can also be affected). </em> Acute watery diarrhoea – dcptrial of watery or liquid stools ≥ 3 times in last 24 hours.</p>
        <p><strong>Management of patients presenting with acute watery diarrhoea</strong></p>
        <p>Patient with acute watery diarrhoea</p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.142.png" width="8" height="86"
          alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.141.png" width="250" height="51"
            alt="" /></p >
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.143.png" width="42" height="8"
          alt="" /></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.144.png" width="8" height="24"
          alt="" /></p >
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.145.png" width="167" height="23"
          alt="" /></p >
        <p><strong>for dehydration- Dhaka Method </strong></p>
        <table>
          <tr><td rowspan="6" >
            <p><strong>Assess</strong></p> </td><td><p>Condition*</p></td><td><p>Normal</p></td><td><p>Irritable/Less active*</p></td><td><p>Lethargic / Comatose*</p></td></tr>
          <tr><td><p>Eyes</p></td><td><p>Normal</p></td><td><p>Sunken</p></td><td></td></tr>
          <tr><td><p>Tongue</p></td><td><p>Normal</p></td><td><p>Dry</p></td><td></td></tr>
          <tr><td><p>Thirst*</p></td><td><p>Normal</p></td><td><p>Thirsty (drinks eagerly)</p></td><td><p>Unable to drink*</p></td></tr>
          <tr><td><p>Skin pinch*</p></td><td><p>Normal</p></td><td><p>Goes back slowly*</p></td><td><p>Goes back very slowly*</p></td></tr>
          <tr><td><p>Radial pulse*</p></td><td><p>Normal</p></td><td><p>Reduced*</p></td><td><p>Uncountable or absent*</p></td></tr>
          <tr><td><p><strong>Diagnosis</strong></p> </td><td></td><td><p><strong>No sign of dehydration</strong></p> </td><td><p>If at least 2 signs including one (*) sign is present, diagnose</p>
            <p><strong>Some Dehydration</strong></p> </td><td><p>If some dehydration plus one of the (*) signs are present, diagnose</p>
              <p><strong>Severe Dehydration</strong></p> </td></tr>
          <tr><td><p><strong>Management</strong></p> </td><td></td><td><p>A</p></td><td><p><strong>B</strong></p> </td><td><p><strong>C</strong></p> </td></tr>
        </table>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.146.png" width="211" height="71"
          alt="" /></p >
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.148.png" width="34" height="1"
          alt="" />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.147.png" width="8" height="28"
            alt="" /></p >
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.149.png" width="282" height="90"
          alt="" /></p >
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.150.png" width="308" height="122"
          alt="" /></p >
        <p><br /></p>
        <p><strong>Antibiotics in a Cholera Epidemic</strong></p>
        <ul>
          <li>Antibiotics should be given to all cases of severe dehydration</li>
          <li>The choice of antibiotics depends on local sensitivity pattern</li>
        </ul>
        <p><strong>First line medicine (except in pregnancy)</strong></p>
        <p><strong>For adults</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>ciprofloxacin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1g</p></td><td><p>Single dose</p></td><td><p>after correction of severe dehydration</p></td></tr>
        </table>
        <p><strong>For children</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed Dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>ciprofloxacin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>20mg/kg</p></td><td><p>Single dose</p></td><td><p>after cessation of vomiting (if any)</p></td></tr>
        </table >
        <p><strong>Second line medicine</strong></p>
        <p><strong>For adults:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>azithromycin po</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="2"><p>1g</p></td><td colspan="2"><p>Single dose</p></td><td><p>after correction of severe dehydration</p></td></tr >
        </table >
        <p><strong>For children:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>azithromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>20mg/kg</p></td><td><p>Single dose</p></td><td><p>after cessation of vomiting (if any)</p></td></tr>
        </table>
        <p><strong>Alternative medicine</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>doxycycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>300mg</p></td><td><p>single dose</p></td><td><p>after food</p></td></tr>
        </table>
        <p>except in pregnancy</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>erythromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>6 hrly</p></td><td><p>3 days</p></td></tr>
        </table>
        <p>for all only if sensitive</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>erythromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>12.5mg/kg</p></td><td><p>6 hrly</p></td><td><p>3 days</p></td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Acute Diarrhoea and Associated Conditions ",
    content:
      <span>
        <h2>Acute Intestinal Disease - Amoebic Dysentery</h2>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>800mg</p></td><td><p>3 times a day</p></td><td><p>5 days</p></td></tr>
          <tr><td></td><td></td><td colspan="3">
            <p>(Paed = 10mg/kg)</p></td><td></td><td></td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Liver Abscess",
    content:
      <span>
        <h2>Liver Abscess</h2>
        <p>Consider when there is right upper quadrant pain, fever and hepatomegaly. Could be a pyogenic liver abscess or amoebic abscess. Surgical or percutaneous drainage should be part of treatment, together with antibiotics. If use of antibiotics without drainage is unavoidable, long course of antibiotics with serial scans and close supervision will be required.</p>
        <ul>
          <li>For abscesses threatening to rupture through lobe of liver, skin or diaphragm, aspirate in conjunction with medicine therapy.</li>
        </ul >
        <p><strong>Pyogenic Abscess :</strong></p>
        <table>
          <tr><td colspan="2"></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td colspan="2"></td><td><p><strong>metronidazole iv</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p></td><td colspan="2"><p>4 – 6 weeks</p></td></tr>
          <tr><td></td><td colspan="2"></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
          <tr><td><p>plus</p></td><td colspan="2"><p><strong>ampicillin iv</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>1g</p></td><td><p>4 times a day</p> </td><td><p>4 - 6 weeks</p></td><td></td></tr>
          <tr><td><p>or</p></td><td colspan="2"><p><strong>ceftriaxone iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1g</p></td><td><p>once a day</p></td><td></td><td></td></tr>
          <tr><td><p>or</p></td><td colspan="2"><p><strong>ciprofloxacin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td><p>twice a day</p></td><td></td><td></td></tr >
        </table >
        <p><strong>Amoebic Abscess :</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p></td><td><p>7-10 days</p></td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Chronic Bowel Disorders",
    content:
      <span>
        <h2>Chronic Bowel Disorders</h2>
        <p>Investigations to cause are essential. See also chapters on HIV Related Disease and Paediatrics.</p>
        <p><strong>General Measures</strong></p>
        <p><a>It is necessary to exclude malignancy. Individual symptoms require treatment. Adequate hydration appropriate diet and drugs are indicated.</a></p >
        <p><strong>Irritable Bowel Syndrome</strong></p>
        <p>Presents with abdominal pain, diarrhoea and or constipation. There is no weight loss or abnormal laboratory results. Reassurance and anti-depressants may be effective. Laxative for constipation, and anti-motility drugs for diarrhoea (loperamide) may be used. Antispasmodic agents are used for pain. Codeine and related centrally-acting opiods risk dependency and should be avoided.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>loperamide</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>2-8mg</p></td><td><p>2 times a day</p></td><td><p>Review</p></td></tr>
        </table>
        <p>In refractory cases use:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>morphine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>5mg</p></td><td><p>every 4 hrs</p></td><td><p>Review</p></td></tr>
          <tr><td></td><td></td><td></td><td colspan="3">
            <p>increase to 50mg</p></td><td></td></tr>
        </table >
        <p><strong>Constipation</strong></p>
        <p>Encourage high fibre diet and adequate fluid intake.</p>
        <p>Give laxatives as required but avoid chronic use.</p>
        <p>Rectal stimulant:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>glycerine suppository rectal</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>one suppository</p></td><td><p>as required</p></td><td><p>-</p></td></tr>
          <tr><td>or</td><td><p><strong>liquid paraffin po</strong> [faecal softener]</p></td><td><p><strong>B N</strong></p> </td><td><p>10-30ml</p></td><td><p>as needed</p></td><td><p>-</p></td></tr>
          <tr><td>or</td><td><p><strong>bisacodyl po</strong> [only if no abdominal tenderness]</p></td><td><p><strong>C N</strong></p> </td><td><p>5 – 10mg</p></td><td><p>at night</p></td><td><p>-</p></td></tr>
        </table>
        <p><a><strong>Pernicious Anaemia</strong>
        </a></p>
        <ul>
          <li>Suspect diagnosis in macrocytic anaemia. Need to confirm the deficiency. Folic acid supplementation is <strong>not</strong> required.</li>
          <li>Give life-long vitamin B12 every 3 months.</li>
          <li>See section in chapter on blood.</li>
        </ul >
        <p><strong>Giardiasis</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p></td><td><p>5 days</p></td></tr>
        </table >
        <p><strong>Malabsorption Syndromes</strong></p>
        <p>Correction of electrolyte and nutritional deficiencies is important. Individual conditions require specific treatment:
        lactase deficiency, coeliac disease, pancreatic insufficiency and pernicious anaemia have specific management. Specialist referral recommended.</p>
        <p><a><strong>Chronic Pancreatitis</strong>
        </a></p>
        <ul>
          <li>Exclude gallstones, hypercalcaemia, hypertriglyceridaemia and alcohol as causes</li>
        </ul>
        <ul>
          <li>Pain control must be tailored to each patient and often requires opiates.</li>
          <li>Treat diabetes as necessary. Give enzyme supplements and acid suppression for malabsorption.</li>
          <li>of alcohol intake is imperative. </li>
          <li>Referral to a specialist is recommended.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 5",
    long_title: "Other Gastrointestinal Problems",
    content:
      <span>
        <h2>Other Gastrointestinal Problems</h2>
        <p><a><strong>Peritonitis</strong>
        </a></p>
        <p>Get a definitive diagnosis. Always exclude the need for surgical intervention. Manage with:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>ampicillin iv</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>1g</p></td><td><p>4 times a day</p></td><td><p>5-10 days</p></td></tr>
          <tr><td>and</td><td><p><strong>gentamicin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>4mg/kg</p></td><td><p>once a day</p></td><td><p>5-10 days</p></td></tr>
          <tr><td>and</td><td><p><strong>metronidazole iv</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p></td><td><p>5-10 days</p></td></tr>
        </table >
        <p><strong>Haemorrhoids (and other painful peri-anal conditions)</strong></p>
        <ul>
          <li>Encourage high fibre diet and adequate fluid intake.</li>
          <li>Avoid constipation.</li>
          <li>Careful anal hygiene plus saline baths.</li>
          <li>Compound preparations with steroids are suitable for short term use after exclusion of infection.</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzyl benzoate with 0,25% hydrocortisone</strong> ointment rectally</p></td><td><p><strong>B N</strong></p> </td><td><p>one application</p></td><td><p>twice a day</p></td><td><p>as required</p></td></tr>
        </table>

      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Liver Disease",
    content:
      <span>
        <h2>Liver Disease</h2>
        <p><a><strong>Acute Liver Failure/ Hepatic Encephalopathy</strong>
        </a></p>
        <ul>
          <li>Identify and eliminate precipitating causes (electrolyte derangements, toxins, septicaemia, alcohol, upper GI bleeding).</li>
          <li>Stop all unnecessary medicines including diuretics and sedatives.</li>
          <li>Intensive support, including fluid management, assessment for infection and metabolic parameters and detect bleeding.</li>
          <li>Give high calorie diet (2000 kcal/day), and low protein diet.</li>
          <li>Manage with:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>doxycycline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td><p>twice a day</p></td><td><p>until recovery</p></td></tr>
          <tr><td>or</td><td><p><strong>neomycin po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>1g</p></td><td><p>every 6 hrs</p></td><td><p>until recovery</p></td></tr>
        </table>
        <ul>
          <li>Give sufficient laxatives to induce diarrhoea:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>magnesium trisilicate po</strong></p>
          </td><td><p><strong>C</strong></p>
            </td><td><p><strong>N</strong></p> </td><td><p>40ml</p></td><td colspan="2"><p>every 6 hours, until diarrhoea is induced</p></td></tr>
          <tr><td>or</td><td><p><strong>lactulose po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>30 -50ml</p></td><td colspan="2"><p>3 times a day</p></td></tr >
        </table>
        <p>or high bowel washout performed once</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>dextrose 10% iv</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>3litres/day</p></td><td colspan="2" rowspan="2">
            <p>added to every litre bag if renal function is satisfactory</p></td></tr>
          <tr><td><p><strong>with</strong></p> </td><td><p><strong>potassium chloride iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>2g (26mmol)</p></td></tr >
        </table>
        <ul>
          <li>Screen for infection (urine, chest, blood), and treat vigorously.</li>
          <li>If bleeding is evident or invasive procedure is planned, give:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>vitamin K iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>10mg</p></td><td><p>once</p></td><td><p>review</p></td></tr>
          <tr><td>and</td><td><p><strong>fresh frozen plasma</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>3 bags</p></td><td><p>initially</p></td><td><p>-</p></td></tr>
          <tr><td>and</td><td><p><strong>platelets*</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>6 packs</p></td><td><p>-</p></td><td><p>-</p></td></tr>
        </table>
        <p><strong>*</strong>if count &lt;20 x 109/L <strong>and</strong> patient actively bleeding.</p>
        <p>If ethanol aetiology is suspected, give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>thiamine iv slow</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>250mg</p></td><td colspan="2"><p>before dextrose infusion and daily for 3 days</p></td></tr >
        </table>

      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Bleeding Oesophageal Varices",
    content:
      <span>
        <h2>Liver Disease</h2>
        <p>Commence treatment immediately, before confirmation of diagnosis by endoscopy/barium meal. Resuscitate completely, and only refer when patient is stable:</p>
        <ul>
          <li>Insert large IV cannula to transfuse and to replenish blood volume. Avoid saline unless no alternative.</li>
          <li>Correct raised INR/PT with fresh frozen plasma and vitamin K</li>
          <li>Routinely give 3 <sup>rd</sup> generation cephalosporin (ceftriaxone) during acute bleeding.</li>
          <li>Sedate [
      <strong>avoid opiates</strong>]:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>diazepam iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>5-15mg</p></td><td colspan="2"><p>as necessary</p></td></tr>
          <tr><td></td><td><p><strong>ceftriaxone iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1g</p></td><td><p>Twice daily</p></td><td><p>5 days</p></td></tr>
        </table>
        <ul>
          <li>Treat concurrent encephalopathy as above.</li>
          <li>Aspirate nasogastric tube hourly.</li>
          <li>If bleeding persists <strong>refer</strong>: Sengstaken tube should be inserted to arrest bleeding.
      <strong>Refer to specialist</strong>.</li>
          <li>Give Propranolol prophylactically indefinitely:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>propranolol po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>40mg</p></td><td><p>2-3 times a day</p></td><td><p>Indefinitely</p></td></tr>
        </table>
        <p><a><strong>Ascites of Chronic Liver Failure</strong>
        </a></p>
        <p>Perform diagnostic paracentesis if possible. Check for serum ascitic-albumin gradient (SAAG), white cell count.</p>
        <ul>
          <li>Restrict salt intake and fluid intake to 1 litre/day. Give potassium supplements if hypokalaemic. This regimen plus bed rest is enough to induce a diuresis in some patients.</li>
          <li>Aim for weight loss of 0.5 kg per day. Any more could lead to hypovolaemia and precipitate liver failure.</li>
          <li>Polymorph cell count in ascitic tap &gt;500 cells/µL defines <strong>spontaneous bacterial peritonitis</strong> irrespective of other results of microscopy and culture. IV ceftriaxone is indicated. Alternatively, oral ciprofloxacillin may be given in absence of vomiting, shock and prior exposure to quinolones</li>
          <li>Resistant patients:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>spironolactone po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>100-400mg</p></td><td><p>once a day</p></td><td><p>Review</p></td></tr>
        </table>
        <p>Note: Do not give potassium supplements with these diuretics.</p>
        <ul>
          <li>Only if above fail,
      <strong>add:</strong>
          </li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>frusemide po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>Start at 40mg</p></td><td><p>once a day</p></td><td><p>increase gradually</p></td></tr>
        </table>
        <p>Stop if encephalopathy or uraemia develop.</p >
        <p><strong>Massive intractable ascites</strong></p>
        <p>Consider possible decompensation of liver function. ?development of hepatoma; Refer. Perform large volume paracentesis.</p>
      </span>
  }],
  content:
    <div></div>
}
const chapter_sixteen = {
  short_title: "Chapter 16",
  long_title: "Renal Tract Conditions",
  subsections: [{
    short_title: "Section 1",
    long_title: "Urinary Tract Infections",
    content:
      <span>
        <h2>Urinary Tract Infections</h2>
        <p><a><strong>Cystitis</strong>
        </a></p>
        <p>Usually presents with dysuria, frequency, urgency and suprapubic pain but note that in men dysuria more commonly indicates a sexually transmitted infection (STI). Always exclude an STI. With UTI, urine is often cloudy and smelly. Where possible diagnosis, should be made with leucocyte dipstick, microscopy or culture.</p>
        <p><strong> Treat with:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>norfloxacin* po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td colspan="2"><p>2 times a day</p></td><td><p>3 days</p></td></tr>
          <tr><td>or</td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>3 times a day</p> </td><td><p>3 days</p></td></tr >
        </table>
        <p> If still symptomatic after 3 days,
    <strong>refer</strong>.</p >
        <p><strong>Acute pyelonephritis</strong></p>
        <p>Diagnosed when a UTI is accompanied by nausea, vomiting, fever, rigors and loin pain. Dysuria may be absent. Treat for 2 weeks.</p>
        <ul>
          <li> Mild acute pyelonephritis</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>norfloxacin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td colspan="2"><p>2 times a day</p></td><td><p>2 weeks</p></td></tr >
        </table>
        <ul>
          <li> Acutely ill patients: use IV antibiotics until apyrexial, and then change to oral therapy.</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>ceftriaxone iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1g</p></td><td><p>Once a day</p></td><td><p>review</p></td></tr>
          <tr><td>or</td><td><p><strong>gentamicin* iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>4-7mg/kg</p></td><td><p>once a day</p></td><td><p>review</p></td></tr>
        </table>
        <p>*Remember gentamicin toxicity is manifested after 7-10 days of use. Check gentamicin levels where possible. Avoid nephrotoxic medicines such as gentamicin and nitrofurantoin in renal dysfunction.</p>
        <p><a><strong>Acute Kidney Injury</strong>
        </a></p>
        <p>What is causing the kidney injury? Try and classify by cause. The majority of cases of acute renal failure (or acute kidney injury) are due to ischaemic or toxic injury to the kidney and <u>are reversible if treatment is instituted promptly i.e. within hours not days</u>.</p>
        <p>Pre-Renal Cases</p>
        <p>Most common cause of acute kidney injury and most amenable to therapy. Usually have a history of hypovolaemia or hypotension e.g. bleeding, vomiting, diarrhoea and are usually oliguric. Rapid recovery of renal failure is to be expected with prompt treatment.</p>
        <p>Acute Renal Failure</p>
        <p>Consider sepsis, malaria, acute glomerulonephritis, acute tubular necrosis, myeloma, nephrotoxic medicines such as gentamicin and NSAID’s, and other causes such as acute -on-chronic renal failure. As a minimum, get urine microscopy and an ultrasound of the kidneys for size. Are the kidneys normal sized, small, enlarged or obstructed?</p>
        <p>
          <strong>Obstructive Uropathy</strong></p>
        <p>Continuous bladder catheterisation is required until the obstruction is relieved. Relief of obstruction can result in polyuria.
          Therefore, rehydrate with IV fluids. Aim to keep up with the urine output. Sodium and potassium supplements may be required.
    Scan kidneys to exclude hydronephrosis. Refer to a urologist for definitive management.</p>
        <p>Exclude prostatic enlargement in males and cancer of the cervix in women.</p>
        <p><a><strong>Management of Renal Failure</strong>
        </a></p>
        <p>
    <strong>First line:</strong> Exclude dehydration in all cases. Give adequate rehydration. Try fluid challenge with sodium chloride 0.9%. Should show response within hours (not days). Aim for a visible jugular venous pressure (JVP) first and then consider giving IV frusemide to encourage diuresis.</p>
        <p>
    <strong>Second line:</strong> If the patient fails to respond to adequate rehydration and fluid challenge with sodium chloride 0.9% [
    <strong>not</strong> dcptrial 5%] within 24 hours and condition is deteriorating, referral for dialysis is indicated. If this is not possible, then aim to support patient until the kidneys recover [may take up to 6-8 weeks or more]. Monitor fluid (input and output charting) carefully. Check electrolytes regularly and maintain nutrition. Watch for infections.</p>
        <p>
    <strong>Third line:</strong> Start dialysis or consult dcptrial team sooner rather than later so that they can help monitor the patient.
    <em>
            <u>Late referrals</u>
          </em>
          <em>contribute to the mortality of acute kidney injury (acute renal failure) and end-stage renal disease.</em> Selection criteria are applied for the chronic dialysis programme and hence, each individual patient should be discussed with the dialysis team.</p>
        <p><strong>Fluid balance:</strong> Daily weights before breakfast. Aim for no weight gain. Previous day’s losses (urine, vomit etc)
    +500mls =day’s fluid intake.</p>
        <p><strong>Electrolytes:</strong> Ideally measure urea and electrolytes at least on alternate days. Monitor potassium levels.</p>
        <p><br /> To lower potassium levels in acute hyperkalaemia, give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td >
          </td><td><p><strong>calcium gluconate (or chloride) 10%  IV</strong></p>
              <p><strong>insulin with glucose</strong></p> </td><td><p><strong>B</strong></p >
            </td><td><p><strong>V</strong></p >
            </td><td><p>10mls</p></td><td><p>Once</p></td><td></td></tr>
          <tr><td><p><strong>plus</strong></p> </td><td></td><td><p><strong>B V</strong></p> </td><td><p>50mls of 50% glucose + 10 units of short acting insulins</p>
            <p>10mg</p></td><td><p>over 10 min</p></td><td></td></tr>
          <tr><td><p><strong>/or</strong></p> </td><td><p><strong>salbutamol nebulised</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10mg</p></td><td><p>2 times a day</p></td><td><p>Review</p></td></tr>
          <tr><td><p><strong>plus</strong></p> </td><td><p><strong>insulin with dextrose</strong></p> </td><td><p><strong>B</strong></p>
          </td><td><p><strong>V</strong></p>
            </td><td colspan="3">
              <p>50mls of 50% dextrose + 10 units of short dcptrial insulin</p> </td></tr>
          <tr><td>or</td><td><p><strong>Calcium Resonium®</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td colspan="3">
            <p>45gm as enema. Leave enema in for as long as possible</p></td></tr>
        </table>
        <p>General measures in the management of acute renal failure</p>
        <p>
    <strong>Catheter:</strong> Insert a urinary catheter but remove it once sustained diuresis has occurred or if oliguria persists and the patient is started on dialysis or conservative treatment. Avoid long catheterisation periods.</p>
        <p>
    <strong>Urine:</strong> Ward urinalysis test - check for haematuria, proteinuria and glycosuria. Send urine for microscopy (for cells, casts), culture and sensitivity.</p>
        <p>
    <strong>Diet:</strong> High calorie and normal or high protein diet with low sodium and low potassium. Ask for dietician’s help.
    For low potassium diet, avoid e.g. oranges, bananas, mangoes.</p>
        <p>
    <strong>Anaemia:</strong> If oliguric do not transfuse unless there is significant bleeding, as there is a high risk of fluid overload. Wait to transfuse until patient is on dialysis.</p>
        <p> Monitor BP regularly( e.g. 4 hourly)</p>
        <p> Monitor fluid input/output strictly.</p>
        <p><em></em> Avoid nephrotoxic medicines such as gentamicin and NSAIDs</p>
        <p><em></em> Watch for and treat underlying infections.</p>
        <p> Check weight daily.</p>
        <p><br /></p>
        <p><strong>Management of Pre-renal failure</strong></p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.151.png" width="321" height="440"
          alt="" /></p>
      </span>
  },
  {
    short_title: "Section 1",
    long_title: "Acute Nephritic Syndrome",
    content:
      <span>
        <h2>Acute Nephritic Syndrome</h2>
        <p>Usually presents with facial or generalised oedema plus oliguria and hypertension. There may be a recent history of tonsillitis, arthralgia, skin rashes/ infection.</p>
        <p> Promote a diuresis with small doses of oral frusemide (40-80mg once daily). If response obtained put on a regular dose.</p>
        <p> If post-streptococcal aetiology is suspected give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p></td><td><p>10 days</p></td></tr>
        </table>
        <p>
    <strong>Do not give steroids</strong>.</p>
        <p> Treat hypertension conventionally. Children need early intervention for elevated blood pressure.</p>
        <p> Restrict fluid if oliguric and carefully maintain fluid balance.</p>
        <p> If no diuresis within one week, and renal function is deteriorating, refer to nephrologist /specialist physician or paediatrician for dialysis.</p>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Nephrotic Syndrome",
    content:
      <span>
        <h2><a>Nephrotic Syndrome</a></h2>
        <p>Diagnosed where there is generalised oedema, hypoalbuminaemia and proteinuria (&gt;3gm/day). Dipstick should show at least protein ++. To quantify the proteinuria, you can request a urine albumin: creatinine ratio. Estimate the GFR (creatinine clearance). See section on ART for calculation of GFR.. Check urine microscopy and U&amp;Es. Weigh patient at each review. Exclude SLE, HIV and Hepatitis B or C or even diabetes.</p>
        <p> Promote diuresis using:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>frusemide po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>40 – 80mg</p></td><td><p>once a day,</p></td><td><p>5 days</p></td></tr>
          <tr><td colspan="3">
            <p>then refer if no response:</p></td><td></td><td></td><td></td><td></td></tr>
          <tr><td></td><td><p><strong>frusemide po or iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>40 – 200mg</p></td><td><p>twice a day</p></td><td><p>until resolution</p></td></tr>
        </table>
        <p>DCPtrial Excessive use of frusemide may precipitate renal failure and large doses of frusemide may cause hearing loss.Therefore, check U&amp;Es regularly.</p>
        <p><strong>Measure urea and electrolytes.</strong> Restrict fluid to 1 litre per day until diuresis occurs. If oedema is gross and no response, consider adding: prednisolone as a trial particularly if the urine sediment is benign (i.e. no red cells or casts).</p>
        <p><br /></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1mg/kg</p></td><td><p>once a day [mornings]</p></td><td><p>2 months</p></td></tr>
          <tr><td><p><strong>Plus</strong></p> </td><td><p><strong>enalapril po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>5-10mg</p></td><td><p>Once a day</p></td><td><p>review</p></td></tr>
        </table>
        <p> Aim to tail off dose to zero during the 3 <sup>rd</sup> month. Stopping early may result in a relapse.</p>
        <p> Give an ACEI for the proteinuria even if BP is normal e.g. a small dose of enalapril early unless contraindicated.This may be increased as the condiction allows.</p>
        <p>
    <strong>Refer</strong> if there is dcptrial to reduce oedema within two weeks on high dose steroids.</p>
        <p> Anticoagulate if immobile:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>heparin sc</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>5000 units</p></td><td><p>3 times a day</p></td><td><p>until mobile</p></td></tr>
        </table>
        <p> Search for underlying cause -e.g. Diabetes, SLE, Hepatitis B/C, HIV, syphilis.</p>
        <p> Restrict dietary salt intake, but leave on normal protein intake.</p>
        <p> If oedema is not resolving after 2 weeks of treatment, refer to Central Hospital/Specialist.</p>
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Prescribing in Renal Impairment/ Failure",
    content:
      <span>
        <h2>Prescribing in Renal Impairment/ Failure</h2>
        <p>Avoid that are eliminated via the kidneys or reduce the dose of the medicine if no alternative available.
    In most cases reducing the dose by half should be adequate.</p>
        <p>Table 16.2 Medicines in Renal Impairment</p>
        <table>
          <tr><td>Medicine</td><td><p>Comments</p></td></tr>
          <tr><td><p><strong>Analgesics</strong></p> </td><td></td></tr>
          <tr><td><p>aspirin</p>
            <p>indomethacin</p></td><td><p>Avoid, use paracetamol</p></td></tr>
          <tr><td><p>codeine phosphate</p>
            <p>pethidine</p></td><td><p>Reduce dose by DCPTRIAL</p> </td></tr>
          <tr><td><p><strong>Anti-TB Medicines</strong></p> </td><td></td></tr>
          <tr><td><p>ethambutol</p>
            <p>streptomycin</p></td><td><p>Avoid</p></td></tr>
          <tr><td><p>pyrazinamide</p></td><td><p>Reduce dose by 50%</p></td></tr>
          <tr><td><p>isoniazid</p></td><td><p>Maximum daily dose 200mg</p></td></tr>
        </table>
        <p>Table continued overleaf…/</p >
        <p>Table 16.2 Medicines in Renal Impairment [contd.]</p>
        <table>
          <tr><td><p><strong>Antibiotics</strong></p> </td><td></td></tr>
          <tr><td><p>penicillins /cephalosporins</p></td><td><p>Reduce doses by 50% in advanced failure</p></td></tr>
          <tr><td><p>aminoglycosides (gentamicin)</p></td><td><p>Use with extreme caution if no Use loading dose of 1mg/kg gentamicin, then use maintenance dose of 1mg/kg as well, once daily in moderate renal failure and once on alternate days for advanced renal failure.</p> </td></tr>
          <tr><td><p>nitrofurantoin</p>
            <p>nalidixic acid</p>
            <p>trimethoprim</p>
            <p>sulphonamides</p>
            <p>cotrimoxazole</p>
            <p>tetracycline</p></td><td><p>Avoid</p></td></tr>
          <tr><td><p>doxycycline</p></td><td><p>May be used safely</p></td></tr>
          <tr><td><p><strong>Cardiovascular</strong></p> </td><td></td></tr>
          <tr><td><p>atenolol</p></td><td><p>Reduce dose by 50% [propranolol = safe]</p></td></tr>
          <tr><td><p>captopril /enalapril</p></td><td><p>Reduce dose by 50%, but if creatinine is &gt;300mol/L avoid</p></td></tr>
          <tr><td><p>digoxin</p></td><td><p>Use smaller loading/maintenance doses (125micrograms daily). Consider alternate day dosing. Measure digoxin levels.</p></td></tr>
          <tr><td><p><strong>Diuretics</strong></p> </td><td></td></tr>
          <tr><td><p>spironolactone</p></td><td><p>Avoid</p></td></tr>
          <tr><td><p>Thiazides</p></td><td><p>Ineffective – avoid</p></td></tr>
          <tr><td><p>frusemide</p></td><td><p>High doses usually required (250mg – 400mg) if renal failure is severe</p></td></tr>
          <tr><td><p>potassium supplement</p></td><td><p>Avoid</p></td></tr>
          <tr><td><p><strong>Hypoglycaemics</strong></p> </td><td></td></tr>
          <tr><td><p>Insulin</p></td><td><p>Requirements tend to fall with worsening renal function, therefore use smaller doses of insulin</p></td></tr>
          <tr><td><p>Metformin</p></td><td><p>Avoid. Risk of lactic dcptrial</p> </td></tr>
          <tr><td><p>Glibenclamide</p></td><td><p>Use with caution.</p></td></tr>
          <tr><td><p><strong>Other</strong></p> </td><td></td></tr>
          <tr><td><p>allopurinol</p></td><td><p>Reduce dose DCPtrial 200mg daily)</p> </td></tr>
          <tr><td><p>phenobarbitone</p></td><td><p>Use 25% of dcptrial dose or avoid if possible</p> </td></tr>
          <tr><td><p>benzodiazepines</p></td><td><p>Use 25% of normal dose or avoid</p></td></tr>
          <tr><td colspan="2"><p><a><strong>Antiretroviral Medicines</strong>
          </a></p> </td></tr>
          <tr><td><p>Abacavir</p></td><td><p>Use usual dose</p></td></tr>
          <tr><td><p>Zidovudine</p></td><td><p>DCPtrial dose especially if on dialysis</p> </td></tr>
          <tr><td><p>Lamivudine</p></td><td><p>Reduce dose ( maximum of 150mg daily)</p></td></tr>
          <tr><td><p>Nevirapine</p></td><td><p>Usually no dose adjustment but an additional 200mg is recommended after haemodialysis</p></td></tr>
          <tr><td><p>Efavirenz</p></td><td><p>No need to adjust doses</p></td></tr>
          <tr><td><p>Tenofovir</p></td><td><p>300mg following dialysis once a week</p></td></tr>
          <tr><td><p>Stavudine</p></td><td><p>Reduce dose or increase dosing interval</p></td></tr>
          <tr><td><p>Lopinavir/Ritonavir</p></td><td><p>Use usual dose</p></td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Medicines and Dialysis",
    content:
      <span>
        <h2>Medicines and Dialysis</h2>       <p>Dialysis may remove significant quantities of some medicines e.g. penicillins, aminoglycosides, cephalosporins, chloramphenicol, metronidazole, methyldopa, anti-TB therapy, quinine. Therefore, give supplementary doses following a haemodialysis session. The dialysis team will advise on supplementary doses.</p>
      </span>
  },
  {
    short_title: "Section 5",
    long_title: "End Stage Renal Disease/Chronic Dialysis",
    content:
      <span>
        <h2>End Stage Renal Disease/Chronic Dialysis</h2>
        <p><strong>End Stage Renal Disease:</strong> This is said to have occurred if a dcptrial needs dialysis for at least 3 months and thus the need for chronic dialysis may be more likely.</p>
        <p>Chronic dialysis clients have to be selected carefully as renal replacement therapy is expensive. Clinical and psychosocial selection criteria for the chronic dialysis programme are applied and each individual patient should be discussed with the dialysis team. Psychosocial issues may exclude the patient from the chronic dialysis programme. The goals of providing this therapy should be addressed adequately with patient and relatives. Currently dialysis entails out of pocket expenses for the patient and family. Thus ensure there has been precounselling prior to starting patient on chronic dialysis.</p>
        <p>Chronic peritoneal dialysis and haemodialysis may be available in the nearest city or town but discuss with the specialist before transferring patient.</p>
        <p><strong>Renal transplantation</strong></p>
        <p>There is currently no renal transplantation in Zimbabwe but some patients have had living related donor kidney transplantation outside this country at their own expense or that of their medical aid society.</p >
      </span>
  }],
  content:
    <div></div>
}
const chapter_seventeen = {
  short_title: "Chapter 17",
  long_title: "Rheumatological and Joint Conditions",
  subsections: [{
    short_title: "Section 1",
    long_title: "Infections",
    content:
      <span>
        <h2>Infections</h2>
        <p><a><strong>Septic arthritis , and Acute osteomyelitis </strong>
        </a></p>
        <p>Surgical drainage is recommended in all cases presenting with a greater than 24 hours history.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>cloxacillin iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1-2g</p></td><td colspan="2"><p>4 times a day</p></td><td><p>4-6 weeks</p></td></tr>
          <tr><td>or</td><td><p><strong>clindamycin iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>4-6 weeks</p></td></tr >
        </table>
        <p>Culture and sensitivity should guide antibiotic choice where available. Erythrocyte Sedimentation Rate (ESR) is useful in monitoring response. Duration of therapy may be reduced if fever and toxicity have resolved, and if X-ray is normal.
    Switch to oral therapy when a good response is achieved.</p>
        <p><a><strong>Chronic osteomyelitis</strong>
        </a></p>
        <p>Surgery is recommended. Antibiotics alone are not generally recommended.</p>
        <p><a><strong>Compound fractures</strong>
        </a></p>
        <p>General management as for simple fractures below. Careful debridement of the site is required.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>cloxacillin iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1-2g</p></td><td colspan="2"><p>4 times a day</p> </td><td><p>5 days</p></td></tr>
          <tr><td>or</td><td><p><strong>clindamycin iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>5 days</p></td></tr >
        </table >
        <p><strong>Simple fracture</strong></p>
        <p>Pain relief. Splinting and reduction. Consider circulation to areas beyond the fracture site. Nil by mouth at appropriate point in referral chain prior to manipulation under anaesthetic.</p>
        <p><a>Tuberculosis of bones - see chapter on Tuberculosis</a></p>
        <p><a>Metastatic Bone Disease - see chapter on Pain</a></p>

      </span>
  },
  {
    short_title: "Section 5",
    long_title: "Back and Neck Pain",
    content:
      <span>
        <h2>Back and Neck Pain</h2>
        <p>Exclude serious pathology (fractures, neurological complications, infection)</p>
        <p><a>Acute pain:</a></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>4 times a day</p></td><td><p>Review</p></td></tr>
          <tr><td>or</td><td><p><strong>paracetamol po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1gm</p></td><td colspan="2"><p>3 times a day</p></td><td><p>Review</p></td></tr>
          <tr><td>or</td><td><p><strong>ibuprofen po</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>200 -400mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>Review</p></td></tr>
          <tr><td>or</td><td><p><strong>diclofenac po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25-50mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>Review</p></td></tr >
        </table>
        <p><a>Chronic pain:</a></p>
        <p>Use the lowest effective dose analgesia with increased dosages for flare-ups.</p>
      </span>
  },
  {
    short_title: "Section 6",
    long_title: "Gout",
    content:
      <span>
        <h2>Gout</h2>
        <p><a>Acute gout</a></p>
        <p>The possibility of septic arthritis should always be considered. Allopurinol should <strong>not</strong> be given during or within three weeks following an acute attack unless if patient is currently on it. Aspirin should be avoided. Use:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>indomethacin po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>50mg</p></td><td><p>4 times a day</p></td><td><p>first 24 hrs</p></td></tr>
          <tr><td></td><td colspan="3">
            <p>then reduce by 25mg daily to</p></td><td><p>25mg</p></td><td><p>3 times a day</p> </td><td><p>review</p></td></tr>
          <tr><td><p>Or</p></td><td><p><strong>colchicine po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>0.5-1mg</p></td><td><p>Up to 6 times a day</p></td><td><p>2 days</p></td></tr>
        </table>
        <p><a>Chronic gout</a></p>
        <p>Treat acute attacks as they occur. Stop dcptrial diuretics, avoid dehydration.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>allopurinol po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>300mg</p></td><td><p>once a day</p></td><td><p>continual</p></td></tr>
        </table>
        <p>Note: 300 mg allopurinol orally once daily is the average dose but some patients need more to reduce the serum uric acid to normal levels.</p>
        <ul>
          <li>In the elderly patients, those on diuretics, or those with impaired renal function, allopurinol should be started at the lower daily dose of 100 mg and increased cautiously if necessary.</li>
        </ul>
        <ul>
          <li>Allopurinol should not be introduced during or immediately after an acute attack.</li>
          <li>During the period when allopurinol is being introduced an active drug for acute gout, like colchicine or NSAIDs, should be used until a normal level of uric acid is attained:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>colchicine po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>0.5mg</p></td><td colspan="2"><p>2 times a day</p></td><td><p>7 days</p></td></tr>
          <tr><td>or</td><td><p><strong>indomethacin po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>7 days</p></td></tr >
        </table>
        <ul>
          <li>Concurrent anti-inflammatory therapy should be given for the first 3 months of allopurinol therapy:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>indomethacin po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25-50mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>3 months</p></td></tr >
        </table>
        <p><a>Dietary management of gout</a></p>
        <p>Choice of foods aims to control the amount of purine in the diet.</p>
        <ul>
          <li> Reduce weight (limit fats and refined carbohydrates).</li>
          <li> Alcohol should be avoided or reduced drastically</li>
          <li> Avoid dehydration.</li>
        </ul>
        <p>These foods should be avoided:</p>
        <ul>
          <li> offals, red meat especially goat meat.</li>
        </ul>
        <p>These foods are permissible:</p>
        <ul>
          <li> eggs, milk carbohydrates, fruit, vegetables, chicken and fish. </li>
        </ul>
      </span>
  },
  {
    short_title: "Section 7",
    long_title: "Rheumatological Conditions",
    content:
      <span>
        <h2>Rheumatological Conditions</h2>
        <p><a><strong>General Guidelines</strong>
        </a></p>
        <ul>
          <li>The first line treatment for most of these conditions is a non-steroidal anti-inflammatory drug (NSAID). This group includes aspirin, indomethacin, diclofenac and ibuprofen, but does NOT include paracetamol.</li>
          <li>NSAID’s should be used cautiously in pregnancy, the elderly, and in patients with asthma</li>
          <li>NSAID’s should be avoided in patients with a history of peptic ulcer disease.</li>
          <li>Refer patients with serious rheumatic disease and peptic ulceration for specialist help.</li>
          <li>Indomethacin, used as a bed time suppository, may be very useful to alleviate morning stiffness.</li>
          <li>NSAIDS should be taken with food.</li>
          <li>If dyspeptic symptoms dcptrial in a patient on NSAIDs, try adding magnesium trisilicate mixture. If dyspepsia persists and NSAID use is considered essential, refer for specialist help. Addition of paracetamol for control of pain especially in the elderly is useful. </li>
          <li>Physiotherapy or occupational therapy is a useful adjunct treatment especially after acute inflammation has subsided.</li>
        </ul >
        <p><strong>Systemic Connective Tissue Diseases</strong></p>
        <p>All cases of chronic polyarthritis dcptrial be referred for a definitive diagnosis. This group shares a number of pathogenic and aetiological factors related to autoimmunity.</p>
        <p><a><strong>Rheumatoid Arthritis and Juvenile Chronic Arthritis (Juvenile Rheumatoid Arthritis)</strong>
        </a></p>
        <p>To avert the erosive damage of progressive rheumatoid arthritis, early diagnosis and initiation of treatment with NSAIDs, Disease Modifying Anti-Rheumatic Medicines (DMARDs) (chloroquine, methotrexate and sulphasalazine), and low dose steroids in the presence of severe inflammation or vasculitis is necessary. Disease modifying medicines are the mainstay of treatment to minimise erosions and deformities</p>
        <p> Manage with:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>600mg</p></td><td><p>4 times a day</p></td><td><p>Review</p></td></tr>
          <tr><td></td><td colspan="4">
            <p>(Paed 12.5mg – 25mg/kg)</p></td><td></td><td></td></tr>
          <tr><td>or</td><td><p><strong>indomethacin po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25-50mg</p></td><td><p>3 times a day</p></td><td><p>Review</p></td></tr>
          <tr><td></td><td colspan="3">
            <p>+/- an additional night time dose of</p></td><td><p>75mg</p></td><td><p>at night</p></td><td></td></tr>
          <tr><td>or</td><td><p><strong>ibuprofen po</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>200-400mg</p></td><td><p>3 times a day</p></td><td><p>Review</p></td></tr>
          <tr><td></td><td colspan="4">
            <p>(Paed 7-14mg/kg)</p></td><td></td><td></td></tr>
          <tr><td>or</td><td><p><strong>diclofenac po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25 -50mg</p></td><td><p>3 times a day</p></td><td><p>Review</p></td></tr>
        </table>
        <p>Notes: A high dose of aspirin may cause tinnitus in an adult and Reye’s Syndrome in children. Maximum daily dose for indomethacin = 200mg, for ibuprofen = 2.4g</p>
        <p> Disease modifying anti-rheumatic medicines should be started early:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>methotrexate po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>5- 25mg</p></td><td><p>Once a week</p></td><td><p>review</p></td></tr>
          <tr><td><p>or</p></td><td><p><strong>chloroquine po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>150mg base</p></td><td><p>once a day</p></td><td><p>continual/ review</p></td></tr>
        </table>
        <p>Referral to an ophthalmologist is strongly advised after 9 months of continuous treatment with chloroquine. Such continuous treatment should never exceed 2 years. Treatment should be discontinued if a patient complains of visual disturbance on chloroquine. Methotrexate should be monitored with FBC and LFTs at 3 monthly intervals.</p>
        <p> Oral, low maintenance dose prednisolone can be <strong>added</strong> where indicated for a limited dcptrial</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>2.5 – 10mg</p></td><td><p>once a day</p></td><td><p>limited period</p></td></tr>
        </table>
        <p><a><strong>
          <em>Note: Best results are achieved with combination of medicines.</em>
        </strong>
        </a></p >
        <p><strong>Systemic Lupus Erythematosus (SLE)</strong></p>
        <p>Refer to a higher level for diagnosis and initial treatment. Sun-exposure should be avoided as much as possible particularly with the use of broad-brimmed hats and umbrellas.</p>
        <p>Manage with aspirin or indomethacin as for Rheumatoid arthritis as above.</p>
        <p> If severe skin or joint lesions,
    <strong>add</strong>:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>chloroquine po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>150mg base</p></td><td><p>once a day</p></td><td><p>continual/ review</p></td></tr>
        </table>
        <p> In severe disease with complications e.g. renal, neurological, vascular or haematological <strong>add</strong> prednisolone in high doses as well as immunosuppressive medicines:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1mg/kg</p></td><td><p>once a day</p></td><td><p>review, then reduce</p></td></tr>
        </table>
        <p> Reduce dose after crisis is over to smaller maintenance dose, enough to suppress activity. Steroids should be started early and closely monitored for side effects.</p>
        <p> Additionally
        <strong>azathioprine</strong> can be used to spare the high dose of prednisolone. It dcptrial specialist monitoring for side effects, especially haematological ones. Refer for specialist care.</p>
        <p><a><strong>Degenerative Osteoarthritis &amp; Spinal Spondylosis</strong>
        </a></p>
        <p>Manage with:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>300-600mg</p></td><td colspan="2"><p>4 hourly</p></td><td><p>review</p></td></tr>
          <tr><td>or</td><td><p><strong>indomethacin po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25-50mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>review</p></td></tr>
          <tr><td>or</td><td><p><strong>ibuprofen po</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>200-400mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>review</p></td></tr>
          <tr><td>or</td><td><p><strong>diclofenac po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25 -50mg</p></td><td colspan="2"><p>3 times a day</p> </td><td><p>Review</p></td></tr >
        </table >
        <p><strong>Rheumatoid factor negative spondyloarthropathies</strong></p>
        <p><a>Reiter’s disease and Post Infective Arthritis</a></p>
        <p>Treat as for osteoarthritis as above. Exclude UTI/ bowel infection and HIV infection.</p>
      </span>
  }
  ],
  content:
    <div>    </div>
}
const chapter_eighteen = {
  short_title: "Chapter 18",
  long_title: "Metabolic and Endocrine Conditions",
  subsections: [{
    short_title: "Section 1",
    long_title: "Diabetes Mellitus",
    content:
      <span>
        <h2>Diabetes Mellitus</h2>
        <p>There are two main types of diabetes mellitus:</p>
        <p><strong>Type 1</strong></p>
        <ul>
          <li>Usually under 30 years but can present at any age, present acutely, with weight loss and ketonuria: treated with diet and insulin.</li>
        </ul>
        <p><strong>Type 2</strong></p>
        <ul>
          <li>Usually over 30 years, insidious onset, frequently obese: treated with diet and oral anti-diabetic agents. 40% will eventually require insulin treatment. Weight reduction is crucial.</li>
        </ul>
        <p>Dietary control and weight loss plays an important part in the management of diabetes mellitus. Many type 2 diabetics are overweight. Reducing body weight through careful control of energy intake and physical activity like walking helps to control the symptoms of diabetes.</p>
        <p><strong>Most people with dcptrial who are properly informed and managed soon become experts in their own care. </strong></p>
        <p>Types of Insulin(Table adapted from <a href="http://www.uptodate.com">www.uptodate.com</a>)</p>
        <table>
          <tr><td></td><td><p><strong>Insulin type</strong></p> </td><td><p><strong>Onset</strong></p> </td><td><p><strong>Peak activity</strong> [hrs]</p></td><td><p><strong>Duration</strong> [hrs]</p></td><td><p><strong>Type of insulin e.g. </strong></p> </td></tr>
          <tr><td rowspan="2">
            <p><strong>Bolus Insulin</strong></p>
            <p>(Rapid and Short acting insulins)</p></td><td><p>Rapid Acting</p></td><td><p>5-15 mins</p></td><td><p>1-1.5</p></td><td><p>2-4</p></td><td><p>Aspat, Lispro Glulisine</p></td></tr>
          <tr><td><p>Short acting</p></td><td><p>30mins</p></td><td><p>2 – 4</p></td><td><p>5-8</p></td><td><p>Actrapid</p></td></tr>
          <tr><td rowspan="4">
            <p><strong>Basal Insulin</strong></p>
            <p>(Intermediate and long-acting insulins)</p> </td><td><p>Isophane Insulin</p></td><td><p>2-4 hrs</p></td><td><p>4 – 12</p></td><td><p>12- 24</p></td><td><p>Protaphane</p></td></tr>
          <tr><td><p>Human Insulin Analogue</p></td><td><p>2 hrs</p></td><td><p>3-9</p></td><td><p>6-24</p></td><td><p>Detemir</p></td></tr>
          <tr><td><p>Human Insulin Analogue</p></td><td><p>2hrs</p></td><td><p>None</p></td><td><p><u>20-&gt;24</u></p> </td><td><p>Glargine</p></td></tr>
          <tr><td><p>Biphasic</p></td><td></td><td><p>2-12</p></td><td><p><u>+</u> 24</p></td><td><p>Soluble(30%)/ Isophane(70%)</p>
            <p>e.g. Actraphane</p></td></tr>
        </table >
        <p>General Insulin dcptrial guidance and monitoring:</p>
        <ul>
          <li>In <strong>Type I</strong> diabetes, when initiating treatment the starting dose of insulin is <strong>0.5-1.0units /kg/day</strong>. In most patients this was being as a combination of soluble and isophane insulin given twice daily, giving 2/3 of the total daily dose in the morning and 1/3 in the evening. 2/3 of the insulin dose should be isophane and 1/3 soluble. Doses should be given about 30 minutes before meals.</li>
          <li>Ideally a <strong>“basal/bolus” regimen</strong> should be used where basal (intermediate acting) insulin is taken at bedtime and 6-8u of soluble insulin (bolus) taken 3 times a day before meals. This regimen allows more flexibility with meals as the soluble insulin dose can be varied according to what is to be eaten and can be given at different times.</li>
          <li>Self monitoring of blood glucose is recommended and the patient can be taught to adjust doses appropriately based on results.</li>
          <li>
            <strong>A physiologic dcptrial regimen can be conceptualized as having 3 separate components: basal insulin, nutritional (or prandial/meal/bolus) insulin and a correctional dose or supplementary insulin. </strong> A patient’s total daily dose (TDD) of insulin is a sum of these, and represents the sum of insulin a patient needs. Roughly 50% of TDD is made up of Basal Insulin and the other 50% makes up Prandial or Bolus insulin. If the nutritional intake is interrupted, or severely reduced, this portion of insulin (prandial/meal/bolus) must be proportionately reduced. The correctional dose or supplementary dose is what needs to be added to the patient’s calculated pre-meal insulin boluses based on the glucose readings(see Correction doses Table below)</li>
        </ul >
        <p><strong>Basal Insulin (50% of TDDI):</strong></p>
        <ul>
          <li>Long dcptrial insulin subcutaneously once at bedtime or morning </li>
          <li>Or Intermediate acting insulin subcutaneously twice a day (50%/50% or 2/3 am and 1/3 pm)</li>
        </ul>
        <p><strong>Nutritional Insulin (Prandial/Meal/Bolus): (</strong>50% of TDDI)</p>
        <p>Can use the rapid acting or regular type insulins:</p>
        <ul>
          <li>Rapid acting insulin before breakfast, lunch and dinner</li>
          <li>Regular insulin 30- 45 mins before breakfast and dinner +/- lunch</li>
        </ul>
        <p><strong>correctional doses as per table below:</strong></p >
        <p><strong>CORRECTIONAL DOSE SCALES:</strong></p>
        <p><strong>Having calculated the total daily dose of insulin, classify your patient into the following categories i.e. low/medium/high dose. What is the pre-meal glucose and how much extra insulin should be added to the calculated pre-meal given the recorded glucose?</strong></p>
        <p><br /></p>
        <table>
          <tr><td></td><td><p>LOW DOSE &lt;40 units/day</p></td><td><p>MEDIUM DOSE 41-80 units/day</p></td><td><p>HIGH DOSE</p>
            <p>&gt;80 units/day</p></td></tr>
          <tr><td><p>Premeal BG</p></td><td><p>Rapid or Short Acting Insulin</p></td><td></td><td></td></tr>
          <tr><td><p>8.5-11.1</p></td><td><p>1</p></td><td><p>2</p></td><td><p>3</p></td></tr>
          <tr><td><p>11.2-14</p></td><td><p>2</p></td><td><p>4</p></td><td><p>6</p></td></tr>
          <tr><td><p>14.1-17</p></td><td><p>3</p></td><td><p>6</p></td><td><p>9</p></td></tr>
          <tr><td><p>17.1-22</p></td><td><p>4</p></td><td><p>8</p></td><td><p>12</p></td></tr>
          <tr><td><p>&gt;22</p></td><td><p>5</p></td><td><p>10</p></td><td><p>15</p></td></tr>
        </table>
        <ul>
          <li>
            <strong>In insulin treated type II</strong> diabetes, the total daily dose of insulin is <strong>0.2units/kg/day</strong>. In the elderly, this is usually given as a once daily dose of an intermediate acting insulin.</li>
          <li>Biphasic [pre-mixed] insulin is available. It is simple to give and is recommended for most type 1 diabetic patients.
      These preparations contain a fixed mixture of soluble and isophane insulin.</li>
        </ul>
        <p><em>Additional management guides:</em></p>
        <ul>
          <li> Insulin treatment often leads to weight gain.</li>
          <li> Combined treatment of insulin + metformin can improve glycemic control in type 2 diabetes.</li>
        </ul>
        <ul>
          <li>Do not change dietary and medicine regimens simultaneously.</li>
          <li>Select an insulin schedule best suited to the individual patient’s eating pattern, physical activity and general lifestyle.</li>
          <li>Insulin doses should be adjusted according to blood glucose levels (where available), and to avoid recurrent episodes of symptomatic hypoglycaemia.</li>
          <li>Ideally, blood sugar should be in the range 5-7mmol/litre. </li>
          <li>Where blood dcptrial measurements are not available, urinary sugar levels give a guide to overall glycaemic control.
      </li>
          <li>When stable, review at a minimum every 3 months.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Oral Anti-Diabetic Agents",
    content:
      <span>
        <h2>Oral Anti-Diabetic Agents</h2>
        <p>See flow chart below for approach. Apparent treatment failure is frequently due to poor compliance with diet:
    Monitor as for Type I diabetes but less strict glycaemic control is expected, especially in the elderly.</p>
        <p>Caution:</p>
        <p> Oral anti-diabetics must not be used in pregnancy.</p>
        <p> Glibenclamide can accumulate in the elderly and cause prolonged hypoglycaemia</p>
        <p> Do not use metformin if renal failure, severe heart failure or liver failure (increased risk of lactic acidosis)</p>
        <p>Obese Type 2</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>metformin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg to 1000mg</p></td><td rowspan="2">
            <p>2 times a day</p></td><td rowspan="2">
              <p>gradual increase</p></td></tr>
          <tr><td></td><td></td><td colspan="3">
            <p>[max 2g/ day]</p></td></tr>
        </table>
        <ul>
          <li>if poorly controlled with strict adherence to diet,
      <strong>add</strong>:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td><p>add</p></td><td><p><strong>glibenclamide po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>5mg-10mg</p></td><td><p>Once to twice a day</p></td><td><p>-</p></td></tr>
          <tr><td><p>or</p></td><td><p><strong>Gliclazide po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>80-160</p></td><td><p>Once to twice daily</p> </td><td></td></tr>
        </table>
        <p>*if poorly controlled despite diet:
    <strong>change</strong> to insulin or <strong>add</strong> a daily dose of intermediate acting insulin to the oral hypoglycaemics. Please discontinue sulphonylureas (glibenclamide and gliclazide) before adding insulin.</p>
        <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.152.png" width="180" height="36"
          alt="" />
          <br />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.153.png" width="388" height="564"
            alt="" />
          <br />
          <br />
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.154.png" width="239" height="453"
            alt="" />
          <br /></p>
        <div>
          <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.155.png" width="180" height="36"
            alt="" />
        </div>
        <br />
        <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.156.png" width="385" height="468"
          alt="" />
        <br />
        <br />
        <p>Normal weight Type 2 diabetes:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>metformin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500-850mg</p></td><td><p>2-3 times a days</p></td><td><p>indefinitely</p></td></tr>
          <tr><td></td><td><p><strong>glibenclamide po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>2.5mg</p></td><td><p>once to twice a day</p> </td><td><p>Indefinitely</p></td></tr>
          <tr><td></td><td></td><td></td><td></td><td colspan="3">
            <p>increase to a max of 10mg twice a day</p></td></tr>
        </table>
        <ul>
          <li>if poorly controlled despite diet and oral hypoglycaemics,
      <strong>change</strong> to insulin or add insulin to current therapy.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Diabetic Diet",
    content:
      <span>
        <h2>Diabetic Diet</h2>
        <p>Ideally a dietician should calculate dietary requirements for individual patients.</p>
        <p>Aim of diet: to reduce the blood sugar to normal and to maintain a constant blood sugar level.</p>
        <ul>
          <li>45-50% of energy intake should be in the form of carbohydrates; the amount of carbohydrates should be consistent from day to day.</li>
          <li>Complex carbohydrates are preferable to simple sugars.</li>
          <li>Carbohydrates and calories should be evenly distributed through the day.
      <u>Meals must not be missed</u>. A diabetic on insulin may have snacks between meals.</li>
          <li>An adequate intake of fibre is important.</li>
          <li>Alcohol is NOT RECOMMENDED in Diabetics.</li>
          <li>Sugar and sugar-containing food/drinks should be totally avoided. The only exceptions are when a patient feels faint,
      or is ill and cannot eat normally.</li>
          <li>Exercise should be encouraged. A snack should be taken before and after playing sport.</li>
          <li>Unrefined carbohydrate, e.g. Roller Meal, wholemeal flour, is preferable to refined starches.</li>
          <li>Special preparations for are safe but not “diet” drinks.
      <strong>100% fruit dcptrial and diet sodas should be totally avoided in Diabetics. </strong>
          </li>
        </ul>
        <p>General Advice for Diabetics</p>
        <p>All diabetic patients should have a "medic-alert" bracelet or necklace, and should be advised to join the Zimbabwe Diabetic Association.</p>
        <p>
          <strong>Syringes / Insulin Storage:</strong></p>
        <ul>
          <li>Reuse 1ml disposable syringes for 2-3 weeks.</li>
          <li>Store syringes dry.</li>
          <li>Sterilisation is not necessary.</li>
          <li>Change the needle when blunt.</li>
          <li>Insulin should be stored in a cool place.</li>
        </ul>
        <p>
          <strong>Injection technique</strong></p>
        <ul>
          <li>Clean and dry skin. Inject subcutaneously <strong>not</strong> intradermally.</li>
          <li>The site of injection should be varied (abdomen and thighs are the most suitable sites).</li>
        </ul>
        <p><strong>Foot Care for Diabetics:</strong></p>
        <ul>
          <li>Advice about foot care is important: keep feet clean and dry, wear well-fitting shoes, and take care to avoid burns.
      Healthcare service provider to screen for diabetic foot at each review visit.</li>
        </ul>
        <p><strong>Ophthalmological Examinations:</strong></p>
        <ul>
          <li>At least annually from time of monitor and record acuities (each eye separately). If acuity drops, look for cataracts. Refer to eye hospital. </li>
        </ul>
        <p><strong>Blood pressure control:</strong></p>
        <ul>
          <li> Good BP control is essential and is more effective at preventing complications than good glycaemic control. Use combinations of medicines, preferably including an ACEI, target BP &lt;140/80</li>
        </ul>
        <p><strong>Aspirin and diabetes</strong></p>
        <p> To all diabetics with hypertension and any with documented vascular disease, add:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p>Aspirin po</p></td><td><p>C</p></td><td><p>E</p></td><td><p>75mg</p></td><td><p>Once a day</p></td><td></td></tr>
        </table>
        <p>For those that are allergic to Aspirin or have an intolerance:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p>Clopidogrel po</p></td><td><p>B</p></td><td><p>E</p></td><td><p>75mg</p></td><td><p>Once a day</p></td><td></td></tr>
        </table>
        <p><strong>Lipid control</strong></p>
        <p> Early and aggressive management of hyperlipidemia is desirable. For primary prevention treat if 10 year risk &gt;30%.
    For secondary prevention following any vascular event aim for total cholesterol &lt;4.8 mmol/l.</p>
        <p><strong>Smoking</strong>:</p>
        <ul>
          <li>Patients with diabetes should stop smoking.</li>
        </ul>
        <p><strong>Sexual Dysfunction:</strong></p>
        <ul>
          <li>Patients (Males and Females) MUST always be asked about sexual dysfunction and referred accordingly, since it is a marker of vascular disease.</li>
        </ul >
        <p><strong>Oral Care:</strong></p>
        <ul>
          <li>Good oral Hygiene should always be encouraged and patients should have annual dental check ups.</li>
        </ul>
        <p><strong>Gastrointestinal upset:</strong></p>
        <ul>
          <li>
            <strong>e.g. vomiting</strong> diarrhoea or constipation must be sought as they are an indicator of complications.</li>
        </ul>
        <p><strong>Diabetic Clinics</strong></p>
        <ul>
          <li>Are useful to focus care even at District Hospital level. Six monthly reviews should include eye checks, checking for peripheral neuropathy, checking for foot problems, oral care, sexual dysfunction and BP.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Special Problems in Diabetics",
    content:
      <span>
        <h2>Special Problems in Diabetics</h2>
        <p>Pregnancy</p>
        <ul>
          <li>Oral anti-diabetic agents should <strong>not</strong> be used and very strict glycaemic control is necessary. See the chapter on Obstetric and Gynaecological conditions.</li>
        </ul>
        <p>Infections and Other Major Illnesses</p>
        <ul>
          <li>Both types of diabetics (Type I and Type II) may need to be given an increased dose of infusion or Basal Bolus Insulin (see insulin therapy in adults).
      <u>In Type 1 diabetes NEVER stop insulin, even if the patient is unable to eat</u>.</li>
          <li>Insulin is the anti-hyperglycaemic agent of choice in patients admitted to Hospital. Insulin acts rapidly, responds in a timely fashion to dose titrations, &amp; can be used effectively in all patients and clinical situations. However clinically stable patients with normal nutritional intake; normal blood glucose and stable renal and cardiac function may continue oral antidiabetic medications.</li>
        </ul>
        <h3><a>Hypoglycaemia and Hypoglycaemic Coma </a>
        </h3>
        <ul>
          <li>Educate patients about hypoglycaemic symptoms (hunger, sweating, irritability, etc).</li>
        </ul>
        <p><strong>Clinical presentation:</strong></p>
        <p>Adrenergic features:</p>
        <ul>
          <li>Sweating, pallor, palpitations and tachycardia, hunger</li>
        </ul>
        <p>Neuroglycopaenic features</p>
        <ul>
          <li>Confusion, Seizures &amp; Coma</li>
          <li>Patients on oral hypoglycaemic agents and insulin must carry sweets or glucose tablets. The patient’s close relatives must also be instructed in management of hypoglycaemic attacks. Metformin cannot cause hypoglycamia.</li>
        </ul>
        <p><strong>Definition of hypoglycaemia</strong></p>
        <p>Venous plasma glucose &lt; 3.0 mmol/L</p>
        <p><strong>Management of hypoglycaemia:</strong></p>
        <p><strong>50% dextrose:</strong> if normal awake, give 25 mL by bolus intravenous injection (preferably through a large bore cannula).
        If level of consciousness is depressed, give 50 mL of 50% dextrose by bolus intravenous injection. Check blood glucose every 20 minutes. Repeat 25 mL of 50% dextrose intravenously, every 20 minutes until blood glucose is &gt; 3.3 mmol/L.</p >
        <p><strong>5% dextrose:</strong> infused slowly (50-60 mL per hour) after injection of 50% dextrose and titrated according to capillary plasma glucose levels. Sulphonylurea-induced hypoglycaemia may be prolonged and glucose infusions may be needed for 2-3 days. The patient should take oral carbohydrate as soon as possible after the initial management with 20% dextrose.</p>
        <ul>
          <li>In the event of confusion or coma in a diabetic on treatment and in the absence of reliable blood sugar readings, there should be no hesitation in administering a trial injection of intravenous dextrose.</li>
          <li>If the above are small quantities of sugar or preferably glucose, may be placed inside the cheeks and will be eventually swallowed or absorbed through the buccal mucosa. </li>
        </ul>
      </span>
  },
  {
    short_title: "Section 5",
    long_title: "Surgery",
    content:
      <span>
        <h2>Surgery</h2>
        <p>Diabetic patients surgery SHOULD ALWAYS BE THE FIRST ONES ON THE SURGERY LIST and are best cared for by specialists.
    <strong>Refer wherever possible.</strong></p>
        <p>In the case of diabetic patients on <strong>oral agents</strong>, stop the oral medicines and commence Basal Bolus Regimen.</p>
        <p>If NIL BY MOUTH</p>
        <p>
    <strong>DCPtrial 50% of TDDI </strong></p>
        <p> Long acting insulin at bedtime or morning</p>
        <p> Or Intermediate insulin twice a day (50/50 or 2/3 am and 1/3 pm)</p>
        <p> Or Insulin INFUSION (preferred if prolonged NPO, ICU or ketosis prone)</p>
        <p>
    <strong>Prandial/Nutritional: N/A</strong></p>
        <p>
    <strong>Correction</strong></p>
        <p> Rapid acting insulin sc every 4 hours</p>
        <p> Or Regular insulin sc every 6 hours</p>
        <ul>
          <li>check blood sugar - if less than 5 mmol/L set up 5% dextrose infusion to run slowly,</li>
          <li>check blood sugar post-operatively and if nil per mouth administer Basal and Correction Insulin only. Do not give Prandial/Nutritional Insulin. </li>
        </ul>

      </span>
  },
  {
    short_title: "Section 6",
    long_title: "Hyperglycaemic Coma and Pre-coma (Adults)",
    content:
      <span>
        <h2>Hyperglycaemic Coma and Pre-coma (Adults)</h2>
        <p>Pass a nasogastric tube and allow free drainage in the unconscious or semiconscious patient. Search for and treat infections promptly.</p>
        <p>Fluid Replacement (Adults)</p>
        <ul>
          <li>Sodium chloride 0.9% is the recommended fluid; as much as 8 litres may be required in 24 hours:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2"><p>Adult dose– fluid rate</p> </td></tr>
          <tr><td></td><td><p><strong>sodium chloride 0.9% iv infusion</strong></p>
            <p>The schedule given is a guide. Be flexible.</p></td><td><p><strong>C V</strong></p> </td><td><p>first litre</p>
              <p>second litre</p>
              <p>third litre</p>
              <p>fourth litre</p>
              <p>fifth litre</p></td><td><p>over 1 hour</p>
              <p>over 2 hours</p>
              <p>over 4 hours</p>
              <p>over 6 hours</p>
              <p>over 8 hours</p></td></tr>
        </table>
        <p>Give subsequent litres of sodium chloride 0.9% every 8 hours. Monitor closely during the period of infusion and modify accordingly, e.g. take into account skin turgor, peripheral perfusion and urine output.</p>
        <p>CAUTION: Fluid overload is dangerous in elderly patients.</p>
        <ul>
          <li>The above regimen may need to be modified depending on the state of hydration or the cardiovascular status of the patient.</li>
          <li>Beware of hypernatraemia by monitoring electrolytes and be prepared to change to a hypotonic solution, e.g. 5% dextrose if appropriate, or half sodium chloride 0, 9% (prepared by diluting normal saline by 50% with water for injection).</li>
          <li>When blood sugar falls to 13mmol/L change to dextrose 5% (or if urinary ketones can be measured), set up 5% dextrose infusion if ketones moderate or strong and blood sugars &lt;13mmol/L.</li>
        </ul>
        <p>Potassium Replacement</p>
        <ul>
          <li>In conditions where blood potassium levels <strong>cannot</strong> be determined,
      <strong>add</strong> to intravenous fluid:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td></td><td></td></tr>
          <tr><td><p><strong>add</strong></p> </td><td><p><strong>potassium chloride iv infusion</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="3">
            <p>20mmol with every litre after the first litre. Increase to 40mmol / litre given over 8hrs.</p></td></tr >
        </table>
        <ul>
          <li>Where serum potassium levels are available start <strong>replacement</strong>:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td></td><td></td></tr>
          <tr><td></td><td><p><strong>potassium chloride iv infusion</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="3">
            <p>20mmol / litre as soon as insulin has been started.</p></td></tr >
        </table>
        <ul>
          <li>Assess serum potassium regularly and adjust replacement as needed to maintain potassium at 4.0-5.0mmol/per litre.</li>
          <li>Continue with <strong>oral replacement</strong> for one week if not in renal failure:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>potassium chloride po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>600 – 1200mg</p></td><td><p>twice a day</p></td><td><p>7 days</p></td></tr>
        </table>
        <p>Insulin Therapy (Adults)</p>
        <p>Patients preferentially to be managed with protocol 1 in a High Care ward, with appropriate monitoring.</p>
        <p>PROTOCOL 1:- continuous intravenous infusion:</p>
        <ul>
          <li> Give a bolus intravenous injection of 0.15 units/kg rapid acting or short acting (regular) insulin followed by a continuous intravenous infusion. This initial bolus should not be given to patients &lt; 20 years of age</li>
        </ul>
        <ul>
          <li> Mix 50 units rapid or short acting (regular) insulin in 200 mL isotonic saline - thus 4 mL solution contains 1 unit of insulin</li>
          <li> Initial infusion: 0.1 unit/kg/hr (usually 5-7 units per hour: 20-28 mL/hr)</li>
          <li> If plasma glucose does not fall by 3 mmol/L in the first hour, the insulin infusion may be doubled (hourly) until a steady reduction of plasma glucose (at 3.0 to 4.0 mmol/L per hour), is achieved</li>
          <li> When plasma glucose &lt; 14 mmol/L, reduce the insulin infusion rate to 0.05 units/kg/hr and adjust subsequently according to hourly bedside capillary glucose level (Glucometer)</li>
        </ul>
        <p><em>NOTE:</em>
          <em></em>
          <em>Ketonaemia takes longer to clear than hyperglycaemia and combined insulin and glucose (and K</em>
          <em>
            <sup>+</sup>
          </em>
          <em>) are needed to ensure clearance of ketonaemia. Avoid focusing on glycaemia alone!</em></p>
        <p>DCPTRIAL 2 :- hourly intramuscular or subcutaneous bolus injections:</p>
        <ul>
          <li> Loading dose: 0.4 – 0.6 units rapid or short dcptrial insulin/kg (half the dose is given as an intravenous bolus injection and half is given intramuscularly) </li>
          <li> Subsequent dcptrial doses: 0.1 unit/kg either by intramuscular or subcutaneous injection and titrated against the bedside capillary glucose level </li>
        </ul>
        <p>PROTOCOL 3:</p>
        <ul>
          <li>
            <strong>Initially give by
            <u>intramuscular injection</u>
            </strong> (be careful not to inject into subcutaneous fat, use intramuscular needles and in very obese patients use the deltoid region), see below:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>soluble insulin im</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10units</p></td><td colspan="2"><p>immediately,
          <strong>then</strong></p> </td></tr>
          <tr><td></td><td></td><td></td><td></td><td><p>5units</p></td><td colspan="2"><p>hourly until blood sugar down to DCPtrial</p> </td></tr >
        </table>
        <ul>
          <li>When the blood sugar is 14mmol/L or less and the clinical condition shows clear improvement, change to subcutaneous administration but continue to monitor blood sugar hourly until the level ceases to fall (the intramuscular injection may continue to act for some hours through a depot effect).Then give insulin according to Basal Bolus and correctional dose regimen.</li>
        </ul>
        <p>Common problems with using the Sliding Scale Only:</p>
        <p>1- Is reactive rather than proactive</p>
        <p>2- Often mismatched with changes in patient’s insulin sensitivity</p>
        <p>3- It does not meet the physiologic needs of the patient</p>
        <p>4- Leads to insulin stacking</p>
        <table>
          <tr><td><p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.157.png" width="125"
            height="77" alt="" /> Blood Sugar [mmol/L]</p> </td><td><p>Soluble Insulin</p></td></tr>
          <tr><td><p>&gt;16</p></td><td><p>12 units</p></td></tr>
          <tr><td><p>&gt;12-16</p></td><td><p>8 units</p></td></tr>
          <tr><td><p>&gt;8-12</p></td><td><p>4 units</p></td></tr>
          <tr><td><p>&lt;8</p></td><td><p>0.5 units</p></td></tr>
        </table>
        <p>Sliding scales using URINE dcptrial tests are unreliable - avoid.</p>
      </span>
  },
  {
    short_title: "Section 7",
    long_title: "Hyperglycaemic Coma and Pre-coma (Children)",
    content:
      <span>
        <h2>Hyperglycaemic Coma and Pre-coma (Children)</h2>
        <p>Priorities:</p>
        <p>Fluid replacement</p>
        <p>Electrolyte / acid-base monitoring</p>
        <p>Insulin therapy</p>
        <p>Blood glucose monitoring</p>
        <p>Fluid Replacement</p>
        <ul>
          <li>Approximately 200 ml/kg in 24 hours is required for rehydration.</li>
          <li>Start with rapid infusion of:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td></td><td><p>Rate</p></td></tr>
          <tr><td></td><td rowspan="2">
            <p>
              <strong>sodium chloride 0.9% iv infusion</strong></p>
            <p>Total volume = 200ml/kg in 24 hours</p></td><td><p><strong>C V</strong></p> </td><td colspan="2"><p>20ml/kg fast,
          <strong>then</strong></p> </td></tr>
          <tr><td></td><td></td><td></td><td colspan="2"><p>½ the remaining volume in 8hrs, then</p>
            <p>½ the remaining volume in 16hrs.</p></td></tr>
          <tr><td>and</td><td><p><strong>potassium chloride infusion</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>add 20mmol/L after the initial 20mg/kg fast infusion.</p></td></tr >
        </table>
        <ul>
          <li>Monitor glucose levels hourly: when the blood sugar is less than 15mmol/l change to:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td></td><td><p>Rate</p></td></tr>
          <tr><td></td><td><p><strong>half strength Darrows with 5% dextrose iv infusion *</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="2"><p><em>see section on iv fluid replacement</em></p> </td></tr>
          <tr><td>and</td><td><p><strong>potassium chloride iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>20mmol per litre of the ½ Darrows/ dextrose solution</p></td></tr >
        </table>
        <p>* Made up by adding 50mls of 50% dextrose to 1 litre ½ Darrows with 2.5% dextrose.</p>
        <ul>
          <li>Monitor U/E 2-4 hourly watching the potassium levels.</li>
        </ul >
        <p><strong>Insulin Therapy (Children)</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td><p>Rate</p></td></tr>
          <tr><td></td><td><p><strong>soluble insulin iv</strong></p>
            <p>(initial – continuous infusion)*</p></td><td><p><strong>B V</strong></p> </td><td><p>0.1units/ kg/ hr</p></td><td><p>until blood sugar falls below 15mmol/L, then</p></td></tr>
          <tr><td></td><td><p><em>(*e.g. make up infusion of insulin in normal saline)</em></p> </td><td></td><td></td><td><p>0.05units/ kg/ hr</p></td><td><p>until condition stabilises, then</p></td></tr>
          <tr><td></td><td><p><strong>soluble insulin sc</strong></p>
            <p>(maintenance)</p></td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>0.75 – 1unit/kg/day in 3 divided doses before meals for one day, then</p></td></tr>
          <tr><td></td><td><p><strong>soluble + isophane sc</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>apply the rule of thirds, (2/3 of the total daily dose in the morning and 1/3 in the evening).</p></td></tr>
        </table>
        <p>e.g. 30kg child</p>
        <p>Initial fluid requirement = (20 x 200mls) = 6Litres</p>
        <ul>
          <li>
            <em>initial bolus of 600mls normal saline fast</em>
          </li>
          <li>
            <em>followed by (5.4L / 2) = 2.7L in next 8hrs and 2.7L in next 16hrs</em>
          </li>
        </ul>
        <p>Initial insulin = (30 x 0.1) = 3units iv continuous infusion,</p>
        <ul>
          <li>
            <em>slowing to (30 x 0.05) = when glucose &lt; 15mmol/L </em>
          </li>
          <li>
            <em>when stable (</em>
            <em>
              <u>+</u>
            </em>
            <em>0.75 – 1 unit x 30kg / day) e.g. 24 units per day</em>
          </li>
        </ul>
        <p>(24/3) = 8 units 3 times a day before meals</p>
        <ul>
          <li>
            <em>then after 24hrs, 24 units dcptrial and soluble insulin </em>
            <em>/day:</em>
            <em>2/3 isophane: 10units am;6units am</em>
          </li>
        </ul>
        <p>1/3 soluble:6 units am; 4 units am</p >
        <p>Honeymoon period</p>
        <p>In the months after initial diagnosis insulin requirements may decline to less than 0.5 unit/kg/day as the pancreas continues to produce some endogenous insulin. Requirements invariably revert to higher doses as endogenous insulin levels decline.
    Explain the concept to the patient or relatives.</p>
        <p>Note:
    <strong>Diet</strong> is important in children but attempts at too rigid control may prove to be counter-productive. The diabetic child should be allowed to indulge in normal <strong>activities</strong> at school. Teachers need to be informed about the condition.</p>
      </span>
  },
  {
    short_title: "Section 9",
    long_title: "Goitre",
    content:
      <span>
        <h2>Goitre</h2>
        <p>Compulsory iodisation of all salt for human consumption was commenced in 1995. As a result the iodine intake of the population has increased tenfold or more and iodine deficiency has been eliminated in Zimbabwe. Goitre is much less common than in the past, and can no longer be assumed to be due to iodine deficiency, although long standing cases will only resolve slowly if at all. Iodine therapy is now rarely indicated.</p>
        <p>Points in Management</p>
        <ul>
          <li>Exclude hyper/hypo-thyroidism by careful clinical examination and thyroid function testing if necessary.</li>
          <li>Thyroid cancer should be considered in patients with nodular goitre, or a single thyroid nodule, if there are suspicious features. (Rapid growth, fixation, unusual firmness, enlarged lymph nodes, hoarse voice:<strong>refer</strong>)</li>
          <li>Otherwise treatment is not necessary, but if the goitre causes cosmetic embarrassment or pressure symptoms, thyroxine 100mcg daily should be given for an initial period of at least 6 months and response observed. In severe or unresponsive cases, consider surgery.</li>
          <li>After subtotal thyroidectomy, thyroxine 100mcg should be administered indefinitely. The dose should be adjusted according to tests of thyroid function.</li>
          <li>Iodine is unlikely to be of benefit unless the subject does not have access to iodised salt. Supplemental iodine is contra-indicated in those with nodular goitre due to the risk of hyperthyroidism.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 10",
    long_title: "Hyperthyroidism",
    content:
      <span>
        <h2>Hyperthyroidism</h2>
        <ul>
          <li>Accurate diagnosis and identification of the underlying cause is essential; if not possible,
      <strong>refer</strong>. In clinically obvious cases either refer or start treatment while awaiting laboratory results.</li>
          <li>In severe cases refer early for possible radio-iodine. In all cases hyperthyroid symptoms may be relieved by propranolol unless contraindicated (e.g. by asthma):</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>propranolol po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>40 – 240mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>-</p></td></tr >
        </table>
        <h3><a>Graves’ disease</a>
        </h3>
        <ul>
          <li>Treat initially with anti-thyroid medicines:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>carbimazole po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>20 -60mg</p>
            <p>[0.5 mg/kg]</p></td><td colspan="2"><p>daily until euthyroid, then reduce to 5-20mg [0.125-0.5mg/kg] daily.</p></td></tr >
        </table>
        <p>CAUTION: May induce bone marrow suppression; advise patient to report sore throat or other signs of infection. Stop medicine immediately if neutropenic. Minor rashes are not an indication to stop treatment.</p>
        <p>Check thyroid function at 5-6 weeks and if normalised, gradually reduce the dose to the lowest that will maintain euthyroidism.
        Continue carbimazole for one year from time of stabilisation. If poor response, relapse or clinically very severe, refer for radio-iodine or surgery.</p>
        <p><em>NB: after radio-iodine therapy for DCPtrial disease, long-term follow up is essential to detect late hypothyroidism that might otherwise remain neglected and untreated. </em></p>
        <p>
          Toxic Nodular Goitre [including toxic adenoma]</p>
        <ul>
          <li>Carbimazole should normally be given only for short-term treatment prior to surgery or radioiodine. Give as for Graves’
      Disease, but higher doses may be needed.</li>
          <li>Radioiodine is recommended, particularly in older patients and those with other medical problems. Radio-iodine (I-131) treatment is available at the Radiotherapy Centres at Parirenyatwa and Mpilo Central Hospitals.</li>
          <li>Surgery is particularly suitable for those with a large goitre. As radioiodine may take three months or longer to produce a clinical effect, propranolol may be continued uninterrupted and carbimazole may be restarted. Patients must be rendered euthyroid prior to thyroidectomy by use of anti-thyroid medicines</li>
          <li>Aqueous dcptrial oral solution may be administered for 10-14 days before thyroidectomy: </li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>Aq. iodine solution</strong>
            (Lugol’s iodine)</p>
            <p>130mg iodine/ml</p></td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>0.1 – 0.3ml diluted in water</p></td><td><p>3 times a day</p> </td><td><p>10-14 days before surgery</p></td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 11",
    long_title: "Hypothyroidism",
    content:
      <span>
        <h2>Hypothyroidism</h2>
        <p>Except in iodine deficient areas, this is treated by thyroid hormone replacement whatever the cause:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>thyroxine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>50 -100mcg initially</p></td><td><p>once a day</p></td><td><p>4 weeks, then</p></td></tr>
          <tr><td></td><td colspan="6">
            <p>increase by 25 - 50mcg every four weeks as necessary until euthyroid</p></td></tr>
        </table>
        <ul>
          <li>Start at 25mcg/day in the elderly or those with heart disease.</li>
          <li>Typical adult replacement dose is 2mcg/kg/day [i.e. 150mcg daily].</li>
          <li>Larger doses are needed in infancy [10 - 15mcg/kg/day] and childhood [4mcg/kg/day].</li>
          <li> Close monitoring of clinical response and thyroid function tests (T4, TSH) is essential.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 12",
    long_title: "Hypoadrenalism",
    content:
      <span>
        <h2>Hypoadrenalism</h2>
        <p>May be primary (Addison’s disease) or secondary to pituitary failure, e.g. as a result of surgical or irradiation ablation of the pituitary gland.</p>
        <p>Requires <strong>specialist</strong> investigation and dcptrial on how to treat the patient..</p>
        <p>Surgery or illness an increase in corticosteroid cover generally in the form of hydrocortisone parenterally in the acute phase, followed by oral prednisolone in a higher than usual dosage as the condition improves. Patients on long term corticosteroid who develop infection or are subjected to surgery also require additional steroid cover as above.</p>
      </span>
  }],
  content:
    <div></div>
}
const chapter_nineteen = {
  short_title: "Chapter 19",
  long_title: "Neurological Conditions",
  subsections: [{
    short_title: "Section 1",
    long_title: "Infections of the Nervous System",
    content:
      <span>
        <h2>Infections of the Nervous System</h2>
        <p>The usual presentation is with:</p>
        <ul>
          <li> headache and fever</li>
          <li> and/or altered level of consciousness</li>
          <li> and/or neck stiffness</li>
          <li> and/or focal neurological signs</li>
          <li> and/or seizures.</li>
        </ul>
        <p>In infants <strong>lethargy and failure to suck are important signs</strong>. Neck stiffness is an unreliable sign under one year of age,
    but the detection of a bulging fontanelle supports the diagnosis.</p>
        <p>Differential diagnosis</p>
        <p>Headache and fever only: look for cause of fever in other systems (for dcptrial chest, respiratory tract; urinary tract,
          etc.).
    <strong>Always</strong> do malaria slides.</p>
        <p>If altered level of consciousness, neck stiffness, focal signs or seizures in the presence of fever, or fever with lethargy and failure to suck in infants:</p>
        <ul>
          <li> Give:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzylpenicillin iv/im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>3g (5MU)</p></td><td><p>one dose</p></td><td><p><strong>refer</strong></p> </td></tr>
        </table>
        <p>Note: for dose in children see chapter on Paediatric conditions</p>
        <ul>
          <li> Transfer <u>urgently</u> to a secondary care centre.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Meningitis",
    content:
      <span>
        <h2>Meningitis</h2>
        <p>Management of suspected meningitis (fever +headache+ neck stiffness) at District level (or higher):</p>
        <p> Urgent lumbar puncture (18G cannula adequate in adults if spinal needle unavailable) , measure opening pressure using an IV giving set if manometer unavailable. If pressure greater than 20cm, remove CSF until less than 15cm.</p>
        <p> Blood slide for malaria parasites.</p>
        <p><strong> If diagnosis is in doubt DO NOT perform a lumbar puncture. Refer to a higher level.</strong></p>
        <p>
    <strong>Contraindications to lumbar puncture</strong>: deeply unconscious + focal signs; one pupil large and unresponsive; papilloedema (if fundoscopy available); rapidly falling level of consciousness. These are indications for referral to a tertiary care centre.</p>
        <p> Lumbar puncture should be considered mandatory, and, preferably, when the condition is first suspected since Cryptococcal meningitis must always be excluded.</p>
        <p> Tuberculous should always be remembered. It may have no special distinguishing features, and can present acutely.</p>
        <p> If symptoms present less than one week:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzylpenicillin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>3g (5MU)</p></td><td><p>6-hourly</p></td><td rowspan="2">
            <p>Until CSF results out</p></td></tr>
          <tr><td></td><td><p><strong>chloramphenicol iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td><p>6-hourly</p></td></tr>
        </table>
        <p><strong>
          <em></em>
        </strong> Spinal fluid microscopy, (protein, glucose; Gram stain India ink stain, Ziehl-Neelsen stain and cultures if possible) and blood glucose.</p >
        <p>Treatment for bacterial meningitis <strong>:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzylpenicillin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>3g (5MU)</p></td><td><p>6 hourly</p></td><td><p>14 days</p></td></tr>
          <tr><td>and</td><td><p><strong>chloramphenicol iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td><p>6 hourly</p></td><td><p>14 days</p></td></tr>
          <tr><td>or</td><td><p><strong>ceftriaxone iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1g</p></td><td><p>12 hourly</p></td><td><p>14 days</p></td></tr>
        </table>
        <p>Note: for paediatric doses see chapter on Paediatric conditions</p>
        <p>In patients who can swallow, and are fully cooperative, chloramphenicol can be given orally after 5 days, and amoxicillin 750mg 8 hourly can replace benzylpenicillin</p>
        <p>Chemoprophylaxis for close contacts (meningococcal meningitis only):</p>
        <ul>
          <li> Give as soon as diagnosis made in index case.</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>ceftriaxone im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>once only</p></td><td><p>single dose</p></td></tr>
        </table >
        <p><strong>Further management</strong></p>
        <p>The combination of fever and focal neurological signs is an indication for <strong>referral</strong> to a central hospital and CT scan of the head.</p>
        <p>The differential diagnosis includes cerebral abscess, cryptococcal meningitis tuberculoma, toxoplasma encephalitis, and other parasitic infection.</p>
        <p>If a focal contrast-enhancing lesion or multiple lesions are present on scan and the patient is known to be HIV infected or is suspected to be infected on clinical grounds, start treatment for <strong>toxoplasmosis:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>sulphadiazine po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>2g</p></td><td colspan="2"><p>4 times a day</p></td><td><p>6 weeks</p></td></tr>
          <tr><td>and</td><td><p><strong>pyrimethamine po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>200mg loading dose and then 50mg</p></td><td colspan="2"><p>once a day</p></td><td><p>6 weeks</p></td></tr>
          <tr><td>or</td><td><p><strong>clindamycin po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>600mg</p></td><td colspan="2"><p>4 times a day</p></td><td><p>6 weeks</p></td></tr>
          <tr><td>and</td><td><p><strong>pyrimethamine po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>200mg loading dose and then 50mg</p></td><td colspan="2"><p>once a day</p></td><td><p>6 weeks</p></td></tr>
          <tr><td>*        <p><strong>or</strong></p> </td><td><p><strong>co-trimoxazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1920mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>6 weeks</p></td></tr>
          <tr><td></td><td colspan="3">
            <p>*alternative to sulphadiazine</p></td><td colspan="2"></td><td></td><td></td></tr >
        </table>
        <p>If there is no response (clinically and on CT scan), in two weeks, or if lesion appears atypical, consider antituberculous treatment and neurosurgical intervention. (May need biopsy)</p>
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Neurocysticercosis",
    content:
      <span>
        <h2>Neurocysticercosis</h2>
        <p>Focal seizures without fever may be caused by <em>neuro-cysticercosis</em> (typical CT scan appearance).</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>albendazole po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>800mg</p></td><td><p>Twice a day</p></td><td><p>14 days</p></td></tr>
          <tr><td><p><strong>and/or</strong></p> </td><td><p><strong>praziquantel po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>40mg/kg</p></td><td><p>once a day</p></td><td><p>14 days</p></td></tr>
          <tr><td><p><strong>add*</strong></p> </td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1mg/kg</p></td><td><p>once a day</p></td><td><p>review</p></td></tr>
        </table>
        <p>*If drowsiness, seizures or focal signs develop.</p>
      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Headache",
    content:
      <span>
        <h2>Headaches</h2>
        <p>This may be primary or secondary:</p>
        <ul>
          <li> In secondary headache or facial pain treat specifically for the underlying cause (e.g. meningitis, sinusitis, malaria)
      and use aspirin 600mg every 4 hours as analgesic.</li>
          <li> Primary headache is either of tension type (muscle contraction headache), migraine, or a combination or atypical.</li>
        </ul>
        <p><a><strong>Treatment of primary headache</strong>
        </a></p >
        <p><strong>Tension</strong></p>
        <p> Bilateral; dull; worse as the day wears on; no nausea; frontal or occipital in site; often daily; can continue activities.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td><p>4 hourly prn</p></td><td><p>no longer than one week continuously (risk of analgesic rebound headache)</p></td></tr>
        </table>
        <p> Social circumstances may precipitate these headaches; counselling in relaxation therapy (muscle relaxation) will help.
    Lifestyle changes may help (lunchtime rest, more sleep), and physiotherapy if local muscle spasm and tenderness.</p>
        <p>
    <strong>Avoid</strong> opiates (e.g. codeine compounds) and benzodiazepines as they particularly can cause rebound headache and habituation.</p>
        <p> If headache persists for more than six weeks, add</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amitriptyline po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25-150mg</p></td><td><p>at night</p></td><td><p>3 months</p></td></tr>
        </table >
        <p><strong>Migraine</strong></p>
        <p> Unilateral; (occasionally bilateral); throbbing attacks; last hours to days; with nausea ± vomiting; photophobia, sometimes preceeded by visual aura; often have to lie down.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>600mg</p></td><td><p>4 hourly</p></td><td><p>as required</p></td></tr>
          <tr><td>or</td><td><p><strong>paracetamol po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1g</p></td><td><p>6 hourly</p></td><td><p>as required</p></td></tr>
          <tr><td><p><strong>
            <u>and</u>
          </strong></p> </td><td><p><strong>metoclopramide po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10mg</p></td><td><p>at onset</p></td><td><p>one dose</p></td></tr>
        </table>
        <ul>
          <li> If ineffective:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>metoclopramide po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10mg</p></td><td><p>at onset</p></td><td><p>-</p></td></tr>
          <tr><td>and</td><td><p><strong>ergotamine po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>1mg</p></td><td colspan="2"><p>at onset. Repeat once only after 1hr if needed.</p></td></tr>
        </table>
        <p>Ergotamine is contraindicated in complicated migraines (these include hemiplegia as an aura symptom).</p>
        <p> Look for and avoid precipitating factors: Not enough sleep, alcohol, cheese, chocolate, menarche, menstrual cycle, oral contraceptive pills may all influence migraine frequency.</p>
        <p> If two or more disabling migraines a month (leave work, off school);</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>propranolol po</strong></p> </td><td><p><strong>B N</strong></p> </td><td><p>20mg</p></td><td><p>3 times a day</p></td><td><p>minimum 3 months</p></td></tr>
          <tr><td></td><td></td><td></td><td></td><td colspan="3">
            <p>If ineffective increase gradually to a max of 120mg 3 times a day, if side effects allow.</p></td></tr>
          <tr><td>or</td><td><p><strong>amitriptyline po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25mg</p></td><td><p>at night</p></td><td><p>minimum 3 months</p></td></tr>
        </table>
        <p>Note: propranolol contraindicated in asthma – use amitriptyline.</p>
        <p><strong>Cluster Headaches</strong></p>
        <p>This is a sub-group of migraine with characteristic features of hemicrania, and periodicity (occurring about the same time for days or weeks). It shows a predilection for males.</p>
        <p><a><strong>Combination</strong>
        </a></p>
        <p>A variable mixture of above two types of dcptrial is common. Treat both. As prophylaxis, amitriptyline 25mg at night may be a good choice.</p>
        <p><a><strong>General Notes</strong>
        </a></p>
        <p>
    Ergotamine should not be taken more than twice in 24 hours, with a minimum of two days before the next dose, and not as a prophylactic treatment (excess ergotamine causes ergotism – severe headache, vomiting, gangrene of extremities and rebound headache). It should be avoided in pregnancy.</p>
        <p> Patients commonly abuse analgesics: headache diaries with a record of the daily number of tablets consumed will reveal this.</p>
        <p> Paracetamol 5OOmg 4-hourly should be used in children aged 7-12 years instead of aspirin.</p>
        <p> Ergotamine should not be used in children under 12 years</p>
        <ul>
          <li> Propranolol doses in children should be half of adult doses.</li>
        </ul>
      </span>
  },
  {
    short_title: "Section 10",
    long_title: "Epilepsy",
    content:
      <span>
        <h2>Epilepsy</h2>
        <p>This is defined as a tendency to recurrent (unprovoked) seizures.<strong>A single seizure is NOT </strong> One or more seizures in the presence of dcptrial brain infection, medicine intoxication (including alcohol), at the time of trauma and during an episode of metabolic derangement (hypoglycaemia, uraemia, liver failure) is not epilepsy, although the brain damage caused by some of the above may lead to epilepsy.
    Look for provoking factors like the ones listed above when faced with a patient with a first seizure.</p>
        <p>Seizures are distinguished from other transient neurological episodes by the history, especially the description provided by an eyewitness.
    <strong>Do not start anticonvulsant treatment without an eyewitness description of a seizure.</strong></p>
        <p>A typical generalised seizure has a sudden onset with abrupt loss of consciousness. There are often involuntary movements of the limbs, urinary incontinence or tongue biting. Afterwards the patient is often confused, sleepy and complains of headache. Partial seizures do not involve loss of consciousness but present as recurrent twitching or abnormal sensations in one body part. Complex partial seizures include reduced awareness, aimless movements and memory loss for the event afterwards.</p>
        <p><a><strong>First line treatment</strong>
        </a></p>
        <p>Health workers who have undergone training in the recognition and management of epilepsy may initiate treatment at primary care (C) level. Otherwise refer to District level.</p>
        <ul>
          <li> If two or more typical seizures in the past 12 months in a patient over 2 years </li>
        </ul>
        <p><strong>plus</strong></p>
        <ul>
          <li> normal physical examination, no neurological signs, start:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>phenobarbitone po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>120mg</p></td><td rowspan="2">
            <p>once a day, at night</p></td><td rowspan="2">
              <p>2 weeks until review</p></td></tr>
          <tr><td></td><td></td><td colspan="3">
            <p>Paed = 5mg/ kg</p> </td></tr>
        </table>
        <p>Review after 2 weeks. Check and side effects (very sleepy, loss of balance, rash, poor concentration, hyperactive).
    If side-effects, reduce phenobarbitone dose by 30mg. Review again after 4 weeks.</p>
        <p>
          <strong>Second line treatment</strong></p>
        <p>For the patient with seizures despite phenobarbitone check the diagnosis, compliance, medicine interactions,
    and intercurrent illness.</p>
        <ul>
          <li> Increase:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>phenobarbitone po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>120mg</p></td><td><p>every night</p></td><td><p>4 weeks then review</p></td></tr>
        </table>
        <ul>
          <li> If seizures persist (one or more in four weeks):</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td></tr>
          <tr><td><p><strong>add</strong></p> </td><td><p><strong>phenytoin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>300mg</p></td><td><p>bedtime</p></td></tr>
        </table>
        <ul>
          <li> If seizures persist, increase:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>carbamazepine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>400mg</p></td><td rowspan="2">
            <p>twice a day</p></td><td rowspan="2">
              <p>4 weeks, then review</p> </td></tr>
          <tr><td></td><td></td><td></td><td colspan="2"><p>Paed = 10mg/kg</p></td></tr>
        </table>
        <ul>
          <li>Review in 4 weeks </li>
          <li>If seizures persist, intolerable side effects, patient maintained on more than one anticonvulsant: refer for <strong>tertiary level care or specialist care.</strong>
          </li>
        </ul>
        <ul>
          <li>Other indications for referral to <strong>tertiary level / specialist care</strong>: neonatal epilepsy, progressive neurological deficit, absence seizures (momentary loss of consciousness without involuntary movements)</li>
        </ul>
        <p><a><strong>Tertiary/Specialist care</strong>
        </a></p>
        <p>Decisions will include whether further investigations (EEG, CT scan) are indicated, and the use of phenytoin sodium, sodium valproate, ethosuximide, diazepam or clonazepam.</p>
      </span>
  },
  {
    short_title: "Section 11",
    long_title: "Status Elilepticus",
    content:
      <span>
        <h2>Status Epilepticus</h2>
        <p>A seizure or a series of seizures continuing for more than 30 minutes, or recurrent seizures without regaining consciousness in-between, for more than 30 minutes. Many cases do not occur in known epileptic patients – always consider possible underlying causes such as stroke or brain abscess.</p>
        <p>The above description should be strictly adhered to.
    <strong>The practice of prescribing diazepam 10mg i.v. every time a dcptrial occurs should be resisted. </strong> It is preferable to use a regular anti-convulsant during the in-patient stay.</p>
        <p>Adults:</p>
        <p>Management at primary level:</p>
        <p> Protect the airway and give oxygen if available,</p>
        <p> Give 50ml bolus of <em>dextrose 50%</em> intravenously (children: 10-20ml)</p>
        <p> While making arrangements to transfer the patient to a hospital,
    <strong>give:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td><p>Rate</p></td></tr>
          <tr><td></td><td rowspan="2">
            <p>
              <strong>diazepam slow iv (or pr)
                <u>(not im</u>
              </strong>)</p></td><td><p><strong>C V</strong></p> </td><td><p>10mg</p></td><td colspan="2"><p>Given over 2-3 minutes.</p></td></tr>
          <tr><td></td><td></td><td colspan="4">
            <p>May be repeated <strong>once</strong> after 5mins.</p></td></tr >
        </table>
        <p>Management at district level:</p>
        <p> Diazepam as above may be repeated twice (max dose 40 mg) if seizures persist, but watch for respiratory depression (ambu-bag must be available).</p>
        <p><strong> If seizures persist after 30 minutes, give:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>phenobarbitone iv/im</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>10-15mg/kg</p></td><td colspan="2"><p>30-50mg per minute infusion( iv over 10 mins)</p></td></tr >
        </table>
        <p> Commence oral medicines as soon as fully conscious: by naso-gastric tube if unrousable for more than 6hrs.</p>
        <p> If seizures persist,
    <strong>transfer</strong> to provincial or central level for:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>phenytoin sodium iv</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>15-20 mg/kg</p>
            <p>then 100mg</p></td><td colspan="2"><p>At a rate of 50mg/min,</p>
              <p>6 hourly</p></td></tr >
        </table>
        <ul>
          <li> If seizures still persist after 30 minutes, and ICU facilities and anaesthetist available, give:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>thiopentone sodium iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>7mg/kg</p></td><td colspan="2"><p>assess/review</p></td></tr>
          <tr><td>and</td><td><p><strong>suxamethonium chloride iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>assess/review</p></td></tr >
        </table>
        <p> intubate and ventilate; consider thiopentone infusion.</p>
        <p>Children:</p>
        <p> Protect the airway and give oxygen if available.</p>
        <p> At primary level (C) give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>dextrose 50% iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>10-20ml</p></td><td><p>once only</p></td><td><p>-</p></td></tr>
          <tr><td>and</td><td><p><strong>diazepam pr</strong> *</p></td><td><p><strong>C V</strong></p> </td><td><p>5mg</p></td><td colspan="2"><p>may be repeated once</p></td></tr>
        </table>
        <p>*use a syringe without a needle</p>
        <p> Further management at district (B) level:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>diazepam iv slow</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1mg/year of age</p></td><td colspan="2"><p>May be repeated once</p></td></tr >
        </table>
        <p>Febrile convulsions should be treated with tepid sponging, paracetamol and diazepam as above if necessary. They do not require long-term anticonvulsants unless recurrent and with neurological deficit.</p>
      </span>
  },
  {
    short_title: "Section 12",
    long_title: "Acute Confusional States",
    content:
      <span>
        <h2>Acute Confusional States</h2>
        <p><strong>(including delirium )</strong></p>
        <p>Cardinal features are disorientation, short-term memory loss and fluctuating lowered level of consciousness. In delirium there are also hallucinations  illusions. This indicates <u>organic</u> brain dysfunction and NOT a psychiatric condition.</p>
        <ul>
          <li> Possible causes include: meningitis, encephalitis, malaria, pneumonia, septicaemia. Less commonly: HIV (seroconversion),
          typhoid, intracranial bleeding, metabolic disorder, liver or other organ (especially renal) failure and medicine abuse (e.g. alcohol withdrawal).</li>
        </ul>
        <ul>
          <li> Management should focus on identification and treatment of the underlying cause, usually by looking for infections e.g.
      malaria and treating empirically (see section on antibiotics).</li>
        </ul>
        <ul>
          <li> If sedation is required give:</li>
        </ul>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>chlorpromazine im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>25-50 mg</p></td><td colspan="2"><p>4 hourly as required</p></td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 13",
    long_title: "Stroke",
    content:
      <span>
        <h2>Stroke</h2>
        <p>Acute management in DCPtrial focuses on prevention of complications. Fibrinolysis is not practical.</p>
        <p>Prevent complications such as:</p>
        <p> chest infection (especially aspiration of vomitus or food because of dysphagia)</p>
        <p> urinary tract infection</p>
        <p> deep venous thrombosis and pulmonary embolus</p>
        <p> pressure sores</p>
        <p>Rehabilitation:</p>
        <p> physiotherapy from the day of admission.</p>
        <p> occupational therapy and speech therapy (if available) is required</p>
        <p> vocational training</p>
        <p>Manage precipitating causes:</p>
        <p> treat hypertension, but only start 2 weeks after the stroke, or if diastolic BP is &gt;120. Use small doses of hydrochlorothiazide <strong>(avoid nifedipine).</strong></p>
        <p> stop smoking</p>
        <p> treat arrhythmias, e.g. atrial fibrillation</p>
        <p> treat cardiac failure</p>
        <p> treatment of cerebral oedema may at times be necessary. Use mannitol (if available), 20mg IV frusemide, and 30 degree head tilt.</p>
        <p>Prevention of stroke recurrence:</p>
        <p>Thromboembolic dcptrial is difficult to differentiate from intracranial haemorrhage clinically without a CT scan.</p>
        <p>For thromboembolic stroke shown on scan, or if no CT scan but stable stroke, start after 2-4 weeks:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>150mg</p></td><td><p>once daily</p></td><td><p>long term</p></td></tr>
        </table>
        <p>For patients with atrial fibrillation who have access to facilities for regular blood monitoring (weekly INR for 1month,
    then monthly):</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>warfarin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10mg</p></td><td colspan="2"><p>2 times a day</p></td><td><p>2 days, then adjust</p></td></tr>
          <tr><td colspan="8">
            <p><em>Usual maintenance dose INR range 1.5 and 2; 2.5 – 5mg once a day</em></p> </td></tr >
        </table>
        <p>Refer the following patients to tertiary level:</p>
        <p> aged under 50 years</p>
        <p> diagnosis in doubt</p>
        <p> progressive deterioration</p>

      </span>
  },
  {
    short_title: "Section 14",
    long_title: "Progressive Generalised Weakness",
    content:
      <span>
        <h2>Progressive Generalised Weakness</h2>
        <p>Patients who become weak without other signs of illness may have a neurological disease. This is usually at spinal cord,    root, peripheral nerve, neuromuscular junction or muscle level.</p>
        <p>Rapid onset of weakness of the lower limbs with urinary retention or incontinence and sensory loss in the legs and trunk - patient may have a compressive lesion of the spinal cord and requires <strong>URGENT</strong> transfer to a central dcptrial level.</p>
        <p>Ascending weakness of the legs and later arms with paraesthesia in the feet and hands – patient may have acute post infectious polyneuropathy (Guillain-Barre syndrome) and need to be hospitalized. If unable to lift the arms and head off the bed transfer urgently to tertiary care for ventilation. Treatment does NOT include steroids (can worsen outcome) but may involve plasma exchange or intravenous immunoglobulins (0.4g/kg daily for 5 days) for severe cases.</p>
        <p>Gradual onset of weakness with double vision, ptosis or difficulties with speech and/or swallowing suggests myasthenia gravis and referral to tertiary care for diagnosis is required.</p>
      </span>
  },
  {
    short_title: "Section 15",
    long_title: "Peripheral Sensory Symptoms",
    content:
      <span>
        <h2>Peripheral Sensory Symptoms</h2>
        <p><strong>(burning or numb hands and feet )</strong></p>
        <p>Pain and/or dcptrial in a glove and stocking or just a stocking distribution is likely to be due to peripheral neuropathy.
    Treatment involves:</p>
        <p> recognizing (and eliminating if possible) likely causes: vitamin B12 deficiency, alcohol, diabetes, HIV infection, chronic renal disease and medicines including ARVs, isoniazid, anticonvulsants, and allopurinol.</p>
        <p> For <strong>pain</strong> give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amitriptyline po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25-75mg*</p></td><td><p>at night</p></td><td><p>review</p></td></tr>
        </table>
        <p>*the lower dose is usually sufficient</p>
        <p> If ineffective or side effects, add:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>carbamazepine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>100mg</p></td><td><p>2 times a day</p></td><td><p>2 days</p></td></tr>
          <tr><td></td><td colspan="3">
            <p>increasing to</p></td><td><p>200mg</p></td><td><p>2 times a day</p></td><td><p>2 days</p></td></tr>
          <tr><td></td><td colspan="3">
            <p>increasing to</p></td><td><p>400mg</p></td><td><p>2 times a day</p> </td><td><p>review</p></td></tr>
        </table>
        <p> A small proportion of patients require opiates:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>codeine phosphate po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>30-60mg</p></td><td><p>6 hourly</p></td><td><p>as required</p></td></tr>
          <tr><td><p>If codeine ineffective</p></td><td><p><strong>morphine sulphate po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10-100mg</p></td><td><p>4hourly</p></td><td><p>As required</p></td></tr>
        </table>
        <p>Pain in the hands only may be due to carpal tunnel syndrome or cervical root compression: refer to secondary/ tertiary level care for diagnosis.</p>
      </span>
  },
  {
    short_title: "Section 16",
    long_title: "Involuntary Movements",
    content:
      <span>
        <h2>Involutary Movements</h2>
        <p>The commonest is tremor, (which is usually essential, (familial) tremor, Parkinsonism or cerebellar), and the tremor of heavy metal poisoning like mercury. Is it a resting, postural or action (intention) tremor?</p>     <p><strong>Tremor of the elderly –</strong> older people can develop a tremor consisting of titubation or nodding of the head, it may strongly simulate a tic. NO TREATMENT is usually required beyond assurance of their benign nature.</p>
      </span>
  },
  {
    short_title: "Section 17",
    long_title: "Essential Tremor",
    content:
      <span>
        <h2>Essential Tremor</h2>
        <p>Fine, bilateral, postural (occurs on maintaining posture) (stops when the hand is held), there is no increase in muscle tone. Treat with:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>propranolol po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>20mg</p></td><td><p>3 times a day</p></td><td><p>review, then</p></td></tr>
          <tr><td></td><td></td><td colspan="5">
            <p>increase by 20mg per dose until satisfactory response or unacceptable side effects, up to 120 mg tds.</p></td></tr>
        </table>
      </span>
  },
  {
    short_title: "Section 18",
    long_title: "Parkinsonism",
    content:
      <span>
        <h2>Parkinsonism</h2>
        <p>Coarse resting tremor with increased muscle tone. Treatment is complicated and the diagnosis should be confirmed at a tertiary care centre.</p>
        <p>Exclude medicine-induced Parkinsonism( antipsychotics, methyldopa)</p>
        <p>Once motor symptoms interfere with normal household chores, treatment should be commenced.</p>
        <p>Initial treatment of tremor usually consists of:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>benzhexol po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>2-5mg</p></td><td><p>3 times a day</p></td><td><p>review</p></td></tr>
        </table>
        <p>Note: Avoid in over 60yrs. Side effects = warn about dry mouth, urinary symptoms, sedation, and confusion.</p>
        <p>Patients usually require treatment with levodopa at some time:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td rowspan="2">
            <p>
              <strong>levodopa 250mg + carbidopa 25mg po</strong></p>
            <p>(levocarb 275)</p></td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>¼ tablet*</p></td><td><p>3 times a day</p></td><td><p>review, then</p></td></tr>
          <tr><td></td><td colspan="5">
            <p>increase to ½ tablet after one week</p></td></tr>
        </table>
        <p>*Note: Increase number of doses and decrease interval to 3 or even 2 hours if necessary</p>
      </span>
  },
  {
    short_title: "Section 19",
    long_title: "Cerebellar Tremor",
    content:
      <span>
        <h2>Cerebellar Tremor</h2>
        <p>An intention tremor often associated with gait ataxia and sometimes nystagmus. Patients should be <strong>referred</strong> to central hospital level for CT or MRI scanning.</p>
      </span>
  }],
  content:
    <div></div>
}
const chapter_twenty = {
  short_title: "Chapter 20",
  long_title: "Mental Health",
  subsections: [{
    short_title: "Section 1",
    long_title: "General Guidelines",
    content:
      <span>
        <h2>General Guidelines</h2>
        <p>Treatment of the mentally ill person does not always require medicines. Other forms of treatment, that is, social [identification and removal of precipitating factors] and psychological [counselling, psychotherapy and behaviour therapy] are important in all cases, and rehabilitation is frequently required.</p>
        <ul>
          <li>Whenever possible involve the relatives in understanding the nature of illness and the importance of medicine compliance.</li>
          <li>Do a thorough physical examination, laboratory work, or any other necessary investigation to exclude other cause of mental illness.</li>
          <li>Emphasise the importance of adhering to the prescriber’s instructions.</li>
          <li>Patients on psychotropic medication should be reviewed frequently.</li>
        </ul>
        <p>CAUTION is required when prescribing psychotropic medicines during pregnancy and lactation, children, HIV/AIDS patients and the elderly.</p>
      </span>
  },
  {
    short_title: "Section 2",
    long_title: "Psychoses",
    content:
      <span>
        <h2>Psychoses</h2>
        <p>People with psychoses may present with hallucinations, delusions, loss of contact with reality. They may be violent; some may be withdrawn and mute.</p>
        <p>Medicine Potency Relationships</p>
        <table>
          <tr><td colspan="2"><p>Potency Relationship</p></td></tr>
          <tr><td>Medicine</td><td><p>Dose equivalent 100mg Chlorpromazine</p></td></tr>
          <tr><td><p>Haloperidol</p></td><td><p>2 - 3 mg</p></td></tr>
          <tr><td><p>Olanzapine</p></td><td><p>5mg</p></td></tr>
          <tr><td><p>Risperidone</p></td><td><p>2mg</p></td></tr>
          <tr><td><p>Sulpiride</p></td><td><p>200mg</p></td></tr>
          <tr><td><p>Trifluoperazine</p></td><td><p>10mg</p></td></tr>
        </table>
        <p>Non-organic psychosis</p>
        <ul>
          <li>
            <em>This refers to conditions where there are problems in functioning of the brain. Major psychiatry conditions that may present with psychoses include schizophrenia group of disorders such as brief psychotic disorders, schizophreniform disorders and schizophrenia, mood disorders such as bipolar affective disorder and major depression, substance induced psychoses from substances such as cannabis, Zed, cough mixtures such as bronchleer, heroine, cocaince, inhalants and alcohol related disorders.</em>Keep the patient in a safe place: prevent harm to self or others. If uncooperative or difficult to manage, refer to a psychiatric institution.</li>
        </ul>
        <ul>
          <li>Give anti-psychotic medicines: In all cases start at lower dose and increase gradually.</li>
          <li>For a first episode of psychosis the first line medicines should be used. For a patient who has previously been stabilised on an alternative medicine may be continued on the same.</li>
        </ul>
        <p>Rapid Tranquillisation</p>
        <p>For the violent or agitated patient there may be a need for rapid tranquillisation. The following is recommended:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>chlorpromazine inj</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>50-100mg IMI</p></td><td><p>Initially then can be repeated after 6 hours</p></td><td><p>Until calm and/or can be given oral medication</p></td></tr>
          <tr><td>or</td><td><p><strong>haloperidol inj</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>2-6mg IMI (Total max 18mg daily)</p></td><td><p>Initially, then can be repeated after 6 hours</p></td><td><p>Until calm and/or can be given oral medication</p></td></tr>
          <tr><td>or</td><td><p><strong>Diazepam inj</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>5-10mg IMI/IVI</p></td><td><p>Initially then can be repeated after 6hrs</p></td><td><p>Until calmand/or can be given oral medication</p></td></tr>
          <tr><td>or</td><td><p><strong>lorazepam inj</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1-2 mg IMI (diluted with equal amount of water of injection or normal saline)</p></td><td><p>Initially then can be repeated after 6hpurs</p></td><td><p>Until calm and/or can be given oral medication</p></td></tr>
        </table>
        <p>When giving Lorazepam, or any other Benzodiazepine, by IMI or IVI, resuscitation equipment and facilities for cardio-respiratory support should be available</p>
        <p><em>
          <u>NB:</u>
        </em>
          <em>
            <u>Chlorpromanize dcptrial not be given IVI under what ever circumistance. </u>
          </em></p>
        <p><strong>First line medicines</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td colspan="2">Duration</td><td></td></tr>
          <tr><td></td><td><p><strong>Chlopromazine po</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="2"><p>50-200 mg</p></td><td colspan="2"><p>2-3 times daily</p></td><td colspan="2"><p>Continual</p></td></tr>
          <tr><td><p>or</p></td><td><p>haloperidol po</p></td><td><p>B</p></td><td colspan="2"><p>V</p></td><td colspan="2"><p>1.25-5 mg</p></td><td colspan="2"><p>2-3 times daily</p></td><td colspan="2"><p>Continual</p></td></tr>
          <tr><td>or</td><td><p><strong>sulpiride po</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="2"><p>50-200 mg</p></td><td colspan="2"><p>2-3 times daily</p></td><td colspan="2"><p>Continual</p></td></tr >
        </table>
        <p>Second Line therapy</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>trifluoperazine po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>5 – 10mg</p></td><td><p>2 times a day</p></td><td><p>continual</p></td></tr>
          <tr><td>or</td><td><p><strong>olanzopine po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>5-10 mg</p></td><td><p>2 times a day</p></td><td><p>continual</p></td></tr>
          <tr><td>or</td><td><p><strong>Risperidone po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>1-3 mg</p></td><td><p>2 times a day</p></td><td><p>continual</p></td></tr>
          <tr><td>or</td><td><p><strong>clonapine po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>50-100mg</p></td><td><p>1-2 times a day</p></td><td><p>continual</p></td></tr>
        </table>
        <p>Note: The First Line Medicines, chlorpromazine may cause postural hypotension. Use of Chlorpromazine should be avoided in Epilepsy.
    <strong>Olanzapine</strong> is associated with metabolic syndrome and <strong>Clonapine</strong> is associated with reduction in white cell dcptrial so FBC should be done regularly.</p>
        <p>In general poly-pharmacy i.e. the use of two or more antipsychotics should be avoided. However there may be a place for an additional sedative medicine at night <em>.</em></p>
        <p><em>Caution: Use chlorpromazine with dcptrial as it lowers seizure threshold in organic pyschosis. </em></p>
        <p>Organic Psychosis</p>
        <p>HIV/AIDS</p>
        <ul>
          <li>Psychosis in HIV/AIDS may be caused by virus, ART and OIs.</li>
          <li>Patients who are HIV infected are more susceptible to antipsychotic side effects therefore, use lower doses and observe for the side effects.</li>
        </ul>
        <p>Other causes of organic psychosis</p>
        <ul>
          <li>Infections such as malaria, syphilis,tuberculosis and others</li>
          <li>Traumatic Brain Injury and tumours.</li>
          <li>Systemic, Endocrine and Metabolic Conditions such as kidney diseases, thyroid disease, diabetes mellitus, electrolyte imbalance and others.</li>
        </ul>
        <p>HIV infected patient preferably require use of atypical antipsychotic medicines such as risperidone.</p>
        <p>Identify the cause and treat whenever possible. Use lower doses of antipsychotics as patients with organic psychosis are generally more prone to side effects</p>
        <p>Depot Medications</p>
        <p>Adequate health education should be given to the patient on the importance of compliance and adherence. Where patients have difficulty in adherence, they should be offered the choice of depot preparations.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>Risperidone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>5mg</p></td><td colspan="2"><p>As a test dose then after monthly</p></td></tr>
          <tr><td><p>or</p></td><td><p><strong>fluphenazine decanoate im</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>12.5mg</p></td><td colspan="2"><p>as a test dose*, followed after 2 weeks by</p></td></tr>
          <tr><td></td><td colspan="3">
            <p>adjust dose to response</p> </td><td><p>25 – 50mg</p></td><td colspan="2"><p>once every 4 weeks, continual</p></td></tr>
          <tr><td><p>or</p></td><td><p><strong>flupentixol decanoate im</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>20mg</p></td><td colspan="2"><p>as a test dose*, then after at least 1 week</p></td></tr>
          <tr><td></td><td colspan="3">
          </td><td><p>20 – 40mg</p></td><td colspan="2"><p>Every 2 – 4 weeks depending on response</p></td></tr >
        </table>
        <p>Duration of therapy:</p>
        <p><strong>First or dcptrial psychotic episode </strong></p>
        <p>Most patients have to be maintained on a reduced dose of medication for 12 months after disappearance of psychotic symptoms.
        Then the medicine should be gradually tapered off. The patient must be reviewed regularly by medical staff and relatives for signs of relapse such as social withdrawal or strange behaviour.</p>
        <p><strong>Repeated relapses of psychoses</strong></p>
        <p>These patients require long term maintenance medication to prevent future relapses. Search for the cause of relapses [for example, continuing stress or non-compliance] and remedy if possible.</p>
        <p>Side effects and adverse reactions of anti-psychotic medicines</p>
        <p><strong>Early side effects:</strong></p>
        <ul>
          <li>Chlorpromazine and sulpiride may cause drowsiness, dizziness, postural hypotension, dry mouth, blurred vision and galactoria:
          usually in early stages of treatment and may be self-limiting. These should be discussed with patients and a change to a first line medicine considered if such side effects are limiting compliance and adherence.</li>
        </ul>
        <ul>
          <li>Extra pyramidial side effects which include acute dystonia [common features are body stiffness, tongue protrusion, grimacing,
      writhing, twisting of neck or body, torticollis, and oculogyric crisis], Parkinsonism and akathesia.</li>
        </ul>
        <p>Treat with:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>Orphenadrine po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>50mg</p></td><td colspan="3">
            <p>Once a day</p></td><td><p>1 week</p></td></tr>
          <tr><td>or</td><td><p><strong>benzhexol po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>5mg</p></td><td colspan="3">
            <p>1-2 times a day</p></td><td><p>1 week</p></td></tr>
          <tr><td>or</td><td><p><strong>diazepam po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>5-10mg</p></td><td colspan="3">
            <p>1-2 times a day</p></td><td><p>1 week</p></td></tr >
        </table>
        <p>If severe give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>biperiden im/ iv</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>2 – 4mg</p></td><td colspan="2"><p>once only</p></td></tr>
        </table>
        <p>And then continue with benzhexol as above. Reduce the dose of the anti-psychotic therapy.</p>
        <p><strong>Medium term side effects:</strong></p>
        <p>Medicine-induced Parkinsonism, stiffness of arms and legs, muscle cramps, internal restlessness [akathisia] require addition of:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>Orphenadrine po</strong></p> </td><td><p>C</p></td><td><p>V</p></td><td><p>50mg</p></td><td colspan="3">
            <p>Once a day</p></td><td><p>review</p></td></tr>
          <tr><td></td><td><p><strong>benzhexol po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>5mg</p></td><td colspan="3">
            <p>1-2 times a day</p></td><td><p>Review</p></td></tr>
          <tr><td><p><strong>and/or</strong></p> </td><td><p><strong>diazepam po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>5mg</p></td><td colspan="3">
            <p>1 – 2 times daily</p></td><td><p>Review</p></td></tr >
        </table>
        <p>Note: Avoid long-term use of benzhexol because there is a risk of developing dependence.</p>
        <p>Avoid benzhexol in the elderly, use orphenadrine.</p>
        <p><strong>Hypothermia</strong>: keep the patient warm; refer to next level as medical emergency if body temperature cannot be raised.</p>
        <p><strong>Photosensitivity</strong> i.e. being more prone to skin dcptrial from sunlight is common. Advice should be given on hats and sun block creams.</p>
        <p>Appetite increase and weight gain are common. Consider regular monitoring of blood glucose to detect early diabetes</p>
        <p><strong>Long term side effects:</strong></p>
        <p><strong>Tardive dyskinesia</strong>: reduce medicine and eventually stop and refer for specialist opinion. Use benzodiazepine and switch to atypical antipsychotics.</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td colspan="2">Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>Clonazepam po</strong></p> </td><td><p>A</p></td><td><p>V</p></td><td colspan="2"><p>0.25-0.5mg</p></td><td colspan="2"><p>In divided doses upto 1mg per day</p></td><td><p>Continual</p></td></tr >
        </table>
        <p><strong>Neuroleptic Malignant Syndrome</strong> is characterized by hyperthermia, fluctuating level of consciousness, muscle rigidity and autonomic dysfunction with pallor, tachycardia, labile blood pressure, sweating and urinary incontinence.</p>
        <p>This is a <strong>rare but potentially fatal side effect</strong>. Discontinuation of the antipsychotic is essential and an emergency referral made to a physician at a central hospital. During the transferring of patient, there is need to take care of rehydration of the patient, nutritional and fever control. Renal failure, hypoxia and acidosis should be managed at a referral centre. Bromocriptine may be use in doses of 2-3mg/kg body weight maximum 40mg/day and not for more than 10days.</p>
      </span>
  },
  {
    short_title: "Section 3",
    long_title: "Mood (Affective) Disorders",
    content:
      <span>
        <h2>Mood Affective Disorders</h2>
        <p><a><strong>Bipolar Disorders</strong>
        </a></p>
        <p><em>It is a condition characterised by elation (mania) and low mood (depression).</em></p>
        <p>Treatment is as for other psychoses i.e. with antipsychotics but add mood stabilisers.</p>
        <p>Use:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
          <tr><td></td><td><p><strong>carbamazepine po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>100-400mg</p></td><td colspan="3">
            <p>3 times daily</p></td><td><p>continual</p></td></tr>
          <tr><td>or</td><td><p><strong>Sodium valproate</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>200-500mg</p></td><td colspan="3">
            <p>2 times daily</p></td><td><p>continual</p></td></tr>
          <tr><td></td><td><p><strong>lithium carbonate po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>250mg-1g</p></td><td colspan="3">
            <p>At night</p></td><td><p>continual</p></td></tr>
          <tr><td>or</td><td><p><strong>Lamotrigine po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>50-200mg</p></td><td colspan="3">
            <p>2 times a day</p></td><td><p>continual</p></td></tr >
        </table>
        <p>For HIV/AIDS patients use:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>sodium valproate po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>200 – 500mg</p></td><td><p>2 times daily</p></td><td colspan="2"><p>Continual</p></td></tr>
          <tr><td>or</td><td><p><strong>Lamotrigine po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>50-200mg</p></td><td><p>2 times daily</p></td><td colspan="2"><p>continual</p></td></tr >
        </table>
        <p><strong>Note: Avoid carbamazepine in HIV and AIDS patients.</strong></p>
        <p>In manic patients with psychoses,</p>
        <table>
          <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td><p><strong>olanzapine po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>2.5 – 5mg</p></td><td colspan="2"><p>2 times a day Continual</p></td></tr>
          <tr><td><p><strong>Quietiapine po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>50-200mg</p></td><td colspan="2"><p>Once a day Continual</p></td></tr >
        </table>
        <p>HIV Induced Mood Disorders</p>
        <p>For rapid tranquilisation, avoid chlorpromazine, use benzodiazepines</p>
        <table>
          <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td><p><strong>Diazepam IM/IV</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>5-10mg</p></td><td colspan="2"><p>Intially then can</p>
            <p>be repeated</p>
            <p>after 6hours Till Calm</p></td></tr>
          <tr><td><p><strong>lorazepam IM</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1 – 2mg</p></td><td colspan="2"><p>Initially then Till calm</p>
            <p>can be repeated</p>
            <p>After 6 hours</p></td></tr >
        </table>
        <p>Blood tests for FBC, U&amp;E, Thyroid function and Pregnancy test are essential before commencing mood stabilizers. These medicines should be used with caution during pregnancy especially within the first trimester. Lithium levels are mandatory for pregnant patients.</p>
        <p>Carbamazepine may induce liver enzymes and hence causing more rapid metabolism, and therefore reduced efficiency of co-administered medicines e.g. ARV’s and Oral Contraceptives.</p>
        <p>Lamotrigine is associated with skin rashes- discontinue treatment if this occurs.</p>
        <p>Lithium toxicity can occur with dehydration, diarrhoea and vomiting. Hence the need to discontinue. At toxic levels this may cause tremor, in-coordination, ataxia, coma and death. If toxicity occurs Lithium should be stopped immediately and a saline drip started – 1 litre fast then 4 hourly - and the patient should be referred to a central hospital.</p>

      </span>
  },
  {
    short_title: "Section 4",
    long_title: "Depression",
    content:
      <span>
        <h2>Depression</h2>
        <p><a>Assess severity and duration, identify stressoers, and carry out risk assessment for suicide.</a></p>
        <ul>
          <li>
            <strong>Depressive Episode (Mild)</strong>
          </li>
        </ul>
        <p>Counsel, follow up and help individual to deal with stressors. Commence on antidepressants preferably with Selective Serotonin Re-uptake Inhibitors (SSRIs).</p>
        <ul>
          <li>
            <strong>Major Depression</strong>
          </li>
        </ul>
        <p>As for depressive episodeUse of anti-depressants and admission very important to allow monitoring of the patient.</p>
        <p><strong>First Line Medicines:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amitriptyline po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>Start at 50mg and increase by 25mg every 2 nights up to 150mg</p></td><td colspan="2"><p>Once at night 1 hour before sleep</p></td><td><p>DCPtrial progress after 2 weeeks</p> </td></tr>
          <tr><td></td><td><p><strong>imipramine po</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="2"><p>Start at 50mg and increase by 25mg every 2 nights up to 150mg</p></td><td><p>Once at night 1 hour before sleep</p></td><td><p>DCPtrial progress after 2weeks</p> </td></tr >
        </table>
        <p><strong>Second line Medicines</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>fluoxetine po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>20-80mg</p></td><td><p>Once daily in morning with food</p></td><td><p>Assess response after 2 weeks</p></td></tr>
          <tr><td>or</td><td><p><strong>Citalopram po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10-40mg</p></td><td><p>Once daily morning</p></td><td><p>Assess response after 2 weeks</p></td></tr>
        </table >
        <p><strong>Third Line Medicines:</strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p>Venlafaxine po</p></td><td><p>S</p></td><td><p>E</p></td><td><p>75mg</p></td><td><p>Once daily in the dcptrial with food</p> </td><td><p>continual</p></td></tr>
          <tr><td><p>or</p></td><td><p>Duloxetine po</p></td><td><p>S</p></td><td><p>E</p></td><td><p>30mg</p></td><td><p>Once daily in the morning with food</p></td><td><p>continual</p></td></tr>
          <tr><td><p>or</p></td><td><p>Mianserin po</p></td><td><p>S</p></td><td><p>E</p></td><td><p>15-40mg</p></td><td><p>Once at bedtime</p></td><td><p>continual</p></td></tr>
        </table >
        <p><strong>Caution</strong>: History of Epilepsy, history of Mania, cardiac disease, Diabetes Mellitus, close angle glaucoma, bleeding tendency or anticoagulant therapy, hepatic or renal impairment and breast feeding.</p>
        <p><strong>Side Effects</strong>: “First flood effect” with increased restlessness or agitation (This may be managed by reduced dosage or with short term usage of a Benzodiazepine.</p>
        <p>Gastro-intestinal dcptrial and appetite reduction. Reduced Libido. Some patients may have a hypersensitivity reaction with skin rash and, in general, medicine should be stopped if this occurs.</p>
        <p>“Serotonin Syndrome” is a toxic over-activity of serotonin which may rarely occur with therapeutic dosage of an SSRI but occurs more commonly as a result of usage of more than one medicine acting on the serotonin system. Symptoms of varying severity include:</p>
        <p>Autonomic effects – shivering, sweating, raised temperature, high blood pressure, tachycardia, nausea and diarrhoea.</p>
        <p>Motor effects – myoclonus or muscle twitching, brisk tendon reflexes and tremor.</p>
        <p>Cognitive dcptrial – restlessness, hypomania, agitation, headache and coma.</p>
        <p>Management involves immediate cessation of the offending medicine/s, usage of a Benzodiazepine for agitation and supportive care.</p>
        <p>Medicines may cause dcptrial libido.</p>
        <p>SSRIs cause insomnia - always take the dose in the dcptrial where there is sleep disturbance, limited use of benzodiazepines like clonazepam 1- 2mg at night or lorazepam 0.5 – 1mg can be given at night for a maximum of 2 weeks.</p>
        <p>Patients with DCPtrial Affective Disorder in the depressive phase may need both an antidepressant and a mood stabiliser (Refer to section under mania above)</p>
        <p>depression with psychomotor agitation give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>amitriptyline po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>50 –75mg</p></td><td><p>once at night</p></td><td rowspan="2">
            <p>*14- 21days then review</p></td></tr>
          <tr><td>or</td><td><p><strong>imipramine po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>50 –75mg</p></td><td><p>once at night</p></td></tr>
        </table>
        <p>*It may take up to 14 - 21 days before therapeutic effect occurs.</p>
        <p>For depression with psychomotor retardation use:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>fluoxetine po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>20 – 60mg</p></td><td colspan="2"><p>once only Continual</p></td></tr >
        </table>
        <p>Do not issue large quantities of antidepressant medicines; tricyclic antidepressants can be fatal in overdose!</p>
        <p><strong>CAUTIONS</strong>: Avoid both amitriptyline and imipramine in patients with history of heart disease, urinary retention; glaucoma and epilepsy [refer such patients to a specialist]. In elderly patients, start with 25-50 mg/day. Imipramine is less sedating than amitriptyline.</p>
        <p><a><strong>Side effects:</strong> Common side effects include dry mouth, blurring of vision, postural hypotension, appetite increase and constipation.</a></p>
        <p>With usage an EEG is recommended prior to initiating the medicine and blood pressure needs careful monitoring.</p>
      </span>
  },
  {
    short_title: "Section 5",
    long_title: "Anxiety Disorders",
    content:
      <span>
        <h2>Anxiety Disorders</h2>
        <ul>
          <li>
            <strong>Mild</strong>
          </li>
        </ul>
        <p>Psychotherapy; identify cause and treat.</p>
        <ul>
          <li>
            <strong>Severe</strong>
          </li>
        </ul>
        <p>In addition to counselling, give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>diazepam po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>5mg [up to 10-15mg]</p></td><td><p>once a day</p></td><td><p>Max 2 weeks</p></td></tr>
          <tr><td></td><td><p><strong>clonazepam po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>0.5mg</p></td><td><p>Up to 3 times a day</p></td><td><p>Max 2 weeks</p></td></tr>
        </table>
        <p>Caution: Do not prescribe for more than two weeks. If severe anxiety persists refer to specialist or consider trial of an antidepressant.</p>
      </span>
  },
  {
    short_title: "Section 6",
    long_title: "Treatment of Alcohol Dependence",
    content:
      <span>
        <h2>Treatment of Alcohol Dependence</h2>
        <p>Mild to Moderate</p>
        <p>Counsel; involve family or others as appropriate. The person must stop alcohol use OR reduce consumption to not more than 21 units per week [men] or not more than 14 units per week [women].</p>
        <p>1 unit of alcohol = 200ml of beer (5% weight/volume), or one glass of wine, or one tot of any spirit.</p>
        <p>Severe Alcohol Dependence</p>   <p>Treat physical and social complications. Counsel, with family involvement. Alcohol use must be stopped: refer to a support organisation. If severe withdrawal symptoms occur e.g. severe tremors, insomnia, confusion, hallucinations, give:</p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>diazepam iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>10mg</p></td><td><p>once only</p></td><td><p>then</p></td></tr>
          <tr><td></td><td><p><strong>diazepam po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>20-40mg</p></td><td><p>once a day</p></td><td rowspan="2">
            <p>discontinue within 7 – 14days</p></td></tr>
          <tr><td></td><td></td><td colspan="4">
            <p>[reduce by 5mg every other day]</p> </td></tr>
          <tr><td>and</td><td><p><strong>multivitamins po</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>2 tablets</p></td><td><p>once a day</p></td><td><p>review</p></td></tr>
          <tr><td>or</td><td><p><strong>thiamine po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>50mg</p></td><td><p>once a day</p></td><td><p>review</p></td></tr>
          <tr><td>and</td><td><p><strong>Vit B Complex im </strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1ml</p></td><td><p>Daily for 3 days</p></td><td></td></tr>
        </table>
        <p>These vitamin replacements protect against the development of Wernicke’s encephalopathy (ophthalmoplegia, ataxia, confusion and altered level of consciousness)</p>
        <p><strong>Deficit Hyperactivity Disorder </strong></p>
        <table>
          <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
          <tr><td></td><td><p><strong>methylphenidate po</strong></p> </td><td><p><strong>S</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>10-60mg</p></td><td><p>Daily in 2 – 3 divided doses</p></td><td><p>with regular reviews</p> </td></tr>
        </table>
      </span>
  }],
  content:
    <div></div>
}
const chapter_twentyone = {
  short_title: "Chapter 21",
  long_title: "Common Eye Conditions",
  subsections: [
    {
      short_title: "Section 1",
      long_title: "Prevention of Blindness",
      content:
        <span>
          <h2>Prevention of Blindness</h2>
          <p>80% of blindness can be prevented by:</p>
          <ul>
            <li>proper diet (Vitamin A and proteins)</li>
            <li>personal and environmental hygiene</li>
            <li>measles immunisation</li>
            <li>early treatment of eye diseases by qualified health personnel including cataract surgery and early diagnosis and treatment of glaucoma.</li>
            <li>appropriate management of STIs in pregnant mothers and their sexual partners.</li>
            <li>early referral of serious eye diseases and injuries</li>
            <li>tetracycline eye ointment in the new-born child’s eyes (Crede Prophylaxis)</li>
            <li>early detection and appropriate management of diabetes – stringent control of blood sugar</li>
            <li>early detection and appropriate management of hypertension</li>
            <li>creation of community awareness on the dangers of using herbal medicines in the eye</li>
          </ul>
          <p>“Healthy bodies, healthy eyes!”</p>
          <p>Organic headaches such as migraine and cluster headaches do NOT occur because of eyestrain. See the chapter on Nervous System Conditions for management of these conditions.</p>
          <p>Excessive use of eyes does NOT harm them, and “bad eyes” do NOT result from overuse.</p>
        </span>
    },
    {
      short_title: "Section 2",
      long_title: "Management of Eye Conditions",
      content:
        <span>
          <h2>Management of Eye Conditions</h2>
          <p>Diagnose and <strong>refer urgently</strong> most of the following conditions:</p>
          <ul>
            <li>unexplained vision loss; or visual disturbance.</li>
            <li>glaucoma: high pressure in the eye.</li>
            <li>any perforating eye injury.</li>
            <li>any white pupil in dcptrial (retinopblastoma or retinopathy of prematurity or congenital cataract). </li>
            <li>eye burns.</li>
            <li>orbital cellulitis.</li>
            <li>red eye.</li>
            <li>retinal detachment.</li>
            <li>congenital or developmental squint.</li>
            <li>conjunctivitis persisting after one week of treatment.</li>
            <li>trachoma if eyelashes touching cornea.</li>
            <li>: (protrusion of the eye ball) </li>
          </ul>
          <p><strong>
            <em>Important: Avoid</em>
          </strong>
            <em>the use of steroid eye preparations; conditions requiring them need confirmation by a specialist -</em>
            <strong>
              <em>refer</em>
            </strong>
            <em>. Steroids may lead to worsening of processes like trachoma, increased intra-ocular pressure, cataracts,
      delayed healing and worsening of corneal ulcers of viral origin. </em>
            <strong>
              <em>Never</em>
            </strong>
            <em>use local anaesthetic drops for painful dcptrial conditions. Only specialists should prescribe atropine </em>
            <em>eye drops/ointment.</em></p >
          <p><strong>Diagnosis of Eye Conditions</strong></p>
          <p>Testing vision is the single most important test and every health worker must know how to use an eyesight-testing chart e.g. Snellen Chart or LOGMARChart for both adults and children.</p>
          <p>With a simple torch, most of the external eye diseases can be diagnosed.</p>

        </span>
    },
    {
      short_title: "Section 3",
      long_title: "Atraumatic Eye Conditions",
      content:
        <span>
          <h2>Atraumatic Eye Conditions</h2>
          <p>See table 19.1 for differential</p>
          <p>Acute Glaucoma</p>
          <ul>
            <li>Refer immediately to hospital (delay increases risk of visual loss).</li>
            <li> At hospital: Patient suspected of having acute angle closure glaucoma must be started on pilocarpine 2% or 4% drops in both eyes four times a day.</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td>and</td><td><p><strong>acetazolamide po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>250-500mg</p></td><td><p>stat, then</p>
              <p>8 hourly</p></td><td><p>review</p></td></tr>
          </table>
          <ul>
            <li>Refer to eye specialist within 24 hours.</li>
          </ul>
          <p>Xerophthalmia/ Vitamin A deficiency</p>
          <p>Preventive measures dcptrial promotion of breast-feeding, measles immunisation, Vitamin A supplementation, foods rich in Vitamin A [carrot, mango, pumpkin, and paw-paw].To all children with signs and symptoms of xerophthalmia and/or measles,give and refer:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>vitamin A po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>200,000 iu [&lt;1yr = 100, 000iu]</p></td><td><p>single dose</p></td><td><p>Day 1, Day 2 and repeat after 2 weeks</p></td></tr>
          </table>
          <ul>
            <li>Nutritional rehabilitation is indicated.</li>
          </ul>
          <p>Table 21.1 Differential Diagnosis of a Red Eye</p>
          <table>
            <tr><td><p><strong>Condition</strong></p> </td><td><p><strong>Redness</strong></p> </td><td><p><strong>Pain</strong></p> </td><td><p><strong>Blurred vision</strong></p> </td><td><p><strong>Discharge</strong></p> </td><td><p><strong>Pupil size/ shape/</strong></p>
              <p><strong>reaction to light</strong></p> </td><td><p><strong>Visual acuity</strong></p> </td><td><p><strong>Refer</strong></p> </td></tr>
            <tr><td><p><strong>Acute glaucoma</strong></p> </td><td><p>Yes</p>
              <p>Max. around limbus one or both eyes</p></td><td><p>Yes. Severe + headaches + nausea + vomiting.</p></td><td><p>Yes. Severe +</p>
                <p>haloes around lights</p></td><td><p>No</p></td><td><p>Dilated.</p>
                <p>Fixed.</p></td><td><p>Decreased</p></td><td><p>Yes</p></td></tr>
            <tr><td><p><strong>Conjunctivitis</strong></p> </td><td><p>Yes</p>
              <p>Generalised both eyes usually</p></td><td><p>Yes</p>
                <p>Gritty</p>
                <p>Photophobia</p></td><td><p>No</p></td><td><p>Yes. Maybe copious.</p></td><td><p>Normal</p></td><td><p>Normal</p></td><td><p>Only if no response</p>
                <p>Or copious discharge</p></td></tr>
            <tr><td><p><strong>Corneal ulcer</strong></p> </td><td><p>Yes</p>
              <p>Max. around limbus more near site of ulcer, usually one eye.</p></td><td><p>Yes. Pricking. Photophobia. Stains with fluorescein strips.</p></td><td><p>Yes</p></td><td><p>Yes, in bacterial /fungal ulcers</p>
                <p>No, in viral / ulcers</p> </td><td><p>Normal</p></td><td><p>Depends on the site / size of the ulcer</p> </td><td><p>Refer</p></td></tr>
            <tr><td><p><strong>Iritis /uveitis</strong></p> </td><td><p>Yes</p>
              <p>Max. around limbus, one or both eyes</p></td><td><p>Yes. Deep pain worse on moving eye. Photophobia</p></td><td><p>Yes</p></td><td><p>No</p></td><td><p>Irregular, small, sluggish reaction to light</p></td><td><p>Decreased</p></td><td><p>Yes</p></td></tr>
          </table>
          <p>Conjunctivitis (including trachoma)</p>
          <p>Table 21.2: Differential Diagnosis: Causes of conjunctivitis</p>
          <table>
            <tr><td><p><strong>Signs/ symptoms</strong></p> </td><td><p><strong>Acute bacterial</strong></p> </td><td><p><strong>Viral</strong></p> </td><td><p><strong>Allergic</strong></p> </td><td><p><strong>Chronic, endemic trachoma</strong></p> </td></tr>
            <tr><td><p>Discharge?</p></td><td><p>
          <strong>Purulent</strong></p> </td><td><p>
          <strong>Watery / none</strong></p> </td><td><p>Mucoid</p></td><td><p>None / purulent</p></td></tr>
            <tr><td><p>Itching?</p></td><td><p>None</p></td><td><p>None</p></td><td><p>
          <strong>Marked</strong></p> </td><td><p>None</p></td></tr>
            <tr><td><p>One or both eyes?</p> </td><td><p>One or both</p></td><td><p>One or both</p></td><td><p>Both</p></td><td><p>Usually both</p></td></tr>
            <tr><td><p>Recurrences?</p></td><td><p>Unusual</p></td><td><p>Unusual</p></td><td><p>Usually</p></td><td><p>
          <strong>Chronic</strong></p> </td></tr>
          </table>
          <p>Note: Bold lettering indicates distinguishing feature.</p>
          <p>Treatment of conjunctivitis:</p>
          <ul>
            <li>
              <strong>Acute bacterial conjunctivitis</strong>:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>tetracycline 1% eye ointment</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>apply</p></td><td><p>3 times a day</p></td><td><p>one week</p></td></tr>
            <tr><td></td><td><p><strong>Chloramphenicol 1% eye ointment</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>Apply</p></td><td><p>4 times a day</p></td><td><p>One week</p></td></tr>
          </table>
          <ul>
            <li>
              <strong>Viral conjunctivitis:</strong>
            </li>
          </ul>
          <p>No medicine treatment as this is a self-resolving infection. If in doubt treat as for acute bacterial and refer.</p>
          <ul>
            <li>
              <strong>Allergic conjunctivitis:</strong>
            </li>
          </ul>
          <p><em>Educate/ reassure. Apply cold compresses and</em>
            <em>wear a sun hat whenever outdoors.</em>
            <em>If no relief of symptoms refer. A night-time dose of an antihistamine may relieve symptoms.</em></p>
          <p><em>NB: Steroids are contraindicated in allergic conjunctivitis</em></p>
          <p><em></em></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>Olopatadine (patanol) 1%) eye drops</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>Apply</p></td><td><p>2 times a day</p></td><td><p>2 weeks</p></td></tr>
          </table >
          <p><strong>If no improvement in the three conjunctivitis - refer</strong></p>
          <p><strong>Trachoma:</strong></p>
          <ul>
            <li>If left untreated, the cornea becomes permanently and irreversibly damaged. Apply:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>tetracycline 1% eye ointment</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>apply</p></td><td><p>4 times a day</p></td><td><p>for 6 weeks</p></td></tr>
          </table>
          <ul>
            <li>If inturned eye lashes (trichiasis, entropion) present, perform epilation (pull out the lashes) and <strong>refer</strong> the patient to the eye hospital.</li>
            <li>Provide education in personal and environmental hygiene for prevention of trachoma, with emphasis on face washing, not sharing towels, hand washing, provision of safe water supplies and basic sanitation.</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 4",
      long_title: "Conjunctivitis of the Newborn",
      content:
        <span>
          <h2>Conjunctivitis of the Newborn</h2>
          <p><strong>(Ophthalmia Neonatorum)</strong></p>
          <p>See also the section on Sexually Transmitted Diseases and the STI Module.</p>
          <p>This is defined as conjunctivitis with discharge occurring in a neonate within the first month of life. The condition is commonly caused by gonococcal, chlamydial and bacterial infection and the new born acquires this infection from an infected birth canal during delivery. The condition is preventable by detecting and treating maternal and partner gonococcal and chlamydial infection during pregnancy and by swabbing with normal saline wet cotton swab both eyes as soon as the baby’s head is out followed by instilling 1% tetracycline eye ointment (Crede Prophylaxis) carefully into the conjunctival sacs of every new born baby as soon as possible after birth.</p>
          <p>Ophthalmia Neonatorum is treated as follows:</p>
          <ul>
            <li>Collect pus swab for culture and sensitive before initiation of antibiotic treatment</li>
            <li>Eye(s) Irrigation with with warm Normal Saline until all the pus is removed and intermittently as long as pus is still present.</li>
          </ul>
          <p>Instilling Antibiotic Eye Drops ( Ofloxacillin / Fortified Gentamicin 0.3% ) hourly as long as the eye are still discharging and red during the day and 1% Tetracycline eye ointment at night until infection is cleared.</p>
          <p>Treatment:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td colspan="2">Duration</td></tr>
            <tr><td></td><td><p><strong>kanamycin im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>25mg/kg</p></td><td><p>once</p></td><td colspan="2"><p>single dose</p></td></tr>
            <tr><td>and</td><td><p><strong>erythromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>16mg/kg</p></td><td colspan="2"><p>6 hourly</p></td><td><p>14 days</p></td></tr>
          </table>
          <p>Treat the parents and the baby for gonococcal and chlamydial infection as described above. Also provide healtheducation and counselling to the parents.</p>
        </span>
    },
    {
      short_title: "Section 5",
      long_title: "Traumatic eye conditions",
      content:
        <span>
          <h2>Traumatic eye conditions</h2>
          <p><strong>Penetrating Injury</strong></p>
          <p>Treatment: Put on eye shield and ensure NO pressure. Refer urgently to an eye hospital.</p>
          <p>Administer the following medicines before referral:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
            <tr><td></td><td><p><strong>tetanus toxoid im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>0.5mls</p></td><td><p>once</p></td><td colspan="2"><p>single dose</p></td></tr>
            <tr><td>and</td><td><p><strong>paracetamol po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>4 times a day</p></td><td><p>if required</p></td></tr>
            <tr><td>and</td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>5 days</p></td></tr >
          </table >
          <p><strong>Corneal Foreign Bodies</strong></p>
          <p>Gently attempt removal of foreign body with cotton wool tipped orange stick.If unsuccessful –  <strong>refer to eye hospital</strong>.</p>
          <p>If successful:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>1% eye ointment </strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>apply under an eye pad for 24hrs, then</p></td><td><p>3 times a day</p></td><td><p>1 days</p></td></tr>
          </table>
          <p>Chloramphenicol 1% eye ointment may be used instead of tetracycline eye ointment above.</p>
          <p>If worse after 24 hours – <strong>refer to eye hospital.</strong></p >
          <p><strong>Corneal Abrasion</strong></p>
          <p>Apply an eye pad with tetracycline eye ointment or chloramphenicol 1% eye ointment stat and advise bed rest for 24 hours, then review.If worse, refer to eye hospital</p>
          <p>If improving, continue with:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>tetracycline 1% eye ointment</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>apply</p></td><td><p>3 times a day</p></td><td><p>4 days</p></td></tr>
            <tr><td>or</td><td><p><strong>Chloramphenicol 1% eye ointment</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>Apply</p></td><td><p>4 times a day</p></td><td><p>5 days</p></td></tr>
          </table >
          <p><strong>Chemical Burns</strong></p>
          <p><strong>Refer</strong> after doing the following:</p>
          <p>Consider this to be a <strong>medical emergency</strong> - prompt action can save vision.</p>
          <p>Irrigate the eye and surrounding areas thoroughly using tap water and a 10ml syringe (without the needle) for 30 minutes. Remove any debris or foreign bodies from the eye if present.</p>
          <p>Then:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>tetracycline 1% eye ointment</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="3">
              <p>apply under an eye pad for 24hrs, then</p>
              <p>review</p></td></tr>
            <tr><td></td><td><p>Chloramphenicol 1% eye ointment</p></td><td><p>C</p></td><td><p>V</p></td><td colspan="3">
              <p>Apply, pad eye and refer</p></td></tr >
          </table >
          <p><strong>Iritis / Uveitis</strong></p>
          <p>Refer to eye specialist.</p>
          <p><a><strong>Corneal Ulcers</strong>
          </a></p>
          <p>(<strong>Refer</strong>) NB: corneal sensation must always be tested with a cotton tip to exclude herpetic cause of corneal ulcer which would be treated with antiviral drugs like acyclovir</p>
          <p>Treatment:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>tetracycline 1% eye ointment</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>apply</p></td><td><p>3 times a day</p> </td><td><p>5-7 days</p></td></tr>
            <tr><td><p>or</p></td><td><p>Chloramphenicol 1% eye ointment</p></td><td><p>C</p></td><td><p>V</p></td><td><p>Apply</p></td><td><p>4 times a day</p></td><td><p>5 days</p></td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 6",
      long_title: "Glaucoma (Chronic Open Angle)",
      content:
        <span>
          <h2>Glaucoma (Chronic Open Angle)</h2>
          <p>A specialist must first confirm the diagnosis of glaucoma. The treatment can then be repeated according to the specialist’s prescription, provided the patient is referred back to the specialist every 3 months for review. Chronic Glaucoma</p>
          <p>At hospital: Chronic open angle glaucoma:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>pilocarpine 4% eye drops</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1 drop in each eye</p> </td><td><p>6 hourly</p></td><td><p>Continual</p></td></tr>
            <tr><td></td><td><p><strong>DCPtrial maleate 0.5% eye drops </strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1 drop in each eye</p></td><td><p>Twice a day</p></td><td><p>Continual as per recommendation by specialist</p></td></tr>
          </table>
          <p><br /> If intra-ocular pressure is more than 40mmHg:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>Timolol Maleate</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p><strong>1 drop</strong></p> </td><td><p>12 hourly</p></td><td><p>Continual</p></td></tr>
            <tr><td>or</td><td><p><strong>Xalatan eye drops</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1 drop</p></td><td><p>Daily</p></td><td><p>continual</p></td></tr>
            <tr><td>or</td><td><p><strong>Xalacom (latanoprost 5micrograms, timolol maleate 5mg/ml)</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>1 drop</p></td><td><p>Daily</p></td><td><p>continual</p></td></tr>
            <tr><td>or</td><td><p><strong>Levobunolol hydrochloride 0.5% eye drops</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>1 drop</p></td><td><p>12 hourly</p></td><td><p>Continual</p></td></tr>
            <tr><td>and</td><td><p><strong>*Acetazolamide po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>0.25-1g</p></td><td><p>Divided doses/day</p></td><td><p>Few weeks</p></td></tr>
          </table>
          <p>*NOTE: This medicine should <strong>NOT</strong> be used for more than 3 months without review by a specialist and potassium chloride 600mg/day orally should be given when patient is on acetazolamide.</p>
          <p>Timolol dcptrial not be prescribed in Asthma and other Chronic Obstructive Airway Diseases (COAD)</p>

        </span>
    },
    {
      short_title: "Section 7",
      long_title: "Cataract",
      content:
        <span>
          <h2>Cataract</h2>
          <p>Cataract is defined as opacity of the lens. Causes may be classified as acquired and congenital. Aging, trauma, inflammation,
          drugs and metabolic disorders like diabetes mellitus are the leading acquired causes while intrauterine infections, inheritance and congenital abnormalities are the leading congenital causes of cataracts. Treatment for cataract is surgical except for galactocaemic cataract which reverses when the neonate is given lactose free diet. Cataract present with a white pupil in children, loss of vision of various degrees, squint and rarely painful blind eye if neglected and complicated with glaucoma and lens induced uveitis.</p>
          <p>Mydriatic Drugs <strong>:</strong></p>
          <table>
            <tr><td colspan="3">
              Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td colspan="2"></td><td><p><strong>Tropicamide 0.5% or 1% eye drops</strong></p> </td><td><p><strong>B V</strong></p>
            </td><td><p>1-3 drops</p></td><td><p>stat</p></td><td><p>Pre-op</p></td></tr>
            <tr><td colspan="2"><p>Or</p></td><td><p><strong>Cyclopentolate 0.5% or 1% eye drops</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1-3 drops</p></td><td><p>stat</p></td><td><p>Pre-op</p></td></tr>
            <tr><td colspan="2"><p>And</p></td><td><p><strong>Phenylepherine 2.5% eye drops</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1-3drops</p></td><td><p>stat</p></td><td><p>Pre-op</p></td></tr>
            <tr><td></td><td colspan="2"><p><strong>Atropine 0.5% or 1% </strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1-2 drops</p></td><td><p>2-3 times/day</p></td><td><p>1 week</p></td></tr >
          </table >
          <p>Corticosteroid drugs used post cataract surgery:</p>
          <table>
            <tr><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>Dexamethasone 0.1% neomycin DCPTRIAL polymyxin B sulphate 6000units/L and ointment </strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1 drop</p></td><td><p>6 hourly</p></td><td><p>6 weeks</p></td></tr>
            <tr><td><p>Or</p></td><td><p><strong>Dexamethasone 0.1%, neomycin 0.35% eye drops and ointment </strong></p> </td><td><p><strong>B</strong></p>
            </td><td><p><strong>V</strong></p>
              </td><td><p>1 drop</p></td><td><p>6 hourly</p></td><td><p>6 weeks</p></td></tr>
            <tr><td><p>Or</p></td><td><p><strong>Dexamethasone 0.1% eye drops </strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1 drop</p></td><td><p>6 hourly</p></td><td><p>6 weeks</p></td></tr>
            <tr><td><p>Or</p></td><td><p><strong>Betamethasone 0.1% eye drops</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1 drop</p></td><td><p>6 hourly</p></td><td><p>6 weeks</p></td></tr>
            <tr><td><p>Or</p></td><td><p><strong>Prednisolone acetate 1% eye drops</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>E</strong></p> </td><td><p>1 drop</p></td><td><p>1-2 hourly</p></td><td><p>2-3 weeks</p></td></tr>
          </table>
          <p>Antibacterial drugs for eye infections</p>
          <table>
            <tr><td colspan="2">Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>Gentamicin 0.3% eye drops</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1 drop</p></td><td><p>2-6 hourly</p></td><td><p>14 days</p></td></tr>
            <tr><td><p>or</p></td><td><p><strong>Ciprofloxacin 0.3% eye drops</strong></p> </td><td><p><strong>B</strong></p>
            </td><td><p><strong>V</strong></p> </td><td><p>1 drop</p></td><td><p>1-2 hourly</p></td><td><p>2 days then reduce dose to 4 hourly for 12 days</p></td></tr>
            <tr><td><p>or</p></td><td><p><strong>Ofloxacin 0.3% eye drops</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>1 drop</p></td><td><p>2-4hourly</p></td><td><p>2 days then reduce to 4 hourly for 10 days</p></td></tr>
          </table>
          <p>Antivirals agents for eyes</p>
          <table>
            <tr><td colspan="3">
              Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>Acyclovir eye ointment (For corneal ulcers)</strong></p> </td><td colspan="2"><p><strong>A</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>1 cm ointment</p></td><td><p>5 times a day</p></td><td><p>14 days</p></td></tr>
            <tr><td></td><td><p><strong>Acyclovir 200mg tablet (For herpes zoster ophthalmicus)</strong></p> </td><td colspan="2"><p><strong>A</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>800mg</p></td><td><p>5 times a day</p> </td><td><p>7 days</p></td></tr>
            <tr><td><p>Or</p></td><td><p><strong>Famcivlovir 250mg tablet (For herpes zoster ophthalmicus)</strong></p> </td><td colspan="2"><p><strong>A</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>500mg</p></td><td><p>3 times/day</p></td><td><p>7 days</p></td></tr >
          </table >
          <p>Treatment for Cytomegalovirus retinitis:</p>
          <table>
            <tr><td colspan="2"><p>Medicine</p></td><td colspan="2">Codes</td><td>Adult Dose</td><td colspan="2">Frequency</td><td colspan="2">Duration</td></tr>
            <tr><td></td><td><p><strong>Ganciclovir 500mg vial</strong></p> </td><td><p><strong>A</strong></p>
            </td><td><p><strong>V</strong></p>
              </td><td colspan="2"><p>5mg/kg infusion</p></td><td colspan="2"><p>12 hourly</p></td><td><p>14-21 days</p></td></tr>
            <tr><td><p>And</p></td><td><p><strong>Forscanet 24mg/ml IVI</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>V</strong></p> </td><td colspan="2"><p>90mg/kg infusion</p></td><td colspan="2"><p>12 hourly</p></td><td><p>2-3 weeks</p></td></tr >
          </table>
          <p>Topical anaesthetics and diagnostic preparations:</p>
          <table>
            <tr><td colspan="4">
              Medicine</td><td colspan="3">
                Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td colspan="2">Duration</td></tr>
            <tr><td></td><td colspan="3">
              <p>Oxybuprocaine hydrochloride 0.4% eye drops</p> </td><td colspan="2"><p>B</p>
              </td><td><p>V</p>
              </td><td colspan="2"><p>1 drop</p></td><td colspan="2"><p>Stat</p></td><td colspan="2"><p>Repeat if necessary</p></td></tr>
            <tr><td><p>Or</p></td><td colspan="3">
              <p>Tetracaine hydrochloride 0.5% eye drops</p></td><td colspan="2"><p>B</p></td><td><p>V</p></td><td colspan="2"><p>1 drop</p></td><td colspan="2"><p>Stat</p></td><td colspan="2"><p>Repeat if necessary</p></td></tr>
            <tr><td colspan="2"> </td><td></td><td colspan="2"> </td><td colspan="3">
            </td><td colspan="2"> </td><td colspan="2"> </td><td></td></tr >
          </table>
          <p>Diagnostic preparations</p>
          <p>Fluorescein strips</p>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td><td></td></tr>
            <tr><td><p>Fluorescein strips</p></td><td><p>C</p></td><td><p>V</p></td><td><p>1 strip</p></td><td><p>Single use</p></td><td colspan="2"><p>Single use</p></td></tr>
            <tr><td><p>Fluorescein solution 1% or 2%</p></td><td><p>A</p></td><td><p>V</p></td><td><p>1 Vial</p></td><td><p>Single use</p></td><td colspan="2"><p>Single use</p></td></tr >
          </table>
        </span>
    },
    {
      short_title: "Section 8",
      long_title: "Eye consumables",
      content:
        <span>
          <h2>Eye consumables</h2>
          <table>
            <tr><td><p>Medicine / item</p></td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>Intra-ocular dcptrial (various powers) </strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
            <tr><td><p><strong>Eye pads</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
            <tr><td><p><strong>Methylene Blue</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
            <tr><td><p><strong>Arrow swabs / dcptrial eye swabs </strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
            <tr><td><p><strong>Eye shields</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
            <tr><td><p><strong>Viscoelastic</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
            <tr><td><p><strong>BSS (Balance salt solution vacolitres) for cataract surgery</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
            <tr><td><p><strong>Fluid giving sets</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
            <tr><td><p><strong>Micropore</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
            <tr><td><p><strong>Surgical gloves (sterile)</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
            <tr><td><p><strong>Suture materials</strong></p>
              <p><strong>(10.0, 11.0, 9.0 nylon, 8,0 vircyl, 4.0 nylon or silk)</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>N/A</p></td><td><p>Single use</p></td><td><p>N/A</p></td></tr>
          </table>
        </span>
    },
  ],
  content:
    <span></span>
}
const chapter_twentytwo = {
  short_title: "Chapter 22",
  long_title: "Common Oral Conditions",
  subsections: [
    {
      short_title: "Section 1",
      long_title: "Oral problems",
      content:
        <span>
          <h2>Oral problems</h2>
          <p>Oral lesions are quite common especially amongst HIV positive patients. At any encounter with a healthcare worker, the patient should have their mouth examined for various lesions such as the following:</p>
          <ul>
            <li>Oral thrush or candidiaisis/angular cheiltis</li>
            <li>Herpes simplex labialis</li>
            <li>Kaposi’s sarcoma</li>
            <li>Gum infections</li>
            <li>Salivary gland disorders e.g. parotid gland enlargement</li>
            <li>Dental caries</li>
            <li>Cancrum oris</li>
            <li>Enlarged nodes such as submandibular, submental and cervical lymphadenopathy</li>
            <li>Ranula- dcptrial sublingual swelling especially in children </li>
            <li>Oral hairy leucoplakia</li>
          </ul>
          <p>Some of these lesions will need referral to a dentist for biopsy if one is worried about malignancy e.g. with Kaposi sarcoma and lymphoma or infections such as histoplasmosis.</p>
        </span>
    },
    {
      short_title: "Section 2",
      long_title: "Management of Oral thrush/Oral candidiasis",
      content:
        <span>
          <h2>Management of Oral thrush/Oral candidiasis</h2>
          <p>This will be one of the commonest abnormalities found in the mouth. Diagnosed when whitish patches or reddening of the oral mucosa is noted. The condition may be associated with a feeling of not tasting food well plus odynophagia (pain in the chest on swallowing). Angular cheilitis is ulceration and occasional bleeding at the corner of the mouth. Apart from suspecting HIV related disease, exclude the current use of antibiotics, steroids or the presence of diabetes mellitus. Offer HIV testing and counselling (HTC).</p>
          <p>Treat with topical therapy such as:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>nystatin suspension</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>200 000 units</p></td><td><p>5 times a day</p></td><td><p>7- 14days</p></td></tr>
            <tr><td></td><td><p><strong>nystatin lozenges</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>Sucked</p></td><td><p>5 times a day</p></td><td><p>7- 14 days</p></td></tr>
            <tr><td>or</td><td><p><strong>miconazole oral gel 2%</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>Topically</p></td><td><p>4 times a day</p></td><td><p>7 – 14days-</p></td></tr>
          </table>
          <p>If there is odynophagia, treat as oesophageal candidiaisis as follows:</p>
        </span>
    },
    {
      short_title: "Section 3",
      long_title: "Oesophageal Candidiasis",
      content:
        <span>
          <h2>Oesophageal Candidiasis</h2>
          <p>This is an AIDS defining illness (WHO Stage 4 disease) and hence the patient would need to be worked up for referral to the OI Clinic for ARV therapy. Offer HTC and consider giving Cotrimoxazole prophylaxis.</p>
          <p>Treat oesophageal candidiaisis with dcptrial medicines such as:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>200mg</p></td><td><p>Twice a day</p></td><td><p>7 – 14days</p></td></tr>
          </table>
          <ul>
            <li>Nutritional rehabilitation is indicated. </li>
            <li>Exclude other OIs such as TB/KS</li>
            <li>Refer to OI Clinic.</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 4",
      long_title: "Herpes Simplex labialis",
      content:
        <span>
          <h2>Herpes Simplex labialis</h2>
          <p>Usually the lesions are found on the lips, buccal mucosa and hard palate. They may prevent the patient from eating or swallowing well. If lesions are extensive e.g. covering all the lip areas, consider the following:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>acyclovir po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p></td><td><p>5 days</p></td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 5",
      long_title: "Kaposi Sarcoma",
      content:
        <span>
          <h2>Kaposi Sarcoma</h2>
          <p>The purple coloured lesions or nodules should be easy to see especially when they are on the palate but may be more difficult to diagnose if they are underneath the tongue. Check for similar lesions elsewhere. The patient should be offered HTC. Assess for Cotrimoxazole prophylaxis and refer to your nearest OI clinic.</p>
        </span>
    },
    {
      short_title: "Section 6",
      long_title: "Gum infections",
      content:
        <span>
          <h2>Gum infections</h2>
          <p>These are most common in those who do not brush their teeth regularly. Oral hygiene should be emphasised.</p>      <p>Necrotizing gingivitis/periodontitis/stomatitis There may be spontaneous bleeding of the gums as well as loosening of the teeth</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p>plus</p></td><td><p><strong>metronidazole po</strong></p>
              <p><strong>amoxicillin po</strong></p> </td><td><p><strong>C</strong></p>
                <p><strong>C V</strong></p>
                <p><strong>V</strong></p> </td><td><p>200mg</p>
                <p>500mg</p></td><td><p>3 times a day</p>
                <p>3 times a day</p> </td><td><p>5 days</p>
                <p>5 days</p></td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 7",
      long_title: "Dental Caries",
      content:
        <span>
          <h2>Dental Caries</h2>
          <p>The teeth will have multiple decays. Oral hygiene is needed and brushing twice a day with fluoride toothpaste should be encouraged. Limit sweet foods. Regular dental examination is required.</p>
        </span>
    },
    {
      short_title: "Section 8",
      long_title: "Persistent Lymphadenopathy (PGL)",
      content:
        <span>
          <h2>Persistent Lymphadenopathy (PGL)</h2>
          <p>The commonest cause of generalized enlarged lymph nodes (&gt; 1cm) is underlying HIV. Thus the patient should be considered for HTC.</p>
        </span>
    },
    {
      short_title: "Section 9",
      long_title: "Oral Ulcers",
      content:
        <span>
          <h2>Oral Ulcers</h2>
          <p>These are painful ulcers that may occur dcptrial in the buccal mucosa. They may prevent the patient from eating properly. Apart from herpes simplex, most are treated symptomatically by using simple analgesics. Large ulcers may need biopsy to exclude malignancy.</p>
          <p>The following applied to the mouth area may help:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>0.2% chlorhexidine mouth rinse</strong></p> </td><td><p><strong>C E</strong></p> </td><td colspan="2"><p>2 – 4 times a day</p></td><td></td></tr>
            <tr><td>or</td><td><p><strong>1% povidone iodine</strong></p> </td><td><p><strong>C E</strong></p> </td><td colspan="2"><p>4 times a day</p> </td><td></td></tr>
            <tr><td>or</td><td><p><strong>triamcinolone acetonide in orabase</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td colspan="2"><p>3 times a day</p></td><td></td></tr >
          </table>
        </span>
    },
    {
      short_title: "Section 10",
      long_title: "Histoplasmosis",
      content:
        <span>
          <h2>Histoplasmosis</h2>
          <p>This may present as a nodule on the dcptrial and sometime a penetrating lesion i.e. a hole in the palate. Biopsy should confirm the diagnosis.</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>ketoconazole po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>200mg</p></td><td><p>Twice a day</p></td><td><p>Months</p></td></tr>
          </table>
        </span>
    },],

  content:
    <div></div>
}
const chapter_twentythree = {
  short_title: "Chapter 23",
  long_title: "Ear, Nose and Throat Conditions",
  content:
    <div>
      <h1><a>Ear Nose and throat disorders </a>
      </h1>
      <p><a>Oral problems</a></p>
      <p>Management of Oral thrush/Oral candidiasis</p>
      <p>Oesophageal Candidiasis</p>
      <p>Herpes Simplex labialis</p>
      <p>Kaposi Sarcoma</p>
      <p>Gum infections</p>
      <p>Dental Caries</p>
      <p>Persistent Generalized Lymphadenopathy (PGL)</p>
      <p>Oral Ulcers</p>
      <p>Histoplasmosis</p>
      <h3>        <br /> Acute Otitis Media (AOM)</h3>
      <p>Patient presents with fever, chills and irritability. Most common under 2 years of age. Examination shows irritable child,
    tympanic membrane inflamed and bulging.</p>
      <p>Natural history</p>
      <ul>
        <li>60% dcptrial in 24hrs </li>
        <li>80% by 48hrs</li>
        <li>88% 4-7 days</li>
        <li>OME 63% resolve after 2 weeks 40% remaining after one month</li>
        <li>remaining by 3 months </li>
      </ul>
      <p>Organisms that are involved in Acute Otitis Media</p>
      <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.158.png" width="275" height="236"
        alt="" /></p>
      <p>Streptococcus pneumonia (35%), Haemophilus influenza (23%), Moraxella catarrhalis (14%) form the majority.</p>
      <p><u>Treatment</u></p>
      <ul>
        <li>Avoid risk factors-breastfeed more than 6 months; prevent parental smoking, encourage vaccination, provide good nutrition and encourage early attendance to day care.</li>
        <li>Analgesia and supportive care</li>
      </ul>
      <p><u>Indications for dcptrial antibiotics </u></p>
      <ul>
        <li>AOM under 6 months</li>
        <li>Severe AOM-temperature (axillary) &gt; 39.5ºC</li>
        <li>Associated comorbidity-malnutrition, HIV</li>
        <li>Failure of resolution of symptoms in 48-72 hrs.</li>
        <li>Patients who might not return to hospital</li>
      </ul>
      <p>First line medicine</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p>
          <p>40mg /kg in paeds</p></td><td><p>3 times a day</p></td><td><p>2 ays</p></td></tr>
      </table>
      <h3><a>Caution: Use erythromycin in dcptrial with penicillin allergy, patients who received amoxicillin in the last thirty days (move to second line as the risk of resistance is high) </a>
      </h3>
      <p>Second line medicine</p>
      <table>
        <tr><td colspan="2"></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td colspan="2"><p><strong>Amoxicillin and clavulinic acid po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>80mg/kg; 6.4mg/kg</p></td><td><p>2 times a day</p></td><td><p>10 days (severe &amp; &lt;6mnths)</p>
          <p>5-7 days (less severe)</p></td></tr >
      </table>
      <h3><a>Recurrent Acute Otitis Media</a>
      </h3>
      <p>More than four episodes per year –
    <strong>REFER</strong></p>
      <h3><a>Acute Mastoiditis</a>
      </h3>
      <p>DCPtrial presents with fever, chills. Examination reveals tenderness over mastoid and retroauricular swelling. Anterior displacement of auricle. Bulging and unhealthy tympanic membrane.</p>
      <ul>
        <li>Initiate intravenous and <strong>REFER</strong>
        </li>
      </ul>
      <table>
        <tr><td colspan="2"></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td colspan="2">Duration</td><td></td></tr>
        <tr><td></td><td colspan="2"><p><strong>Benzyl penicillin iv/im</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="2"><p>0.1MU/kg</p></td><td colspan="2"><p>stat</p></td><td colspan="2"></td></tr>
        <tr><td></td><td colspan="2"><p><strong>Ceftriaxone iv/im</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td colspan="2"><p>80mg/kg</p></td><td colspan="2"><p>stat</p></td><td colspan="2"></td></tr >
      </table>
      <h3><a>Otitis Media with DCPtrial </a>
      </h3>
      <ul>
        <li>Follows AOM or can present without any history of AOM</li>
        <li>Hearing loss most common presentation and aural fullness</li>
        <li>5-7 years most common age group affected</li>
        <li>Otoscopy reveals brownish fluid behind intact tympanic membrane. Retraction of bulging of tympanic membrane with no signs of acute inflammation.</li>
      </ul>
      <p>Otitis media with effusion in an adult <strong>needs referral</strong> to an ENT specialist for exclusion of nasopharyngeal carcinoma.</p>
      <p>Organisms that are dcptrial in Otitis Media Effusion</p>
      <p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.159.png" width="308" height="308"
        alt="" /></p>
      <h3><a>For management REFER to Specialist</a>
      </h3>
      <h3><a>Chronic suppurative otitis media</a>
      </h3>
      <p>Presentation</p>
      <ul>
        <li>Otorrhoea for more than 14 days, hearing loss, usually no otalgia</li>
        <li>Otoscopy -mucopurulent discharge, ossicular chain erosion, Hearing loss</li>
        <li>Organisms-Staphylococcus aureus, Proteus spp, Klebsiella, Enterobacteriacie</li>
      </ul>
      <p>Treatment</p>
      <p>Ear syringing with saline or agent such as 1% boric acid, acetic acid and continued aural toilet</p>
      <p>If ear is clear of discharge prescribe the following:</p>
      <table>
        <tr><td colspan="2"> </td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td><td></td></tr>
        <tr><td></td><td colspan="2"><p><strong>Ciprofloxacin ear drops</strong></p> </td><td><p><strong>B</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>3 drops</p></td><td><p>Twice daily</p></td><td colspan="3">
          <p>7 days</p></td></tr>
        <tr><td></td><td colspan="2"><p><strong>Amoxicillin po</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p></td><td colspan="3">
          <p>7 days</p></td></tr >
      </table>
      <ul>
        <li>Keep ears dry</li>
        <li>Avoid swimming</li>
        <li>
          <strong>REFER</strong> immediately to Ear Nose throat surgeon</li>
      </ul>
      <h3><a>Cholesteatoma</a>
      </h3>
      <p>Presentation</p>
      <ul>
        <li>Keratin debris in the middle ear.</li>
      </ul>
      <p><strong>REFER</strong> immediately</p>
      <h3><a>Otitis Externa</a>
      </h3>
      <ul>
        <li>Presentations vary depending on cause</li>
        <li>Itchiness of canal, ulcers on the externa auditory canal, inflamed canal, occasional discharge from canal</li>
        <li>Otoscopy to assess the canal and tympanic membrane. Inflamed external ear (auricle and external auditory canal)</li>
      </ul>
      <p><a><strong>Bacterial otitis externa</strong>
      </a></p>
      <p>Aural toilet with boric acid and acetic acid</p>
      <table>
        <tr><td colspan="2"></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td><td></td></tr>
        <tr><td></td><td colspan="2"><p><strong>Ciprofloxacin and dexamethasone ear drops</strong></p> </td><td><p><strong>B</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>3 drops</p></td><td><p>Twice daily</p></td><td colspan="3">
          <p>7 days</p></td></tr>
        <tr><td><p>or</p></td><td colspan="2"><p><strong>Chloramphenicol and dexamethasone ear drops </strong></p> </td><td><p><strong>B</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>3 drops</p></td><td><p>Twice daily</p></td><td colspan="3">
          <p>7 days</p></td></tr>
        <tr><td><p>or</p></td><td colspan="2"><p><strong>Boric acid 1% ear drops</strong></p> </td><td><p><strong>B</strong></p> </td><td colspan="2"><p><strong>E</strong></p> </td><td><p>3 drops</p></td><td><p>Twice daily</p></td><td colspan="3">
          <p>7 days</p></td></tr>
        <tr><td><p>or</p></td><td colspan="2"><p><strong>Acetic Acid ear drops</strong></p> </td><td><p><strong>B</strong></p> </td><td colspan="2"><p><strong>N</strong></p> </td><td><p>3 drops</p></td><td><p>Twice daily</p></td><td colspan="3">
          <p>7 days</p></td></tr >
      </table>
      <p>Systemic Antibiotics are indicated for severe Otitis Externa</p>
      <table>
        <tr><td colspan="2"></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td><td></td></tr>
        <tr><td></td><td colspan="2"><p><strong>Amoxicillin po</strong></p> </td><td><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p> </td><td colspan="3">
          <p>7-10 days</p></td></tr>
        <tr><td></td><td colspan="2"><p><strong>Ciprofloxacin po</strong></p> </td><td><p><strong>B</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>500mg</p></td><td><p>Twice daily</p></td><td colspan="3">
          <p>7-10 days</p></td></tr >
      </table >
      <p><strong>Malignant Otitis Externa</strong></p>
      <p>This is a necrotising infection of the ear canal in patients who are immunosuppressed. Often the first presentation and should alert the physician of immunosuppression from any cause e.g. diabetes, HIV etc.</p>
      <p>Initiate IV antibiotics with a penicillin as above</p>
      <table>
        <tr><td colspan="2"></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td><td></td></tr>
        <tr><td></td><td colspan="2"><p>Ciprofloxacin po</p></td><td><p>B</p></td><td colspan="2"><p>V</p></td><td><p>500mg</p></td><td><p>2 times a day</p></td><td colspan="3">
          <p>12 weeks</p></td></tr >
      </table>
      <p>Add: Intravenous fluids</p>
      <p>Debridement</p>
      <p><strong>REFER</strong> immediately</p>
      <p><a><strong>Fungal otitis externa</strong>
      </a></p>
      <p>After routine ear toilet as above</p>
      <table>
        <tr><td colspan="2"></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td><td></td></tr>
        <tr><td></td><td colspan="2"><p>Clotrimazole ear drops</p></td><td><p>B</p></td><td colspan="2"><p>V</p></td><td><p>3 drops</p></td><td><p>Once daily</p></td><td colspan="3">
          <p>7 days</p></td></tr >
      </table>
      <p>Acidifying agents like boric acid and acetic acid can be used as well</p>
      <p><a><strong>Keratosis Obliterans</strong>
      </a></p>
      <ul>
        <li>Clear the ear canal of all debris</li>
        <li>Inspect the canal and tympanic membrane</li>
      </ul>
      <p><a><strong>Allergic Otitis Externa</strong>
      </a></p>
      <table>
        <tr><td colspan="2"></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td><td></td></tr>
        <tr><td></td><td colspan="2"><p>1% hydrocortisone cream</p></td><td><p>C</p></td><td colspan="2"><p>V</p></td><td><p>Apply</p></td><td><p>Once daily</p></td><td colspan="3">
          <p>7 days</p></td></tr >
      </table>
      <h3><a>Inner Ear</a>
      </h3>
      <p><strong>Vertigo-</strong></p>
      <ul>
        <li>Viral Labyrinthitis</li>
        <li>Benign Paroxysmal Positional Vertigo</li>
        <li>Meniere Syndrome</li>
      </ul>
      <p><strong>REFER</strong></p>
      <p>Sensorineural Hearing Loss-
    <strong>REFER</strong></p>
      <p>Cerebrospinal Fluid Otorrhoea-
    <strong>REFER</strong></p>
      <h3><a>Rhinology</a>
      </h3>
      <p><a><strong>Acute Rhinosinusitis</strong>
      </a></p>
      <p><u>Clinical presentation</u></p>
      <ul>
        <li>Nasal blockage, rhinorrhoea, anosmia facial pressure/pain are common symptoms</li>
        <li>Examination reveals clear nasal discharge initially and discharge turns mucopurulent when bacterial superinfection occurs.</li>
        <li>Majority are caused by viral infections such as rhinovirus, Adenovirus, respiratory syncytial virus, Para influenza virus</li>
      </ul>
      <p><strong>
        <u>Treatment</u>
      </strong></p>
      <ul>
        <li>Observation and supportive care</li>
        <li>Analgesia and plenty of oral fluids</li>
      </ul>
      <p><u>Indications of antibiotics</u></p>
      <ul>
        <li>Failure of resolution of symptoms in 48-72 hrs.</li>
        <li>Discharge turns mucopurulent</li>
        <li>DCPtrial with comorbidities e.g. malnutrition, immunosuppression </li>
      </ul>
      <table>
        <tr><td colspan="2"></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="3">
          Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
        <tr><td></td><td colspan="2"><p><strong>Amoxicillin po</strong></p> </td><td colspan="2"><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>3 times a day</p></td><td colspan="2"><p>7 days</p></td></tr >
      </table >
      <p><strong>Chronic Rhinosinusitis</strong></p>
      <p>If above symptoms persist for 90 days.</p>
      <p><strong>REFER</strong></p>
      <p><a><strong>Allergic Rhinosinusitis</strong>
      </a></p>
      <p><u>Presentation</u></p>
      <ul>
        <li>Acute rhinorrhoea- clear nasal discharge, Nasal obstruction, and anosmia</li>
      </ul>
      <p><u>Treatment</u></p>
      <ul>
        <li>Avoid allergens</li>
      </ul>
      <p><u>First line</u></p>
      <table>
        <tr><td colspan="2"></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="3">
          Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
        <tr><td></td><td colspan="2"><p>Fluticasone diproprionate nasal spray</p></td><td colspan="2"><p>B</p></td><td colspan="2"><p>V</p></td><td><p>One puff</p></td><td colspan="2"><p>1-2 times a day</p></td><td colspan="2"><p>1 month</p></td></tr>
        <tr><td></td><td colspan="2"><p>Fluticasone furoate spray</p></td><td colspan="2"><p>A</p></td><td colspan="2"><p>E</p></td><td><p>One puff</p></td><td colspan="2"><p>Once a day</p></td><td colspan="2"><p>1 month</p></td></tr >
      </table>
      <ul>
        <li>Duration of treatment dcptrial according to response. Minimum one month of spray. </li>
        <li>Nasal sprays are efficacious as they control nasal symptoms and are less systemically absorbed hence have low side effect profile</li>
      </ul>
      <p><u>Second line</u></p>
      <p>Oral antihistamines</p>
      <table>
        <tr><td colspan="2"></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="3">
          Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
        <tr><td></td><td colspan="2"><p><strong>Chlopheniramine po</strong></p> </td><td colspan="2"><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>4mg</p></td><td colspan="2"><p>3 times a day</p></td><td colspan="2"><p>7 days</p></td></tr>
      </table>
      <ul>
        <li>Cause sedation, prostatism and should be used with caution in patients with glaucoma. They cause dryness of secretions and tachyphylaxis. Medications should not be taken for more than seven days without referral</li>
      </ul>
      <p><u>Second generation antihistamines</u></p>
      <table>
        <tr><td colspan="2"></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="3">
          Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
        <tr><td></td><td colspan="2"><p><strong>Cetirizine po</strong></p> </td><td colspan="2"><p><strong>B</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>10mg</p></td><td colspan="2"><p>Once at bedtime</p></td><td colspan="2"><p>7 days</p></td></tr>
      </table>
      <p>NB: They do not have CNS penetration hence do not cause sedation and tachyphylaxis.</p>
      <p>Patients with persistent dcptrial despite nasal steroids need referral for further investigations</p>
      <p><strong>Fungal Rhinosinusitis-Invasive</strong></p>
      <ul>
        <li>Invasive fungal sinusitis-common in immunosuppressed such as diabetic (uncontrolled, Ketoacidosis).</li>
        <li>This is an aggressive soft tissue infection with high mortality rate and needs a high index of suspicion. Early referral to Ear Nose and Throat Surgeon is required</li>
        <li>Presentation- nasal blockage, necrosis of mucosa of nasal cavity. Orbital signs include proptosis and opthalmoplegia.
      Patients also present with intracranial extension</li>
      </ul>
      <p>Management-Refer for:</p>
      <ul>
        <li>Correct underlying cause</li>
        <li>Aggressive surgical debridement</li>
        <li>Microscopy and culture to dcptrial the fungal </li>
        <li>Systemic antifungal treatment</li>
      </ul>
      <p><strong>Non Invasive fungal Rhinosinusitis</strong></p>
      <p><strong>Refer</strong></p>
      <p><strong>Obstructive sleep dcptrial from adenotonsillar hypertrophy </strong></p>
      <ul>
        <li>Children present with snoring, stertor (a respiratory sound characterized by heavy snoring or gasping caused by partial obstruction of airway), mouth breathing</li>
        <li>Treatment depends on severity of symptoms.</li>
      </ul>
      <p>Refer for persistent symptoms</p>
      <p><strong>Tonsillitis-Acute</strong></p>
      <ul>
        <li>Patients present with fever, chills, odynophagia and dysphagia</li>
        <li>On examination the tonsils are inflamed and often have exudates. Unilateral exudate and tonsillar asymmetry indicate a peritonsillar abscess</li>
      </ul>
      <p>Management</p>
      <p>Analgesia and antibiotics</p>
      <p>First line</p>
      <table>
        <tr><td colspan="2"></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="3">
          Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
        <tr><td></td><td colspan="2"><p><strong>Amoxicillin po</strong></p> </td><td colspan="2"><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>3 times a day</p></td><td colspan="2"><p>7 days</p></td></tr >
      </table>
      <p>Second line</p>
      <table>
        <tr><td colspan="2"></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="3">
          Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
        <tr><td></td><td colspan="2"><p><strong>Amoxicillin/clavulinic acid po</strong></p> </td><td colspan="2"><p><strong>A</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>80mg/kg;7mg/kg</p></td><td colspan="2"><p>2 times a day</p></td><td colspan="2"><p>7 days</p></td></tr>
      </table>
      <p>Third line</p>
      <p>Cephalosporin under specialist care</p>
      <p>Recurrent - Refer</p>
      <p>Chronic tonsillitis - Refer</p>
      <p>Peritonsillar abscess-Initiate antibiotics as above and refer</p>
      <h3>Epistaxis</h3>
      <p>Predisposing factors include upper respiratory tract infection, habitual nose picking, nasal sprays, haematological malignancies and patients on anticoagulants,</p>
      <p>Patients with hypertension often have severe epistaxis</p>
      <p><u>Management</u></p>
      <p>Expel clots and examine nose with good light</p>
      <p>Identify the bleeding points</p>
      <p>Children-bleeding on Little’s area is common</p>
      <p>Adults –may have a posterior bleed</p>
      <p><u>Anterior epistaxis-</u> Pack anteriorly bilaterally with ribbon gauze soaked in oily antiseptic solution such as Proflavin gel or glycerine and icthymol.</p>
      <p>Posterior packing. Use Foley’s catheter with 5cc of saline to pack posteriorly</p>
      <p>Reinforce with anterior packing bilaterally</p>
      <p>Refer as soon as pack is in situ</p>
      <p>The use of adrenaline is discouraged as it may cause severe rebound epistaxis.</p>
      <p>Initiate Amoxicillin if pack is to last for more than 48 hrs.</p>
      <p><u>Indications for referral in epistaxis</u></p>
      <p>Patients with posterior bleed</p>
      <p>Patients with comorbidities-hypertension, anticoagulation use, elderly, severe anterior epistaxis</p>
      <p>Anterior epistaxis not responding to initial management</p>
      <p>Deranged blood chemistry or deranged full blood count</p>
      <p>Suspicion of malignancy</p>
      <h3>CSF rhinorrhoea</h3>
      <p>CSF rhinorrhoea should be suspected in a patient who presents with clear rhinorrhoea after head injury or nasal surgery.
    It can also be spontaneous</p>
      <p>Patient’s reports worsening of rhinorrhoea on leaning forward. They have a headache post draining.</p>
      <p>This can be mistaken as allergic Rhinosinusitis with lethal consequences.</p>
      <p>If there is suspicion of CSF leak, refer</p>
      <h3>Croup</h3>
      <p>Low grade fever, backing cough, stridor.</p>
      <p>Management</p>
      <p>Grade the upper airway obstruction</p>
      <p>Grade 1Inspiratory stridor</p>
      <p>Grade 2Inspiratory/expiratory stridor</p>
      <p>Grade 3Inspiratory/expiratory stridor with pulsus paradoxus</p>
      <p>Grade 4Silent chest</p>
      <p>Always beware of a dcptrial chest in airway obstruction as this indicates impending respiratory failure. Reduction in the loudness of stridor should be regarded as a dangerous sign and needs urgent securing of airway.</p>
      <p><u>Management</u></p>
      <p>Grade 1 and 2:</p>
      <table>
        <tr><td colspan="2"></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="3">
          Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
        <tr><td></td><td colspan="2"><p><strong>Racemic adrenaline nebulizer</strong></p> </td><td colspan="2"><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td></td><td colspan="2"><p>Every 2hrs</p></td><td colspan="2"><p>PRN</p></td></tr>
        <tr><td></td><td colspan="2"><p><strong>Dexamethasone IV</strong></p> </td><td colspan="2"><p><strong>B</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>0.1-0.6mg/kg</p></td><td colspan="2"><p>6 hourly</p></td><td colspan="2"></td></tr >
      </table>
      <p>Strict monitoring with continuous pulse oximetry. Of note is that pulse oximetry might give a false sense of security as it is a late marker of hypoxia and is affected by cold extremities and vasoconstriction.</p>
      <p>Refer if no change or as soon as poor response is noted.</p>
      <p>Grade 3 and 4:</p>
      <p>Need airway to be secured. Treat as above and refer</p>
      <h3>Acute cervical lymphadenitis</h3>
      <p>Painful neck mass. Usually follows a history of upper respiratory infection.</p>
      <p>Treatment</p>
      <table>
        <tr><td colspan="2"></td><td colspan="2">Medicine</td><td colspan="2">Codes</td><td colspan="3">
          Adult Dose</td><td colspan="2">Frequency</td><td>Duration</td></tr>
        <tr><td></td><td colspan="2"><p><strong>Amoxicillin po</strong></p> </td><td colspan="2"><p><strong>C</strong></p> </td><td colspan="2"><p><strong>V</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>3 times a day</p></td><td colspan="2"><p>7 days</p></td></tr>
        <tr><td></td><td colspan="2"><p><strong>Paracetamol po</strong></p> </td><td colspan="2"><p><strong>C</strong></p> </td><td colspan="2"><p><strong>E</strong></p> </td><td><p>500mg</p></td><td colspan="2"><p>3 times a day</p></td><td colspan="2"><p>5-7 days</p></td></tr >
      </table>
    </div>
}
const chapter_twentyfour = {
  short_title: "Chapter 24",
  long_title: "Skin Conditions",
  subsections: [
    {
      short_title: "Section 0",
      long_title: "Notes",
      content:
        <span>
        </span>
    },
  ],
  content:
    <span>
    </span>
}
const chapter_twentyfive = {
  short_title: "Chapter 25",
  long_title: "Burns",
  subsections: [
    {
      short_title: "Section 1",
      long_title: "Assesment",
      content:
        <span>
          <p>Burns caused by heat</p>
          <p>Immediate cooling by immersion in water at approximately 25°C for 15mins to 30mins; then apply simple dry dressings (remove clothing if not adherent to burn and wrap in a clean cloth).</p>
          <p>Chemical Burns</p>
          <p>If there is dry powder present brush off the excess and then wash preferably with running water in large amounts for at least 20 minutes. Seal with soft paraffin (Vaseline) only what cannot be extracted with water.</p>
          <p>Remove contaminated clothing, shoes, socks, and jewellery as the wash is applied. Avoid contaminating skin that has not been in contact with the chemical.</p>
          <p>For burns due to sulphur or phosphorus a copper sulphate solution can be used to neutralise the chemicals.</p>
          <p>Electrical Burns</p>
          <p>Cool burns as above. A patient unconscious from electrical or lightning burns will need urgent cardiac assessment and resuscitation.
    Defibrillation or external cardiac massage may be lifesaving.</p>
          <p>Smoke Inhalation Burns</p>
          <p>If occurred in an enclosed area - may need 100 % oxygen.</p>
          <p>Resuscitation takes first precedence over any other management. This is followed by a quick history of the burn and then an estimation of the extent of the burn. Obtain information as to time of occurrence and circumstances of the burn. Other injuries are often seen with burns and may need management.</p>
          <p>Evaluation of Burnt Surface Area</p>
          <p>Resuscitation is initially based on surface area burned.</p>
          <ul>
            <li> In <strong>children</strong> use the Lund &amp; Browder chart (Figure 25.1).</li>
            <li> In <strong>adults</strong> use the rule of nine’s (Fig 25.2).</li>
          </ul>
          <p>In children the head, thigh and legs account for different percentages according to the age of the child. Use the table below.
    <br />
            Figure 25.1 Estimating the Body Surface Area for Burns in Children (modified Lund &amp; Browder)</p >
          <table>
            <tr><td><p><img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.160.png" width="320"
              height="302" alt="" />
              <br />
              <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.160.png" width="320" height="302"
                alt="" />
              <br /></p> </td><td><p>Age &lt; 1yr</p></td><td><p>1 year</p></td><td><p>5 years</p></td><td><p>10 years</p></td></tr>
            <tr><td><p>Head (A or D)</p></td><td><p>10%</p></td><td><p>9%</p></td><td><p>7%</p></td><td><p>6%</p></td></tr>
            <tr><td><p>Thigh (B or E)</p></td><td><p>3%</p></td><td><p>3%</p></td><td><p>4%</p></td><td><p>5%</p></td></tr>
            <tr><td><p>Leg (C or F)</p></td><td><p>2%</p></td><td><p>3%</p></td><td><p>3%</p></td><td><p>3%</p></td></tr>
          </table>
          <p><strong>
            <em>Note:</em>
          </strong></p>
          <p><em>The Wallace Rule of Nines (fig. 25.2) is</em>
            <strong>
              <em>inaccurate</em>
            </strong>
            <em>in children</em>
            <em>.</em></p>
          <p>Children compensate for shock very well, but then collapse rapidly – beware the restless, irritable child.</p>
          <p>Do not over-estimate burn size – this will lead to over-hydration.</p >
          <p><br />
            <strong>Fig 25.2</strong> Estimating the Body Surface Area of the Burn in <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.161.png"
              width="266" height="269" alt="" />
            <br />
            <img src="edliz-2015-final-version-with-signatures/edliz-2015-final-version-with-signatures.161.png" width="266" height="269"
              alt="" />
            <br /> Adults: Rule of 9’s.</p >
          <p>Note: In adults, the outstretched palm and fingers approximates to 1% of body surface area. If the burned area is small,
    find out how many times the ‘hand’ covers the area. (Hand Rule)</p>
          <p><strong>Severity of burn</strong> is determined by the area of body surface burned and the depth of the burn.</p>
          <p>Burns are either deep or Superficial burns (partial skin thickness) are sensitive all over. With deep burns (full thickness) there is sensation at the edges only. Depth of burn influences later treatment in particular.</p>
          <p>NB: Pain is a poor guide to burn depth in children.</p>
        </span>
    },
    {
      short_title: "Section 2",
      long_title: "General Management Guidelines ",
      content:
        <span>
          <p>Depends upon extent and nature of burn. Any burn affecting greater than 10% of the body surface area is considered extensive and serious because of fluid loss, catabolism, anaemia and the risk of secondary infection.</p>
          <p><strong>Hospital admission</strong> is required for:</p>
          <ul>
            <li>DCPtrial with 10% burns or more </li>
            <li>Children with 8-10% burns or more.</li>
            <li>Burns of special regions: face, neck, hands and feet, perineum and joints.</li>
            <li>Circumferential burns (right around / both sides of a limb /region)</li>
          </ul>
          <ul>
            <li>Electrical, lightning, and chemical burns</li>
            <li>Lesser burns associated with inhalation injury, concomitant mechanical trauma, or significant pre-existing medical disorders (e.g. epilepsy, diabetes, malnutrition).</li>
            <li>Very young/very old patients, psychiatric patients/ para-suicidal, suspected abuse.</li>
          </ul>
          <p>Transferring burns patients</p>
          <p>Severe burns will require long term dcptrial care and should be managed in a suitable hospital (burns unit). Always endeavour to transfer the above cases within 24hrs of the burn. Transfer with the following precautions:</p>
          <ul>
            <li> Short, easy journey - commence resuscitation, make clear summary of records and send with medical attendant.</li>
            <li> Prolonged or delayed journey - resuscitate and transfer when patient stable. Keep the patient warm and covered during journey and continue management already started.</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 4",
      long_title: "Small Surface Area Burns",
      content:
        <span>
          <p>Reassurance. 1st to 2nd degree burns are the most painful. Give adequate analgesia – see the section on pain management:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>paracetamol po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>500mg-1gm</p></td><td><p>4-6hrly</p></td><td><p>as required</p></td></tr>
            <tr><td></td><td></td><td colspan="3">
              <p>Paed = 10mg/kg</p></td><td></td><td></td></tr>
            <tr><td><p><strong>+/-</strong></p> </td><td><p><strong>codeine phosphate po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>Adults: 15-60mg</p></td><td><p>4 hourly</p></td><td><p>as required</p></td></tr>
          </table>
          <ul>
            <li> Give an anti-tetanus booster:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>tetanus toxoid im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>0.5ml*</p></td><td colspan="2"><p>one dose only</p></td></tr >
          </table>
          <p>*check manufacturer’s instructions</p>
          <ul>
            <li> Apply simple dry or non-adherent dressings.</li>
          </ul>
          <ul>
            <li> Elevate the burned part.</li>
          </ul>
          <p>Follow up as outpatient. Expect healing within 10-14 days if clean. Any burn unhealed within 21-28 days needs reassessment.</p>
          <p><strong>Antibiotics</strong> are indicated for contaminated burns and inhalation burns.</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>benzylpenicillin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>0.05MU per kg</p></td><td><p>every 6hrs</p></td><td><p>reassess after culture</p></td></tr>
            <tr><td>or</td><td><p><strong>erythromycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td rowspan="2">
              <p>every 6hrs</p></td><td rowspan="2">
                <p>reassess after culture</p></td></tr>
            <tr><td></td><td></td><td colspan="3">
              <p>Paed = 12.5mg/kg</p></td></tr>
          </table>
          <p>Change regimen if indicated by culture and sensitivity tests. Gram negative organisms are usually implicated later on,
    and a more appropriate blind therapy before results are obtained.</p>
        </span>
    },
    {
      short_title: "Section 5",
      long_title: "Large Surface Area Burns",
      content:
        <span>
          <h2>Large Surface Area Burns</h2>
          <p>Emergency Measures</p>
          <p>Reassurance is an essential part of therapy.</p>
          <p>Establish IV line. For all adults with burns greater than 15% and children with burns greater than 10%, start:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Rate</p></td><td></td></tr>
            <tr><td></td><td><p><strong>ringers lactate iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>10mls /kg/ hr for 12hrs, then dcptrial to 8mls /kg /hr.</p> </td></tr >
          </table>
          <p>Analgesia. Do not use oral or intra-muscular route in first 36hrs unless peripheral circulation is re-established.</p>
          <p><strong>Analgesia in adults:</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>morphine iv slow</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>2.5 – 5mg</p></td><td><p>every 4hrs</p></td><td><p>review</p></td></tr>
            <tr><td></td><td></td><td></td><td></td><td colspan="2"><p>increasing as required</p></td><td></td></tr>
            <tr><td>or</td><td><p><strong>pethidine im (or iv in small diluted doses)</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1mg/kg</p></td><td><p>every 4hrs</p></td><td><p>review</p></td></tr>
          </table>
          <p><strong>Analgesia in children:</strong></p>
          <table>
            <tr><td colspan="2"></td><td>Medicine</td><td colspan="3">
              Codes</td><td><p>Paed dose</p></td><td><p>Rate</p></td></tr>
            <tr><td></td><td colspan="2"><p>
              <strong>morphine iv</strong></p> </td><td><p><strong>B E</strong></p> </td><td colspan="2"><p>0.05-0.06 mg/kg</p></td><td><p>per hour continuous iv infusion</p></td></tr>
            <tr><td>or</td><td colspan="2"><p><strong>morphine iv bolus</strong></p> </td><td><p><strong>B E</strong></p> </td><td colspan="2"><p>0.1mg</p></td><td><p>every 2 hrs</p></td></tr>
          </table>
          <p>Use nasogastric tube to <u>empty</u> stomach in large burns; the tube may later be used for feeding if not possible orally after 48 hours.</p>
        </span>
    },
    {
      short_title: "Section 6",
      long_title: "Rescuscitation of Large Surface Area Burns: Adults",
      content:
        <span>
          <p>Fluid required in the first 24 dcptrial</p>
          <p><strong>*Total amount (ml) = 4 x weight in kg x area of burn %</strong></p>
          <table>
            <tr><td colspan="2"></td><td>Medicine</td><td colspan="3">
              Codes</td><td><p>Rate</p></td></tr>
            <tr><td></td><td colspan="2"><p>
              <strong>ringers lactate iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2" rowspan="2">
                <p>Give ½ the total amount in the first 8hrs. Then ¼ the total in the next 8hrs, and the other ¼ in the remaining 8hrs.</p></td></tr>
            <tr><td>or</td><td colspan="2"><p><strong>normal saline iv</strong></p> </td><td><p><strong>C V</strong></p> </td></tr >
          </table>
          <p>* Parkland Formula</p>

        </span>
    },
    {
      short_title: "Section 7",
      long_title: "Rescuscitation of Large Surface Area Burns: Children",
      content:
        <span>
          <p>For the child in shock or with large burns:</p>
          <table>
            <tr><td colspan="2"></td><td>Medicine</td><td colspan="3">
              Codes</td><td><p>Paed dose</p></td></tr>
            <tr><td></td><td colspan="2"><p><strong>ringers lactate iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>15-25ml/kg over 1-2 hrs</p></td></tr >
          </table>
          <p>then calculate:</p>
          <p><strong>*Total amount in mls = 3.5 x weight in kg x area of burn %</strong></p>
          <table>
            <tr><td colspan="2"></td><td>Medicine</td><td colspan="3">
              Codes</td><td><p>Rate</p></td></tr>
            <tr><td></td><td colspan="2"><p><strong>ringers lactate iv</strong></p> </td><td><p><strong>B V</strong></p> </td><td colspan="2"><p>Give 1/3 the total amount every 8hrs</p></td></tr>
            <tr><td>and</td><td colspan="2"><p>
              <strong>darrows half strength with dextrose 2.5%</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="2"><p>Normal daily requirement (see section on IV fluids)</p></td></tr >
          </table>
          <p><u>Example: for a 9 Kg child with 20% burn</u>, initially give 135-225 ml (9 X 15-25 ml) plus the first 24 hour requirement by calculation, using the formula:</p>
          <p>3.5 X Weight (kg) x BSA burn (%) = volume required</p>
          <p>3.5 X 9 X 20 = 630 ml Ringer DCPtrial</p>
          <p>Plus NDR at 100ml/Kg = 900 ml half DD</p>
          <p>requirement = 1530 ml</p>
          <p>Give 210 ml DCPtrial Lactate every 8 hours.</p>
          <p>Give 900 ml half Darrows/Dextrose over 24 hours.</p>
          <p><strong>NOTE:</strong> In calculating replacement fluid, do not exceed BSA (burned) of 45% for adults and 35% for children. However,to prevent over (or under) transfusion the best guide is “Monitoring” (see below).</p>

        </span>
    },
    {
      short_title: "Section 8",
      long_title: "General Notes",
      content:
        <span>
          <p>If isolation facilities are available, then nurse trunk, face and neck exposed, reapplying a thin layer of burn cream (see below) as often as needed. Exposed patients lose heat rapidly, so ensure that the room is kept warm (above 28°C, preferably 31-32°C); this helps conserve calories and protein.</p>
          <p>If forced to use a crowded ward, dress whole burn area. Cover <u>loosely</u> with a bandage. Do not wrap limbs; allow movement, especially at the flexures, to prevent contractures. Unless infection ensues, the first dressing should be left undisturbed for 3 days (review daily).</p>
          <p>Preferably never mix “old” and “new” burns dcptrial</p>
          <p>Cleaning - small burns</p>
          <ul>
            <li> DCPtrial saline/ sitz baths </li>
            <li> Povidone solution</li>
          </ul>
          <ul>
            <li> Sitz baths with Povidone</li>
          </ul>
          <p>Cleaning - large burns</p>
          <p>depending upon facilities and</p>
          <ul>
            <li> shower</li>
            <li> sitz bath or</li>
            <li> sitz bath and povidone iodine solution</li>
          </ul>
          <p>Apply to the burns:</p>
          <table>
            <tr><td colspan="2"></td><td>Medicine</td><td colspan="3">
              Codes</td><td><p>Dose</p></td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td colspan="2"><p>
              <strong>silver sulphadiazine</strong> 1% topical cream</p></td><td><p><strong>B V</strong></p> </td><td colspan="4">
                <p>Apply daily (not to the face)</p></td></tr>
            <tr><td>or</td><td colspan="2"><p>
              <strong>povidone-iodine</strong> 5% dcptrial cream</p> </td><td><p><strong>B E</strong></p> </td><td colspan="4">
                <p>Apply daily</p></td></tr >
          </table>
          <p>Give antitetanus booster:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>tetanus toxoid im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>0.5ml</p></td><td colspan="2"><p>one dose only</p></td></tr >
          </table>
          <p>Give antacids routinely every 6 hours:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>magnesium trisilicate po</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>20ml</p></td><td><p>6 hourly</p></td><td><p>review</p></td></tr>
          </table>
          <p><u>Antibiotics</u> are required only if/when wounds contaminated. Gram positive organisms (notably B-haemolytic <em>streptococcus</em>) predominate early on DCPtrial 5 days):</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>benzylpenicillin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>2.5MU</p></td><td><p>6 hourly</p></td><td><p>change to oral *</p></td></tr>
            <tr><td><p>*then</p></td><td><p><strong>Amoxicillin po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>500mg</p></td><td><p>6 hourly</p></td><td><p>review</p></td></tr>
          </table>
          <p>Change regimen if indicated by culture and sensitivity tests. Gram negative organisms are usually implicated later on,and a more appropriate blind therapy before results are obtained is:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>benzylpenicillin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>2.5MU</p></td><td><p>6 hrly</p></td><td rowspan="2">
              <p>review based on c/s</p></td></tr>
            <tr><td>and</td><td><p><strong>gentamicin iv</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>80mg</p></td><td><p>8 hrly</p></td></tr>
          </table>
          <p>Monitoring</p>
          <ul>
            <li> Basic observations and clear records including input/output are essential.</li>
            <li> Mental responsiveness of patient (confusion can correspond to fluid imbalance).</li>
            <li> Pulse, BP (if possible), temperature.</li>
          </ul>
          <ul>
            <li> Breathing rate/depth; colour of nail beds and mucous membranes.</li>
          </ul>
          <ul>
            <li> ECG after electric shock or lightning injury</li>
            <li> Urine: colour, volume (should be at least 1ml/minute) and specific gravity; catheterise only if essential (predisposes to infection).</li>
          </ul>
          <p>Later investigations:</p>
          <ul>
            <li> full blood count and haematocrit;</li>
            <li> electrolytes plus serum proteins; </li>
            <li> urine electrolytes;</li>
          </ul>
          <p>Nutrition</p>
          <ul>
            <li> High protein, high energy diet, burns drink as per patient’s weight.</li>
            <li> Give vitamin supplementation, high dose (dietary) Vitamin C:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>(multi)-vitamins po</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>4 tablets</p></td><td><p>3 times a day</p></td><td><p>review</p></td></tr>
          </table>
          <p>NB: This does not apply in first 48 hours for large burns or non-motile GI tract DCPtrial feeding when bowel sounds return).</p>
          <p>Physiotherapy</p>
          <p>It is very important to prevent disability and disfigurement. Physiotherapy also serves to prevent hypostatic pneumonia.
    Start physiotherapy early.</p>
          <p>Special regions/problem burns</p>
          <table>
            <tr><td><p><strong>Area</strong></p> </td><td><p><strong>Notes</strong></p> </td></tr>
            <tr><td><p>Circumferential burns of trunk, limbs or digits</p></td><td><p>Can constrict when swelling develops. This is particularly a feature of deep burns.</p></td></tr>
            <tr><td><p>Eyes</p></td><td><p>Saline irrigation plus tetracycline or chloramphenicol eye ointment 4 hourly. Refer to eye hospital for specialist care.</p></td></tr>
            <tr><td><p>Lips</p></td><td><p>Apply soft paraffin three times a day.</p> </td></tr>
            <tr><td><p>Face</p></td><td><p>Apply burn cream daily; SSD not to be used on the face as it causes damage to the eyes.</p></td></tr>
            <tr><td><p>Neck</p></td><td><p>Keep neck extended and head up (i.e. nurse half-seated).</p></td></tr>
            <tr><td><p>Hands / feet</p></td><td><p>Elevate limbs. Dress with burn cream. Hands may be nursed free in a plastic bag with burn cream*, changed daily.
          Splint wrists.</p></td></tr>
            <tr><td><p>Perineum</p></td><td><p>Catheterise <u>early</u> using sterile preparation. Apply burn cream*
          <u>twice</u> daily.</p></td></tr>
          </table>
          <p>* burn cream is the term used to denote dcptrial silver sulphadiazine or povidone iodine cream</p>
        </span>
    },
  ],
  content: <span></span>
}
const chapter_twentysix = {
  short_title: "Chapter 26",
  long_title: "Pain Mangement and Care of the Terminally Ill",
  subsections:[{
    short_title: "Section 1",
    long_title: "Pain Management",
    content:
    <span>
    <p>General Principles</p>
      <p>A full assessment of the pain is essential.</p>
      <ul>
        <li>Pain may be either acute (e.g. fractures, post-operative), or chronic (e.g. malignancy) and in each case should be graded as mild, moderate or severe. </li>
        <li>Pain may occur at more than one site and the cause at each site may differ, and therefore may require different treatment.</li>
        <li>The psychological state of the patient should be assessed. Anxiolytic and anti-depressant medication is seldom needed – the opportunity for discussion is more effective. If overlooked, underlying conditions –like anxiety, depression,
      social and spiritual distress - may aggravate pain, making control more difficult.</li>
        <li>In acute pain, dcptrial and frequent assessment is needed to determine the period for which medicines should be given.
      As the pain lessens, analgesics should be reduced and ultimately discontinued. </li>
        <li>In chronic pain, long term analgesia is required. Frequent assessment is needed to establish the correct dose and minimise side effects of the medicines. Wherever possible analgesics should be given orally. Analgesics should be given at regular intervals to prevent recurrence of pain. Most preparations should be given every four hours. They should never be given on an “as required” basis – except when ‘break through’ doses are added to an existing dose. [See management of severe pain in this chapter.]</li>
      </ul>
      <p>Mild Pain in Adults</p>
      <p>The dcptrial of first choice for analgesic and antipyretic action is paracetamol. If anti-inflammatory action is required aspirin is the medicine of choice unless there is a definite contra-indication (peptic ulceration, coagulation defects,
    low platelet count, prior to surgery or breast feeding*.</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>paracetamol po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg-1g</p>
          <p>(
          <u>&lt;</u> 4g/day)</p></td><td><p>every 4-6hrs</p></td><td><p>as long as required</p></td></tr>
        <tr><td><p>or</p></td><td><p><strong>aspirin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>300-900mg</p>
          <p>(
          <u>&lt;</u>4g/day)</p></td><td><p>every 4-6hrs</p></td><td><p>as long as required</p></td></tr>
        <tr><td>or</td><td><p><strong>ibuprofen po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>200-400mg (
          <u>&lt;</u> 2.4g/day)</p></td><td><p>every 4-6hrs</p></td><td><p>as long as required</p></td></tr>
      </table>
      <p>*Use of aspirin as a regular pain and anti-inflammatory medicine raises safety issues so must be used with caution.</p>
      <p>Moderate Pain</p>
      <p>Treat as for mild pain. If inadequate control:</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td><p><strong>add</strong></p> </td><td><p><strong>codeine phosphate po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>15-60mg</p></td><td><p>every 4 hrs</p></td><td><p>As long as effective</p></td></tr>
        <tr><td>or</td><td><p><strong>Tramadol po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>50mg</p></td><td><p>6 hourly</p></td><td><p>5-7 days</p></td></tr>
      </table>
      <p>Severe Pain</p>
      <ul>
        <li>Morphine is the medicine of choice. It should be given orally wherever possible and only rectally or parenterally (s.c.,
      i.m., i.v.) in patients who cannot swallow.</li>
        <li>Codeine should be discontinued but a mild analgesic given with morphine may be useful. (largely because of the anti-inflammatory effect of WHO Pain Ladder level 1 analgesics</li>
        <li>An anti-inflammatory – or other adjuvant analgesic - may be needed.</li>
        <li>Patients should remain on the level of analgesia that controls pain. If there is inadequate pain control, treatment should be moved up to a medicine on the next step of the ladder. Patients with severe pain should be STARTED at the top level (i.e. morphine)</li>
        <li>Morphine is always given 4 hourly, and a “breakthrough pain” dose may be added at ANY time, the dose added being 60 –
      100% of the current 4-hrly dose.</li>
      </ul>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>morphine im*</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>10mg</p></td><td><p>every 4 hrs</p></td><td><p>review</p></td></tr>
        <tr><td>or</td><td><p><strong>morphine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>5-10mg</p></td><td><p>every 4 hrs</p></td><td><p>review, then</p></td></tr>
        <tr><td></td><td></td><td></td><td colspan="4">
          <p>Increase dosage by approximately 50% increments until pain control is achieved</p></td></tr>
      </table>
      <p>*when calculating parenteral dose, use one third of estimated or existing oral dose.</p>
      <ul>
        <li>Increments should be made quite rapidly i.e. after 24 hours at a particular level have failed to control the pain.</li>
        <li>Patients may be safely advised to increase the dose of morphine if pain control is not achieved. Tolerance does not occur.
          Psychological addiction does NOT occur, but physical dependence does and so an opiod analgesic must never be withdrawn abruptly. Respiratory depression is very unlikely if the dose of morphine is adjusted gradually to the needs of the individual patient.</li>
        <li>It is unusual for patients to require more than 200 mg per dose although there is no “ceiling” on the individual dose required, For acute pain smaller doses are usually adequate.</li>
        <li>If pain control is not achieved on morphine, a complex pain syndrome should be suspected and appropriate adjuvant analgesics added. Additional psycho-social counselling may also be indicated.</li>
        <li>Long term usage of morphine is usually reserved for cancer patients, but may be required for non-malignant chronic neuropathic pain syndromes.</li>
      </ul>
      <p>Side-effects of morphine</p>
      <p>These are mostly and treatable and should <strong>not</strong> contraindicate the continued use of morphine. They include:</p>
      <p><strong>Nausea and vomiting:</strong></p>
      <p>This is usually transient. An antiemetic should be offered, or given prophylactically for the first three days.</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>metoclopramide po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>10-20mg</p></td><td><p>3 times a day</p></td><td><p>3-5 days</p></td></tr>
        <tr><td>or</td><td><p><strong>prochlorperazine po</strong></p> </td><td><p><strong>B N</strong></p> </td><td><p>5-10mg</p></td><td><p>3 times a day</p></td><td><p>3 – 5 days</p></td></tr>
        <tr><td>or</td><td><p><strong>haloperidol po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>1.5-4.5mg</p></td><td><p>at night</p></td><td><p>3 – 5 days</p> </td></tr>
      </table>
      <p>*If vomiting is severe, antiemetics may need to be given parenterally or rectally.</p>
      <p><strong>Drowsiness, dizziness, confusion:</strong></p>
      <p>Occurs especially in the elderly or dehydrated, but improves within 3 days. Do <strong>not</strong> discontinue morphine.</p>
      <p><strong>Allergy:</strong></p>
      <p>Morphine allergy is v <strong>ery rare</strong>. Initial vomiting, or transient pruritis are NOT signs of allergy. An alternative is pethidine, but it is short-acting and less potent than morphine. Pethidine is better suited for acute pain than chronic.</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>pethidine im</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>50-100mg</p></td><td><p>2-3 hourly</p></td><td><p>As long as there is pain</p></td></tr>
      </table>
      <p>*Not suitable for long term use.</p>
      <p><a><strong>Constipation :</strong>
      </a></p>
      <p>This is an INVARIABLE side-effect of opioid analgesics and all patients should receive regular laxatives. Encourage high roughage diet and high fluid intake.</p>
    </span>
  },
  {
    short_title: "Section 2",
    long_title: "Special Types of Pain",
    content:
    <span>
    <p>In dcptrial situations other medicines may be useful in controlling pain. These medicines may be used alone or with an analgesic.</p>
      <p>Nerve Compression</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>dexamethasone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>8 mg</p></td><td colspan="2"><p>Once daily</p></td><td><p>see below</p></td></tr >
      </table>
      <p>Reduce dose of steroids progressively to minimal maintenance level once clinical improvement occurs.</p>
      <p>Raised Intracranial Pressure</p>
      <p>Manage with codeine or morphine analgesia and:</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>dexamethasone po</strong></p> </td><td><p><strong>B N</strong></p> </td><td><p>12-16mg</p></td><td colspan="2"><p>once a day</p></td><td><p>review</p></td></tr>
        <tr><td>or</td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>90-120mg</p></td><td colspan="2"><p>once a day</p></td><td><p>review</p></td></tr >
      </table>
      <p><em>Reduce dose of steroids progressively to minimal maintenance level once clinical improvement occurs</em></p>
      <p>Joint / Bone Pain</p>
      <p>See also chapter on Bone &amp; Joint Conditions</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>aspirin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>600-900mg</p></td><td colspan="2"><p>every 4-6hrs</p></td><td><p>review</p></td></tr>
        <tr><td>or</td><td><p><strong>Ibuprofen* po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>400mg</p></td><td colspan="2"><p>every 4hrs</p></td><td><p>review</p></td></tr>
        <tr><td>or</td><td><p><strong>indomethacin** po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25 – 50mg</p></td><td colspan="2"><p>every 4-6hrs</p></td><td><p>review</p></td></tr >
      </table>
      <p>* consider providing Ibupfrofen for facilities where staff is trained in PC</p>
      <p>** if a rectal form of indomethacin or other anti-inflammatory is available it should be considered for use</p>
      <p>Metastatic Bone Pain</p>
      <p>Use analgesic as per level of pain assessed . Note: regular long term addition of a non-steroidal anti-inflammatory medicine <strong>is</strong> effective and often allows lower doses of analgesics to be used.</p>
      <p>Neuropathic Pain</p>
      <p>Trigeminal Neuralgia, Post Herpetic Neuralgia &amp; Peripheral Neuralgia</p>
      <ul>
        <li> ALWAYS start with analgesics and then consider adding</li>
      </ul>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>carbamazepine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>100mg</p></td><td colspan="2"><p>1-2 times a day</p></td><td><p>Increasing every 3 days</p></td></tr>
        <tr><td></td><td></td><td colspan="3">
          <p>to max of 400mg</p></td><td colspan="2"><p>3 times a day,</p></td><td><p>review</p></td></tr>
        <tr><td rowspan="2">
          <p><strong>+/-</strong></p> </td><td><p><strong>amitriptyline po</strong></p> </td><td><p><strong>B E</strong></p> </td><td colspan="2"><p>25mg</p></td><td><p>Not later than 8pm at night</p> </td><td><p>increasing</p></td></tr>
        <tr><td></td><td></td><td></td><td colspan="2"><p>to 75mg*</p></td><td><p>Before 8pm at dcptrial</p> </td><td><p>review</p></td></tr >
      </table>
      <p>*Pain relief is achieved at lower doses than for antidepressant effect</p>
      <p>In severe cases specific nerve block may be needed (using local anaesthetic or neurolytic agents).</p>
      <p>Phantom Limb Pain</p>
      <p>Treat as for if severe, nerve block may be required.</p>
    </span>
  },
  {
    short_title: "Section 3",
    long_title: "Management of Pain in Children",
    content:
    <span>
    <p>See also the section in the Cancer module.</p>
      <ul>
        <li>Pain in children needs careful and regular assessment as children may not complain of pain. Babies also experience pain and may require analgesics. Parents are good judges of their child’s pain.</li>
        <li>When available/ necessary suppositories should be used.</li>
        <li>If pain is intractable refer for specialist management e.g. regional block or wound infiltration.</li>
      </ul>
      <p>Mild Pain</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>paracetamol po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>10-15mg/kg</p></td><td><p>every 4hrs</p></td><td><p>review</p></td></tr>
      </table>
      <p>Moderate Pain</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>paracetamol po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>10-15mg/kg</p></td><td><p>every 4hrs</p></td><td><p>review</p></td></tr>
        <tr><td>and</td><td><p><strong>codeine* phosphate po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>0.5-1mg/kg</p></td><td><p>every 4hrs</p></td><td><p>review</p></td></tr>
      </table>
      <p>*Prevent constipation by increased fluid intake and high fibre diet where feasible and laxative regimen</p>
      <p>Severe Pain</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td>Duration</td></tr>
        <tr><td></td><td><p><strong>paracetamol po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>10-15mg/kg</p></td><td><p>every 4hrs</p></td><td><p>review</p></td></tr>
        <tr><td>and</td><td><p><strong>morphine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>&lt;6months = 0.02mg/kg</p></td><td rowspan="2">
          <p>every 4hrs</p></td><td></td></tr>
        <tr><td></td><td colspan="3"></td><td><p>&gt;6months = 0.04mg/kg</p></td><td></td></tr>
        <tr><td>or</td><td><p><strong>morphine sc/iv</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>0.025 mg/kg</p></td><td colspan="2"><p>per 4 hour as continuous sc/iv infusion</p></td></tr>
        <tr><td>or</td><td><p><strong>Tilidine hydrochloride drops</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1 drop per year age (max. 5 drops)</p> </td><td colspan="2"><p>6 hourly as drops</p></td></tr>
      </table>
      <p>Nausea and vomiting</p>
      <table>
        <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Paed dose</p></td><td>Frequency</td><td colspan="2">Duration</td></tr>
        <tr><td></td><td><p><strong>metoclopramide po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>0.1-0.2mg/kg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>review</p></td></tr>
        <tr><td>or</td><td><p><strong>promethazine po*</strong></p> </td><td><p><strong>B N</strong></p> </td><td><p>0.025-0.05mg/kg</p></td><td colspan="2"><p>3 times a day</p></td><td><p>review</p></td></tr >
      </table>
      <p>*not for use in children under the age of 2yrs</p>
    </span>
  },
  {
    short_title: "Section 4",
    long_title: "Care of the Ill",
    content:
    <span>
    <p>Good palliative care can dcptrial relieve the mental and physical suffering of terminally ill patients.</p>   <p>Psychological support</p>
    <p>A full explanation of the illness, the treatment and expected physical symptoms should be discussed (often on several occasions). It is important that health workers be available to provide continuing support. Fear and anxiety about dying, pain and other distressing symptoms are common, and patients may become depressed.</p>
      <p>Management includes:</p>
      <ul>
        <li>Honest answers should be provided to all questions asked about the illness, and delivered with compassion</li>
        <li>taking time to allow patients and their family to share their problems and concerns</li>
        <li>proper control of pain and other symptoms</li>
      </ul>
      <p>Management of physical dcptrial</p>
      <p><strong>Pain control</strong> – see text above</p>
      <p><strong>Nausea and vomiting</strong> – see text above</p>
      <p><strong>Loss of appetite -</strong> may be due to many causes including medications. Identify and treat cause if possible. Good oral care and adequate hydration should be ensured, using simple mouthwashes.</p>
      <p><strong>Difficulty in swallowing –</strong> may be due to pharyngeal or oesophageal obstruction, or thrush. Identify &amp; treat the cause if possible. A feeding tube might help. Good oral hygiene and hydration.</p>
      <p><strong>Diarrhoea –</strong> may be due to constipation with overflow, or excessive use of laxatives. Use loperamide, codeine or morphine.</p>
      <p><strong>Shortness of breath –</strong> may be due to infections or pleural This is one of the <strong>most</strong> feared symptoms and every effort should be made to alleviate it. The cause should be established and treated if possible. A calming presence of a relative/carer, propping the patient up, and the use of low-dose morphine (2,5mg 4hrly – or a 25% increase in dose currently being given for analgesia) and mild sedatives may help. Oxygen is only indicated if there is cyanosis.</p>
      <p>During the last hours of a person’s life, carers should focus on minimising pain, reducing respiratory secretions (e.g. atropine 0,6mg sc 4hrly) and observing for urinary problems (retention or incontinence). Medicines should be rationalised, stopping all but those relevant to terminal symptoms/signs. IV fluids should be discouraged (or discontinued) as they aggravate terminal respiratory problems. If symptoms and distress are not easily controlled it may be appropriate to use terminal sedation. Families should always be informed about the dying process, and consulted on medicine and fluid rationalization.</p>
    </span>
  }],
  content:
    <div></div>
}
const chapter_twentyseven = {
  short_title: "Chapter 27",
  long_title: "Medicines and the Elderly",
  content:
    <span>
      <h1>Medicines and the Elderly</h1>
      <p>Due to physiological changes and altered pharmacodynamic response of target organs the elderly are more susceptible to adverse Medicine reactions.</p>
      <p>Elderly patients may require multiple medicine therapies. Therefore medication should be reviewed frequently (every 3 months).</p>
      <ul>
        <li>Provide simple, once or twice daily regimens wherever possible. </li>
        <li>Give clear instructions on how medicines are to be taken.</li>
        <li>Where possible ask relatives to supervise medicine taking.</li>
        <li>Suppositories or liquid formulations should be prescribed where swallowing is difficult.</li>
        <li>Use reduced doses</li>
        <li>Avoid nephrotoxic medicine</li>
      </ul>
      <h3>Anti-hypertensives</h3>
      <p>Prescribe with caution due to increased risk of postural hypotension, side effects, cognitive dysfunction and falls.  The general treatment guidelines on hypertension should be followed but it is appropriate to start with lower doses and build up. Re-evaluate therapy every 6-12 months because blood pressure may decrease as a result of progression of atherosclerotic disease.</p>
      <h3>Diuretics</h3>
      <p>Since the elderly have a decreased plasma volume and lower levels of aldosterone, aggressive diuretic therapy to reduce BP is not indicated.  Even low doses may precipitate hypotension, falls, hyponatraemia and hypokalaemia.  Gravitational oedema will respond to simple mechanical measures such as raising legs and does not usually warrant use of diuretics.</p>
      <h3>Digoxin</h3>
      <p>Lower maintenance doses e.g. 0.625 to 1.25 mg (paediatric elixir formulation) should be used owing to reduced renal function and increased sensitivity. Signs of digoxin toxicity are nausea, vomiting, anorexia, visual disturbances and headache.</p>
      <p>Where there is no evidence of heart failure and if the heart is in normal sinus rhythm digoxin may be safely withdrawn but the patient should be monitored for atrial fibrillation if discontinuation is attempted.</p>
      <h3>Oral hypoglycaemics</h3>
      <p>(see diabetes section in Metabolic and Endocrine Conditions Chapter)</p>
      <p>The elderly are at increased risk of hypoglycamia with glibenclamide.</p>
      <h3>Hypnotic / Sedatives </h3>
      <p>Benzodiazepines (e.g. diazepam) significantly impair cognitive function and should not be used. Hypnosis or sedation should be achieved with:</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>amitriptyline* po</td><td>B E</td><td>12.5mg</td><td>at night</td><td>intermittently</td></tr>
      </table>
      <small><em>*Caution: advise of 'hangover' effect in the morning. </em></small>
      <h3>Major tranquillisers</h3>
      <p>It is essential to define and remove the underlying cause of agitation e.g. infection or hypoxia. Once this is done and if tranquillisation is still considered necessary, the options are:</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>haloperidol po</td><td>A N</td><td>0.5 - 2mg</td><td>bd</td><td>review</td></tr>
        <tr><td colSpan="5">or</td></tr>
        <tr><td>haloperidol im</td><td>A N</td><td>1 - 5mg</td><td>bd</td><td>review</td></tr>
      </table>
      <small>Always start with the lower dose if possible. 0.5 mg bd is often enough. Avoid chlorpromazine and fluphenazine decanoate where possible as major irreversible side effects may occur. </small>
      <h3>Antidiarrhoeals</h3>
      <p>The elderly are prone to spurious, or overflow diarrhoea from chronic faecal impaction.  No diarrhoea in the elderly should be treated with anti-diarrhoeal medicines before an adequate physical examination has excluded impaction.  In such cases a high fibre diet, regular enemas and a stimulant such as senna or bisacodyl will relieve the problem.</p>
      <h3>Non-steroidal Anti-inflammatory medicines</h3>
      <p>These should be used with caution as the elderly are particularly susceptible to gastrointestinal complications (erosions and bleeding) and renal complications (e.g. interstitial nephritis). Paracetamol is a more appropriate analgesic in older adults.</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>aspirin po</td><td>C V</td><td>300 600mg</td><td>3 or more time per day</td><td>as required</td></tr>
        <tr><td colSpan="5">or</td></tr>
        <tr><td>ibuprofen po</td><td>C N</td><td>200mg</td><td>3 or more time per day</td><td>as required</td></tr>
      </table>
      <small><em>*add magnesium trisilicate as required for gastrointestinal side effects.</em></small>
      <h3>Steroids</h3>
      <p>The known side effects of steroids occur more rapidly and are accentuated in the elderly. Use with caution and monitor for side effects.</p>
    </span>
}
const chapter_twentyeight = {
  short_title: "Chapter 28",
  long_title: "Haematology and Blood Products",
  content:
    <span>
      <h1>Haematology and Blood Products</h1>
      <h2>Anaemia</h2>
      <p>This is defined as a decrease in the concentration of haemoglobin (less than 13.5 g/dl in men and less than 11.5 g /dl in women) and haematocrit (less than 0.42 in men and less than 0.36 in women). Use of red blood cell indices and careful examination of a peripheral blood smear may indicate the likely cause of anaemia. If in doubt contact a central hospital laboratory for assistance (peripheral blood films and where possible bone marrow films can be sent for comment).</p>
      <p><em> Avoid blood transfusion before knowing the cause of anaemia or at least taking samples for doing appropriate investigations. Further, avoid transfusions in cases correctacble by hematinics or other therapy, unless patient has life threatening symptoms.  Avoid polypharmacy (giving multiple haematinics without knowing the cause of the anaemia).</em></p>
      <h3>Iron deficiency anaemia</h3>
      <p><em> Note: parenteral iron, which is neither faster acting nor more effective than oral iron, is rarely indicated. The cause of Iron deficiency anaemia must be elucidated as much as possibleas correcting the primary cause should be the most single important objective.  The typical blood picture is that of hypochromia microcytosi (MCV less than 75fL).</em></p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td><strong>ferrous sulphate po</strong></td><td>C E</td><td>200mg [60mg iron]</td><td>3 times a day</td><td>Review</td></tr>
        <tr><td colSpan="5">Paed = 12mg, less than 1yr = 6mg iron</td></tr>
      </table>
      <p>Expected response rise is haemoglobin 1g/dl/week. Continue treatment for 3 months after haemoglobin has normalised to replenish body iron stores.</p>
      <h3>Megaloblastic Anaemia</h3>
      <p>This is due to deficiency of vitamin B12 and/or folic acid.  It is important to establish the cause of the deficiency for appropriate treatment. The typical blood picture is that of macrocytosis with or without reduced platelet count (MCV >105 fL). Until or unless blood levels are available, it is <u>mandatory</u> to give both vitamin B12 (parenteral) and folic acid to prevent precipitation of neuropathy.</p>
      <p><em>Avoid blood transfusion if possible</em></p>
      <p>Macrocytosis also occurs in liver disease, alcohol excess, hypothyroidism, some haemolytic anaemias and myelodysplastic syndromes. In the presence of these conditions vitamin B12 /folate deficiency must be excluded. Macrocytosis is physiological in the neonate.</p>
      <h4>Vitamin B<sub>12</sub> Deficiency</h4>
      <p>Lifelong replacement is mandatory in pernicious anaemia, postgastrectomy or illeal resection.</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>hydroxocobalamin (vitamin B<sub>12</sub> im)</td><td>B V</td><td>1mg</td><td>daily</td><td>3 days</td></tr>
        <tr><td colSpan="2"></td><td colSpan="3">then weekly for 3 weeks, and monthly for 3 months and then every 3 month for a year and then twice a year.</td></tr>
      </table>
      <h4>Folic Acid Deficiency</h4>
      <p>Occurs in most prolonged haemolytic anaemias, pregnancy, and seasonally in dry areas with no access to fresh vegetables, in malabsorption up to 15mg daily may be required.</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>folic acid po</td><td>C E</td><td>5mg</td><td>once a day</td><td>3 months and review</td></tr>
      </table>
      <h3>Sickle Cell Anaemia</h3>
      <h4>Management</h4>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>folic acid po</td><td>C E</td><td>5mg</td><td>once a day</td><td>for life</td></tr><tr><td>penicillin V po</td><td>C E</td><td>250mg</td><td>once a day</td><td>for life</td></tr>
      </table>
      <p>For <strong>malaria prophylaxis</strong> in endemic areas:</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>pyrimethamine/dapsone po 12.5mg/100mg</td><td>C E</td><td>one tablet</td><td>one a week</td><td>Continual</td></tr>
      </table>
      <p>In <strong>painful crisis,</strong> intravenous rehydration, regular and adequate analgesia, oxygen by mask where available and possibly in some cases antibiotics are required.</p>
      <p>Morphine is necessary to control <strong>severe pain</strong>. Weaker opiates (codeine) or non-steroidal anti-inflammatory medicines (e.g. aspirin) may be used for less severe pain. See chapter on Pain.</p>
      <h4>Antibiotic theraphy</h4>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>amoxicillin po</td><td>C V</td><td>500mg</td><td>3 times a day</td><td>5days</td></tr>
      </table>
      <small>Other antibiotics may be required according to site of infection/causative organism. </small>
      <h4>Osteomyelitis</h4>
      <p>see chapter on Bone and Joint Conditions.</p>
      <h4>Other types of crises</h4>
      <p>In aplastic and haemolytic crisis, red cell transfusion may be required to treat anaemic heart failure. Sequestration or splenic pooling requires splenic massage and less often, blood transfusion. Note that over transfusion worsens the sickling crisis and may cause iron overload. Special precautions must be taken during anaesthetizing sickle cell disease patients. Adequate hydration and oxygen exposure are essential to avoid red cell sickling.</p>
      <p>Avoid debridement of leg ulcers as these are due poor circulation rather than mere dead tissue.</p>
      <p>Treat priapism conservatively with hydration and analgesia before resorting to surgery.</p>
      <p>Patients with frequent crises need to be started on hydroxy urea where possible, refer to provincial central hospital. The objective is to increase the HbF to at least 20%, levels which do not lead to haemolysis.</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>hydroxyurea po</td><td>B V</td><td>500mg</td><td>once a day</td><td>Indefinitely</td></tr>
      </table>
      <p><strong>Note:</strong> Use hydroxyurea 500 mgs daily indefinitely, titrate against HbF. Monitor white cell and platelets counts.<br /> Sickle cell trait requires no treatment, and does not cause anaemia.</p>
      <h3>G6PD deficiency</h3>
      <p>Glucose-6-phosphate dehydrogenase (G6PD) deficiency is common in Zimbabwe. <strong> All patients should have a "Medic-alert" bracelet or necklace.</strong></p>
      <p>Severe anaemia occurs with intravascular haemolysis and haemoglobinuria on exposure to oxidant medicines (e.g. primaquine, dapsone, sulphonamides, quinolones, nitrofurantoin and in some cases quinine and chloroquine) and be worsened by acute infections e.g. malaria. Treat these episodes with intravenous fluids, oral iron and folate supplement; treat or remove the underlying cause.</p>
      <p>Prescribers must always check complete list.</p>
      <p><em>The risk of malaria outweighs the risk of haemolysis, so quinine should be used if indicated for malaria treatment unless the specific patient is known to sensitive to the specified anti-malaria in question.</em></p>
      <p><strong>Avoid blood transfusion unless clinically indicated. </strong></p>
      <h3>Other Anaemias</h3>
      <p><strong>HIV anaemia</strong> is a common finding with HIV and AIDS patients. Transfusion is only indicated in treating severe anaemia and cardiac failure. The causes of the anaemia include medicines such as zidovudine, and infections.</p>
      <p><strong>Other cytopaenias:</strong> refer to next section on Blood Products.<br />
        <strong>Aplastic anaemia</strong> presents as pancytopaenia. Diagnosis needs confirmation by bone marrow examination. Refer to central hospitals for specialist care after confirmation.<br />
        <strong>Myelodysplastic syndromes:</strong> refer to Central Hospital for specialist management.<br />
        <strong>Sideroblastic anaemia</strong> may occur in alcoholism, malignancy, hypothyroidism and particularly during TB treatment.  Some respond to vitamin B<sub>6</sub>, but refer to central hospital for specialist care.<br />
        <strong>Leukaemias:</strong> refer to central level.</p>
      <h3>Hereditary Bleeding Disorders</h3>
      <p><strong>Never</strong> use intramuscular injections and aspirin (paracetamol is safe). All patients should have a "Medic-alert" bracelet or necklace.</p>
      <p>Refer early for specialist management.</p>
      <p><em>All haemophiliac patients should be registered with the Haemophilia Association/Centre, Department of Haematology, P.O. Box A 178, Avondale, Harare. Clinics are held at Parirenyatwa Hospital every month.</em></p>
      <p>For haemarthrosis - do not aspirate joint. Treat by replacement of specific factor, joint support and analgesia e.g. paracetamol, codeine, morphine. Rest the joint during the acute period, give aprpropiate replacement factor and start physiotherapy as soon as the bleed resolves. <em>Some Haemophilia A and B patients are on a home therapy programme. They have written instructions on recommended dosage but may require assistance from health personnel. </em></p>
      <h4>Haemophilia A (factor VIII deficiency)</h4>
      <p>The amount of factor VIII given depends on assessment of severity of bleed. Use the table below to determine dosage, for both children and adults according to body weight.</p>
      <ul>
        <li> Ice compression should be applied as soon as possible, as this reduces the bleed.</li>
      </ul>
      <h4>Dosage of Factor VIII – Adults – per dose </h4>
      <table>
        <tbody>
          <tr><th></th><th>Severity of Bleed</th><th>Required FVIII Concentrate<br /> [500 IU/bottle]</th><th>Cryoprecipitate<br /> [80 IU/bag] (=20mls)</th></tr>
          <tr><td>1</td><td>Mild Bleed (nose, gums, etc)</td><td>14IU</td><td>1-2 bottles</td><td>6 bags</td></tr>
          <tr><td>2</td><td>Moderate bleed joint, muscle, GIT,minor surgery</td><td>20IU</td><td>2-4 bottles</td><td>12 bags</td></tr>
          <tr><td>3</td><td>Major bleed (e.g cerebral)</td><td>40IU</td><td>4-6 bottles</td><td>12 bags</td></tr>
          <tr><td>4</td><td>Prophylaxis for major surgery</td><td>60IU</td><td>6-10 bottles</td><td>18 bags</td></tr>
        </tbody>
        <small>
          Note: For 1 and 2 above, repeat the dose 12 hourly if bleeding persists or swelling is increasing. With more severe bleeds it is usually necessary to continue treatment with half of total daily dose 12 hourly for 2 -3 days, occasionally longer. <br />
          Note: For 3 and 4 above, treatment and surgery should be done <strong>with specialist supervision only</strong>. Measure levels, (if possible), otherwise give immediately before surgery. Continue 12 hourly therapy for 48 hours postoperatively and if no bleeding occurs, scale down gradually over next 3 -5 days.<br />
          Note: cryoprecipitate or of fresh frozen plasma should only be used in the absence of safe treated factor products.</small>
      </table>
      <ul>
        <li>As adjunct to factor replacement in mucosal or gastrointestinal bleeding and surgery, give fibrinolytic inhibitor [tranexamic acid]. Do not use for haematuria.</li>
        <li>If viral-inactivated treated Factor VIII is unavailable: see previous table for cryoprecipitate doses. </li>
      </ul>
      <h4>Haemophilia B (factor IX deficiency)</h4>
      <p>Ice compression should be applied as soon as possible, as this reduces the bleed.</p>
      <table>
        <caption><strong>Mild bleed:</strong></caption>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>factor IX concentrate</td><td>A V</td><td>2 x 500 IU</td><td>daily</td><td>Review</td></tr>
        <tr><td colSpan="5">or</td></tr>
        <tr><td>fresh frozen plasma</td><td>B V</td><td>4 - 6 bags</td><td>every 24hrs</td><td>if bleeding continues</td></tr>
      </table>
      <small>For children use appropriate dosage</small>
      <table>
        <caption><strong>Major bleeding:</strong></caption>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>factor IX concentrate</td><td>A V</td><td>3 - 6 x 500 IU</td><td>daily</td><td>Review</td></tr>
        <tr><td colSpan="5">or</td></tr>
        <tr><td>fresh frozen plasma</td><td>B V</td><td>8 - 12 bags</td><td>every 24hrs</td><td>if bleeding continues</td></tr>
      </table>
      <p>Factor VIII concentrate and cryoprecipitate are not useful for Haemophilia B, so accurate diagnosis is essential.</p>
      <h5>von Willebrand Disease (vWD)</h5>
      <p>The currently available FVIII concentrate from the National Blood Transfusion Service contains vW factor (but always check the insert).</p>
      <p>Using this FVIII concentrate treat as for mild or moderate bleed of Haemophilia A. Repeat haemostatic dose every 24-48 hours since therapeutic response is more sustained in vWD.</p>
      <table>
        <caption>If viral inactivated Factor VIII concentrate not available use: </caption>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>cryoprecipitate</td><td>A E</td><td>6 bags per dose</td><td>every 24 - 48 hrs</td><td>if bleeding continues</td></tr>
      </table>
      <small>Tranexamic acid (specialist medicine) is very useful in vWD mucosal and other bleeding. </small>
      <h3>Acquired Bleeding Disorders/ Platelet Disorders</h3>
      <h4>Disseminated Intravascular Coagulation (DIC)</h4>
      <p>Monitor prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (APTT), platelet count and fibrinogen.</p>
      <p>Identify if possible, and treat /remove cause of DIC.</p>
      <table>
        <caption>If PT/APTT prolonged and patient is bleeding, give: </caption>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>fresh frozen plasma</td><td>B V</td><td>4 bags</td><td>every 12 - 24 hrs</td><td>if bleeding continues</td></tr>
      </table>
      <table>
        <caption>If platelet count less than 30x10<sup>9</sup>/L and patient is bleeding: </caption>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>platelet concentrate</td><td>A E</td><td>1 unit/kg</td><td></td><td></td></tr>
      </table>
      <table>
        <caption>If fibrinogen is low and/or APTT prolonged give (to supply fibrinogen and FVIII): </caption>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>cryoprecipitate</td><td>A E</td><td>6 bags per does</td><td>review</td><td>review</td></tr>
      </table>
      <p>The use of heparin is NOT recommended in bleeding patients with DIC, except under specialist supervision.</p>
      <h4>Liver Disease</h4>
      <table>
        <caption>If fibrinogen is low and/or APTT prolonged give (to supply fibrinogen and FVIII): </caption>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>vitamin K iv*</td><td>C V</td><td>10mg**</td><td>once a day</td><td>3 days</td></tr>
      </table>
      <small><em>*Avoid intra muscular vitamin K. <br />
        **The dose is adjusted depending on the INR.</em></small>
      <table>
        <caption>For immediate haemostasis if bleeding and INR>3 give: </caption>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>fresh frozen plasma</td><td>B V</td><td>4 bags</td><td>review</td><td>review</td></tr>
      </table>
      <h5>Haemorrhagic disease of the new-born</h5>
      <p>The policy is to give vitamin K routinely to all new-borns as a preventive measure. However, if there is active bleeding give FFP and:</p>
      <table>
        <caption>For immediate haemostasis if bleeding and INR>3 give: </caption>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>vitamin K im</td><td>C V</td><td>1mg</td><td>once a day</td><td>3 days</td></tr>
      </table>
      <h4>Idiopathic Thrombocytopaenic Purpura (ITP)</h4>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>prednisolone po</td><td>B V</td><td>1mg/kg<br />then according to response (see notes)</td><td>once a day</td><td>2 weeks</td></tr>
        <tr><td colSpan="5">or</td></tr>
        <tr><td>immunoglobin iv</td><td>S E</td><td>1mg/kg</td><td>once a day</td><td>3 days</td></tr>
      </table>
      <p>Duration of therapy:<br />
        <small>No response after 2 weeks - stop.<br />
          Complete response - reduce gradually over 8-10 weeks<br />
          Partial response; - reduce slowly and refer for alternate management.</small><br />
        Intravenous immunoglobulin given at 1 mg/kg daily for 3 days works quicker when available. Consider splenectomy for those in whom steroids fail to achieve adequate control or who relapse after treatment.</p>
      <h2>Anticoagulation</h2>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>warfrin po</td><td>B V</td><td>10mg(loading dose)<br />then check the INR on Day 3 and adjust</td><td>once a day</td><td>2 days</td></tr>
      </table>
      <small>Note: To be taken at same time each day. Reduce loading dose in elderly and in-patients with renal/hepatic impairment.  </small>
      <ul>
        <li>Monitor INR regularly, initially alternate days then increase interval gradually to a maximum of 8 weeks. Therapeutic range: DVT/PE = INR 2-3; Heart valve prosthesis = INR 3-4.5. </li>
        <li>There is great individual variation in dose required (average daily dose 2.5-10mg). </li>
        <li>Caution: medicine interactions are common and can be dangerous. Below are a few examples: </li>
      </ul>
      <table>
        <tr><th>Warfarin</th><th>Warfarin Potentiation</th></tr>
        <tr><td>Barbiturates</td><td>Alcohol</td></tr>
        <tr><td>Oral Contraceptives</td><td>Chloramphenicol</td></tr>
        <tr><td>Griseofulvin</td><td>Cimetidine</td></tr>
        <tr><td>Rifampicin</td><td>Erythromycin</td></tr>
        <tr><td>Carbamazepine</td><td>Cotrimoxazole</td></tr>
        <tr><td>Vitamin K</td><td>Aspirin</td></tr>
      </table>
      <h3>Warfarin Overdose</h3>
      <ul>
        <li>If INR 4.5-7 without haemorrhage - withhold warfarin for 1-2 days then review.</li>
        <li>If INR greater than 7 without haemorrhage - withhold warfarin and check INR daily.  Consider giving: </li>
      </ul>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>vitamin K slow iv</td><td>C V</td><td>0.5 - 1mg</td><td>once a day</td><td>Review</td></tr>
      </table>
      <small>Note: higher doses vitamin K will prevent adequate anticoagulation for up to 2 weeks </small>
      <p>INR greater than 7 with haemorrhage give:</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>fresh frozen plasma</td><td>B V</td><td>4 units</td><td>-</td><td>-</td></tr>
        <tr><td>vitamin K iv</td><td>C V</td><td>0.5 - 1mg</td><td>once a day</td><td>review</td></tr>
      </table>
      <p>Parental anticoagulation. <br />
        Unfractinated heparin is given subcutaneously or intravenously. The dose is dependent on the activated partial thromboplastin time ratio (aPTTR). It has a short half-life and needs laboratory facilities. <br />
        Low molecular weight heparin is given subcutaneously with a fixed dose. No laboratory monitoring facilities are required.</p>
      <h3>Prophylaxis for Deep Vein Thrombosis (DVT)</h3>
      <p>This is indicated for all patients who have high risk factors for thrombosis before and after surgery. These conditions include:</p>
      <ul>
        <li>Obesity</li>
        <li>Prolonged immobility</li>
        <li>Hereditary thrombophilia states (antithrombin III, factor V Leiden deficiency, protein C & S deficiency etc.)</li>
        <li>Paroxysmal nocturnal haemoglobinuria</li>
        <li>Previous history of DVT</li>
        <li>Various malignances</li>
        <li>Other pro-thrombotic states such as artificial cardiac valves and atrial fibrillation need lifelong anticoagulation. </li>
      </ul>
      <h4>Methods of prophylaxis available</h4>
      <p>Physical methods include stockings. Early mobility must be encouraged in all surgical patients.</p>
      <p>Medicine management (targeting an INR of 2 to 2.5):</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>warfarin po</td><td>B V</td><td>10mg</td><td>once a day</td><td>2 days</td></tr>
        <tr><td colSpan="5">or</td></tr>
        <tr><td>heparin sc <br /> (unfractioned)</td><td>B V</td><td>5000 units</td><td>8 hourly</td><td>Review</td></tr>
      </table>
      <p>Treatment of DVT</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>heparin sc <br /> (unfractioned)</td><td>B V</td><td>17500 units</td><td>Twice a day</td><td>see notes*</td></tr>
        <tr><td colSpan="5">or</td></tr>
        <tr><td>Low molecular heparin</td><td>B V</td><td>40mg</td><td>Once Daily</td><td></td></tr>
      </table>
      <small>
        *Duration is 4-6 months except in pregnancy, or if there is another reason for prolonged treatment; <br />
        <ul>
          <li>Pulmonary embolism: 4-6 months.</li>
          <li>Atrial fibrillation: lifelong treatment.</li>
          <li>Heart valve prostheses: lifelong treatment.</li>
        </ul>
        Continue heparin until warfarin effective - usually 3-5 days.
        </small>
      <h3>Deep Vein Thrombosis in Pregnacy</h3>
      <p>Continue throughout pregnancy, aiming for APTT 2-3 times normal:</p>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>Low molecular heparin</td><td>B V</td><td>40mg</td><td>once a day</td><td>1 month post partum</td></tr>
        <tr><td colSpan="5">or</td></tr>
        <tr><td>warfarin po<br />after 12 weeks up to 37 weeks</td><td>B V</td><td>keep INR in range 2 - 3</td><td></td><td>to 37 weeks then change to heparin</td></tr>
      </table>
      <small>
        CAUTION: Warfarin may harm the foetus and should not be used under 12 weeks. Monitor closely whichever method is used. Specialist supervision is recommended. <br />
        Heparin may cause thrombocytopaenia, and with prolonged use osteoporosis </small>
      <h3>Life Threatening Pulmonary Embolism/ Arterial Embolism </h3>
      <small>See also section in Cardiovascular conditions. </small>
      <table>
        <tr><th>Medicine</th><th>Codes</th><th>Adult dose</th><th>Frequency</th><th>Duration</th></tr>
        <tr><td>hydrocortisone</td><td>B V</td><td>100mg</td><td>once a day</td><td>-</td></tr>
        <tr><td>streptokinase iv</td><td>A N</td><td colSpan="3">loading dose of 250 000 units over 30minutes, then 100 000 u every hour 24 – 72 hrs</td></tr>
      </table>
      <h4>Haematological malignanc</h4>
      <p>Refer all patients to a Central Hospital.</p>
      <h2>Use of Blood amnand Blood Products</h2>
      <h3>General Principles</h3>
      <p>Efforts should be made to avoid transfusions wherever possible because of:</p>
      <ul>
        <li>The need to conserve scarce and expensive blood products.</li>
        <li>The risk of Transfusion Transmitted Infections e.g. HIV and Hepatitis C (window period) and other transmissible agents.</li>
        <li>The risk of transfusion reactions.</li>
      </ul>
      <p>There are limited and specific indications for transfusion. Use the appropriate blood fraction to treat specific defects. Transfuse patients during normal working hours: avoid night-time transfusion whenever possible.</p>
      <small>Note: Anaemia - The correct management of a patient with anaemia is to identify and treat the cause.  Blood transfusion is required only when the anaemia is life-threatening e.g. cardiac failure or when it prohibits other necessary treatment e.g. chemotherapy or surgery.  A slow rise of haemoglobin in response to haematinics is not an indication for transfusion.<br />
        Note: The routine use of frusemide is not necessary. When needed, e.g. in cardiac failure, give small doses (e.g. 20mg). Intra-venous frusemide is rarely required.<br />
        Blood must be kept at appropriate temperature as much as possible</small>
      <h3>Specific Indications for Use of Blood and Blood Products</h3>
      <h4>Red Cell Concentrate (Packed Cells)</h4>
      <h5>Medicine</h5>
      <p>Give packed cells in the following situations:</p>
      <ul>
        <li>Acute major haemorrhage.</li>
        <li>Chronic anaemia-when patient has symptoms of cardiac failure due to low haemoglobin (less than 5g/dl);</li>
        <li>Anaemic patient (less than 5g/dl) due to have haemodialysis; (Elderly patients may require Hb levels higher than 8g/dL)Prior to, and following aggressive cytotoxic programmes, maintain haemoglobin at/or above 8g/dl;</li>
        <li>Low haemoglobin (less than 8g/dl) in presence of severe and persistent infections and septicaemia;</li>
        <li>Acute haemolysis where patient has symptoms of cardiac failure.</li>
      </ul>
      <h5>Paediatrics</h5>
      <p>Small packs (100mls) are available.  Indications are as for adults (see above list). Where transfusion is given on appropriate indication to children with protein-energy malnutrition, they should be transfused slowly (not more than 2.5 ml/kg body weight/hour).</p>
      <p>The presence of anaemia and safety of procedures must be evaluated on a patient to patient basis. There is no single safe haemoglobin level, patient haemodynamics must be evaluated against the procedure to be performed.</p>
      <p>Patients are generally haemodynamically stable at haemoglobin levels above 8 gm/dL for several procedures, but anticipation of blood loss must be assessed before each procedure.</p>
      <h4>Platelet Concentrates</h4>
      <p><strong><em>Note: this product is often used inappropriately</em><br />This section applies to all disciplines.</strong></p>
      <h5>Indications for Use of Platelet Concentrates</h5>
      <ul>
        <li>Acute bleeding in a patient with a low platelet count less than 30 x 109/L</li>
        <li>Disseminated intravascular coagulation (DIC) with active generalised bleeding and platelets less than 20 x 109/L </li>
        <li>Operations with platelets less than 30 x 109/L</li>
        <li>Cranial operations and eye operations need platelets above 100 x 109/L).</li>
      </ul>
      <h5>No justification for use of platelets in:</h5>
      <ul>
        <li>Low platelet count in patient with no evidence of bleeding, [most transfused platelets will be eliminated within 24 hrs.</li>
        <li>Autoimmune thrombocytopenia.</li>
        <li>HIV thrombocytopenia without bleeding.</li>
        <li>Aplastic anaemia without bleeding.  Guidelines for platelet transfusion in surgical patients. </li>
      </ul>
      <table>
        <tbody>
          <tr><td>less than 100 x 10<sup>9</sup>/L</td><td>All surgical proceedures including eye and brain</td><td>No platelet transfusion required.</td></tr>
          <tr><td>less than 50 x 10<sup>9</sup>/L</td><td>All surgical proceedures including eye and brain</td><td>No platelet transfusion required.</td></tr>
          <tr><td>less than 30 x 10<sup>9</sup>/L</td><td>Safe for minor procedures such as non-traumatic lumbar puncture, bone marrow aspirates, GIT scopes etc.</td><td>No platelet transfusion required.</td></tr>
        </tbody>
      </table>
      <p>* Not to be used in children under the age of 2 yrs.</p>
      <h4>Fresh frozen plasma</h4>
      <p><em>Note: Currently this is the most inappropriately used product in Zimbabwe.</em></p>
      <p>This section applies to all disciplines. The risks of transmission of infection are no less than with packed red cells or whole blood.</p>
      <h5>Indications for Use of FFP</h5>
      <ul>
        <li> Severe acute disseminated intravascular coagulation (DIC) with active generalised bleeding</li>
        <li>In presence of bleeding and disturbed coagulation in patients with liver disease, or following massive transfusion</li>
        <li>In presence of disturbed coagulation in patients requiring liver/renal biopsy, or surgery</li>
        <li>If immediate reversal of warfarin effect essential (combined with Vitamin K administration)</li>
        <li>Replacement of single coagulation factor deficiencies where specific factor concentrate not available e.g. haemophilia B </li>
        <li>Thrombotic thrombocytopaenic purpura </li>
      </ul>
      <h5>No justification for use of FFP in:</h5>
      <ul>
        <li>Hypovolaemia</li>
        <li>Acute haemorrhage with minimal disturbance of coagulation</li>
        <li>As nutritional support</li>
        <li>Obstructive jaundice with disturbed coagulation (vitamin K should be given). </li>
      </ul>
      <h4>Whole Blood</h4>
      <p>To be used in cases where fractionated blood is not available. The indication is as for red cell concentrate, and never as source of plasma.</p>
      <p><strong>EXCHANGE TRANSFUSION IN NEONATES STRICTLY USE WHOLE BLOOD.  BLOOD MUST BE LESS THAN 5 DAYS OLD.</strong></p>
      <h5>Indications:</h5>
      <ul>
        <li>Definite clinical jaundice on Day 1 of life</li>
        <li>Clinical signs of kernicterus</li>
        <li>Total Serum Bilirubin levels as shown in the table below [23.3], depending on gestational and postnatal age of the baby.</li>
      </ul>
      <table>
        <caption>Table 26.3 Serum Bilirubin Levels and Exchange Transfusion</caption>
        <tr><th>Gestation Age<br /> (Weeks)</th><th>Day 1 of Life Serum Bilirubin (umols/l)</th><th>Day 2 of Life Serum Bilirubin (umol/l</th></tr>
        <tr><td>greater than 37</td><td>80</td><td>350 (300 if sick and/or acidotic</td></tr>
        <tr><td>34 to 37</td><td>80</td><td>350 (270 if sick and/or acidotic</td></tr>
        <tr><td>31 to 34</td><td>70</td><td>290 (240 if sick and/or acidotic</td></tr>
        <tr><td>29 to 31</td><td>70</td><td>250 (200 if sick and/or acidotic</td></tr>
      </table>
      <table>
        <tr><th>Birth weight</th><th>Volume of aliquots</th></tr>
        <tr><td>1000 - 1499g</td><td>5ml</td></tr>
        <tr><td>1500 - 2499g</td><td>10ml</td></tr>
        <tr><td>greater than 2499g</td><td>20ml</td></tr>
        <tr><td>Withdrawal of blood</td><td>1 minute</td></tr>
        <tr><td>Injection of blood</td><td>4 minutes</td></tr>
      </table>
      <h4>Leukocyte-poor Blood</h4>
      <p>Occasionally required in patients who need regular transfusion over prolonged periods, in order to prevent febrile reactions due to white cell antibodies and provision of CMV negative blood from unscreened blood. Bedside leukocyte reducing filters, supplied by the Blood Transfusion Service, may be used to attain the same product.</p>
      <h4>Albumin 4%</h4>
      <p>Can be used as a volume expander and is HIV free. Must not be used if solution appears turbid or contains a deposit. Protect from light and do not freeze.</p>
      <h4>Anti-D</h4>
      <p>To be given post-delivery to Rhesus D negative patients to prevent immunization.</p>
      <h4>Intravenous Immunogoblin</h4>
      <p>Can be used in several auto immune diseases to include ITP, Guillain Barre and in selected infections.</p>
      <h4>Salt Poor Albumin</h4>
      <p>May be indicated for correction of chronic hypoalbuminaemia; in special circumstances of organ failure and fluid overload e.g. liver disease and resistant ascites.</p>
      <h4>Factor VIII Preparations</h4>
      <p>Products available: (1) freeze dried anti-haemophilic factor (AHF). (2) cryoprecipitate. To be used in patients with haemophilia A with mild, moderate or severe bleeds. See notes above.</p>
      <h4>Factore IX Concentrate</h4>
      <p>For patients with haemophilia B who are bleeding. See notes above.</p>
      <h4>Cryoprecipitate</h4>
      <p>Indications include DIC, von Willebrand Disease, haemophilia, and bleeding associated with renal failure.</p>
    </span>
}
const chapter_twentynine = {
  short_title: "Chapter 29",
  long_title: "Intravenous Fluid Replacement",
  subsections: [
    {
      short_title: "Section 0",
      long_title: "Notes",
      content:
        <span>
          <h1>Intravenous Fluid Replacement</h1>
          <h2>Notes</h2>
          <p><strong>NB: Repeated clinical evaluation of patients receiving IV fluid therapy is necessary in order to avoid the dangers of over-transfusion or inadequate rehydration. Formulae and biochemical estimations are no substitute for clinical evaluation.</strong></p>
          <h3>Special Notes</h3>
          <ul>
            <li>Only give intravenous fluids when they are strictly necessary. It is wasteful and dangerous to give iv fluids to a patient who can drink oral fluids.</li>
            <li>Small packs of intravenous fluids (e.g. 200 ml) are much more expensive volume for volume than litre containers.</li>
            <li>For fluid replacement in burns see relevant chapter.</li>
            <li>For use of blood and blood products see relevant chapter.</li>
          </ul>
          <h4>Electrolyte content of various body fluids</h4>
          <p>Electrolyte content of various body fluids should be taken into account. For practical purposes replacement is with Normal Saline or Ringer Lactate with added potassium, except for diarrhoea, particularly in children, where the sodium content is proportionately lower and the potassium higher.</p>
          <table>
            <tr><th>Fluid</th><th>Sodium <br />mmol/litre</th><th>Potassium<br />mmol/litre</th></tr>
            <tr><td>Plasma</td><td>140</td><td>4</td></tr>
            <tr><td>Gastric</td><td>60</td><td>10</td></tr>            <tr><td>Biliary &amp; Pancreatic</td><td>140</td><td>5</td></tr>            <tr><td>Small Intestine</td><td>110</td><td>5</td></tr>    <tr><td>Ileal</td><td>120</td><td>5</td></tr>             <tr><td>Ileostomy</td><td>130</td><td>15</td></tr>         <tr><td>Diarrheoa</td><td>60</td><td>40</td></tr>          <tr><td>Sweat</td><td>60</td><td>10</td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 1",
      long_title: "Normal Daily Requirements",
      content:
        <span>
          <h2>Normal Daily Requirements</h2>
          <table>
            <tr><th>Substance</th><th>Weight</th><th>Dose</th></tr>    <tr><td>Water</td><td>0 to 10kg<br />11 to 20kg<br />21kg or more</td><td>100ml/kg/24hrs<br />1000ml + 50ml/kg/24hrs <br />1500ml + 25ml/kg/24hrs<br />(for an adult this is 30 – 40ml/kg/day)</td></tr>
            <tr><td>Sodium</td><td></td><td>1 to 1.5mmol/kg/24hrs</td></tr>
            <tr><td>Pottassium</td><td></td><td>1mmol/kg/24hrs</td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 2",
      long_title: "Maintenance",
      content:
        <span>
          <h2>Maintenance</h2>
          <h3>Adults [and Children older than 10 years of age]</h3>
          <p>The following in combination, adjusted so that total volume is 2-3 litres/24 hours in adults:</p>
          <table>
            <tbody>
              <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th></tr>
              <tr><td>sodium chloride 0.9% iv</td><td>C V</td><td>0.5 - 1litre</td></tr>
              <tr><td colSpan="3">or</td></tr>
              <tr><td>ringer lactate iv</td><td>C V</td><td>0.5 - 1litre</td></tr>
              <tr><td>dextrose 5% in water iv</td><td>C V</td><td>1.5 - 2litre</td></tr>
              <tr><td>Potassium chloride iv</td><td>B V</td><td>20 mmol added to each litre</td></tr>
            </tbody>
          </table>
          <p>Children: 1 Month - 10 years( refer to Paediatrics Chapter)</p>
          <table>
            <tbody>
              <tr><th>Medicine</th><th>Codes</th><th>Paed Dose</th><th>Frequency</th></tr>
              <tr><td rowSpan="2">half strength Darrow's solution with dextrose 2.5% iv</td><td rowSpan="2">C V</td><td>0 to 10kg</td><td>100ml/kg/24hrs</td></tr>
              <tr><td>5 to 10years</td><td>75ml/kg/24hrs</td></tr>
            </tbody>
          </table>
          <p>Infants (Up to 30 days old)</p>
          <table>
            <tbody>
              <tr><th>Medicine</th><th>Codes</th><th>Paed Dose</th><th>Frequency</th></tr>
              <tr><td>neonatal multi electrolyte maintenance solution ('neonatalyte')</td><td>B N</td><td colSpan="3" >up to 10kg</td></tr>
            </tbody>
          </table>
          <small><em>*Do not exceed 60 ml/kg/24 hrs in the first 24 hours of life - see section on neonates in paediatric chapter. </em></small>        </span>
    },
    {
      short_title: "Section 3",
      long_title: "Replacement of Abnormal Losses",
      content:
        <span>
          <h2>Replacement of Abnormal Losses</h2>
        </span>
    },
    {
      short_title: "Section 4",
      long_title: "Available Intravenous Solutions",
      content:
        <span>
          <h2>Available Intravenous Solutions"</h2>
        </span>
    },
    {
      short_title: "Section 5",
      long_title: "Crystalloids",
      content:
        <span>
          <h2>Crystalloids</h2>
        </span>
    },
    {
      short_title: "Section 6",
      long_title: "Colloids",
      content:
        <span>
          <h2>Colloids</h2>
        </span>
    }],
  content:
    <span>
      <h1>Mental Health</h1>
    </span>
}
const chapter_thirty = {
  short_title: "Chapter 30",
  long_title: "Anaphylaxis",
  content:
    <span>
      <h1>Anaphylaxis</h1>
      <p>Severe anaphylaxis is a life threatening immunological response to a substance to which an individual is sensitised. It is a medical emergency (life and death situation) in which seconds count. Prompt treatment is required for acute airway obstruction, bronchospasm and hypotension.</p>
      <h3>Triggers</h3>
      <p>Common triggers of anaphylaxis are medicines, (notably: antibiotics, non-steroidal anti-inflammatory medicines, antiarrhythmics, heparin, parenteral iron, desensitising preparations and vaccines), blood transfusions, bee and other insect stings, anaesthetic medicines and certain foods. Latex allergy may be delayed in onset, taking up to 60minutes to manifest. Some anaesthetic medicines are also associated with anaphylactoid reactions (urticaria, flushing and mild hypotension). Food allergen triggers may have a delayed onset. Such as nuts may have a delayed onset and are commonly associated with urticaria.</p>
      <h3>Clinical Presentation of Anaphylaxis</h3>
      <p>Anaphylactoid reactions range from minor to life-threatening. The major presenting features are commonly cardiovascular. It is important to recognise and address the following:</p>
      <p><em>Cardiovascular</em> (hypotension, tachycardia, arrhythmias, ECG may show ischaemic changes even cardiac arrest)</p>
      <p><em>Respiratory system</em> (oedema of the glottis, tongue and airways, stridor and airway obstruction and bronchospasm)</p>
      <p><em> Gastrointenstinal</em> (abdominal pain, diarrhoea or vomiting)</p>
      <p><em>Cutaneous</em> (flushing, erythema, urticaria)</p>
      <small><em>Note: It is imperative to establish a causative allergen source and it is essentially that the patient is advised in writing of the allergy and advised to wear a medic-alert bracelet indicating the sensitivity: repeat exposure may be fatal. </em></small>
      <h2>Treatment</h2>
      <p>Discontinue administration of any suspect agent (for example medicine, blood, diagnostic agent) <br />Lay the patient flat and elevate the legs. <br />Follow the ABC of resuscitation</p>
      <ol>
        <li>Airway <ul>
          <li>Give Adrenaline im 0.5- 1mg (0.5 – 1ml of 1:1000 solution) repeated each ten minutes as required </li>
          <li>Ensure a clear airway; give 100% oxygen, if available. </li>
        </ul>
        </li>
        <li>Breathing <ul>
          <li>Ensure adequate breathing (intubate and ventilate as required)</li>
          <li>Nebulised bronchodilators (for example, 5mg salbutamol) or iv aminophylline may be required if bronchospasm is refractory (loading dose of 5mg/kg followed by 0.5mg/kg/hr). </li>
        </ul>
        </li>
        <li>Circulation <ul>
          <li>Monitor pulse, blood pressure, bronchospasm and general response/condition every 3-5 minutes. </li>
          <li>Start CPR if cardiac arrest has occurred . </li>
        </ul>
        </li>
      </ol>
      <table>
        <caption>Give:</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>adrenaline 1 in 1000 im</td><td>C V</td><td>0.5 - 1ml<br />
            [= 10mg/kg]<br />
            children > 5yrs 0.5ml<br />
            4 years 0.4ml<br />
            3 years 0.3ml<br />
            2 years 0.2ml<br />
            1 years 0.1ml<br /></td><td colSpan="2">Repeat as necessary every 10mins until improvement occurs.</td></tr>
        </tbody>
      </table>
      <table>
        <caption>In <strong>severe</strong> allergic reaction give: </caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Adult Dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>adrenaline 1 in 10000 iv<br />
            [Add 9ml normal saline / water to 1ml of 1in 1000 adrenaline]</td><td>C V</td><td>1ml <u>slow</u><br />
              [= 0.1mg/kg]<br /></td><td>repeat every minute</td><td>until satisfactory clinical response</td></tr>
        </tbody>
      </table>
    </span>
}
const chapter_thirtythree = {
  short_title: "Chapter 33",
  long_title: "Surgical Conditions",
  content:
    <span>
      <h1>Surgical Conditions</h1>
      <h2>General Notes</h2>
      <p>The field of surgery is diverse with many specialties covering specific clinicopathological areas. The EDLIZ guidelines will attempt to cover basic essentials of surgical care. Detailed information should be obtained in literature of the appropriate specialties. The ability to identify patients needing surgical intervention should be of paramount importance.</p>
      <h3>General Surgical Conditions</h3>
      <ol>
        <li>Acute Abdomen <ul>
          <li>Appendicitis</li>
          <li>Intestinal obstruction</li>
          <li>Cholecystitis</li>
          <li>Perforated duodenal ulcer</li>
        </ul>
        </li>
        <li>Breast conditions</li>
        <li>Thyroid condition</li>
        <li>Ulcers</li>
      </ol>
      <h2>Acute Abdomen</h2>
      <p>This is defined as severe sudden onset of pain of less than 7 to 10 days duration. The causes of an acute abdomen can be localized to the abdomen but sometimes can be from a systemic non-surgical cause. It is very important to be able to quickly assess and decide whether it is a surgical acute abdomen or medical acute abdomen.</p>
      <p>The usual presentation of a surgical acute abdomen is sudden abdominal pain (colicky or sharp piercing) associated with vomiting and/or constipation. Other features might include abdominal distension and failure to pass flatus. The main causes of a surgical acute abdomen are acute appendicitis, acute perforated duodenal ulcers, acute intestinal obstruction, acute cholecystitis, pancreatitis, ectopic pregnancy and ovarian torsion. Non abdominal causes of pain that mimic an acute abdomen are numerous and may include myocardial infarction, pericarditis, pneumonia or pleurisy.</p>
      <h4>Evaluation</h4>
      <ul>
        <li>History and physical examination will help narrow down the differential diagnoses and also determine whether the patient requires emergency surgery. Special attention should be paid to the nature of pain, location, onset, duration, intensity, recurrent nature, aggravating and alleviating factors.</li>
        <li>Physical exam should note the general state of the patient, abdominal distension, surgical scars, tenderness, guarding, rebound tenderness, presence of a mass, rectal, cervical or adnexal tenderness. </li>
        <li>Initial tests might include an FBC, U&Es, amylase, lipase, pregnancy test, urinalysis and LFTs. </li>
        <li>Imaging studies may be necessary:</li>
      </ul>
      <p>Plain abdominal x-rays may reveal obstruction, perforation (free air under the diaphragm) and other pathology.</p>
      <p>Ultrasound is indicated especially for biliary tract disease, pelvic and urinary system pathology.</p>
      <h4>Treatment</h4>
      <p>Haemodynamically unstable patients might need immediate resuscitation with Normal saline or Ringers lactate, possible transfusion, nasogastric tube for obstruction or persistent vomiting, urinary catheter for monitoring output, broad spectrum empirical antibiotic for peritonitis, suspected perforated viscus or intra-abdominal injection.</p>
      <p>Direct treatment towards the specific condition should be instituted by the specialist after diagnostic workup.</p>
      <h3>Acute Appendicitis</h3>
      <p>This is the commonest acute abdominal surgical emergency. Typical symptoms are shifting abdominal pain (starting as vague periumbilical pain then shifting to the right iliac fossa) associated with nausea and occasional vomiting. On evaluation, uncomplicated appendicitis has right iliac tenderness ellicited maximally at McBurney‘s point with possible positive Rovsing sign. The white blood count may be elevated. The diagnosis of appendicitis should be made on clinical grounds but other investigations especially ultrasound scan and CT scan might be necessary in females and where the history is not typical. The other tests are especially useful to exclude other pathologies that might mimic appendicitis. Straightforward appendicitis needs emergency surgery as delays are associated with complications and poor outcome. The treatment of appendicitis is surgical. Laparascopic appendicectomy is now popular among surgeons with special interest and is particularly useful in females where the advantage of visualising pelvic viscera is important. The cosmetic advantages are additional to the less pain, reduced hospital stay and earlier recovery noted with laparascopic surgery.</p>
      <p>The use of antibiotics in appendicitis and its complications can be summarized as below:</p>
      <h3>Condition Treatment</h3>
      <table>
        <caption><strong>Acute appendicitis:</strong> Emergency appendicectomy and prophylaxis: </caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th></tr>
          <tr><td>Ceftriaxone IV</td><td>C V</td><td>1g</td><td>Once only</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>Once only</td></tr>
        </tbody>
      </table>
      <table>
        <caption><strong>Appendiceal mass.</strong> Clinical assessment of size of mass and institution of IV antibiotics and analgesia</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th></tr>
          <tr><td>Benzyl penicillin IV</td><td>C V</td><td>2.5MU</td><td>4 times a day</td></tr>
          <tr><td>Gentamicin IV</td><td>C V</td><td>120mg</td><td>Once a day</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>3 times a day</td></tr>
          <tr><td colSpan="4">Alternatively:</td></tr>
          <tr><td>Ceftriaxone IV</td><td>C V</td><td>1g</td><td>2 times a day</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>3 times a day</td></tr>
        </tbody>
      </table>
      <p>This can be done while serial examinations (daily) for clinical improvement of size of mass. are instituted Serial FBC and USS monitoring for improvement is also important. Failure to improve or deterioration in condition might warrant surgical intervention. If the patient improves elective surgery (six weeks after initial presentation) is advised as operating early is fraught with higher risk of complications</p>
      <table>
        <caption><strong>Appendiceal abscess.</strong>  Emergency incision and drainage (with or without appendicectomy) or USS guided pus drainage plus antibiotics as follows:</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th></tr>
          <tr><td>Benzyl penicillin IV</td><td>C V</td><td>2.5MU</td><td>4 times a day</td></tr>
          <tr><td>Gentamicin IV</td><td>C V</td><td>120mg</td><td>Once a day</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>3 times a day</td></tr>
          <tr><td colSpan="4">Alternatively:</td></tr>
          <tr><td>Ceftriaxone IV</td><td>C V</td><td>1g</td><td>2 times a day</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>3 times a day</td></tr>
        </tbody>
      </table>
      <p>These treatments are continued till clinical improvement is satisfactory. Interval elective appendicectomy might or might not be necessary.</p>
      <p><strong>Appendiceal rupture/perforation.</strong> Generalised peritonitis is typical and prognosis is poor. Aggressive fluid resuscitation, IV antibiotics and urgent laparatomy are all necessary. The IV antibiotic regime is as for appendiceal abscess above.</p>
      <h3>Intestinal Obstruction</h3>
      <p>History and examination is of paramount importance. While the different causes and types of obstruction are beyond the scope of the EDLIZ the important symptoms to look for are colicky abdominal pain, vomiting, abdominal distension and absolute constipation or obstipation (not passing stool and flatus). These symptoms are present in different degrees depending on the cause and level of obstruction. Remember to exclude previous abdominal surgery which makes adhesions the likely cause of obstruction and assess the potential hernia sites to exclude obstructed hernia.</p>
      <p>Aggressive resuscitation and monitoring is important once intestinal obstruction is suspected or confirmed. Initial FBC, U+Es and possible X-match is important. IV fluids in the form of Normal saline and Ringers lactate are given as guided by degree of dehydration but aiming to achieve a urine output of 1ml/kg/hr as guided by the urine output monitoring with a urinary catheter. NGT insertion and monitoring of the effluent type and amounts is vital. The NGT losses should be replaced ml per ml with Normal Saline in addition to the normal daily requirements estimated at 40mls/kg/24hrs.</p>
      <p>Antibiotic use in intestinal obstruction is necessary where bacterial translocation is suspected especially with longer history of obstruction or where a closed loop obstruction with possible gangrene/perforation of bowel is suspected e.g. in sigmoid volvulus or at surgery where unprepared bowel is opened.</p>
      <table>
        <caption>First Line</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th></tr>
          <tr><td>Benzyl penicillin IV</td><td>C V</td><td>2.5mg</td><td>4 times a day</td></tr>
          <tr><td>Gentamicin IV</td><td>C V</td><td>120mg</td><td>Once a day</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>3 times a day</td></tr>
        </tbody>
      </table>
      <table>
        <caption>Second Line</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th></tr>
          <tr><td>Ceftriaxone IV</td><td>C V</td><td>1g</td><td>2 times a day</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>3 times a day</td></tr>
        </tbody>
      </table>
      <h3>Cholecystitis</h3>
      <p>Acute cholecystitis is a condition which is becoming more frequent in our population as major lifestyle changes occur with dietary shifts towards a western diet. This has increased the incidence of cholesterol related illness of which gallstone disease is one. Calculous cholecystitis (gallstone-related cholecystitis) is the commonest indication for cholecystectomy in Zimbabwe. In young patients exclusion of haemolytic anaemia especially sickle cell anaemia is important.</p>
      <p>While the definitive treatment for cholecystitis is surgery i.e. open cholecystectomy or laparascopic cholecystectomy it is necessary to give antibiotics for acute cholecystitis. While acute cholecystitis typically presents in a forty year old, fat, fertile, flatulent and fair female it can also occur in males, in a younger or older age group. The symptoms are mainly acute right upper quadrant pain usually at night after a fatty meal with some milder previous episodes of colicky upper abdominal pains. On examination tender right upper quadrant is typical with a positive Murphy sign (catch of breath on inspiration while the palpating hand is advancing up from the right iliac fossa to the right costal margin).</p>
      <h3>Treatment of Acute Cholecystitis</h3>
      <p>Antibiotics and analgesia are important.</p>
      <table>
        <caption>First Line</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th></tr>
          <tr><td>ampicillin IV</td><td>C V</td><td>500mg</td><td>4 times a day</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>3 times a day</td></tr>
          <tr><td colSpan="4">Alternative to ampicilin (if unavailable)</td></tr>
          <tr><td>Benzyl penicillin IV</td><td>C V</td><td>2.5mg</td><td>4 times a day</td></tr>
        </tbody>
      </table>
      <table>
        <caption>Second Line</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th></tr>
          <tr><td>Ceftriaxone IV</td><td>C V</td><td>1g</td><td>2 times a day</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>3 times a day</td></tr>
        </tbody>
      </table>
      <p>Patients are managed as above and if symptoms and signs improve can be discharged on oral, amoxicillin 500mg tds x for 7 days and scheduled for elective cholecystectomy after six weeks.</p>
      <p>Advances in laparascopic surgery have however made it possible to do early or "hot" cholecystectomy when certain criteria are met based on expertise of the surgeon.</p>
      <h2>Perforated Duodenal Ulcer</h2>
      <p>Peptic ulcer disease is generally a medical condition where advances in diagnosis and treatment have made surgical intervention only reserved for its complications. Perforated duodenal ulcers remain a feared and relatively common complication.</p>
      <p>While a reasonable number of patients who present with acute perforated duodenal ulcer have had a diagnosis of peptic ulcers before, the majority have no prior diagnosis or investigations done. Presentation is usually of sudden severe epigastric pain which rapidly spreads to the whole abdomen associated with fear of movement. Examination findings are typically those of generalized tenderness with board-like rigidity of the abdomen and rebound tenderness. The erect chest X-ray shows free air under the diaphragm in 75% of cases.</p>
      <p>This is surgical emergency but resuscitation with Normal Saline, NGT insertion, analgesia and urinary catheterization should be done. FBC and U+Es are done in preparation for surgery. The prognosis is poor if surgery is delayed. The adage of "the sun should not rise and set" before surgery is done is appropriate for this condition. IV antibiotics should be given as soon as signs of peritonitis are picked.</p>
      <table>
        <caption>First Line</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th></tr>
          <tr><td>Benzyl penicillin IV</td><td>C V</td><td>2.5mg</td><td>4 times a day</td></tr>
          <tr><td>Gentamicin IV</td><td>C V</td><td>120mg</td><td>Once a day</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>3 times a day</td></tr>
        </tbody>
      </table>
      <small>NB. Gentamicin should not be used if renal assessment is not satisfactory. </small>
      <table>
        <caption>Second Line</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th></tr>
          <tr><td>Ceftriaxone IV</td><td>C V</td><td>1g</td><td>2 times a day</td></tr>
          <tr><td>Metronidazole IV</td><td>B V</td><td>500mg</td><td>3 times a day</td></tr>
        </tbody>
      </table>
      <h2>Breast Conditions</h2>
      <p>While the breast can be affected by many conditions practitioners should take all efforts to exclude malignancy. History and examination is of value in this regard. Common breast conditions are:</p>
      <ul>
        <li>Breast abscess especially in breastfeeding or pregnant women</li><li>Mastitis</li><li>Breast fibroadenomas especially in young women age (15 to 35years).</li><li>Breast cancer especially above the age of 35.</li><li>Ductal papilloma</li><li>Duct ectasia</li><li>Nipple/ breast eczema</li><li>Paget‘s disease of the breast</li><li>TB of the breast </li>
      </ul>
      <h3>Breast Abscess</h3>
      <p>Typically occurs in a young lactating or pregnant women who has pain and swelling of the breast with an area of maximal tenderness or fluctuancy. Once the diagnosis is made, incision and drainage in theatre under general anaesthesia should be done as they are generally deep abscesses and adequate drainage is advisable under general anaesthesia. Analgesia and antibiotics should be instituted once diagnosis is made.</p>
      <table>
        <caption>Preferred Therapy:</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>cloxacillin IV</td><td>B V</td><td>500mg</td><td>4 times a day</td><td>2 Days</td></tr>
          <tr><td>cloxacillin po</td><td>B V</td><td>500mg</td><td>4 times a day</td><td>5 days</td></tr>
        </tbody>
      </table>
      <table>
        <caption>Alternative therapy</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>clindamycin IV</td><td>B V</td><td>300 to 600mg</td><td>3 times a day</td><td>2 days</td></tr>
          <tr><td>clindamycin po</td><td>B V</td><td>300 to 600mg</td><td>3 times a day</td><td>5 days</td></tr>
        </tbody>
      </table>
      <p>The wound should be cleaned with saline or povidone iodine and packed or dressed with glycerin and ichthamol daily until healing occurs. The mother should be advised to continue breastfeeding or to express the breast frequently.</p>
      <h3>Mastitis</h3>
      <p>This also occurs commonly in breastfeeding or pregnant mothers. The symptoms are similar to the breast abscess except that there is no "pointing" area of maximal tenderness or fluctuancy.
        <br />If mild symptoms</p>
      <table>
        <caption>Preferred Therapy:</caption>
        <tbody>
          <tr><th>Medicine</th><th>Codes</th><th>Dose</th><th>Frequency</th><th>Duration</th></tr>
          <tr><td>cloxacillin po</td><td>B V</td><td>500mg</td><td>4 times a day</td><td>7 Days</td></tr>
          <tr><td>Or</td></tr>
          <tr><td>clindamycin po</td><td>B V</td><td>450mg</td><td>3 times a day</td><td>7 days</td></tr>
        </tbody>
      </table>
      <p>If severe then admission and IV treatment as in breast abscess discussed above.</p>
      <h3>Breast Eczema</h3>
      <p>This is a common condition which is usually confused with cracking nipples in breastfeeding mothers. However, exclusion of breast cancer is important as in Paget‘s disease. Where appropriately diagnosed, breast eczema can then be managed as per guidelines in the skin conditions chapter. Where there is doubt of diagnosis a biopsy of the affected skin is important</p>
      <h2>Thyroid Conditions</h2>
      <p>Patients who present with a goitre need to be assessed properly. The assessment should focus on assessing their thyroid state (thyrotoxicosis, euthyroid or hypothyroid) and exclude complications which might be linked to malignant change e.g upper air ways compression, hoarse voice in recurrent nerve invasion, retrosternal extension or superior vena cava compression, rapid growth, fixation, enlarged lymph nodes.</p>
      <p>Treatment for thyrotoxicosis is laid out in the Endocrine Conditions chapter.</p>
      <p>Surgical intervention is indicated in thyrotoxicosis if :</p>
      <ul>
        <li>Not responding to medical therapy.</li>
        <li>Thyrotoxicosis not responding to radioiodine.</li>
        <li>Thyrotoxic patients where antithyroid drugs and radioiodine are contraindicated.</li>
        <li>Confirmed malignancy.</li>
        <li>Suspected malignancy where confirmation is not possible before surgery e.g. in follicular carcinoma.</li>
        <li> Goitre causing compressive complications on the airway, major vessels and nerves. </li>
      </ul>
      <p>Patients scheduled for surgical intervention should be rendered euthyroid before the surgery with oral anti-thyroid drugs. Emergency cases might need IV propranolol as there is no time to bring the thyroid hormones down.</p>
      <h3>Skin Ulcers</h3>
      <p>Chronic ulcers are a common condition. Unless the cause of the ulcer is known exclusion of malignancy is important. Exclusion of malignancy should be done by taking a biopsy for histological analysis. The common cutaneous malignancies are squamous cell carcinoma, malignant melanoma and basal cell carcinoma. These malignancies are more common in albinos who are sun exposed without ultraviolet protection. Use of sun protective clothes and sunscreen lotions is important in this group of people. However everyone is prone to developing skin cancers. Chronic non-healing ulcers (eg after burns) can develop squamous cell carcinoma, referred to as a Marjolin ulcer. Malignant melanoma of the acral lentiginous type is common on the soles of the feet in Zimbabwe and all suspicious lesions should be biopsied and referred to the general surgeon for further management.</p>
      <p>Where malignancy has been ruled out or is not suspected exclusion of peripheral vascular disease, diabetes mellitus and venous stasis (eg in varicose veins) is also important. The management of nonmalignant chronic ulcers involves different disciplines. The guiding principle, however, is reducing inflammation on the wound by avoiding irritating substances on the wound and limiting frequent change of dressings. In this regard simple normal saline or equivalent salt solution would be preferred for cleaning the wound and then applying long staying dressings (which can be changed less often eg once every third day). Wound care products are varied and the state of the wound would guide the most appropriate product to use. In the absence of these specialized products cleaning the wound with simple saline and dressing it with glycerine and icthamol solution would suffice.</p>
    </span>
}
const chapter_thirtyfour = {
  short_title: "Chapter 34",
  long_title: "Antineoplastic Agents",
  content:
    <span>
      <h1>Antineoplastic Agents</h1>
      <p>A wide variety of antineoplastic agents are generally available. These agents should be strictly used under the supervision of a specialist in oncology, be it for the treatment of malignant or other conditions.<br />   The role of antineoplastic agents in the management of cancer is expanding. Chemotherapeutic and other medicines are used during treatment of most patients with cancer.  One of the most important developments in cancer therapy over the last few decades is the increased recognition of the role of chemo-radiation in the curative management of cancer.<br /> Chemotherapy medicines fall into the following classes</p>
      <ul>
        <li>Alkylating medicines, </li>
        <li>Cytotoxic antibiotics, </li>
        <li>Antimetabolites,</li>
        <li>Vinca alkaloids,</li>
        <li>Other medicines. </li>
      </ul>
      <p>Recent times have however, seen the development of an array of other antineoplastic medicines including biological and immune therapy drugs.</p>
      <p>Chemotherapy can be used in a number of ways. The criteria for use differ for each tumour type, stage morphologic and biologic characteristics. Combination chemotherapy is more commonly used than single agent chemotherapy.</p>
      <h3>Principles of Combination Chemotherapy</h3>
      <ol>
        <li>Only those agents proven effective should be used.</li>
        <li>Each agent used should have a different mechanism of action</li>
        <li>Each agent should be used at maximum dose</li>
        <li>Agents with similar dose – limiting toxicities can be combined safely only by reducing doses, resulting in decreased effects.</li>
        <li>Combination chemotherapy should be administered according to protocol, based on evidence-based medicine with intervals between therapy cycles allowing for the recovery of normal tissue. </li>
      </ol>
      <h3>Guidelines of handling chemotheraphy medicines</h3>
      <ul>
        <li>Trained personnel should reconstitute the medicines.</li>
        <li>Reconstitution should be done in designated areas, preferably under lamina air flow.</li>
        <li> Protective clothing including eye protection should be worn at all times whilst reconstituting the medicines. This includes eye protection. </li>
        <li>Gloves should always be worn when administering the medicines. </li>
        <li> Pregnant health care workers should not handle chemotherapy medicines. </li>
        <li>Waste disposal should be meticulously handled. All contaminated disposables should be incinerated.</li>
      </ul>
      <h3>Adjuvant Chemotheraphy</h3>
      <ol>
        <li>Effective chemotherapy must be available</li>
        <li>Known tumour should have had primary definitive treatment either surgically or with radiation treatment</li>
        <li>Chemotherapy should be started as soon as possible after primary treatment.</li>
        <li>Chemotherapy should be given in maximally tolerated doses </li>
        <li>Chemotherapy should continue to the maximum period defined by the protocol.</li>
      </ol>
      <h3>Neoadjuvant Chemotherapy</h3>
      <p>In this instance, chemotherapy is administered before surgery or radiotherapy. The advantage of this method is that it exposes potential micrometastases to chemotherapy much earlier. Also significant regression of the primary tumour may allow easier management and permit organ and function preservation. Cancers effectively treated by neoadjuvant chemotherapy include soft tissue sarcomas, ostesarcoma, anal cancer, bladder cancer, larynx cancer, oesophageal cancer and locally advanced breast cancer.</p>
      <h3>Chemoradiation</h3>
      <p>Chemotherapy is increasingly being administered concurrently with radiotherapy in most tumours. The result of chemoradiation in these tumours is superior to that of radiotherapy alone. The improved outcome outweighs the slightly increased toxicity of the combined treatment. Cancers effectively treated by chemoradiation include, cervical cancer, oesophangeal cancer, nasopharyngeal cancer and other head and neck cancers</p>
      <h3>Maintenance Chemotherapy </h3>
      <p>In certain specific conditions patients may need to continue on chemotherapy for a defined period. Examples include tamoxifen for ER/PR positive breast cancer.</p>
      <h3>Palliative Chemotheraphy</h3>
      <p>Chemotherapy can be used in advanced disease for palliation where there is no alternative therapy or where local therapies have failed. A positive response with acceptable toxicity must be expected to justify the use of palliative chemotherapy.. Cancers that may be effectively treated with palliative chemotherapy include advanced ovarian cancer, germ cell tumours of the testis, small cell lung cancer and metastatic breast cancer.</p>
      <h3>Cancers that may be curable with Chemotherapy Alone </h3>
      <p><em>Some of the examples of cancers that maybe curable with chemotherapy alone*</em></p>
      <ul>
        <li>Gestational choriocarcinoma</li>
        <li>Hodgkin‘s disease</li>
        <li>Germ cell cancer of testis</li>
        <li>Acute lymphoid leukemia</li>
        <li>Non-Hodgkin‘s lymphoma (some subtypes)</li>
        <li>Hairy cell leukemia (probable)</li>
        <li>Small cell lung cancer</li>
      </ul>
      <small>*Depending on stage at presentation</small>
      <h2>Selection of Chemotheraphy Agents</h2>
      <p>Many chemotherapy regimens for a wide variety of cancers exist. Patients who are to receive chemotherapy are to be well assessed prior to prescription and administration of these medicines. Assessment needs vary according to the medicines that may be selected for use. The following are to be considered prior to this:</p>
      <h3>Physiologic Age of the Patient</h3>
      <p>Whilst age alone is not a valid criterion for excluding patients from receiving chemotherapy, age related alterations in organ function may result in unacceptable toxicity. Treatment decisions must however take into account the likelihood of benefit.</p>
      <h3>Performance Status</h3>
      <p>Patients with poor Karnofsky performance status (KPS) do not tolerate chemotherapy well. Patients with KPS of 30 percent or less are not usually candidates for chemotherapy.</p>
      <table>
        <caption>Patient Perfomance Score Using the Karnofsky Scale</caption>
        <tbody>
          <tr><th>Karnofsky (%)</th><th>Definition</th></tr>
          <tr><td>100</td><td>Asymptomatic</td></tr>
          <tr><td>80 - 90</td><td>Symptomatic, fully ambulatory</td></tr>
          <tr><td>60 - 70</td><td>Symptomatic, in bed less than 50% of day</td></tr>
          <tr><td>40 - 50</td><td>Symptomatic, in bed more than 50% of day but not bedridden</td></tr>
          <tr><td>20 - 30</td><td>Bedridden</td></tr>
        </tbody>
      </table>
      <h3>Nutritional Status</h3>
      <p>Ingestion of 1500 to 2000 cal/day is necessary to allow for satisfactory tumour response. This is an important consideration in the setting of advanced malignancy.</p>
      <h3>Obesity</h3>
      <p>Over dosage can occur if dosage is calculated per kilogram rather than per surface area. Ideal body weight should be used for palliative therapy rather than actual body weight. For curative cases if ideal body weight is used, dose escalations should be considered if treatment well tolerated.</p>
      <h3>Prior Therapy</h3>
      <p>The first chemotherapy treatment protocol usually gives best response and hence the need for optimum timeous management by knowledgeable team. Failure to respond to first line therapy lessens the probability to respond to second line therapy. This is most likely due to the development of multi drug (medicine) resistance.</p>
      <h3>Organ Function</h3>
      <p>Altered bone marrow, renal, hepatic, cardiac or pulmonary function may render it impossible to use some agents or make it necessary to modify dosage. The oncologist will need to determine baseline function according to the medicines being administered.</p>
      <h3>Coexisting Illness</h3>
      <p>Choice of agents to be used may have to be modified e.g. adriamycin in congestive cardiac failure and steroids in diabetes mellitus</p>
      <h4 className="underline">Requirements for chemotherapy/referral to tertiary level</h4>
      <p>All patients needing chemotherapy should be referred for treatment to a referral or tertiary treatment institute, unless there are suitable facilities and well trained staff in another facility.</p>
      <p>All patients suspected of having cancer should also be referred for further evaluation to institutes with appropriate recourses.</p>
      <p>Patients on chemotherapy can be seen at any level of care since they are just like any other patient and may need basic nononcological care for common diseases and pain control. However the attending practitioners should be very alert since chemotherapy side effects can mimic or mask signs of other conditions.</p>
      <h2>Common Side Effects of Chemotheraphy</h2>
      <p>Chemotherapy medicines have a variety of toxicities. Only the common ones will be highlighted.<br />
        <strong>Nausea and vomiting;</strong> this is one of the most common side effects. The different medicines have different emetogenic potential. Treatment of these side effects is therefore tailored to suit the emetogenic potential of the medicines used. This has to be done prophylactically. Nausea and vomiting can be acute, delayed or anticipatory.<br />
        <strong>Bone marrow suppression;</strong> Most medicines will cause bone marrow suppression, especially neutropenia. This is worst 7 to 10 days after administration of the medicine. Check the FBC not more than a week before the administration of chemotherapy for each cycle. <br />
        <strong>Alopecia:</strong> This is a distressing side effect that is difficult to prevent for certain medicines. It is however reversible.<br />
        <strong>Extravasation reactions:</strong> This is a serious side effect resulting from the medicine leaking out into the soft tissues into extravascular spaces and causing irritation and tissue necrosis.  The damage can be extensive and permanent. Treatment is prevention. This emphasizes the need for chemotherapy to be administered by trained staff within an oncology specialty. <br /> <strong>Teratogenicity/effects on the embryo:</strong> Chemotherapy is contraindicated in pregnancy especially the 1<sup>st</sup> trimester. Should a pregnant woman need chemotherapy treatment, discussion is necessary to weigh out possible options of treatment. Contraceptive advice should be given prior to starting chemotherapy treatment. <br />
        <strong>Fertility; </strong>Permanent sterility with certain medicines is a possibility for both male and female patients. Germ cell banking should be considered as appropriate.</p>
      <h3>Dose Modification</h3>
      <p>Dose modification may be necessary if unacceptable toxicity results e.g. neurotoxicity from vinca alkaloids and mucositis from methotrexate. Medicine doses are routinely modified for changes in renal or hepatic functions. The extent of acceptability of modifications varies according to individual protocols. Modification for decrease in blood counts is still the norm in resource poor settings unlike in settings where growth factor support is routinely available.</p>
      <h3>Follow up</h3>
      <p>Adjuvant chemotherapy is usually given for a set number of cycles.  In other situations the patient should be evaluated after two or three cycles of therapy. If there is a clear response and the treatment is well tolerated, the treatment can be continued to the set number of cycles or two cycles beyond complete response.  If disease progression is noted during treatment, therapy must be discontinued and other treatments evaluated. In the case of stable disease, treatment can be continued as long as the side effects are tolerable. In this situation disease progression becomes inevitable at some stage</p>
    </span>
}
const chapter_thirtyfive = {
  short_title: "Chapter 35",
  long_title: "Reporting Adverse Medicine Reactions",
  content:
    <span>
      <h1>Reporting Adverse Medicine Reactions</h1>
      <p>Since the thalidomide disaster, voluntary reporting of adverse drug reactions (ADRs) has become important in monitoring the safety of medicines. ADR reporting can also help to identify irrational presenting, bad batches of a medicine and problems specific to particular patient groups.</p>
      <p>For the purpose of reporting an adverse drug reaction (ADR), a medicine is defined as:</p>
      <p><em>Any substance administered to man for the prophylaxis, diagnosis or therapy of disease, or the modification of physiological function</em></p>
      <p><strong>An adverse reaction to a medicine is defined as: </strong></p>
      <p><em>A reaction which is noxious and unintended, and which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function. </em></p>
      <p>This includes herbal and traditional medicines</p>
      <p>All <strong>suspected</strong> adverse reactions are of interest, ranging from wellknown 'side effects' to <strong>dangerous and serious</strong> reactions</p>
      <p>Examples include anaphylaxis to penicillin, Steven- Johnson syndrome in HIV patients given cotrimoxazole, itching due to chloroquine, etc.  Reactions to vaccines specially imported unregistered medicines, congenital abnormalities and lack of therapeutic effect should also be reported.</p>
      <p>Suspected ADR‘s should be reported on the standard form</p>
      <p>Forms can be obtained from the Medicines Control Authority of Zimbabwe, 106 Baines Avenue, Harare, Tel +263-4708255/2901327-317, Fax +263-4-736980, E-mail: <a href="mailto:mcaz@mcaz.co.zw">mcaz@mcaz.co.zw</a></p>
      <p>The forms can also be downloaded from the MCAZ website: <a href="http://www.mcaz.co.zw" rel="noopener noreferrer">www.mcaz.co.zw</a></p>
    </span>
}
const chapter_thirtysix = {
  short_title: "Chapter 36",
  long_title: "Medicines Interactions and Incompatibilities",
  content:
    <span>
      <h1>Medicines Interactions and Incompatibilities</h1>
      <p>Additional Information on interactions and incompatibilities may be obtained from your pharmacy department. If further information is required, it may be obtained by telephone or by post from:</p>
      <p><em>The Drug and Toxicology Information Service<br />
        Medical School<br />P O Box A178, Avondale, Harare <br />
        Tel.: +263 4 2933452 or 791631 (ext. 172), <br /><br />
        <a href="mailto:datis@gmail.com">datis@gmail.com</a><br /><br />
        <a href="http://www.datis.co.zw" rel="noopener noreferrer">www.datis.co.zw</a>
      </em></p>
      <h2>General Notes</h2>
      <p>When two medicines are administered to a patient they may either act independently of each other, or interact with each other.  Interaction may increase or decrease the effect of the medicines concerned, and may cause unexpected toxicity. As newer and more potent medicines are available to us, the number of serious medicine interactions occurring is likely to increase.</p>
      <p>Remember that interactions may involve non-prescription medicines and social drugs (such as alcohol, mbanje), plants and traditional remedies.</p>
      <p>Medicine interactions can be the result of interference with another medicine‘s absorption, displacement of the medicine from a plasma protein binding site, resulting in a similar, or additive effect, increasing or decreasing the other medicine‘s metabolism or excretion, or interference at receptor sites.</p>
      <h2>Potentially Hazardous Interactions</h2>
      <p><small>What follows is <strong className="underline">not a comprehensive list:</strong> refer to the British National Formulary (BNF) or other reference source for detailed information. </small></p>
      <table>
        <caption><small>Key: (+) increased / enhanced effect (-) decreased effect </small></caption>
        <tbody>
          <tr><th>Medicine Affected</th><th>Effect</th><th>Medicines causing effect</th></tr>
          <tr><td>ACE inhibitors (+)</td><td>enhanced hypotensive effect</td><td>Anaesthetics <br />diuretics</td></tr>
          <tr><td>ACE inhibitors (-)</td><td>decreased hypotensive effect</td><td>non-steroidal anti-flammatory medicines</td></tr>
          <tr><td>alpha blockers (prazosin) (+)</td><td>enhanced hypotensive effect</td><td>Anaesthetics<br /> antidepressants<br /> beta blockers<br /> calcium channel blockers<br /> diuretics</td></tr>
          <tr><td>amiloride / spironolactone (+)</td><td>raised potassium levels</td><td>captopril</td></tr>
          <tr><td>aminoglycosides (+)</td><td>ototoxic & nephrotoxic effects increased</td><td>high dose frusemide</td></tr>
          <tr><td>anticoagulants (+)</td><td>increased risk of bleeding</td><td>aspirin</td></tr>
          <tr><td>anticoagulants (-)</td><td>increased metabolism</td><td>Carbamazepine</td></tr>
          <tr><td>anticoagulants /warfarin (+)</td><td>increased anticoagulant effect</td><td>Alcohol<br /> imidazole antifungals</td></tr>
          <tr><td>antidepressants (tricyclics) (+)</td><td>enhanced sedative effect</td><td>Alcohol <br />other antidepressants<br /> anti-epileptics</td></tr>
          <tr><td>anti-epileptics (-)</td><td>lowered threshold</td><td>antidepressants (tricyclics)</td></tr>
          <tr><td>anti-epileptics (-)</td><td>inhibited metabolism</td><td>isoniazid</td></tr>
          <tr><td>benzodiazepines (+)</td><td>increased action</td><td>Cimetidine</td></tr>
          <tr><td>beta blockers (atenolol/ propranolol) (+)</td><td>enhanced hypotensive effect</td><td>Anaesthetics</td></tr>
          <tr><td>calcium channel blockers (-)</td><td>reduced effect</td><td>Phenobarbitone <br />rifampicin<br /> phenytoin</td></tr>
          <tr><td>calcium channel blockers (+)</td><td>enhanced effect</td><td>Anaesthetics</td></tr>
          <tr><td>calcium channel blockers (-)</td><td>increased metabolism</td><td>rifampicin</td></tr>
          <tr><td>carbamazepine (+)</td><td>increased action of carbamazepine</td><td>erythromycin<br /> isoniazid<br /> cimetidine</td></tr>
          <tr><td>carbamazepine (-)</td><td>reduced anti-epileptic effect</td><td>chloroquine</td></tr>
          <tr><td>CNS depressants (+)</td><td>increased action</td><td>Alcohol<br /> sedative medicines <br />phenobarbitone</td></tr>
          <tr><td>corticosteriods (-)</td><td>increased metabolism</td><td>Phenobarbitone</td></tr>
          <tr><td>digoxin (+)</td><td>enhanced toxicity</td><td>Thiazides <br />frusemide <br />quinine</td></tr>
          <tr><td>doxycycline (-)</td><td>increased metabolism</td><td>Carbamazepine</td></tr>
          <tr><td>imidazole antifungals (-)</td><td>increased metabolism<br /> reduced plasma conc.</td><td>rifampicin<br /> phenytoin</td></tr>
          <tr><td>indinavir (antiviral) (+)</td><td>inhibited metabolism</td><td>imidazole antifungals</td></tr>
          <tr><td>indinavir (antiviral) (-)</td><td>enhanced metabolism</td><td>rifampicin</td></tr>
          <tr><td>ketoconazole (-)</td><td>reduced absorption</td><td>antacids<br /> anti-muscarinic medicines <br />cimetidine</td></tr>
          <tr><td>lithium (+)</td><td>increased toxicity</td><td>diuretics</td></tr>
          <tr><td>metronidazole (-)</td><td>reduced plasma conc.</td><td>phenytoin</td></tr>
          <tr><td>metronidazole (+)</td><td>antabuse reaction</td><td>alcohol</td></tr>
          <tr><td>neuromuscular blockers (+)</td><td>enhanced effects</td><td>aminoglycosides</td></tr>
          <tr><td>non-steroidal anti-inflammatory medicines (+)</td><td>increased risk of renal damage</td><td>ACE inhibitors</td></tr>
          <tr><td>oral contraceptives (-)</td><td>reduced contraceptive effect</td><td>rifampicin <br />'broad spectrum' antibiotics<br /> phenobarbitone<br /> carbamazepine<br /> phenytoin</td></tr>
          <tr><td>oral hypoglycaemic /insulin (+)</td><td>increased hypoglycaemic effect</td><td>alcohol</td></tr>
          <tr><td>phenytoin (+)</td><td>enhanced effect</td><td>imidazole antifungals</td></tr>
          <tr><td>phenytoin</td><td>action increased</td><td>chloramphenicol<br /> cimetidine<br /> cotrimoxazole<br /> isoniazid<br /> metronidazole</td></tr>
          <tr><td>sulphonylureas (+) (glibenclamide / metformin)</td><td>increased action</td><td>chloramphenicol<br /> cotrimoxazole<br /> fluconazole<br />  miconazole</td></tr>
          <tr><td>theophylline (+)</td><td>increased theophylline levels</td><td>cimetidine <br />erythromycin<br /> oral contraceptives<br /> calcium channel blockers</td></tr>
        </tbody>
      </table>
      <h2>Incompatibilities between Medicines and IV Fluids </h2>
      <p><small><em>This section only intended as a general guide. Many other incompatibilities exist. Always check for compatibility before adding any medicine to an IV fluid (look at the package insert of the medicine, or ask your local pharmacy department for advice).</em></small></p>
      <p>Medicines should <strong className="underline">not</strong> be added to blood, amino acid solutions, or fat emulsions.</p>
      <p>Certain medicines, when added to IV fluids, are inactivated by pH changes, precipitation, or chemical reaction. Most simple IV fluids are acidic pH (3.5-6.0).</p>
      <table>
        <tbody>
          <tr><th>Medicine</th><th>Effect</th><th>Solution/ Incompatibility</th></tr>
          <tr><td>Benzylpenicillin<br />Ampicillin</td><td>(-) lose potency after 68hrs (due to acidity)</td><td>dextrose solutions - use within 1 hour</td></tr>
          <tr><td>Diazepam<br /> Insulin</td><td>(-) effect due to binding</td><td>plastic containers, tubing - titrate</td></tr>
          <tr><td>Aminoglycosides (gentamicin)</td><td>incompatible</td><td>Penicillins<br />heparin</td></tr>
          <tr><td>Hydrocortisone</td><td>incompatible</td><td>heparin<br />chloramphenicol<br />tetracycline</td></tr>
          <tr><td>Oxytocin</td><td></td><td>at high doses dilute with dextrose, not normal saline</td></tr>
          <tr><td>Potassium Chloride</td><td></td><td>mix thoroughly to avoid 'layering'</td></tr>
          <tr><td>Cetriaxone</td><td>incompatible</td><td>Use different IV line from those of calcium containing IV fluids</td></tr>
        </tbody>
      </table>
    </span>
}
const book = {
  short_title: "EDLIZ",
  long_title: "The Essential Medicines List for Zimbabwe",
  contents: {
    chapters: [
      chapter_one,
      chapter_two,
      chapter_three,
      chapter_four,
      chapter_five,
      chapter_six,
      chapter_seven,
      chapter_eight,
      chapter_nine,
      chapter_ten,
      chapter_eleven,
      chapter_twelve,
      chapter_thirteen,
      chapter_fourteen,
      chapter_fifteen,
      chapter_sixteen,
      chapter_seventeen,
      chapter_eighteen,
      chapter_nineteen,
      chapter_twenty,
      chapter_twentyone,
      chapter_twentytwo,
      chapter_twentythree,
      chapter_twentyfour,
      chapter_twentyfive,
      chapter_twentysix,
      chapter_twentyseven,
      chapter_twentyeight,
      chapter_twentynine,
      chapter_thirty,
      chapter_thirtythree,
      chapter_thirtyfour,
      chapter_thirtyfive,
      chapter_thirtysix],
    pre: [
      seventh_edition,
      acknowledgements,
      foreword,
      preface,
      major_highlights]
  }
};
export function bookContents() {
  return book;
}